WO2009099929A1 - Mesoionic pesticides - Google Patents

Mesoionic pesticides Download PDF

Info

Publication number
WO2009099929A1
WO2009099929A1 PCT/US2009/032584 US2009032584W WO2009099929A1 WO 2009099929 A1 WO2009099929 A1 WO 2009099929A1 US 2009032584 W US2009032584 W US 2009032584W WO 2009099929 A1 WO2009099929 A1 WO 2009099929A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
hydroxy
methyl
oxo
chloro
Prior art date
Application number
PCT/US2009/032584
Other languages
French (fr)
Inventor
Caleb William Holyoke Jr
My-Hanh Thi Tong
Reed Aaron Coats
Wenming Zhang
Stephen Frederick Mccann
Dominic Ming-Tak Chan
Original Assignee
E. I. Du Pont De Nemours And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40524655&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2009099929(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to DK09709044.3T priority Critical patent/DK2240454T3/en
Priority to KR1020137027699A priority patent/KR101495468B1/en
Priority to KR1020107019689A priority patent/KR101404291B1/en
Priority to NZ586799A priority patent/NZ586799A/en
Priority to CN200980104397.6A priority patent/CN101939302B/en
Priority to US12/866,462 priority patent/US8552007B2/en
Priority to PL09709044T priority patent/PL2240454T3/en
Priority to MX2013013073A priority patent/MX352783B/en
Priority to AU2009212715A priority patent/AU2009212715B2/en
Priority to BRPI0905936A priority patent/BRPI0905936B1/en
Priority to CA2713347A priority patent/CA2713347C/en
Priority to UAA201009923A priority patent/UA103473C2/en
Priority to RS20130222A priority patent/RS52788B/en
Application filed by E. I. Du Pont De Nemours And Company filed Critical E. I. Du Pont De Nemours And Company
Priority to EP09709044.3A priority patent/EP2240454B1/en
Priority to SI200930653T priority patent/SI2240454T1/en
Priority to JP2010545938A priority patent/JP5068378B2/en
Priority to EA201070926A priority patent/EA019955B1/en
Priority to MX2010008532A priority patent/MX2010008532A/en
Priority to ES09709044T priority patent/ES2416083T3/en
Publication of WO2009099929A1 publication Critical patent/WO2009099929A1/en
Priority to ZA2010/05035A priority patent/ZA201005035B/en
Priority to MA33029A priority patent/MA32026B1/en
Priority to IL207087A priority patent/IL207087A/en
Priority to TNP2010000356A priority patent/TN2010000356A1/en
Priority to IL226126A priority patent/IL226126A0/en
Priority to HRP20130501AT priority patent/HRP20130501T1/en
Priority to US13/967,629 priority patent/US9018220B2/en
Priority to PH12014500760A priority patent/PH12014500760A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/48—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with two nitrogen atoms as the only ring hetero atoms
    • A01N43/50—1,3-Diazoles; Hydrogenated 1,3-diazoles
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/48—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with two nitrogen atoms as the only ring hetero atoms
    • A01N43/54—1,3-Diazines; Hydrogenated 1,3-diazines
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/48—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with two nitrogen atoms as the only ring hetero atoms
    • A01N43/56—1,2-Diazoles; Hydrogenated 1,2-diazoles
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/64—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with three nitrogen atoms as the only ring hetero atoms
    • A01N43/647—Triazoles; Hydrogenated triazoles
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/72—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms
    • A01N43/74—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms five-membered rings with one nitrogen atom and either one oxygen atom or one sulfur atom in positions 1,3
    • A01N43/78—1,3-Thiazoles; Hydrogenated 1,3-thiazoles
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/90—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Definitions

  • This invention relates to certain pyrimidinium compounds and their compositions suitable for agronomic, nonagronomic and animal health uses, methods of their use for controlling invertebrate pests such as arthropods in both agronomic and nonagronomic environments, and for treatment of parasite infections in animals or infestations in the general environment.
  • invertebrate pests The control of invertebrate pests is extremely important in achieving high crop efficiency. Damage by invertebrate pests to growing and stored agronomic crops can cause significant reduction in productivity and thereby result in increased costs to the consumer.
  • the control of invertebrate pests in forestry, greenhouse crops, ornamentals, nursery crops, stored food and fiber products, livestock, household, turf, wood products, and public health is also important. Many products are commercially available for these purposes, but the need continues for new compounds that are more effective, less costly, less toxic, environmentally safer or have different sites of action.
  • U.S. Patent No. 5,151,427 discloses mesoionic pyrimidinium compounds of Formula i as anthelmintics
  • R 1 and R 2 are independently C ⁇ -Cg alkyl
  • R 3 is a heteroaromatic 6- membered ring
  • R 4 and R 5 are independently hydrogen or Q-C 4 alkyl.
  • This invention is directed to compounds of Formula 1 (including all geometric and stereoisomers) and compositions containing them and their use for controlling invertebrate pests:
  • R 1 is C 3 -C7 cycloalkyl, C 4 -Cg cycloalkylalkyl or C 5 -C7 cycloalkenyl, each optionally substituted with 1 to 4 substituents independently selected from the group consisting of halogen, C 1 -C 2 alkyl, C 1 -C 2 alkoxy, 1 cyclopropyl, 1 CF 3 and 1 OCF 3 ; or
  • R 1 is phenyl, naphthalenyl or a 5- or 6-membered heteroaromatic ring, each optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, cyano, nitro, C 1 -C 4 alkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, C 1 -C 4 haloalkyl, C 2 -C 4 haloalkenyl, C 2 -C 4 alkylcarbonyl, C 2 -C 4 haloalkylcarbonyl, C 2 -C 4 alkoxycarbonyl, C 2 -C 4 alkylaminocarbonyl, C 3 -C7 dialkylaminocarbonyl, C(O)N-f CH 2 Z 2 CH 2 ⁇ -, C 1 -C 4 alkoxy, C 1 -C 4 haloalkoxy, C 2 -C 6 alkoxyalkyl, S(O) n R
  • R 1 is phenyl or a 5- or 6-membered heteroaromatic ring, each substituted with LQ 1 and optionally substituted with 1 or 2 substituents independently selected from the group consisting of halogen, cyano, nitro, C 1 -C 4 alkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, C 1 -C 4 haloalkyl, C 2 -C 4 alkylcarbonyl, C 2 -C 4 haloalkylcarbonyl, C 2 - C 4 alkoxycarbonyl, C 2 -C 4 alkylaminocarbonyl, C 3 -C 7 dialkylaminocarbonyl, C(O)NfCH 2 Z 2 CH 2 ⁇ -, C 1 -C 4 alkoxy, C 1 -C 4 haloalkoxy, C 2 -C 6 alkoxyalkyl, S(O) n R 12 , S(O) 2 R 13 , C 1 -
  • X 1 is O or S
  • G is a direct bond, O, S(O) n , NH, N(CH 3 ), CH 2 , CH 2 O, OCH 2 , C(O), C(O)O, OC(O), C(O)NH or NHC(O);
  • L is a phenyl or 5- or 6-membered heteroaromatic ring optionally substituted with 1 or 2 substituents independently selected from the group consisting of halogen, cyano, nitro, C 1 -C 4 alkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, C 1 -C 4 haloalkyl, C 2 - C 4 alkylcarbonyl, C 2 -C 4 haloalkylcarbonyl, C 2 -C 4 alkoxycarbonyl, C 2 -C 4 alkylaminocarbonyl, C 3 -C 7 dialkylaminocarbonyl, C(O)N-fCH 2 Z 2 CH 2 >, C 1 -
  • Q 1 is phenyl or a 5- or 6-membered heteroaromatic ring, each optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, cyano, nitro, C 1 -C 4 alkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, C 1 -C 4 haloalkyl, C 2 -C 4 alkylcarbonyl, C 2 -C 4 haloalkylcarbonyl, C 2 -C 4 alkoxycarbonyl, C 2 -C 4 alkylaminocarbonyl, C 3 -C7 dialkylaminocarbonyl,
  • Q 2 is phenyl or a 5- or 6-membered heteroaromatic ring, each optionally substituted with 1 or 2 substituents independently selected from the group consisting of halogen, cyano, nitro, C 1 -C 4 alkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, C 1 -C 4 haloalkyl, C 2 -C 4 alkylcarbonyl, C 2 -C 4 haloalkylcarbonyl, C 2 -C 4 alkoxycarbonyl, C 2 -C 4 alkylaminocarbonyl, C 3 -C7 dialkylaminocarbonyl, C(O)N-f- CH 2 Z 2 CH 2 ⁇ -, C 1 -C 4 alkoxy, C 1 -C 4 haloalkoxy, C 2 -C 6 alkoxyalkyl, S(O) n R 12 , S(O) 2 R 13 , C 1 -C 4 alkyla
  • R 2 is C 2 -C 6 alkyl, C 1 -C 6 haloalkyl, C 3 -C 6 alkenyl, C 3 -C 6 haloalkenyl, C 3 -C 6 alkynyl, C 3 -C 6 haloalkynyl, CH 2 CO 2 R 21 , CR 5 R 6 CH 2 OR 21 , CR 5 R 6 CH 2 CH 2 OR 21 , CR 5 R 6 CH 2 S(O) n R 21 or CR 5 R 6 CH 2 CH 2 S(O) n R 21 ; or
  • R 2 is C 3 -C 6 cycloalkyl or C 4 -C 7 cycloalkylalkyl, each optionally substituted with 1 to 4 substituents selected from the group consisting of halogen, C 1 -C 2 alkyl, 1 cyclopropyl and 1 CF 3 ; or
  • R 2 is CR 5 R 6 Q
  • R 3 is H, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 2 -C 6 alkenyl, C 2 -C 6 haloalkenyl, C 2 -C 6 alkynyl, C 2 -C 6 haloalkynyl or C ⁇ CR 10 ; or
  • R 3 is C 3 -C 6 cycloalkyl or C 4 -C 7 cycloalkylalkyl, each optionally substituted with 1 to 4 substituents independently selected from the group consisting of halogen, C 1 - C 2 alkyl, 1 cyclopropyl and 1 CF 3 ; or R 3 is phenyl, naphthalenyl or a 5- or 6-membered heteroaromatic ring, each optionally substituted with 1 or 2 substituents independently selected from the group consisting of halogen, cyano, nitro, C 1 -C 4 alkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, C 1 -C 4 haloalkyl, C 2 -C 4 alkylcarbonyl, C 2 -C 4 haloalkylcarbonyl, C 2 -C 4 alkoxycarbonyl, C 2 -C 4 alkylaminocarbonyl, C 3 -C 7 dialky
  • R 4 is C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 2 -C 6 alkenyl, C 2 -C 6 haloalkenyl, C 2 -C 6 alkynyl, C 2 -C 6 haloalkynyl or C ⁇ CR 10 ; or
  • R 4 is C 3 -C 6 cycloalkyl or C 4 -C7 cycloalkylalkyl, each optionally substituted with 1 to 4 substituents independently selected from the group consisting of halogen, C 1 - C 2 alkyl, 1 cyclopropyl and 1 CF 3 ; or
  • R 4 is phenyl, naphthalenyl or a 5- or 6-membered heteroaromatic ring, each optionally substituted with 1 or 2 substituents independently selected from the group consisting of halogen, cyano, nitro, C 1 -C 4 alkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, C 1 -C 4 haloalkyl, C 2 -C 4 alkylcarbonyl, C 2 -C 4 haloalkylcarbonyl, C 2 -C 4 alkoxycarbonyl, C 2 -C 4 alkylaminocarbonyl, C 3 -C7 dialkylaminocarbonyl,
  • R 3 and R 4 are taken together with the contiguous linking nitrogen and carbon atoms to form an optionally substituted ring R-I
  • each R 7 is independently H, halogen, cyano, CF 3 , C ⁇ -C 3 alkyl or C 3 -C 6 cycloalkyl;
  • each R 9b is independently H, halogen, cyano, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 1 -C 4 alkoxy or C 1 -C 4 haloalkoxy; or phenyl or pyridinyl, each optionally substituted with 1 or 2 substituents independently selected from the group consisting of halogen, cyano, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 1 -C 4 alkoxy, C 1 -C 4 haloalkoxy, S(O) n R 12 and S(O) 2 R 13 ; each R 10 is independently Si(R 1 !
  • phenyl or pyridinyl each optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, cyano, nitro, SF 5 , C 1 -C 4 alkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, C 1 -C 4 haloalkyl, C 2 -C 4 alkylcarbonyl, C 2 -C 4 haloalkylcarbonyl, C 2 -C 4 alkoxycarbonyl, C 2 -C 4 alkylaminocarbonyl, C 3 -C7 dialkylaminocarbonyl,
  • R 14 is H, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 2 -C 5 alkoxycarbonyl, C 2 -C 5 alkylaminocarbonyl, C 3 -C7 dialkylaminocarbonyl, C(O)N- ⁇ -CH 2 Z 2 CH 2 -)-, S(O) n R 12 or S(O) 2 R 13 ; or phenyl or pyridinyl, each optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, cyano, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, C 1 -C 4 haloalkoxy, S(O) n R 12 and S(O) 2 R 13 ; each R 15 is independently C 1 -C 4 alkyl; each R 16 is independently H or C 1 -C 4 alkyl; each R 17 is independently H, F or CH 3 ; R 18 is H, C 1 -
  • R 23 is H, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 3 -C 6 alkenyl, C 3 -C 6 haloalkenyl, C 3 -C 6 alkynyl, C 3 -C 6 haloalkynyl or CH 2 CO 2 R 21 ; or R 23 is C 3 -C 6 cycloalkyl or C 4 -C 7 cycloalkylalkyl, each optionally substituted with 1 to 4 substituents independently selected from the group consisting of halogen, C 1 -C 2 alkyl, 1 cyclopropyl and 1 CF 3 ; or R 23 is phenyl or a 5- or 6-membered heteroaromatic ring, each optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, cyano, nitro, C 1 -C 4 alkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkyn
  • R 23a is C 1 -C 6 alkyl, C 2 -C 6 haloalkyl, C 3 -C 6 alkenyl or C 3 -C 6 cycloalkyl; each R 24 is independently H, F or CH 3 ; m is 0, 1, 2 or 3; each n is independently 0, 1 or 2; p is 0, 1, 2, 3 or 4; each q is independently 0, 1 or 2; y is 1 or 2; and each Z 2 is independently CH 2 CH 2 , CH 2 CH 2 CH 2 or CH 2 OCH 2 .
  • This invention also provides a composition comprising a compound of Formula 1 and at least one additional component selected from the group consisting of surfactants, solid diluents and liquid diluents.
  • this invention also provides a composition for controlling an invertebrate pest comprising a compound of Formula 1 (i.e. in a biologically effective amount) and at least one additional component selected from the group consisting of surfactants, solid diluents and liquid diluents, said composition optionally further comprising at least one additional biologically active compound or agent (i.e. in a biologically effective amount).
  • This invention further provides a composition for protecting an animal from an invertebrate parasitic pest comprising a parasiticidally effective amount of a compound of Formula 1 (i.e. in a parasiticidally effective amount) and at least one carrier.
  • This invention further provides a spray composition for controlling an invertebrate pest comprising a compound of Formula 1 or the compositions described above (i.e. in a biologically effective amount), and a propellant.
  • This invention also provides a bait composition for controlling an invertebrate pest comprising a compound of Formula 1 or the compositions described in the embodiments above (i.e. in a biologically effective amount), one or more food materials, optionally an attractant, and optionally a humectant.
  • This invention further provides a trap device for controlling an invertebrate pest comprising said bait composition and a housing adapted to receive said bait composition, wherein the housing has at least one opening sized to permit the invertebrate pest to pass through the opening so the invertebrate pest can gain access to said bait composition from a location outside the housing, and wherein the housing is further adapted to be placed in or near a locus of potential or known activity for the invertebrate pest.
  • This invention provides a method for controlling an invertebrate pest comprising contacting the invertebrate pest or its environment with a biologically effective amount of a compound of Formula 1 (e.g., as a composition described herein).
  • a biologically effective amount of a compound of Formula 1 e.g., as a composition described herein.
  • This invention also relates to such method wherein the invertebrate pest or its environment is contacted with a composition comprising a biologically effective amount of a compound of Formula 1 and at least one additional component selected from the group consisting of surfactants, solid diluents and liquid diluents, said composition optionally further comprising a biologically effective amount of at least one additional biologically active compound or agent.
  • This invention also provides a method for protecting a seed from an invertebrate pest comprising contacting the seed with a biologically effective amount of a compound of Formula 1 (e.g., as a composition described herein). This invention also relates to the treated seed. This invention further provides a method for treating, preventing, inhibiting and/or killing ecto and/or endoparasites comprising administering to and/or on the animal a parasiticidally effective amount of a compound of Formula 1 (e.g., as a composition described herein).
  • This invention also relates to such method wherein a parasiticidally effective amount of a compound of Formula 1 (e.g., as a composition described herein) is administered to the environment (e.g., a stall or blanket) in which an animal resides.
  • a parasiticidally effective amount of a compound of Formula 1 e.g., as a composition described herein
  • the environment e.g., a stall or blanket
  • compositions comprising, “comprising,” “includes,” “including,” “has,” “having,” “contains” or “containing,” or any other variation thereof, are intended to cover a non-exclusive inclusion.
  • a composition, a mixture, process, method, article, or apparatus that comprises a list of elements is not necessarily limited to only those elements but may include other elements not expressly listed or inherent to such composition, mixture, process, method, article, or apparatus.
  • “or” refers to an inclusive or and not to an exclusive or. For example, a condition A or B is satisfied by any one of the following: A is true (or present) and B is false (or not present), A is false (or not present) and B is true (or present), and both A and B are true (or present).
  • the term “invertebrate pest” includes arthropods, gastropods and nematodes of economic importance as pests.
  • arthropod includes insects, mites, spiders, scorpions, centipedes, millipedes, pill bugs and symphylans.
  • gastropod includes snails, slugs and other Stylommatophora.
  • nematode includes all of the helminths, such as: roundworms, heartworms, and phytophagous nematodes (Nematoda), flukes (Tematoda), Acanthocephala, and tapeworms (Cestoda).
  • invertebrate pest control means inhibition of invertebrate pest development (including mortality, feeding reduction, and/or mating disruption), and related expressions are defined analogously.
  • agronomic refers to the production of field crops such as for food and fiber and includes the growth of corn, soybeans and other legumes, rice, cereal (e.g., wheat, oats, barley, rye, rice, maize), leafy vegetables (e.g., lettuce, cabbage, and other cole crops), fruiting vegetables (e.g., tomatoes, pepper, eggplant, crucifers and cucurbits), potatoes, sweet potatoes, grapes, cotton, tree fruits (e.g., pome, stone and citrus), small fruit (berries, cherries) and other specialty crops (e.g., canola, sunflower, olives).
  • wheat e.g., wheat, oats, barley, rye, rice, maize
  • leafy vegetables e.g., lettuce, cabbage, and other cole crops
  • fruiting vegetables e.g., tomatoes, pepper, eggplant, crucifers and cucurbits
  • potatoes e.g., sweet potatoes, grapes, cotton, tree fruits (e.g.
  • nonagronomic refers to other than field crops, such as horticultural crops (e.g., greenhouse, nursery or ornamental plants not grown in a field), residential, agricultural, commercial and industrial structures, turf (e.g., sod farm, pasture, golf course, lawn, sports field, etc.), wood products, stored product, agro-forestry and vegetation management, public health (i.e. human) and animal health (e.g., domesticated animals such as pets, livestock and poultry, undomesticated animals such as wildlife) applications.
  • horticultural crops e.g., greenhouse, nursery or ornamental plants not grown in a field
  • turf e.g., sod farm, pasture, golf course, lawn, sports field, etc.
  • wood products e.g., stored product, agro-forestry and vegetation management
  • public health i.e. human
  • animal health e.g., domesticated animals such as pets, livestock and poultry, undomesticated animals such as wildlife
  • Nonagronomic applications include protecting an animal from an invertebrate parasitic pest by administering a parasiticidally effective (i.e. biologically effective) amount of a compound of the invention, typically in the form of a composition formulated for veterinary use, to the animal to be protected.
  • a parasiticidally effective (i.e. biologically effective) amount of a compound of the invention typically in the form of a composition formulated for veterinary use, to the animal to be protected.
  • parasiticidal i.e. biologically effective
  • Parasiticidally refers to observable effects on an invertebrate parasite pest to provide protection of an animal from the pest. Parasiticidal effects typically relate to diminishing the occurrence or activity of the target invertebrate parasitic pest.
  • Such effects on the pest include necrosis, death, retarded growth, diminished mobility or lessened ability to remain on or in the host animal, reduced feeding and inhibition of reproduction.
  • These effects on invertebrate parasite pests provide control (including prevention, reduction or elimination) of parasitic infestation or infection of the animal.
  • alkyl used either alone or in compound words such as “haloalkyl” includes straight-chain or branched alkyl, such as, methyl, ethyl, n-propyl, /-propyl, or the different butyl, pentyl or hexyl isomers.
  • alkenyl includes straight-chain or branched alkenes such as ethenyl, 1-propenyl, 2-propenyl, and the different butenyl, pentenyl and hexenyl isomers.
  • Alkenyl also includes polyenes such as 1 ,2-propadienyl and 2,4-hexadienyl.
  • Alkynyl includes straight-chain or branched alkynes such as ethynyl, 1-propynyl, 2-propynyl and the different butynyl, pentynyl and hexynyl isomers. "Alkynyl” can also include moieties comprised of multiple triple bonds such as 2,5-hexadiynyl. "Alkoxy” includes, for example, methoxy, ethoxy, n-propyloxy, isopropyloxy and the different butoxy, pentoxy and hexyloxy isomers. "Alkoxyalkyl” denotes alkoxy substitution on alkyl. Examples of “alkoxyalkyl” include CH 2 OCH 3 , CH 2 CH 2 OCH 3 , CH 2 OCH 2 CH 3 , CH 2 OCH 2 CH 2 CH 2 CH 3 and CH 2 CH 2 OCH 2 CH 3 .
  • Cycloalkyl includes, for example, cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
  • cycloalkylalkyl denotes cycloalkyl substitution on an alkyl moiety. Examples of “cycloalkylalkyl” include cyclopropylmethyl, cyclopentylethyl, and other cycloalkyl moieties bonded to straight-chain or branched alkyl groups.
  • halogen either alone or in compound words such as “haloalkyl”, or when used in descriptions such as “alkyl substituted with halogen” includes fluorine, chlorine, bromine or iodine. Further, when used in compound words such as “haloalkyl”, or when used in descriptions such as “alkyl substituted with halogen” said alkyl may be partially or fully substituted with halogen atoms which may be the same or different. Examples of “haloalkyl” or “alkyl substituted with halogen” include CF 3 , CH 2 Cl, CH 2 CF 3 and CCl 2 CF 3 .
  • haloalkoxy haloalkenyl
  • haloalkynyl haloalkynyl
  • examples of “haloalkoxy” include OCF 3 , OCH 2 CCl 3 , OCH 2 CH 2 CHF 2 and OCH 2 CF 3 .
  • Examples of "haloalkynyl” include CHCIC ⁇ CH, C ⁇ CCF 3 , C ⁇ CCC1 3 and CH 2 C ⁇ CCH 2 F.
  • Alkylamino denotes an NH radical substituted with straight-chain or branched alkyl.
  • alkylamino examples include NHCH 2 CH 3 , NHCH 2 CH 2 CH 3 , and NHCH 2 CH(CH 3 ) 2 .
  • Dialkylamino denotes an N radical substituted independently with two straight-chain or branched alkyl groups. Examples of “dialkylamino” include N(CH 3 ) 2 , N(CH 3 CH 2 CH 2 ) 2 and N(CH 3 )CH 2 CH 3 .
  • Halodialkylamino denotes one straight-chain or branched alkyl moiety and one straight-chain or branched haloalkyl moiety bonded to an N radical, or two independent straight-chain or branched haloalkyl moieties bonded to an N radical, wherein “haloalkyl” is as defined above.
  • Examples of “halodialkylamino” include
  • Alkylcarbonyl denotes a straight-chain or branched alkyl moiety bonded to a C(O) moiety.
  • alkylcarbonyl include C(O)CH 3 , C(O)CH 2 CH 2 CH 3 and C(O)CH(CH 3 ) 2 .
  • haloalkylcarbonyl include C(O)CF 3 , C(O)CCl 3 , C(O)CH 2 CF 3 and C(O)CF 2 CF 3 .
  • Alkoxycarbonyl denotes a straight-chain or branched alkyl moiety bonded to a CO 2 moiety.
  • the chemical abbreviations CO 2 and C(O)O as used herein represent an ester moiety.
  • Examples of “alkoxycarbonyl” include C(O)OCH 3 , C(O)CH 2 CH 3 ,
  • Alkylaminocarbonyl denotes a straight-chain or branched alkyl moiety bonded to a C(O)NH moiety.
  • the chemical abbreviations C(O)NH, and C(O)N as used herein represent an amide moiety (i.e. an aminocarbonyl group).
  • alkylaminocarbonyl include C(O)NHCH 3 , C(O)NHCH 2 CH 2 CH 3 and C(O)NHCH(CH 3 ) 2 .
  • Dialkylaminocarbonyl denotes two independent straight-chain or branched alkyl moieties bonded to a C(O)N moiety.
  • dialkylaminocarbonyl include C(O)N(CH 3 ) 2 and C(O)N(CH 3 )(CH 2 CH 3 ).
  • C(O)N- (-CH 2 Z 2 CH 2 -)- represents a dialkylaminocarbonyl moiety wherein the two alkyl groups are connected to form a ring as shown below.
  • N- ⁇ -CH 2 Z 2 CH 2 -)- is defined analogously.
  • the wavy line in the above structures and elsewhere in the disclosure indicates the attachment position of the molecular fragment to the remainder of the molecule.
  • the total number of carbon atoms in a substituent group is indicated by the "Ci-C j " prefix where i and j are numbers from 1 to 7.
  • C ⁇ -C 4 alkyl designates methyl through butyl
  • C 2 alkoxyalkyl designates CH 2 OCH 3
  • C 3 alkoxyalkyl designates, for example, CH 3 CH(OCH 3 ), CH 2 CH 2 OCH 3 or CH 2 OCH 2 CH 3
  • C 4 alkoxyalkyl designates the various isomers of an alkyl group substituted with an alkoxy group containing a total of four carbon atoms, examples including CH 2 OCH 2 CH 2 CH 3 and CH 2 CH 2 OCH 2 CH 3 .
  • heteroaromatic ring denotes an aromatic ring in which at least one atom forming the ring backbone is not carbon, e.g., nitrogen, oxygen or sulfur. Typically a heteroaromatic ring contains no more than 4 nitrogens, no more than 1 oxygen and no more than 1 sulfur. Unless otherwise indicated, heteroaromatic rings can be attached through any available carbon or nitrogen by replacement of a hydrogen on said carbon or nitrogen.
  • “Aromatic” indicates that each of the ring atoms is essentially in the same plane and has a /?-orbital perpendicular to the ring plane, and in which (4n + T) ⁇ electrons, where n is a positive integer, are associated with the ring to comply with H ⁇ ckel's rule.
  • heteroaromatic bicyclic ring system denotes a ring system consisting of two fused rings, in which at least one of the two rings is a heteroaromatic ring as defined above.
  • a radical e.g., cycloalkyl in the definition of R 1
  • the radical may be unsubstituted or substituted with a number of substituents ranging up to the high number stated (e.g., "4"), and the attached substituents are independently selected from the substituents listed.
  • the substituent list includes a lower limit for a particular substituent (e.g., "1 cyclopropyl"), this accordingly restricts number of instances of that particular substituent among the substituents attached to the radical.
  • substituent list includes a lower limit for a particular substituent (e.g., "1 cyclopropyl")
  • up to four substituents may be attached to the cycloalkyl radical, only one of the substituents may be cyclopropyl.
  • substituents such as R 1 can be (among others) phenyl optionally substituted with one to three substituents selected from a group of substituents as defined in the Summary of the Invention.
  • R v is as defined in the Summary of the Invention (e.g., for R 1 ) and r is an integer from 0 to 3.
  • substituents such as R 1 can be (among others) a 5- or 6-membered heteroaromatic ring, optionally substituted with one or more substituents selected from a group of substituents as defined in the Summary of Invention.
  • substituents include the rings U-2 through U-61 illustrated in Exhibit 1 wherein R v is any substituent as defined in the Summary of the Invention (e.g., for R 1 ) and r is an integer from 0 to 2, limited by the number of available positions on each U group.
  • U-29, U-30, U-36, U-37, U-38, U-39, U-40, U-41, U-42 and U-43 have only one available position, for these U groups r is limited to the integers 0 or 1 , and r being 0 means that the U group is unsubstituted and a hydrogen is present at the position indicated by (R v ) r .
  • substituents such as R 1 can be (among others) an 8-, 9- or 10-membered heteroaromatic bicyclic ring system optionally substituted with up to 3 substituents selected from a group of substituents as defined in the Summary of Invention.
  • Examples of a 8-, 9- or 10-membered heteroaromatic bicyclic ring system optionally substituted with up to 3 substituents include the ring systems H-I through H-23 illustrated in Exhibit 2 wherein R v is any substituent as defined in the Summary of the Invention (e.g., halogen, cyano, nitro, SF 5 , C 1 -C 4 alkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, C 1 -C 4 haloalkyl, C 2 -C 4 alkylcarbonyl, C 2 -C 4 haloalkylcarbonyl, C 2 -C 4 alkoxycarbonyl, C 2 -C 4 alkylaminocarbonyl, C 3 -C7 dialkylaminocarbonyl, C ⁇ -C 4 alkoxy, C 1 -C 4 haloalkoxy, C 2 - C ⁇ alkoxyalkyl, S(O) n R 12
  • R v groups are shown in the structures U-I through U-61 and H-I through H-23, it is noted that they do not need to be present since they are optional substituents.
  • the nitrogen atoms that require substitution to fill their valence are substituted with H or R v .
  • (R v ) r can be attached to any available carbon atom or nitrogen atom of the U or H group.
  • the U or H group can be attached to the remainder of Formula 1 through any available carbon or nitrogen of the U or H group by replacement of a hydrogen atom.
  • some U groups can only be substituted with less than 2 R v groups (e.g., U-2 through U-5, U-7 through U-48, and U-52 through U-61).
  • the compounds of Formula 1 are mesoionic inner salts.
  • Inner salts also known in the art as “zwitterions” are electrically neutral molecules but carry formal positive and negative charges on different atoms in each valence bond structure according to valence bond theory.
  • molecular structure of the compounds of Formula 1 can be represented by the six valence bond structures shown below, each placing the formal positive and negative charges on different atoms. Because of this resonance, the compounds of Formula 1 are also described as "mesoionic”.
  • the molecular structure of Formula 1 is depicted as a single valence bond structure in the present disclosure and claims, this particular valence bond structure is to be understood as representative of all six valence bond structures relevant to bonding in molecules of compounds of Formula 1. Therefore reference to Formula 1 in the present disclosure and claims relates to all six applicable valence bond structures and other (e.g., molecular orbital theory) structures unless otherwise specified.
  • Stereoisomers of this invention can exist as one or more stereoisomers.
  • the various stereoisomers include enantiomers, diastereomers, atropisomers and geometric isomers.
  • substituents and other molecular constituents such as R 1 may contain chiral centers.
  • one stereoisomer may be more active and/or may exhibit beneficial effects when enriched relative to the other stereoisomer(s) or when separated from the other stereoisomer(s).
  • This invention comprises racemic mixtures as well as enriched and essentially pure stereoconfigurations at these chiral centers.
  • Compounds of this invention can exist as one or more conformational isomers due to restricted bond rotation caused by steric hinderance.
  • a compound of Formula 1 wherein R 1 is phenyl substituted in the ortho-position with a sterically demanding alkyl group e.g., isopropyl
  • This invention comprises mixtures of conformational isomers.
  • this invention includes compounds that are enriched in one conformer relative to others.
  • Polymorphs can exist in the solid phase as polymorphs (i.e. different crystalline forms).
  • polymorph refers to a particular crystalline form of a chemical compound that can crystallize in different crystalline forms, these forms having different arrangements and/or conformations of the molecules in the crystal lattice.
  • polymorphs can have the same chemical composition, they can also differ in composition due the presence or absence of co-crystallized water or other molecules, which can be weakly or strongly bound in the lattice.
  • Polymorphs can differ in such chemical, physical and biological properties as crystal shape, density, hardness, color, chemical stability, melting point, hygroscopicity, suspensibility, dissolution rate and biological availability.
  • a polymorph of a compound of Formula 1 can exhibit beneficial effects (e.g., suitability for preparation of useful formulations) relative to another polymorph or a mixture of polymorphs of the same compound of Formula 1.
  • Preparation and isolation of a particular polymorph of a compound of Formula 1 can be achieved by methods known to those skilled in the art including, for example, crystallization using selected solvents and temperatures.
  • This invention comprises both individual polymorphs and mixtures of polymorphs, including mixtures enriched in one polymorph relative to others.
  • Embodiment 1 A compound of Formula 1 wherein X is O.
  • Embodiment 2. A compound of Formula 1 wherein X is S.
  • Embodiment 3 A compound of Formula 1 or Embodiments 1 or 2 wherein Y is O.
  • Embodiment 4. A compound of Formula 1 or Embodiments 1 or 2 wherein Y is S.
  • Embodiment 5. A compound of Formula 1 or any of Embodiments 1-4 wherein R 1 is H or halogen.
  • R 1 is phenyl or a 6-membered hetero aromatic ring, each optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, cyano, nitro, C 1 -C 4 alkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, C 1 -C 4 haloalkyl, C 2 - C 4 haloalkenyl, C 2 -C 4 alkylcarbonyl, C 2 -C 4 haloalkylcarbonyl, C 2 -C 4 alkoxycarbonyl, C 2 -C 4 alkylaminocarbonyl, C 3 -C7 dialkylaminocarbonyl,
  • Embodiment 7 A compound of Embodiment 6 wherein R 1 is phenyl or pyridinyl, each optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, cyano, nitro, C 1 -C 4 alkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, C 1 -C 4 haloalkyl, C 2 -C 4 haloalkenyl, C 2 -C 4 alkylcarbonyl, C 2 -C 4 haloalkylcarbonyl, C 2 -C 4 alkoxycarbonyl, C 2 -C 4 alkylaminocarbonyl, C 3 -C7 dialkylaminocarbonyl, C(O)N-f CH 2 Z 2 CH 2 ⁇ -, C 1 -C 4 alkoxy, C 1 -C 4 haloalkoxy, C 2 -C 6 alkoxyalkyl, S(O) n R 12
  • Embodiment 8 A compound of Embodiment 7 wherein R 1 is phenyl or pyridinyl, each optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, cyano, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 2 -C 4 alkylcarbonyl, C 2 -C 4 alkoxycarbonyl, C 2 -C 4 alkylaminocarbonyl, C 3 -C 7 dialkylaminocarbonyl, C(O)N-f CH 2 Z 2 CH 2 ⁇ -, C 1 -C 4 alkoxy, C 1 -C 4 haloalkoxy, C 2 -C 6 alkoxyalkyl, S(O) n R 12 and S(O) 2 R 13 .
  • Embodiment 9 A compound of Formula 1 or any of Embodiments 1-4 wherein
  • Embodiment 10 A compound of Formula 1 or any of Embodiments 1-4 wherein R 1 is
  • Embodiment 11 A compound of Embodiment 10 wherein R 1 is C(X ⁇ R 18 .
  • Embodiment 12 A compound of Formula 1 or any of Embodiments 1-11 wherein X 1 is
  • Embodiment 13 A compound of Formula 1 or any of Embodiments 1-11 wherein X 1 is
  • Embodiment 15 A compound of Formula 1 or any of Embodiments 1-4 wherein R 1 is an 8- to 10-membered heteroaromatic bicyclic ring system optionally substituted on carbon ring members with up to 3 substituents independently selected from the group consisting of halogen, cyano, nitro, SF 5 , C 1 -C 4 alkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, C 1 -C 4 haloalkyl, C 2 -C 4 alkylcarbonyl, C 2 -C 4 haloalkylcarbonyl, C 2 -C 4 alkoxycarbonyl, C 2 -C 4 alkylaminocarbonyl, C 3 -C 7 dialkylaminocarbonyl, C(O)N-f CH 2 Z 2 CH 2 ⁇ -, C 1 -C 4 alkoxy, C 1 -C 4 haloalkoxy, C 2 -C 6 alkoxyalkyl, S
  • Embodiment 16 A compound of Formula 1 or any of Embodiments 1-4 wherein R 1 is phenyl or a 5- or 6-membered heteroaromatic ring, each substituted with GQ 1 and further optionally substituted with 1 or 2 substituents independently selected from the group consisting of halogen, cyano, nitro, SF 5 , C 1 -C 4 alkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, C 1 -C 4 haloalkyl, C 2 -C 4 alkylcarbonyl, C 2 -C 4 haloalkylcarbonyl, C 2 -C 4 alkoxycarbonyl, C 2 -C 4 alkylaminocarbonyl, C 3 -C 7 dialkylaminocarbonyl, C(O)N-f CH 2 Z 2 CH 2 ⁇ -, C 1 -C 4 alkoxy, C 1 -C 4 haloalkoxy, C 2 -C 6 alk
  • Embodiment 17 A compound of Embodiment 16 wherein R 1 is phenyl or pyridinyl, each substituted with GQ 1 and further optionally substituted with 1 or 2 substituents independently selected from the group consisting of halogen, cyano, SF 5 , C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 2 -C 4 alkylcarbonyl, C 2 -C 4 alkoxycarbonyl, C 2 -C 4 alkylaminocarbonyl, C 3 -C7 dialkylaminocarbonyl, C(O)N-f CH 2 Z 2 CH 2 ⁇ -, C 1 -C 4 alkoxy, C 1 -C 4 haloalkoxy, C 2 -C 6 alkoxyalkyl, S(O) n R 12 and S(O) 2 R 13 .
  • R 1 is phenyl or pyridinyl, each substituted with GQ 1 and further optionally substituted with 1 or
  • Embodiment 18 A compound of Formula 1 or any of Embodiments 1-17 wherein Q 1 is phenyl or pyridinyl, each optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, cyano, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 2 -C 4 alkylcarbonyl, C 2 -C 4 alkoxycarbonyl, C 2 -C 4 alkylaminocarbonyl, C 3 -C 7 dialkylaminocarbonyl, C(O)N-f CH 2 Z 2 CH 2 ⁇ , C 1 -
  • Embodiment 19 A compound of Formula 1 or any of Embodiments 1-4 wherein R 1 is selected from Embodiments 5, 6, 9, 10, 15 and 16.
  • Embodiment 20 A compound of Formula 1 or any of Embodiments 1-19 wherein R 2 is C 2 -C 6 alkyl, C 1 -C 6 haloalkyl, CH 2 CO 2 R 21 , CR 5 R 6 CH 2 OR 21 ,
  • Embodiment 21 A compound of Formula 1 or any of Embodiments 1-19 wherein R 2 is C 3 -C 6 cycloalkyl or C 4 -C 7 cycloalkylalkyl, each optionally substituted with 1 to 4 substituents selected from the group consisting of halogen, C 1 -C 2 alkyl, 1 cyclopropyl and 1 CF 3 .
  • Embodiment 22 A compound of Formula 1 or any of Embodiments 1-19 wherein R 2 is CR 5 R 6 Q.
  • Embodiment 22a A compound of Formula 1 or any of Embodiments 1-19 wherein R 2 is selected from Embodiments 20, 21 and 22.
  • Embodiment 23 A compound of Embodiment 20 wherein R 2 is C 2 -C 6 alkyl, C 1 -C 6 haloalkyl or CR 5 R 6 CH 2 OR 21 .
  • Embodiment 24 A compound of Embodiment 21 wherein R 2 is C 4 -C 7 cycloalkylalkyl optionally substituted with 1 to 4 substituents selected from the group consisting of halogen, C 1 -C 2 alkyl, 1 cyclopropyl and 1 CF 3 .
  • Embodiment 24a A compound of Formula 1 or any of Embodiments 1-19 wherein R 2 is selected from Embodiments 23 and 24.
  • Embodiment 25 A compound of Formula 1 or any of Embodiments 1-24 wherein G is a direct bond.
  • Embodiment 26. A compound of Formula 1 or any of Embodiments 1-25 wherein R 3 is
  • Embodiment 27 A compound of Formula 1 or any of Embodiments 1-25 wherein R 3 is C 3 -C 6 cycloalkyl or C 4 -C 7 cycloalkylalkyl, each optionally substituted with 1 to
  • Embodiment 28 A compound of Embodiment 26 wherein R 3 is C 1 -C 6 alkyl or C 1 -C 6 haloalkyl.
  • Embodiment 29 A compound of Embodiment 28 wherein R 3 is CH 3 .
  • Embodiment 29a A compound of Formula 1 or any of Embodiments 1-29 wherein R 4 is C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 2 -C 6 alkenyl, C 2 -C 6 haloalkenyl, C 2 -C 6 alkynyl, C 2 -C 6 haloalkynyl or C ⁇ CR 10 .
  • Embodiment 29b A compound of Formula 1 or any of Embodiments 1-29 wherein R 4 is C 3 -C 6 cycloalkyl or C 4 -C 7 cycloalkylalkyl, each optionally substituted with 1 to 4 substituents independently selected from the group consisting of halogen,
  • Embodiment 29c A compound of Embodiment 29a wherein R 4 is C 1 -C 6 alkyl or C 1 -
  • Embodiment 29d A compound of Embodiment 29c wherein R 4 is CH 3 .
  • Embodiment 30 A compound of Formula 1 or any of Embodiments 1-25 wherein R 3 and R 4 are taken together with the contiguous linking nitrogen and carbon atoms to form an optionally substituted ring R-I
  • R-2 Embodiment 31 A compound of Embodiment 30 wherein R 3 and R 4 are taken together with the contiguous linking nitrogen and carbon atoms to form an optionally substituted ring R-I.
  • Embodiment 32 A compound of Embodiment 30 wherein R 3 and R 4 are taken together with the contiguous linking nitrogen and carbon atoms to form an optionally substituted ring R-2.
  • Embodiment 32a A compound of Formula 1 or any of Embodiments 1-25 wherein R 3 is selected from Embodiments 26 and 27, and R 4 is selected from Embodiments
  • R 3 and R 4 are taken together with the contiguous linking nitrogen and carbon atoms to form an optionally substituted ring as described in
  • Embodiment 30 Embodiment 32b. A compound of Formula 1 or any of Embodiments l-32a wherein m is 2 or 3.
  • Embodiment 32c A compound of Formula 1 or any of Embodiments 1-32b wherein p is O.
  • Embodiment 34 A compound of Embodiment 32d wherein Z is S.
  • Embodiment 35 A compound of Formula 1 or any of Embodiments 1-34 wherein each
  • R 5 is independently H or Q-C 4 alkyl.
  • Embodiment 36 A compound of Embodiment 35 wherein each R 5 is independently H or methyl.
  • Embodiment 37 A compound of Formula 1 or any of Embodiments 1-36 wherein R 6 is
  • Embodiment 38 A compound of Formula 1 or any of Embodiments 1-37 wherein Q is Q-I, Q-5, Q-6 or Q-9.
  • Embodiment 39 A compound of Embodiment 38 wherein Q is Q-I, Q-5 or Q-9.
  • Embodiment 40 A compound of Embodiment 38 wherein Q is Q-I.
  • Embodiment 41 A compound of Embodiment 38 wherein Q is Q-5.
  • Embodiment 42 A compound of Embodiment 38 wherein Q is Q-6.
  • Embodiment 43 A compound of Embodiment 38 wherein Q is Q-9.
  • Embodiment 44 A compound of any of Embodiments 38, 39, 41 or 43 wherein Z 1 is O.
  • Embodiment 45 A compound of any of Embodiments 38, 39, 41 or 43 wherein Z 1 is S.
  • Embodiment 46 A compound of any of Embodiments 38, 39, 41 or 43 wherein Z 1 is
  • Embodiment 47 A compound of Formula 1 or any of Embodiments 1-46 wherein each
  • R 9a is independently H, halogen, cyano, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 1 -C 4 alkoxy, C ⁇ C 4 haloalkoxy, SF 5 or S(O) n R 12 ; or C 3 -C 6 cycloalkyl or C 4 -C 7 cycloalkylalkyl, each optionally substituted with 1 to 4 substituents selected from the group consisting of halogen, C 1 -C 2 alkyl, 1 cyclopropyl and 1 CF 3 .
  • Embodiment 48 Embodiment 48.
  • each R 9a is independently H, halogen, cyano, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 1 -C 4 alkoxy, C 1 -C 4 haloalkoxy, SF 5 or S(O) n R 12 .
  • Embodiment 49 A compound of Embodiment 47 wherein each R 9a is independently
  • Embodiment 50 A compound of Formula 1 or any of Embodiments 1-49 wherein each
  • R 9 b is independently H, halogen, cyano, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 1 -C 4 alkoxy or C 1 -C 4 haloalkoxy.
  • R 9 b is independently H, halogen, cyano, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 1 -C 4 alkoxy or C 1 -C 4 haloalkoxy.
  • R 1 is H, halogen, C 1 -Cg alkyl, C 1 -Cg haloalkyl, C 2 -Cg alkenyl, C 2 -Cg haloalkenyl, C 2 -C 6 alkynyl, C 2 -C 6 haloalkynyl or C ⁇ CR 10 ; or
  • R 1 is C 3 -Cg cycloalkyl or C 4 -C 7 cycloalkylalkyl, each optionally substituted with 1 to 4 substituents independently selected from the group consisting of halogen, C 1 - C 2 alkyl, 1 cyclopropyl and 1 CF 3 ; or
  • R 1 is phenyl, naphthalenyl or a 5- or 6-membered heteroaromatic ring, each optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, cyano, nitro, C 1 -C 4 alkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, C 1 -C 4 haloalkyl, C 2 -C 4 alkylcarbonyl, C 2 -C 4 haloalkylcarbonyl, C 2 -C 4 alkoxycarbonyl, C 2 -C 4 alkylaminocarbonyl, C 3 -C7 dialkylaminocarbonyl, C 1 - C 4 alkoxy, C 1 -C 4 haloalkoxy, C 2 -C 6 alkoxyalkyl, S(O) n R 12 , C 1 -C 4 alkylamino and C 2 -C 6 dialkylamino; or
  • R 2 is C 2 -C 6 alkyl, C 1 -C 6 haloalkyl, C 3 -C 6 alkenyl, C 3 -C 6 haloalkenyl, C 3 -C 6 alkynyl, C 3 -C 6 haloalkynyl or C 2 -C 6 alkoxyalkyl; or
  • R 2 is C 3 -C 6 cycloalkyl or C 4 -C7 cycloalkylalkyl, each optionally substituted with 1 to
  • R 2 is CR 5 R 6 Q
  • R 3 is H, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 2 -C 6 alkenyl, C 2 -C 6 haloalkenyl, C 2 -C 6 alkynyl, C 2 -C 6 haloalkynyl or C ⁇ CR 10
  • R 3 is C 3 -C 6 cycloalkyl or C 4 -C7 cycloalkylalkyl, each optionally substituted with 1 to
  • R 3 is phenyl, naphthalenyl or a 5- or 6-membered heteroaromatic ring, each optionally substituted with 1 or 2 substituents independently selected from the group consisting of halogen, cyano, nitro, C 1 -C 4 alkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl,
  • C 1 -C 4 haloalkyl C 2 -C 4 alkylcarbonyl, C 2 -C 4 haloalkylcarbonyl, C 2 -C 4 alkoxycarbonyl, C 2 -C 4 alkylaminocarbonyl, C 3 -C 7 dialkylaminocarbonyl, C 1 - C 4 alkoxy, C 1 -C 4 haloalkoxy, C 2 -C 6 alkoxyalkyl, S(O) n R 12 , C 1 -C 4 alkylamino and C 2 -C 6 dialkylamino;
  • R 4 is C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 2 -C 6 alkenyl, C 2 -C 6 haloalkenyl, C 2 -C 6 alkynyl, C 2 -C 6 haloalkynyl or C ⁇ CR 10 ; or
  • R 4 is C 3 -C 6 cycloalkyl or C 4 -C 7 cycloalkylalkyl, each optionally substituted with 1 to 4 substituents independently selected from the group consisting of halogen, C 1 -
  • R 4 is phenyl, naphthalenyl or a 5- or 6-membered heteroaromatic ring, each optionally substituted with 1 or 2 substituents independently selected from the group consisting of halogen, cyano, nitro, C 1 -C 4 alkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, C 1 -C 4 haloalkyl, C 2 -C 4 alkylcarbonyl, C 2 -C 4 haloalkylcarbonyl, C 2 -C 4 alkoxycarbonyl, C 2 -C 4 alkylaminocarbonyl, C 3 -C 7 dialkylaminocarbonyl, C 1 - C 4 alkoxy, C 1 -C 4 haloalkoxy, C 2 -C 6 alkoxyalkyl, S(O) n R 12 , C 1 -C 4 alkyl, C 1 -C 4 alkyl, C 2 -C 4 alken
  • R 3 and R 4 are taken together with the contiguous linking nitrogen and carbon atoms to form an optionally substituted ring R-I
  • R 5 is H, F, Cl, cyano or C 1 -C 4 alkyl;
  • R 6 is H, F, Cl or CH 3 ;
  • Z 1 is O, S or NR 14 ;
  • each R 10 is independently Si(R 1 ⁇ 3 ; or phenyl optionally substituted with halogen, cyano, nitro, C 1 -C 4 alkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, C 1 -C 4 haloalkyl, C 2 -
  • R 2 is other than C 3 -C 4 alkoxyalkyl; and (h) when R 1 is Br, R 3 and R 4 are taken together to form ring R-2, Z is S, X is O and Y is O, then R 2 is other than CH 2 CH 3 .
  • Embodiment 52 A compound of Embodiment 51 wherein X is O.
  • Embodiment 53 A compound of Embodiment 51 wherein Y is O.
  • Embodiment 54 A compound of Embodiment 51 wherein R 1 is phenyl, naphthalenyl or a 5- or 6-membered heteroaromatic ring, each optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, cyano, nitro, C 1 -C 4 alkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, C 1 -C 4 haloalkyl, C 2 -C 4 alkylcarbonyl, C 2 -C 4 haloalkylcarbonyl, C 2 -C 4 alkoxycarbonyl, C 2 -C 4 alkylaminocarbonyl, C 3 -C 7 dialkylaminocarbonyl, C 1 -C 4 alkoxy, C 1 -C 4 haloalkoxy, C 2 -C 6 alkoxyalkyl, S(O) n R 12 , C 1 -C 4 alkylamino and C
  • Embodiment 55 A compound of Embodiment 54 wherein R 1 is phenyl optionally substituted with 1 or 2 substituents independently selected from the group consisting of halogen, cyano, C 1 -C 2 haloalkyl, C 1 -C 2 alkoxy and C 1 -C 2 haloalkoxy.
  • Embodiment 56 A compound of Embodiment 54 wherein R 1 is 2-, 3- or 4-pyridinyl optionally substituted with halogen, cyano, C 1 -C 2 haloalkyl, C 1 -C 2 alkoxy or C 1 -C 2 haloalkoxy.
  • Embodiment 57 A compound of Formula Ir wherein R 1 is
  • Embodiment 58 A compound of Embodiment 51 wherein R 2 is C 2 -C 6 alkyl, C 1 -C 6 haloalkyl, C 3 -C 6 alkenyl or C 3 -C 6 haloalkenyl.
  • Embodiment 59 A compound of Embodiment 51 wherein R 2 is CH 2 CF 3 or CR 5 R 6 Q.
  • Embodiment 60 A compound of Embodiment 59 wherein R 2 is CR 5 R 6 Q.
  • Embodiment 61 A compound of Embodiment 59 wherein R 2 is CH 2 CF 3 .
  • Embodiment 62 A compound of Embodiment 51 or Embodiment 60 wherein R 5 is H or
  • Embodiment 63 A compound of Embodiment 51 or Embodiment 60 wherein R 6 is H.
  • Embodiment 65 A compound of Embodiment 64 wherein Q is Q-Ia or Q-5a.
  • Embodiment 66. A compound of Embodiment 51 wherein R 9 is F or Cl.
  • Embodiment 67. A compound of Embodiment 51 wherein R 3 and R 4 are taken together with the contiguous linking nitrogen and carbon atoms to form ring R-2
  • Embodiment 68 A compound of Embodiment 51 or Embodiment 67 wherein Z is
  • Embodiment 69 A compound of Embodiment 51 or Embodiment 67 wherein Z is S.
  • Embodiment 70 A compound of Formula Is
  • Y is O or S;
  • R 1 is H, halogen, C ⁇ -C 6 alkyl, C ⁇ -C 6 haloalkyl, C 2 -C 6 alkenyl, C 2 -C 6 haloalkenyl,
  • R 1 is C 3 ⁇ C 6 cycloalkyl or C 4 -C7 cycloalkylalkyl, each optionally substituted with 1 to 4 substituents independently selected from the group consisting of halogen, C ⁇ -
  • R 1 is phenyl, naphthalenyl or a 5- or 6-membered heteroaromatic ring, each optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, cyano, nitro, Q-C 4 alkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, C 1 -C 4 haloalkyl, C 2 -C 4 alkylcarbonyl, C 2 -C 4 haloalkylcarbonyl, C 2 -C 4 alkoxycarbonyl, C 2 -C 4 alkylaminocarbonyl, C 3 -C7 dialkylaminocarbonyl, C ⁇ - C 4 alkoxy, C 1 -C 4 haloalkoxy, C 2 -C 6 alkoxyalkyl, S(O) n R 12 , C 1 -C 4 alkylamino and C 2 -C 6 dialkylamino; or RMs
  • R 2 is C 3 -C 6 cycloalkyl or C 4 -C 7 cycloalkylalkyl, each optionally substituted with 1 to 4 substituents selected from the group consisting of halogen, C 1 -C 2 alkyl, 1 cyclopropyl and 1 CF 3 ; or R 2 is CR 5 R 6 Q; R 3 is H, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 2 -C 6 alkenyl, C 2 -C 6 haloalkenyl, C 2 -C 6 alkynyl, C 2 -C 6 haloalkynyl or C ⁇ CR 10 ; or R 3 is C 3 -C 6 cycloalkyl or C 4 -C 7 cycloalkylalkyl, each optionally substituted with 1 to
  • R 3 is phenyl, naphthalenyl or a 5- or 6-membered heteroaromatic ring, each optionally substituted with 1 or 2 substituents independently selected from the group consisting of halogen, cyano, nitro, C 1 -C 4 alkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl,
  • C 1 -C 4 haloalkyl C 2 -C 4 alkylcarbonyl, C 2 -C 4 haloalkylcarbonyl, C 2 -C 4 alkoxycarbonyl, C 2 -C 4 alkylaminocarbonyl, C 3 -C 7 dialkylaminocarbonyl, C 1 - C 4 alkoxy, C 1 -C 4 haloalkoxy, C 2 -C 6 alkoxyalkyl, S(O) n R 12 , C 1 -C 4 alkylamino and C 2 -C 6 dialkylamino;
  • R 4 is C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 2 -C 6 alkenyl, C 2 -C 6 haloalkenyl, C 2 -C 6 alkynyl, C 2 -C 6 haloalkynyl or C ⁇ CR 10 ; or
  • R 4 is C 3 -C 6 cycloalkyl or C 4 -C 7 cycloalkylalkyl, each optionally substituted with 1 to 4 substituents independently selected from the group consisting of halogen, C 1 - C 2 alkyl, 1 cyclopropyl and 1 CF 3 ; or R 4 is phenyl, naphthalenyl or a 5- or 6-membered heteroaromatic ring, each optionally substituted with 1 or 2 substituents independently selected from the group consisting of halogen, cyano, nitro, C 1 -C 4 alkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, C 1 -C 4 haloalkyl, C 2 -C 4 alkylcarbonyl, C 2 -C 4 haloalkylcarbonyl, C 2 -C 4 alkoxycarbonyl, C 2 -C 4 alkylaminocarbonyl, C 3 -C 7 dialky
  • R 5 is H, F, Cl, cyano or C 1 -C 4 alkyl
  • R 6 is H, F, Cl and CH 3 ;
  • Z 1 is O, S or NR 14 ;
  • Embodiment 71 A compound of Embodiment 70 wherein X is O.
  • Embodiment 72 A compound of Embodiment 70 wherein Y is O.
  • Embodiment 73 A compound of Embodiment 70 wherein R 1 is phenyl, naphthalenyl or a 5- or 6-membered heteroaromatic ring, each optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, cyano, nitro, C 1 -C 4 alkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, C 1 -C 4 haloalkyl, C 2 -C 4 alkylcarbonyl, C 2 -C 4 haloalkylcarbonyl, C 2 -C 4 alkoxycarbonyl, C 2 -C 4 alkylaminocarbonyl, C 3 -C 7 dialkylaminocarbonyl, C 1 -C 4 alkoxy, C 1 -C 4 haloalkoxy, C 2 -C 6 alkoxyalkyl,
  • Embodiment 74 A compound of Embodiment 73 wherein R 1 is phenyl optionally substituted with 1 or 2 substituents independently selected from the group consisting of halogen, cyano, C 1 -C 2 haloalkyl, C 1 -C 2 alkoxy and C 1 -C 2 haloalkoxy.
  • Embodiment 75 A compound of Embodiment 73 wherein R 1 is 2-, 3- or 4-pyridinyl optionally substituted with halogen, cyano, C 1 -C 2 haloalkyl, C 1 -C 2 alkoxy and C 1 -C 2 haloalkoxy.
  • Embodiment 76 A compound of Embodiment 70 wherein R 1 is
  • Embodiment 77 A compound of Formula Is wherein R 2 is C 2 -C 6 alkyl, C 1 -C 6 haloalkyl, C 3 -C 6 alkenyl or C 3 -C 6 haloalkenyl.
  • Embodiment 78 A compound of Embodiment 70 wherein R 2 is CH 2 CF 3 or CR 5 R 6 Q.
  • Embodiment 79 A compound of Embodiment 78 wherein R 2 is CR 5 R 6 Q.
  • Embodiment 80 A compound of Embodiment 78 wherein R 2 is CH 2 CF 3 .
  • Embodiment 81. A compound of Embodiment 70 or Embodiment 79 wherein R 5 is H or
  • Embodiment 82 A compound of Embodiment 70 or Embodiment 79 wherein R 6 is H.
  • Q is Q-Ia, Q-2a, Q-3a, Q-4a or Q-5a.
  • Embodiment 84 A compound of Embodiment 83 wherein Q is Q-Ia or Q-5a.
  • Embodiment 85. A compound of Embodiment 70 wherein R 9 is F or Cl.
  • Embodiment 86. A compound of Embodiment 70 wherein R 3 and R 4 are taken together with the contiguous linking nitrogen and carbon atoms to form an optionally substituted aromatic ring R-2
  • Embodiments of this invention can be combined in any manner, and the descriptions of variables in the embodiments pertain not only to the compounds of Formulae 1, Ir and Is but also to the starting compounds and intermediate compounds useful for preparing the compounds of Formulae 1, Ir and Is.
  • embodiments of this invention including
  • Embodiments 1-87 above as well as any other embodiments described herein, and any combination thereof, pertain to the compositions and methods of the present invention.
  • Embodiment A A compound of Formula 1 wherein X is O; Y is O; R 1 is H or halogen; or
  • R 1 is phenyl or a 6-membered heteroaromatic ring, each optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, cyano, nitro, C 1 -C 4 alkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, C 1 -C 4 haloalkyl, C 2 - C 4 haloalkenyl, C 2 -C 4 alkylcarbonyl, C 2 -C 4 haloalkylcarbonyl, C 2 -C 4 alkoxycarbonyl, C 2 -C 4 alkylaminocarbonyl, C 3 -C7 dialkylaminocarbonyl,
  • R 1 is an 8- to 10-membered heteroaromatic bicyclic ring system optionally substituted on carbon ring members with up to 3 substituents independently selected from the group consisting of halogen, cyano, nitro, SF 5 , C 1 -C 4 alkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, C 1 -C 4 haloalkyl, C 2 -C 4 alkylcarbonyl, C 2 -C 4 haloalkylcarbonyl, C 2 -C 4 alkoxycarbonyl, C 2 -C 4 alkylaminocarbonyl, C 3 -C7 dialkylaminocarbonyl, C(O)N-f CH 2 Z 2 CH 2 ⁇ -, C 1 -C 4 alkoxy, C 1 -C 4 haloalkoxy, C 2 -C 6 alkoxyalkyl, S(O) n R 12 , S(O) 2 R 13 , C 1
  • Q 1 is phenyl or a 5- or 6-membered heteroaromatic ring, each optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, cyano, nitro, C 1 -C 4 alkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, C 1 -C 4 haloalkyl, C 2 -C 4 alkylcarbonyl, C 2 -C 4 haloalkylcarbonyl, C 2 -C 4 alkoxycarbonyl, C 2 -C 4 alkylaminocarbonyl, C 3 -C 7 dialkylaminocarbonyl,
  • R 2 is C 2 -C 6 alkyl, C 1 -C 6 haloalkyl, CH 2 CO 2 R 21 , CR 5 R 6 CH 2 OR 21 , CR 5 R 6 CH 2 CH 2 OR 21 , CR 5 R 6 CH 2 S(O) n R 21 or CR 5 R 6 CH 2 CH 2 S(O) n R 21 ; or
  • R 2 is C 3 -C 6 cycloalkyl or C 4 -C 7 cycloalkylalkyl, each optionally substituted with 1 to 4 substituents selected from the group consisting of halogen, C 1 -C 2 alkyl, 1 cyclopropyl and 1 CF 3 ; or R 2 is CR 5 R 6 Q; R 3 is H, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 2 -C 6 alkenyl, C 2 -C 6 haloalkenyl, C 2 -C 6 alkynyl, C 2 -C 6 haloalkynyl or C ⁇ CR 10 ; or
  • R 3 is C 3 -C 6 cycloalkyl or C 4 -C 7 cycloalkylalkyl, each optionally substituted with 1 to 4 substituents independently selected from the group consisting of halogen, C 1 - C 2 alkyl, 1 cyclopropyl and 1 CF 3 ;
  • R 4 is C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 2 -C 6 alkenyl, C 2 -C 6 haloalkenyl, C 2 -C 6 alkynyl, C 2 -C 6 haloalkynyl or C ⁇ CR 10 ; or
  • R 4 is C 3 -C 6 cycloalkyl or C 4 -C 7 cycloalkylalkyl, each optionally substituted with 1 to 4 substituents independently selected from the group consisting of halogen, C 1 - C 2 alkyl, 1 cyclopropyl and 1 CF 3 ; or R 3 and R 4 are taken together with the contiguous linking nitrogen and carbon atoms to form an optionally substituted ring R-I
  • Embodiment B A compound of Embodiment A wherein
  • Embodiment C A compound of Embodiment B wherein
  • R 3 is C 1 -C 6 alkyl or C 1 -C 6 haloalkyl; and R 4 is C 1 -C 6 alkyl or C 1 -C 6 haloalkyl.
  • Embodiment D A compound of Embodiment C wherein R 3 is CH 3 ; and R 4 is CH 3 .
  • Embodiment E A compound of Embodiment B wherein R 3 and R 4 are taken together with the contiguous linking nitrogen and carbon atoms to form an optionally substituted ring R-I; m is 2 or 3; and p is 0.
  • Embodiment F A compound of Embodiment B wherein R 3 and R 4 are taken together with the contiguous linking nitrogen and carbon atoms to form an optionally substituted ring R-2; and
  • Embodiment G A compound of Embodiment B wherein R 3 and R 4 are taken together with the contiguous linking nitrogen and carbon atoms to form an optionally substituted ring R-2; and Z is S.
  • Embodiment H A compound of any one of Embodiments C-G wherein
  • R 1 is H or halogen.
  • Embodiment I A compound of any one of Embodiments C-G wherein R 1 is phenyl or pyridinyl, each optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, cyano, nitro, C 1 - C 4 alkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, C 1 -C 4 haloalkyl, C 2 -C 4 haloalkenyl,
  • Embodiment J A compound of Embodiment I wherein R 1 is phenyl or pyridinyl, each optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, cyano, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 2 -C 4 alkylcarbonyl, C 2 -C 4 alkoxycarbonyl, C 2 -C 4 alkylaminocarbonyl, C 3 -C 7 dialkylaminocarbonyl, C(O)N-f CH 2 Z 2 CH 2 ⁇ , C 1 -
  • Embodiment L A compound of any one of Embodiments C-G wherein
  • R 1 is phenyl or pyridinyl, each substituted with GQ 1 and further optionally substituted with 1 or 2 substituents independently selected from the group consisting of halogen, cyano, nitro, SF 5 , C 1 -C 4 alkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, C 1 -C 4 haloalkyl, C 2 -C 4 alkylcarbonyl, C 2 -C 4 haloalkylcarbonyl, C 2 -C 4 alkoxycarbonyl, C 2 -C 4 alkylaminocarbonyl, C 3 -C 7 dialkylaminocarbonyl,
  • Embodiment M A compound of Embodiment L wherein
  • R 1 is phenyl or pyridinyl, each substituted with GQ 1 and further optionally substituted with 1 or 2 substituents independently selected from the group consisting of halogen, cyano, SF 5 , C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 2 -C 4 alkylcarbonyl, C 2 - C 4 alkoxycarbonyl, C 2 -C 4 alkylaminocarbonyl, C 3 -C7 dialkylaminocarbonyl,
  • Q 1 is phenyl or pyridinyl, each optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, cyano, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 2 -C 4 alkylcarbonyl, C 2 -C 4 alkoxycarbonyl, C 2 -C 4 alkylaminocarbonyl, C 3 -C 7 dialkylaminocarbonyl, C(O)N-f CH 2 Z 2 CH 2 ⁇ , C 1 - C 4 alkoxy, C 1 -C 4 haloalkoxy, C 2 -C 6 alkoxyalkyl, S(O) n R 12 and
  • R 2 is C 2 -C 6 alkyl, C 1 -C 6 haloalkyl or CR 5 R 6 CH 2 OR 21 ; or R 2 is C 4 -C 7 cycloalkylalkyl optionally substituted with 1 to 4 substituents selected from the group consisting of halogen, C 1 -C 2 alkyl, 1 cyclopropyl and 1 CF 3 .
  • Embodiment O A compound of any one of Embodiments C-G wherein
  • R 2 is CR 5 R 6 Q.
  • Embodiment P A compound of Embodiment O wherein Q is Q-I, Q-5, Q-6 or Q-9;
  • R 5 is H or methyl;
  • R 6 is H;
  • each R 9a is independently H, halogen, cyano, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 1 -C 4 alkoxy, C 1 -C 4 haloalkoxy, SF 5 or S(O) n R 12 ; or C 3 -C 6 cycloalkyl or C 4 -C 7 cycloalkylalkyl, each optionally substituted with 1 to 4 substituents selected from the group consisting of halogen, C 1 -C 2 alkyl, 1 cyclopropyl and 1 CF 3 ; and each R 9b is independently H, halogen, cyano, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 1 -C 4 alkoxy or C 1 -C 4 haloalkoxy.
  • Embodiment Al Combinations of Embodiments 51-69 are illustrated by: Embodiment Al .
  • a compound of Formula Ir A compound of Formula Ir
  • R 3 and R 4 are taken together with the contiguous linking nitrogen and carbon atoms to form ring R-2
  • Embodiment B 1. A compound of Embodiment Al wherein
  • R 1 is phenyl, naphthalenyl or a 5- or 6-membered heteroaromatic ring, each optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, cyano, nitro, C 1 -C 4 alkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl,
  • C 1 -C 4 haloalkyl C 2 -C 4 alkylcarbonyl, C 2 -C 4 haloalkylcarbonyl, C 2 -C 4 alkoxycarbonyl, C 2 -C 4 alkylaminocarbonyl, C 3 -C 7 dialkylaminocarbonyl, C 1 - C 4 alkoxy, C 1 -C 4 haloalkoxy, C 2 -C 6 alkoxyalkyl, S(O) n R 12 , C 1 -C 4 alkylamino and C 2 -C 6 dialkylamino; or R 1 is
  • Embodiment C A compound of Embodiment B 1 wherein
  • R 2 is C 2 -C 6 alkyl, C 1 -C 6 haloalkyl, C 3 -C 6 alkenyl or C 3 -C 6 haloalkenyl; or
  • R 2 is CR 5 R 6 Q; and Q is Q-Ia, Q-2a, Q-3a, Q-4a or Q-5a.
  • Embodiment D A compound of Embodiment C 1 wherein
  • R 1 is phenyl optionally substituted with 1 or 2 substituents independently selected from the group consisting of halogen, cyano, C 1 -C 2 haloalkyl, C 1 -C 2 alkoxy and C 1 - C 2 haloalkoxy;
  • R 2 is CH 2 CF 3 or CR 5 R 6 Q;
  • R 5 is H or CH 3 ;
  • Q is Q-Ia or Q-5a
  • Embodiment E A compound of Embodiment C 1 wherein Z is S;
  • R 1 is phenyl optionally substituted with 1 or 2 substituents independently selected from the group consisting of halogen, cyano, C ⁇ -C 2 haloalkyl, C ⁇ -C 2 alkoxy and C ⁇ - C 2 haloalkoxy;
  • R 2 is CH 2 CF 3 or CR 5 R 6 Q;
  • R 5 is H or CH 3 ;
  • Q is Q-Ia or Q-5a;
  • R 6 is H;
  • R 9 is F or Cl; and
  • r is 1.
  • Embodiment A2 A compound of Formula Is
  • R 3 and R 4 are taken together with the contiguous linking nitrogen and carbon atoms to form an optionally substituted aromatic ring R-2
  • Embodiment B2 A compound of Embodiment A2 wherein
  • R 1 is phenyl, naphthalenyl or a 5- or 6-membered heteroaromatic ring, each optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, cyano, nitro, C 1 -C 4 alkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl,
  • C 1 -C 4 haloalkyl C 2 -C 4 alkylcarbonyl, C 2 -C 4 haloalkylcarbonyl, C 2 -C 4 alkoxycarbonyl, C 2 -C 4 alkylaminocarbonyl, C 3 -C 7 dialkylaminocarbonyl, C ⁇ - C 4 alkoxy, C 1 -C 4 haloalkoxy, C 2 -C 6 alkoxyalkyl, S(O) n R 12 , C 1 -C 4 alkylamino and C 2 -C 6 dialkylamino; or RMs
  • Embodiment C2 A compound of Embodiment B2 wherein
  • R 2 is C 2 -C 6 alkyl, C 1 -C 6 haloalkyl, C 3 -C 6 alkenyl or C 3 -C 6 haloalkenyl; or
  • R 2 is CR 5 R 6 Q
  • Q is Q-Ia, Q-2a, Q-3a, Q-4a or Q-5a.
  • R 1 is phenyl optionally substituted with 1 or 2 substituents independently selected from the group consisting of halogen, cyano, C 1 -C 2 haloalkyl, C 1 -C 2 alkoxy and C 1 - C 2 haloalkoxy;
  • R 2 is CH 2 CF 3 or CR 5 R 6 Q;
  • R 5 is H or CH 3 ;
  • Q is Q-Ia or Q-5a; R 6 is H;
  • R 9 is F or Cl; and r is 1.
  • Specific embodiments include compounds of Formula 1 selected from the group consisting of:
  • compounds of this invention are characterized by favorable metabolic and/or soil residual patterns and exhibit activity controlling a spectrum of agronomic and nonagronomic invertebrate pests.
  • protection of agronomic crops from damage or injury caused by invertebrate pests by controlling invertebrate pests are embodiments of the invention.
  • Compounds of this invention because of their favorable translocation properties or systemicity in plants also protect foliar or other plant parts which are not directly contacted with a compound of Formula 1 or a composition comprising the compound.
  • compositions comprising a compound of any of the preceding Embodiments, as well as any other embodiments described herein, and any combinations thereof, and at least one additional component selected from the group consisting of a surfactant, a solid diluent and a liquid diluent, said compositions optionally further comprising at least one additional biologically active compound or agent.
  • compositions for controlling an invertebrate pest comprising a biologically effective amount of a compound of any of the preceding Embodiments, as well as any other embodiments described herein, and any combinations thereof, and at least one additional component selected from the group consisting of a surfactant, a solid diluent and a liquid diluent, said compositions optionally further comprising a biologically effective amount of at least one additional biologically active compound or agent.
  • Embodiments of the invention also include a composition for protecting an animal comprising a compound (i.e. in a parasiticidally effective amount) of any of the preceding Embodiments and a carrier.
  • Embodiments of the invention further include methods for controlling an invertebrate pest comprising contacting the invertebrate pest or its environment with a biologically effective amount of a compound of any of the preceding Embodiments (e.g., as a composition described herein).
  • a method for protecting an animal comprising administering to the animal a parasiticidally effective amount of a compound of any of the preceding Embodiments (e.g., as a composition described herein).
  • Embodiments of the invention also include a composition comprising a compound of any of the preceding Embodiments, in the form of a soil drench liquid formulation.
  • Embodiments of the invention further include methods for controlling an invertebrate pest comprising contacting the soil with a liquid composition as a soil drench comprising a biologically effective amount of a compound of any of the preceding Embodiments.
  • Embodiments of the invention also include a spray composition for controlling an invertebrate pest comprising a biologically effective amount of a compound of any of the preceding Embodiments and a propellant.
  • Embodiments of the invention further include a bait composition for controlling an invertebrate pest comprising a biologically effective amount of a compound of any of the preceding Embodiments, one or more food materials, optionally an attractant, and optionally a humectant.
  • Embodiments of the invention also include a device for controlling an invertebrate pest comprising said bait composition and a housing adapted to receive said bait composition, wherein the housing has at least one opening sized to permit the invertebrate pest to pass through the opening so the invertebrate pest can gain access to said bait composition from a location outside the housing, and wherein the housing is further adapted to be placed in or near a locus of potential or known activity for the invertebrate pest.
  • Embodiments of the invention also include a method for protecting a seed from an invertebrate pest comprising contacting the seed with a biologically effective amount of a compound of any of the preceding Embodiments (e.g., as a composition described herein).
  • Embodiments of the invention also include methods for protecting an animal from an invertebrate parasitic pest comprising administering to the animal a parasiticidally effective amount of a compound of any of the preceding Embodiments.
  • Embodiments of the invention also include methods for controlling an invertebrate pest comprising contacting the invertebrate pest or its environment with a biologically effective amount of a compound of Formula 1, an JV-oxide or a salt thereof, (e.g., as a composition described herein), provided that the methods are not methods of medical treatment of a human or animal body by therapy.
  • This invention also relates to such methods wherein the invertebrate pest or its environment is contacted with a composition comprising a biologically effective amount of a compound of Formula 1, an JV-oxide or a salt thereof, and at least one additional component selected from the group consisting of surfactants, solid diluents and liquid diluents, said composition optionally further comprising a biologically effective amount of at least one additional biologically active compound or agent, provided that the methods are not methods of medical treatment of a human or animal body by therapy.
  • Compounds of Formula Ia can be prepared by condensation of appropriately substituted compounds of Formula 2 with optionally substituted malonic acids (3a) in the presence of condensing agents as shown in Scheme 1.
  • Condensing agents can be carbodiimides such as dicyclohexyl carbodiimide (see, for example, Koch, A. et al. Tetrahedron 2004, 60, 10011-10018) or other agents well known in the art to form amide bonds with or without activating agents such as JV-hydroxybenzotriazole as described in Science of Synthesis 2005, 21, 17-25 and Tetrahedron 2005, 61, 10827-10852.
  • This reaction is typically carried out in an inert organic solvent, such as dichloromethane or 1 ,2-dichloroethane, at temperatures from about 0 to about 80 0 C for a period of 10 min to several days.
  • Compounds of Formula Ia can also be prepared by the condensation of compounds of Formula 2 with malonic acid esters (3b) wherein R is a C 1 -C 5 alkyl group, preferably a C ⁇ - C 4 alkyl group, as shown in Scheme 2.
  • R is a C 1 -C 5 alkyl group, preferably a C ⁇ - C 4 alkyl group, as shown in Scheme 2.
  • Inert solvents include, but are not limited to, high boiling hydrocarbons such as mesitylene, tetralin or cymene, or high boiling ethers such as diphenyl ether.
  • Typical temperatures range from 50 to 250 0 C. Of note are temperatures from 150 to 200 0 C, which typically provide rapid reaction times and high yields.
  • These reactions can also be performed in microwave reactors within the same temperature ranges. Typical reaction times range from 5 min to several hours.
  • Compounds of the Formula 3a can be prepared by a variety of methods known in the art, for example by base hydrolysis of compounds of Formula 3b.
  • Compounds of Formula 3b can be prepared by arylation of malonate esters catalyzed by palladium (J. Org. Chem 2002, 67, 541-555) or copper (Org. Lett. 2002, 4, 269-272 and Org. Lett. 2005, 7, 4693- 4695).
  • Compounds of Formula Ia can also be prepared by condensation of compounds of Formula 2 with compounds of Formulas 3d or 3e, or by condensation of compounds of Formula 2 with mixtures of compounds of Formulae 3d and 3e as shown in Scheme 4. These reactions are typically performed in an inert solvent, such as dichloromethane, and optionally in the presence of two or more equivalents of an acid acceptor (see, for example, Zeitschrift fiir Naturforschung, Mol B: Anorganische Chemie, Organische Chemie 1982, 37B(2), 222-33).
  • Typical acid acceptors include, but are not limited to, triethylamine, JV,JV-diisopropylethylamine, pyridine and substituted pyridines.
  • Compounds of Formula 2 can be prepared in a variety of ways known in the art; see, for example, Patai, S. The Chemistry of Functional Groups: The Chemistry of Amidines and Imidates; Wiley: Chichester, UK, 1975; The Chemistry of Amidines and Imidates; Patai, S.; Rappoport, Z., Eds.; Wiley: Chichester, UK, 1991; Vol. 2; Mega, T. et al. Bulletin of the Chemical Society of Japan 1988, 61(12), 4315-21; Ife, R. et al. European Journal of Medicinal Chemistry 1989, 24(3), 249-57; Wagaw, S.; Buchwald, S. Journal of Organic Chemistry 1996, 61(21), 7240-7241; Shen, Q. et al. Angewandte Chemie, International Edition 2005, 44(9), 1371-1375; and Okano, K. et al. Organic Letters 2003, 5(26), 4987- 4990.
  • R 1 is Cl, Br or I, preferably wherein R 1 is Br or I
  • Scheme 6
  • Compounds of Formula Ig (i.e. Formula Ia wherein R 1 is phenyl or pyridyl substituted with GQ 1 and G is a direct bond) can be prepared from compounds of Formula Ih (i.e. Formula Ia wherein R 1 is phenyl substituted with Br or I) and compounds of Formula 4b wherein M with Q 1 forms a boronic acid, boronic acid ester or trifluoroborate salt, or M is trialkylstannyl or zinc, and Q 1 is a phenyl or 5- or 6-membered heteroaromatic ring) as shown in Scheme 8.
  • the reactions of Schemes 6, 7 and 8 are typically carried out in the presence of a palladium catalyst and a base optionally under an inert atmosphere.
  • the palladium catalysts used for the reactions of Schemes 6, 7 and 8 typically comprises palladium in a formal oxidation state of either 0 (i.e. Pd(O)) or 2 (i.e. Pd(II)).
  • Pd(O) i.e. Pd(O)
  • Pd(II) i.e. Pd(II)
  • Examples of palladium-containing compounds and complexes useful as catalysts in the methods of Schemes 7, 8 and 9 include PdCl 2 (PPh 3 ) 2 (bis(triphenylphosphine)palladium (II) dichloride), Pd(PPh 3 ) 4 (tetrakis(triphenylphosphine)palladium(O)), Pd(C 5 H 7 O 2 ) 2 (palladium(II) acetyl- acetonate), Pd 2 (dba) 3 (tris(dibenzylideneacetone)dipalladium(O)), and [l,l'-bis(diphenyl- phosphino)ferrocene]dichloropalladium(II).
  • PdCl 2 (PPh 3 ) 2 bis(triphenylphosphine)palladium (II) dichloride
  • Pd(PPh 3 ) 4 tetrakis(triphenylphosphine
  • the methods of Schemes 6, 7 and 8 are generally conducted in a liquid phase, and therefore to be most effective the palladium catalyst preferably has good solubility in the liquid phase.
  • Useful solvents include, for example, water, ethers such as 1 ,2-dimethoxyethane, amides such as N ⁇ /V-dimethyl- acetamide, and non-halogenated aromatic hydrocarbons such as toluene.
  • Compounds of Formula Ia wherein R 1 is optionally substituted phenyl, naphthalenyl, a 5- or 6-membered heteroaromatic ring or an 8- to 10-membered heteroaromatic bicyclic ring system can be prepared from compounds of Formula Ib (i.e. Formula Ia wherein R 1 is H) and compounds of Formula 5 wherein X 1 is Cl, Br or I (preferably wherein X 1 is Br or I) as shown in Scheme 9.
  • the copper catalysts used for the present method typically comprise copper in metallic form (e.g., as a powder) or copper in a formal oxidation state of 1 (i.e. Cu(I)).
  • copper-containing compounds useful as catalysts in the method of Scheme 9 include, but are not limited to, Cu, CuI, CuBr, CuCl.
  • Useful solvents for the method of Scheme 9 include, for example, ethers such as 1,4-dioxane, amides such as JV,iV-dimethylacetamide and dimethyl sulfoxide.
  • the method of Scheme 9 can be conducted over a wide range of temperatures from 25 to 200 0 C. Of note are temperatures from 40 to 150 0 C.
  • the method of Scheme 9 can be conducted in the presence of a ligand.
  • a wide variety of such copper-binding compounds are useful as ligands for the present method. Examples of useful ligands include, but are not limited to, 1,10-phenanthroline, N, ⁇ /-dimethylethylenediamine, L-proline and 2-picolinic acid.
  • the general methods and procedures for copper-catalyzed Ullmann-type coupling reactions are well known in the literature; see, for example, Xie, Ma, et al. Org. Lett. 2005, 7, 4693-4695.
  • Compounds of Formula Ii can be prepared from compounds of Formula Ib by carbonylation with compounds of Formula 6 as shown in Scheme 10.
  • carbonylation agents of Formula 6 useful in the method of Scheme 10 include, but are not limited to, aliphatic or aromatic carboxylic acids, acid anhydrides, acid halides, isocyanates and isothiocyanates.
  • the reaction is performed in an inert solvent, more typically a polar solvent such as JV,iV-dimethylacetamide or l-methyl-2-pyrrolidinone.
  • the reaction is typically performed at temperatures from 0 to 180 0 C, more typically at ambient temperature to 150 0 C. Microwave irradiation can be advantageous in heating the reaction mixture.
  • R a is R 18 or NHR 18a
  • Compounds of the Formula Ij can be prepared by reacting compounds of Formula Ii with an alkoxyamine salt of the Formula 7, where X 3 is a counterion such as halide or oxalate, as shown in Scheme 11.
  • the reaction can be run in an alcoholic solvent such as ethanol or propanol at temperatures ranging from 80 0 C to the reflux temperature of the solvent in 3 to 24 hours.
  • Compounds of Formula Ia wherein R 1 is C 2 -C 6 alkynyl, C 2 -C 6 haloalkynyl or C ⁇ CR 10 can be prepared from compounds of Formula Id (i.e. Formula Ia wherein R 1 is Cl, Br or I) and substituted alkynes of Formula 8 by a Sonigashira coupling reaction as shown in Scheme 12. Sonigashira couplings are well known in the literature. See, for example, K. Sonogashira, Sonogashira Alkyne Synthesis VoI 2, p. 493 in E. Negishi, Handbook of Organopalladium Chemistry for Organic Synthesis, Wiley-Interscience, 2002, New York, New York.
  • Compounds of Formula Id can be prepared from compounds of Formula Ib by halogenation using, for example, liquid bromine or JV-halosuccinimides (9) as shown in Scheme 13.
  • the reaction is performed in an inert solvent, more typically a halogenated solvent such as methylene chloride or 1,2-dichloroethane.
  • the reaction is typically performed at temperatures from 0 to 80 0 C, more typically at ambient temperature.
  • the platinum group metal is platinum or palladium or their oxides and the reduction is performed in an inert solvent (see, for example, Kappe, Thomas, et al. Heterocycles 1995, 40, 681-9).
  • Suitable solvents include, but are not limited to, methanol, ethanol, tetrahydrofuran and methyl t-butyl ether.
  • the reaction is typically performed at ambient temperature and at approximately 100 kPa of pressure.
  • Compounds of Formula Ia can also be prepared by alkylation of compounds of Formula 10 using appropriately substituted alkylating agents and bases such as potassium carbonate as shown in Scheme 15 (see, for example, Kappe, T. et al. Monatschefte fur Chemie 1971, 102, 412-424 and Urban, M. G.; Arnold,W. Helvetica Chimica Acta 1970, 53, 905-922).
  • Alkylating agents include, but are not limited to, alkyl chlorides, bromides, iodides and sulfonate esters.
  • bases and solvents can be employed in the method of Scheme 15, and these bases and solvents are well known in the art.
  • Compounds of Formula 10 can be prepared from compounds of Formula 2a by methods analogous to those shown in Schemes 1 through 5.
  • Compounds of Formula 2a are commercially available or can be prepared by general methods well known in the art.
  • Compounds of Formula 11a can be prepared by direct displacement reaction of alpha-halopyridine compounds of Formula 15 by suitable amines of Formula 16 as shown in Scheme 17.
  • alpha-halopyridine compounds useful in the method of Scheme 17 include, but are not limited to, 2- fluoropyridine and 2-chloropyridine.
  • suitable amines include, but are not limited to, 2,2,2-trifluoroethylamine and 5-aminomethyl-2-chloropyridine.
  • the reaction is performed in an inert solvent, more typically a polar solvent such as JV,iV-dimethylacetamide or l-methyl-2-pyrrolidinone.
  • the reaction is typically performed at temperatures from 0 to 250 0 C, more typically at ambient temperature to 150 0 C.
  • the reaction can be performed in a sealed tube in a laboratory microwave reactor; typical reaction temperatures are from 200 to 240 0 C.
  • the hydrochloride salts of the compounds of Formula 15 are suitable starting materials for this method.
  • X is halogen
  • Compounds of Formula 11 can be prepared by reductive amination reaction between amines of Formula 12 and suitable aldehydes of Formula 17. These reactions are either performed in one-pot or by stepwise reaction via the imine intermediate of Formula 18 as shown in Scheme 18.
  • Examples of amine compounds useful in the method of Scheme 18 include, but are not limited to, 2-aminopyridine and 2-aminothiazole.
  • Examples of suitable aldehydes in the method of Scheme 18 include, but are not limited to, 6- chloronicotinaldehyde.
  • suitable reducing agents in the method of Scheme 18 include, but are limited to, sodium borohydride, zinc borohydride and sodium cyanoborohydride.
  • General methods and procedures for reductive amination reactions are well known in the literature; see, for example, Abdel-Magid, et al. J. Org. Chem. 1996, 61(11), 3849-3862.
  • Compounds of Formula 1 wherein X and/or Y are S can be prepared from corresponding compounds of Formula Ia by general methods known in the art involving treatment with thionating reagents such as P4S10 or Lawessen's Reagent (2,4-bis-(4- methoxyphenyl)-l,3-dithia-2,4-diphosphetane 2,4-disulf ⁇ de).
  • thionating reagents such as P4S10 or Lawessen's Reagent (2,4-bis-(4- methoxyphenyl)-l,3-dithia-2,4-diphosphetane 2,4-disulf ⁇ de).
  • malonic acids of Formula 3a can be treated with P 2 S 6 (CH 3 ) 2 as described in J. Am. Chem. Soc. 1988, 110 (4), 1316-1318.
  • the resulting malonic acid sulfur derivatives can then be used to prepare the compounds of Formula 1 wherein X and/or
  • Schemes 1 through 19 illustrate methods to prepare compounds of Formula 1 having a variety of substituents noted for R 1 , R 2 , R 3 and R 4 .
  • Compounds of Formula 1 having R 1 , R 2 , R 3 and R 4 substituents other than those particularly noted for Schemes 1 through 19 can be prepared by general methods known in the art of synthetic organic chemistry, including methods analogous to those described for Schemes 1 to 19. Examples of intermediates useful in the preparation of compounds of this invention are shown in Tables 1-1 through 1-19. The following abbreviations are used in the Tables which follow: Me means methyl, Et means ethyl and C(O)O(2,4,6-trichlorophenyl) means
  • R x is C(O)OH and RJ is H
  • Table 1-2 is constructed the same as Table 1-1, except that R x is C(O)OMe and Ry is H.
  • Table 1-3 is constructed the same as Table 1-1, except that R x is C(O)OEt and Ry is H.
  • Table 1-4 is constructed the same as Table 1-1, except that R x is C(O)OH and Ry is C(O)OH. TABLE 1-5
  • Table 1-5 is constructed the same as Table 1-1, except that R x is C(O)OH and Ry is C(O)OMe.
  • Table 1-6 is constructed the same as Table I- 1 , except that R x is C(O)OH and RY is C(O)OEt.
  • Table 1-7 is constructed the same as Table 1-1, except that R x is C(O)OH and Ry is C(O)OC(CH 3 ) 3 .
  • Table 1-8 is constructed the same as Table 1-1, except that R x is C(O)Cl and Ry is C(O)Cl.
  • Table 1-9 is constructed the same as Table 1-1, except that R x is C(O)OMe and Ry is C(O)OMe.
  • Table I- 10 is constructed the same as Table 1-1, except that R x is C(O)OEt and Ry is C(O)OEt.
  • Table 1-11 is constructed the same as Table 1-1, except that R x is C(O)OC(CH 3 ) 3 and Ry is C(O)OC(CH 3 ) 3 . TABLE 1-12
  • Table 1-12 is constructed the same as Table 1-1, except that R x is C(O)O(2,4,6- trichlorophenyl) and Ry is C(O)O(2,4,6-trichlorophenyl).
  • Table I- 12a is constructed the same as Table 1-1, except that R x is H and Ry is C(O)OC(CH 3 ) 3 .
  • Step A Preparation of 1 , 1 -dimethylethyl 7V-[(2-chloro-5-thiazolyl)methyl]-7V-2- pyridinylcarbamate (alternatively named 2-chlorothiazol-5-ylmethyl)pyridin- 2-yl-carbamic acid t-butyl ester)
  • the reaction mixture was gradually warmed to room temperature and stirred for 16-24 h. Water (200 mL) was then added, and the reaction mixture was extracted three times with 50 mL of ethyl acetate. The combined organic extracts were washed four times with 20 mL of water, dried over Na 2 SC> 4 , and concentrated under reduced pressure. The resulting residue was purified by chromatography on silica gel by elution with ethyl acetate/hexane to provide the title compound as an amber oil (9.3 g).
  • Step B Preparation of ⁇ /-[(chloro-5-thiazolyl)methyl]-2-pyridinamine (alternatively named (2-chlorothiazol-5 -ylmethyl)-pyridin-2-yl-amine) Trifluoroacetic acid (13.2 mL, 171 mmol) was added to a solution of 1,1-dimethylethyl
  • Step C Preparation of l-[(2-chloro-5-thiazolyl)methyl]-2-hydroxy-4-oxo-4H- pyrido [ 1 ,2- ⁇ ]pyrimidinium inner salt
  • Step D Preparation of l-[(2-chloro-5-thiazolyl)methyl]-2-hydroxy-4-oxo-3-(2,2,2- trifluoroacetyl)-4H-pyrido[l,2- ⁇ ]pyrimidinium inner salt 1 -[(2-Chloro-5-thiazolyl)methyl]-2-hydroxy-4-oxo-4H-pyrido[ 1 ,2- ⁇ ]pyrimidinium inner salt (i.e.
  • Step C the product of Step C) (300 mg, 1.02 mmol), l,4-diazabicyclo[2.2.2]octane (11.5 mg, 0.102 mmol), and trifluoroacetic anhydride (0.14 mL, 1.02 mmol) were dissolved in JV-methyl-2-pyrrolidinone (3 mL), and the reaction mixture was stirred at room temperature for 1 h.
  • Step A Preparation of 6-chloro- ⁇ /-2-pyridinyl-3-pyridinemethanamine A mixture of 2-fluoropyridine (1.4 g, 15 mmol) and 6-chloro-3-pyridinemethanamine
  • Step B Preparation of l-[(6-chloro-3-pyridinyl)methyl]-2-hydroxy-4-oxo-4H- pyrido[l,2- ⁇ ]pyrimidinium inner salt
  • a solution of dicyclohexylcarbodiimide (4.12 g, 20 mmol in 10 mL of dichloromethane) was added to a solution of 6-chloro- ⁇ /-2-pyridinyl-3-pyridinemethanamine (i.e. the product of Step A) (2.19 g, 10 mmol) and malonic acid (1.04 g, 10 mmol) in dichloromethane (10 mL) in a round bottom flask.
  • the reaction mixture was stirred at room temperature for 16-24 h.
  • Step C Preparation of l-[(6-chloro-3-pyridinyl)methyl]-2-hydroxy-3-iodo-4-oxo-4H- pyrido[l,2- ⁇ ]pyrimidinium inner salt iV-iodosuccinimide (1.12 g, 5 mmol) was added to a solution of l-[(6-chloro-3- pyridinyl)methyl]-2-hydroxy-4-oxo-4H-pyrido[l,2- ⁇ ]pyrimidinium inner salt (i.e. the product of Step B) (1.4 g, 5 mmol) in N,N-dimethylformamide (10 mL) and stirred for 5 min.
  • Step D Preparation of l-[(6-chloro-3-pyridinyl)methyl]-3-[2-fluoro-5-
  • Step A Preparation of ⁇ /-(2,2,2-trifluoroethyl)-2-pyridinamine
  • 2-fluoropyridine (2.00 g, 20.6 mmol) and 2,2,2-trifluoroethylamine hydrogen chloride (5.00 g, 36.9 mmol) was heated to 220 0 C for 30 min in a microwave reactor. The same reaction was repeated 5 times. The reaction mixtures from all 6 reactions were cooled, combined and diluted with ethyl acetate (150 mL). The organic mixture was neutralized by washing with saturated aqueous sodium bicarbonate, water (30 mL) and brine (30 mL).
  • Step B Preparation of l,3-bis(2,4,6-trichlorophenyl) 2-phenylpropanedioate
  • the reaction mixture was concentrated under vacuum, and methanol (100 mL) was added to the residue, which resulted in precipitation of a large amount of solid.
  • the solid was collected by filtration, rinsed with methanol (80 mL) and air dried to give the title product as a white solid (13 g).
  • Step A Preparation of ⁇ /-[(6-chloro-3-pyridinyl)methylene]-2-thiazolamine 2-Aminothiazole (0.75 g, 7.5 mmol) was added to 2-chloropyridine-6-carboxaldehyde
  • Step C Preparation of 2- [3 -(trifluoromethoxy)phenyl]propanedioic acid Diethyl 3-trifluoromethoxyphenylmalonate (3.00 g, 9.38 mmol) was stirred in an aqueous sodium hydroxide solution (15 g, 20% by weight) at 65 0 C for 10 min. The reaction mixture was then cooled in an ice bath, and ice (7 g) was added to the reaction mixture, followed by 6 N hydrochloric acid to adjust the pH to about 2. The aqueous mixture was saturated with sodium chloride and extracted with ethyl acetate three times.
  • Step D Preparation of 8-[(6-chloro-3-pyridinyl)methyl]-7-hydroxy-5-oxo-6-[3-
  • Step A Preparation of 2-hydroxy-4-oxo-l-propyl-4H-pyrido[l,2- ⁇ ]-pyrimidinium inner salt
  • a solution of dicyclohexylcarbodiimide (15.63 g in 45 mL of dichloromethane, 75.76 mmol) was added to a solution of JV-propyl-2-aminopyridine (5.16 g, 37.8 mmol) and malonic acid (3.94 g, 37.8 mmol) in dichloromethane (90 mL).
  • the reaction mixture was stirred at room temperature for 24 h.
  • the reaction mixture was then filtered through a pad of Celite®, and the filtration cake was washed with dichloromethane.
  • reaction mixture was heated at 118 0 C under nitrogen for 24 h.
  • the reaction mixture was cooled and concentrated, and the resulting residue was purified by reverse phase liquid chromatography on a XTerra® Cl 8 OBD column (5 micron particle, 30 x 100 mm, manufactured by Waters) using a gradient of 30-90% (1 :1 acetonitrile/methanol)/water to provide the title compound (compound number 308), a compound of this invention, as a solid (20 mg).
  • Step A Preparation of l-[(2-chloro-5-thiazolyl)methyl]-2-hydroxy-3-iodo-4-oxo-
  • Step B Preparation of 2-hydroxy-3 -iodo- 1 - [ [2-(3 -methoxyphenyl)-5 - thiazolyl]methyl]-4-oxo-4H-pyrido[l,2- ⁇ ]-pyrimidinium inner salt 1 -[(2-chloro-5-thiazolyl)methyl]-2-hydroxy-3-iodo-4-oxo-4H-pyrido[ 1 ,2-a]- pyrimidinium inner salt (i.e.
  • Step A the product of Step A) (250 mg, 0.59 mmol), 3-methoxybenzeneboronic acid (89 mg, 0.59 mmol) and bis(triphenylphosphine)- palladium(II) dichloride (20 mg, 0.029 mmol) were dissolved in dioxane (3 mL). Aqueous sodium carbonate solution (2 N, 1 mL) was added, and the reaction mixture was heated in a microwave reactor for 15 min at 150 0 C.
  • Step A Preparation of 2-hydroxy-4-oxo-l-(2,2,2-trifluoroethyl)-4H-pyrido[l,2- ⁇ ]- pyrimidinium inner salt
  • a solution of dicyclohexylcarbodiimide 1.0 M in dichloromethane, 108 mL, 108 mmol
  • ⁇ /-(2,2,2-trifluoroethyl)-2-pyridinamine i.e. the product of Example 5, Step A
  • Step A (9.51 g, 54.0 mmol
  • malonic acid 5.62 g, 54.0 mmol
  • Step B Preparation of 2-hydroxy-4-oxo-3-(2,2,2-trifiuoroacetyl)-l-(2,2,2- trifluoroethyl)-4H-pyrido[ 1 ,2- ⁇ ]-pyrimidinium inner salt
  • Step A Preparation of phenyl ⁇ -cyano-2-methoxybenzeneacetate
  • sodium hydride 3.39 g of 60% in mineral oil, 84.9 mmol
  • 2-(2-methoxyphenyl)acetonitrile 10.0 g, 67.9 mmol
  • the reaction mixture was then heated to reflux and the gray suspension turned dark red over 30 min.
  • Diphenyl carbonate (18.2 g, 84.9 mmol) was added portionwise, and the reaction suspension was heated at reflux for an additional 18 h.
  • the reaction mixture was cooled, poured into 1 N HCl (200 mL) and extracted with ethyl acetate (3 x 200 mL). The organic phases were combined, dried over magnesium sulfate, filtered and concentrated onto Celite® under reduced pressure. The resultant residue was purified by chromatography on silica gel using 10-90% ethyl acetate/hexane as eluant to give the title compound as a light yellow solid (14.3 g).
  • Step B Preparation of l-[(6-chloro-3-pyridinyl)methyl]-4-hydroxy-2-imino-3-(2- methoxyphenyl)-2H-pyrido[l,2- ⁇ ]pyrimidinium inner salt
  • Step A Preparation of ⁇ /-[(6-chloro-3-pyridinyl)methyl]-2-phenyl-JV-(2- pyridinyl)malonamic acid ethyl ester
  • 2-Phenylmalonic acid monoethyl ester was prepared following the procedure in Journal of Organic Chemistry 2000, 65, 5834-5836.
  • 2-Phenylmalonic acid monoethyl ester (1.02 g, 5.0 mmol) was dissolved in anhydrous dichloromethane (10 mL), and oxalyl chloride (0.52 mL, 6.0 mmol) was added, followed by one drop of ⁇ f, ⁇ /-dimethylformamide.
  • the reaction mixture was stirred for 30 min, then concentrated, redissolved in anhydrous dichloromethane (5 mL) and added to a solution of 6-chloro-iV-2-pyridinyl-3- pyridinemethanamine (i.e.
  • Step B Preparation of l-[(6-chloro-3-pyridinyl)methyl]-2-hydroxy-4-oxo-3-phenyl- 4H-pyrido [ 1 ,2- ⁇ ]pyrimidinium inner salt
  • X-50 to X- 128 pertain to the substituted phenyl ring as shown below. Blank entries in the table denote a hydrogen atom.
  • R 2 is Y-I
  • R 2 is Y-3
  • R 2 is Y-9
  • R 2 isY-12
  • R 2 isY-19
  • R 2 is Y-33
  • R 2 is Y-40
  • R 2 is Y-54
  • R 2 isY-61
  • R 2 is Y-68
  • Table 2 is constructed the same as Table 1 , except that the chemical structure under the Table 1 heading is replaced with the following structure:
  • the first compound in Table 2 is the structure shown immediately above wherein R 1 is X-I and R 2 is Y-I as defined for Table 1.
  • Table 3 is constructed the same as Table 1 , except that the chemical structure under the Table 1 heading is replaced with the following structure:
  • the first compound in Table 3 is the structure shown immediately above wherein R 1 is X-I and R 2 is Y-I as defined for Table 1.
  • Table 4 is constructed the same as Table 1 , except that the chemical structure under the Table 1 heading is replaced with the following structure:
  • the first compound in Table 4 is the structure shown immediately above wherein R 1 is X-I and R 2 is Y-I as defined for Table 1. TABLE 5
  • Table 5 is constructed the same as Table 1 , except that the chemical structure under the Table 1 heading is replaced with the following structure:
  • the first compound in Table 5 is the structure shown immediately above wherein R 1 is X-I and R 2 is Y-I as defined for Table 1.
  • Table 6 is constructed the same as Table 1 , except that the chemical structure under the Table 1 heading is replaced with the following structure:
  • the first compound in Table 6 is the structure shown immediately above wherein R 1 is X-I and R 2 is Y-I as defined for Table 1.
  • R 2 is Y-3
  • R 2 isY-19
  • R 2 is Y-38
  • R 2 is Y-65
  • Table 8 is constructed the same as Table 7, except that the chemical structure under the Table 7 heading is replaced with the following structure:
  • the first compound in Table 8 is the structure shown immediately above wherein R 1 is X- 15 and R 2 is Y-3 as defined for Table 7.
  • a compound of this invention will generally be used as an invertebrate pest control active ingredient in a composition, i.e. formulation, with at least one additional component selected from the group consisting of surfactants, solid diluents and liquid diluents, which serves as a carrier.
  • the formulation or composition ingredients are selected to be consistent with the physical properties of the active ingredient, mode of application and environmental factors such as soil type, moisture and temperature.
  • Useful formulations include both liquid and solid compositions.
  • Liquid compositions include solutions (including emulsif ⁇ able concentrates), suspensions, emulsions (including microemulsions and/or suspoemulsions) and the like, which optionally can be thickened into gels.
  • aqueous liquid compositions are soluble concentrate, suspension concentrate, capsule suspension, concentrated emulsion, microemulsion and suspo-emulsion.
  • nonaqueous liquid compositions are emulsifiable concentrate, microemulsifiable concentrate, dispersible concentrate and oil dispersion.
  • the general types of solid compositions are dusts, powders, granules, pellets, prills, pastilles, tablets, filled films (including seed coatings) and the like, which can be water-dispersible ("wettable") or water-soluble. Films and coatings formed from film- forming solutions or flowable suspensions are particularly useful for seed treatment.
  • Active ingredient can be (micro)encapsulated and further formed into a suspension or solid formulation; alternatively the entire formulation of active ingredient can be encapsulated (or "overcoated”). Encapsulation can control or delay release of the active ingredient.
  • An emulsifiable granule combines the advantages of both an emulsifiable concentrate formulation and a dry granular formulation.
  • Sprayable formulations are typically extended in a suitable medium before spraying. Such liquid and solid formulations are formulated to be readily diluted in the spray medium, usually water. Spray volumes can range from about from about one to several thousand liters per hectare, but more typically are in the range from about ten to several hundred liters per hectare. Sprayable formulations can be tank mixed with water or another suitable medium for foliar treatment by aerial or ground application, or for application to the growing medium of the plant. Liquid and dry formulations can be metered directly into drip irrigation systems or metered into the furrow during planting. Liquid and solid formulations can be applied onto seeds of crops and other desirable vegetation as seed treatments before planting to protect developing roots and other subterranean plant parts and/or foliage through systemic uptake.
  • the formulations will typically contain effective amounts of active ingredient, diluent and surfactant within the following approximate ranges which add up to 100 percent by weight.
  • Solid diluents include, for example, clays such as bentonite, montmorillonite, attapulgite and kaolin, gypsum, cellulose, titanium dioxide, zinc oxide, starch, dextrin, sugars (e.g., lactose, sucrose), silica, talc, mica, diatomaceous earth, urea, calcium carbonate, sodium carbonate and bicarbonate, and sodium sulfate.
  • Typical solid diluents are described in Watkins et al., Handbook of Insecticide Dust Diluents and Carriers, 2nd Ed., Dorland Books, Caldwell, New Jersey.
  • Liquid diluents include, for example, water, JV,iV-dimethylalkanamides (e.g., ⁇ /, ⁇ /-dimethylformamide), limonene, dimethyl sulfoxide, JV-alkylpyrrolidones (e.g., JV-methylpyrrolidinone), ethylene glycol, Methylene glycol, propylene glycol, dipropylene glycol, polypropylene glycol, propylene carbonate, butylene carbonate, paraffins (e.g., white mineral oils, normal paraffins, isoparaff ⁇ ns), alkylbenzenes, alkylnaphthalenes, glycerine, glycerol triacetate, sorbitol, triacetin, aromatic hydrocarbons, dearomatized aliphatics, alkylbenzenes, alkylnaphthalenes, ketones such as cyclohexanone, 2-heptanone, is
  • Liquid diluents also include glycerol esters of saturated and unsaturated fatty acids (typically C 6 -C 22 ), such as plant seed and fruit oils (e.g, oils of olive, castor, linseed, sesame, corn (maize), peanut, sunflower, grapeseed, safflower, cottonseed, soybean, rapeseed, coconut and palm kernel), animal-sourced fats (e.g., beef tallow, pork tallow, lard, cod liver oil, fish oil), and mixtures thereof.
  • plant seed and fruit oils e.g, oils of olive, castor, linseed, sesame, corn (maize), peanut, sunflower, grapeseed, safflower, cottonseed, soybean, rapeseed, coconut and palm kernel
  • animal-sourced fats e.g., beef tallow, pork tallow, lard, cod liver oil, fish oil
  • Liquid diluents also include alkylated fatty acids (e.g., methylated, ethylated, butylated) wherein the fatty acids can be obtained by hydrolysis of glycerol esters from plant and animal sources, and can be purified by distillation.
  • alkylated fatty acids e.g., methylated, ethylated, butylated
  • Typical liquid diluents are described in Marsden, Solvents Guide, 2nd Ed., Interscience, New York, 1950.
  • the solid and liquid compositions of the present invention often include one or more surfactants.
  • surfactants also known as “surface-active agents”
  • surface-active agents generally modify, most often reduce, the surface tension of the liquid.
  • surfactants can be useful as wetting agents, dispersants, emulsif ⁇ ers or defoaming agents.
  • Nonionic surfactants useful for the present compositions include, but are not limited to: alcohol alkoxylates such as alcohol alkoxylates based on natural and synthetic alcohols (which are branched or linear) and prepared from the alcohols and ethylene oxide, propylene oxide, butylene oxide or mixtures thereof; amine ethoxylates, alkanolamides and ethoxylated alkanolamides; alkoxylated triglycerides such as ethoxylated soybean, castor and rapeseed oils; alkylphenol alkoxylates such as octylphenol ethoxylates, nonylphenol ethoxylates, dinonyl phenol ethoxylates and dodecyl phenol ethoxylates (prepared from the phenols and ethylene oxide, propylene oxide, butylene oxide or mixtures thereof); block polymers prepared from ethylene oxide or propylene oxide
  • Useful anionic surfactants include, but are not limited to: alkylaryl sulfonic acids and their salts; carboxylated alcohol or alkylphenol ethoxylates; diphenyl sulfonate derivatives; lignin and lignin derivatives such as lignosulfonates; maleic or succinic acids or their anhydrides; olefin sulfonates; phosphate esters such as phosphate esters of alcohol alkoxylates, phosphate esters of alkylphenol alkoxylates and phosphate esters of styryl phenol ethoxylates; protein-based surfactants; sarcosine derivatives; styryl phenol ether sulfate; sulfates and sulfonates of oils and fatty acids; sulfates and sulfonates of ethoxylated alkylphenols; sulfates of alcohols; sulfates of e
  • Useful cationic surfactants include, but are not limited to: amides and ethoxylated amides; amines such as JV-alkyl propanediamines, tripropylenetriamines and dipropylenetetramines, and ethoxylated amines, ethoxylated diamines and propoxylated amines (prepared from the amines and ethylene oxide, propylene oxide, butylene oxide or mixtures thereof); amine salts such as amine acetates and diamine salts; quaternary ammonium salts such as quaternary salts, ethoxylated quaternary salts and diquaternary salts; and amine oxides such as alkyldimethylamine oxides and bis-(2-hydroxyethyl)-alkylamine oxides.
  • amines such as JV-alkyl propanediamines, tripropylenetriamines and dipropylenetetramines, and ethoxylated
  • Nonionic, anionic and cationic surfactants and their recommended uses are disclosed in a variety of published references including McCutcheon 's Emulsifiers and Detergents, annual American and International Editions published by McCutcheon's Division, The Manufacturing Confectioner Publishing Co.; Sisely and Wood, Encyclopedia of Surface Active Agents, Chemical Publ. Co., Inc., New York, 1964; and A. S. Davidson and B. Milwidsky, Synthetic Detergents, Seventh Edition, John Wiley and Sons, New York, 1987.
  • compositions of this invention can also contain formulation auxiliaries and additives, known to those skilled in the art as formulation aids (some of which can be considered to also function as solid diluents, liquid diluents or surfactants).
  • formulation auxiliaries and additives can control: pH (buffers), foaming during processing (antifoams such polyorganosiloxanes), sedimentation of active ingredients (suspending agents), viscosity (thixotropic thickeners), in-container microbial growth (antimicrobials), product freezing (antifreezes), color (dyes/pigment dispersions), wash-off (film formers or stickers), evaporation (evaporation retardants), and other formulation attributes.
  • Film formers include, for example, polyvinyl acetates, polyvinyl acetate copolymers, polyvinylpyrrolidone-vinyl acetate copolymer, polyvinyl alcohols, polyvinyl alcohol copolymers and waxes.
  • formulation auxiliaries and additives include those listed in McCutcheon 's Volume 2: Functional Materials, annual International and North American editions published by McCutcheon' s Division, The Manufacturing Confectioner Publishing Co.; and PCT Publication WO 03/024222.
  • the compound of Formula 1 and any other active ingredients are typically incorporated into the present compositions by dissolving the active ingredient in a solvent or by grinding in a liquid or dry diluent.
  • Solutions including emulsifiable concentrates, can be prepared by simply mixing the ingredients. If the solvent of a liquid composition intended for use as an emulsifiable concentrate is water-immiscible, an emulsifier is typically added to emulsify the active-containing solvent upon dilution with water. Active ingredient slurries, with particle diameters of up to 2,000 ⁇ m can be wet milled using media mills to obtain particles with average diameters below 3 ⁇ m. Aqueous slurries can be made into finished suspension concentrates (see, for example, U.S. 3,060,084) or further processed by spray drying to form water-dispersible granules.
  • Dusts and powders can be prepared by blending and usually grinding (such as with a hammer mill or fluid-energy mill).
  • Granules and pellets can be prepared by spraying the active material upon preformed granular carriers or by agglomeration techniques. See Browning, "Agglomeration", Chemical Engineering, December 4, 1967, pp 147-48, Perry's Chemical Engineer's Handbook, 4th Ed., McGraw-Hill, New York, 1963, pages 8-57 and following, and WO 91/13546.
  • Pellets can be prepared as described in U.S. 4,172,714.
  • Water-dispersible and water-soluble granules can be prepared as taught in U.S. 4,144,050, U.S. 3,920,442 and DE 3,246,493. Tablets can be prepared as taught in U.S. 5,180,587, U.S. 5,232,701 and U.S. 5,208,030. Films can be prepared as taught in GB 2,095,558 and U.S. 3,299,566.
  • Compound 50 65.0% dodecylphenol polyethylene glycol ether 2.0% sodium ligninsulfonate 4.0% sodium silicoaluminate 6.0% montmorillonite (calcined) 23.0%
  • Compound 50 5.0% polyvinylpyrrolidone -vinyl acetate copolymer 30.0% alkylpolyglycoside 30.0% glyceryl monooleate 15.0% water 20.0%
  • Compound 138 20.00% polyvinylpyrrolidone -vinyl acetate copolymer 5.00% montan acid wax 5.00% calcium ligninsulfonate 1.00% polyoxyethylene/polyoxypropylene block copolymers 1.00% stearyl alcohol (POE 20) 2.00% polyorganosilane 0.20% colorant red dye 0.05% water 65.75%
  • invertebrate pests include invertebrates inhabiting a variety of environments such as, for example, plant foliage, roots, soil, harvested crops or other foodstuffs, building structures or animal integuments. These pests include, for example, invertebrates feeding on foliage (including leaves, stems, flowers and fruits), seeds, wood, textile fibers or animal blood or tissues, and thereby causing injury or damage to, for example, growing or stored agronomic crops, forests, greenhouse crops, ornamentals, nursery crops, stored foodstuffs or fiber products, or houses or other structures or their contents, or being harmful to animal health or public health. Those skilled in the art will appreciate that not all compounds are equally effective against all growth stages of all pests.
  • present compounds and compositions are thus useful agronomically for protecting field crops from phytophagous invertebrate pests, and also nonagronomically for protecting other horticultural crops and plants from phytophagous invertebrate pests.
  • This utility includes protecting crops and other plants (i.e. both agronomic and nonagronomic) that contain genetic material introduced by genetic engineering (i.e. transgenic) or modified by mutagenesis to provide advantageous traits.
  • traits include tolerance to herbicides, resistance to phytophagous pests (e.g., insects, mites, aphids, spiders, nematodes, snails, plant-pathogenic fungi, bacteria and viruses), improved plant growth, increased tolerance of adverse growing conditions such as high or low temperatures, low or high soil moisture, and high salinity, increased flowering or fruiting, greater harvest yields, more rapid maturation, higher quality and/or nutritional value of the harvested product, or improved storage or process properties of the harvested products.
  • Transgenic plants can be modified to express multiple traits.
  • plants containing traits provided by genetic engineering or mutagenesis include varieties of corn, cotton, soybean and potato expressing an insecticidal Bacillus thuringiensis toxin such as YIELD GARD ® , KNOCKOUT , STARLINK ® , BOLLGARD ® , NuCOTN ® and NEWLEAF ® , and herbicide-tolerant varieties of corn, cotton, soybean and rapeseed such as ROUNDUP READY ® , LIBERTY LINK ® , IMI , STS and CLEARFIELD , as well as crops expressing JV-acetyltransferase (GAT) to provide resistance to glyphosate herbicide, or crops containing the HRA gene providing resistance to herbicides inhibiting acetolactate synthase (ALS).
  • an insecticidal Bacillus thuringiensis toxin such as YIELD GARD ® , KNOCKOUT , STARLINK ® , BOLLGARD ® , Nu
  • the present compounds and compositions may interact synergistically with traits introduced by genetic engineering or modified by mutagenesis, thus enhancing phenotypic expression or effectiveness of the traits or increasing the invertebrate pest control effectiveness of the present compounds and compositions.
  • the present compounds and compositions may interact synergistically with the phenotypic expression of proteins or other natural products toxic to invertebrate pests to provide greater-than-additive control of these pests.
  • compositions of this invention can also optionally comprise plant nutrients, e.g., a fertilizer composition comprising at least one plant nutrient selected from nitrogen, phosphorus, potassium, sulfur, calcium, magnesium, iron, copper, boron, manganese, zinc, and molybdenum.
  • a fertilizer composition comprising at least one plant nutrient selected from nitrogen, phosphorus, potassium, sulfur, calcium, magnesium, iron, copper, boron, manganese, zinc, and molybdenum.
  • compositions comprising at least one fertilizer composition comprising at least one plant nutrient selected from nitrogen, phosphorus, potassium, sulfur, calcium and magnesium.
  • Compositions of the present invention which further comprise at least one plant nutrient can be in the form of liquids or solids.

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Dentistry (AREA)
  • Environmental Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Pest Control & Pesticides (AREA)
  • Agronomy & Crop Science (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Disclosed are compounds of Formula 1, wherein X is O or S; Y is O or S; and R1, R2, R3 and R4 are as defined in the disclosure. Also disclosed are compositions containing the compounds of Formula 1 and methods for controlling an invertebrate pest comprising contacting the invertebrate pest or its environment with a biologically effective amount of a compound or a composition of the invention.

Description

TITLE MESOIONIC PESTICIDES
FIELD OF THE INVENTION
This invention relates to certain pyrimidinium compounds and their compositions suitable for agronomic, nonagronomic and animal health uses, methods of their use for controlling invertebrate pests such as arthropods in both agronomic and nonagronomic environments, and for treatment of parasite infections in animals or infestations in the general environment.
BACKGROUND OF THE INVENTION The control of invertebrate pests is extremely important in achieving high crop efficiency. Damage by invertebrate pests to growing and stored agronomic crops can cause significant reduction in productivity and thereby result in increased costs to the consumer. The control of invertebrate pests in forestry, greenhouse crops, ornamentals, nursery crops, stored food and fiber products, livestock, household, turf, wood products, and public health is also important. Many products are commercially available for these purposes, but the need continues for new compounds that are more effective, less costly, less toxic, environmentally safer or have different sites of action.
The control of animal parasites in animal health is essential, especially in the areas of food production and companion animals. Existing methods of treatment and parasite control are being compromised due to growing resistance to many current commercial parasiticides. The discovery of more effective ways to control animal parasites is therefore imperative.
U.S. Patent No. 5,151,427 discloses mesoionic pyrimidinium compounds of Formula i as anthelmintics
Figure imgf000002_0001
wherein, inter alia, R1 and R2 are independently C^-Cg alkyl, R3 is a heteroaromatic 6- membered ring, and R4 and R5 are independently hydrogen or Q-C 4 alkyl.
The pyrimidinium compounds of the present invention are not disclosed in this publication. SUMMARY OF THE INVENTION
This invention is directed to compounds of Formula 1 (including all geometric and stereoisomers) and compositions containing them and their use for controlling invertebrate pests:
Figure imgf000003_0001
1 wherein
X is O or S; Y is O or S; R1 is H, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C2-C6 alkenyl, C2-C6 haloalkenyl,
C2-C6 alkynyl, C2-C6 haloalkynyl, CR24=C(R24)R10 or C≡CR10; or R1 is C3-C7 cycloalkyl, C4-Cg cycloalkylalkyl or C5-C7 cycloalkenyl, each optionally substituted with 1 to 4 substituents independently selected from the group consisting of halogen, C1-C2 alkyl, C1-C2 alkoxy, 1 cyclopropyl, 1 CF3 and 1 OCF3; or
R1 is phenyl, naphthalenyl or a 5- or 6-membered heteroaromatic ring, each optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, cyano, nitro, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C1-C4 haloalkyl, C2-C4 haloalkenyl, C2-C4 alkylcarbonyl, C2-C4 haloalkylcarbonyl, C2-C4 alkoxycarbonyl, C2-C4 alkylaminocarbonyl, C3-C7 dialkylaminocarbonyl, C(O)N-f CH2Z2CH2^-, C1-C4 alkoxy, C1-C4 haloalkoxy, C2-C6 alkoxyalkyl, S(O)nR12, S(O)2R13, C1-C4 alkylamino, C2-C6 dialkylamino, SF5, Si(CH3)3, CHO, hydroxy, OC(O)R19 and N(R20)C(O)R19; or R1 is
Figure imgf000003_0002
R1 is C(Xi)R18, C(=NOR23)R18, C(O)NR16R18a, C(=NNR20aR23)R18, C(=NNR20aC(O)R23)R18, C(=NNR20aC(O)OR23a)R18 or C(=NNR20aC(O)NR20aR23)R18; or R1 is an 8- to 10-membered heteroaromatic bicyclic ring system optionally substituted on carbon ring members with up to 3 substituents independently selected from the group consisting of halogen, cyano, nitro, SF5, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C1-C4 haloalkyl, C2-C4 alkylcarbonyl, C2-C4 haloalkylcarbonyl, C2-C4 alkoxycarbonyl, C2-C4 alkylaminocarbonyl, C3-C7 dialkylaminocarbonyl, C(O)NfCH2Z2CH2^-, C1-C4 alkoxy, C1-C4 haloalkoxy, C2-C6 alkoxyalkyl, S(O)nR12, S(O)2R13, C1-C4 alkylamino, C2-C6 dialkylamino, Si(CH3)3, CHO, hydroxy, OC(O)R19 and N(R20)C(O)R19, and optionally substituted on nitrogen ring members with methyl; or R1 is phenyl or a 5- or 6-membered heteroaromatic ring, each substituted with GQ1, each optionally substituted with 1 Q2 and each optionally substituted with 1 or 2 substituents independently selected from the group consisting of halogen, cyano, nitro, SF5, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C1-C4 haloalkyl, C2-C4 alkylcarbonyl, C2-C4 haloalkylcarbonyl, C2-C4 alkoxycarbonyl, C2-C4 alkylaminocarbonyl, C3-C7 dialkylaminocarbonyl, C(O)N-f CH2Z2CH2^, C1-
C4 alkoxy, C1-C4 haloalkoxy, C2-C6 alkoxyalkyl, S(O)nR12, S(O)2R13, C1-C4 alkylamino, C2-C6 dialkylamino, Si(CH3)3, CHO, hydroxy, OC(O)R19 and N(R20)C(O)R19; or
R1 is phenyl or a 5- or 6-membered heteroaromatic ring, each substituted with LQ1 and optionally substituted with 1 or 2 substituents independently selected from the group consisting of halogen, cyano, nitro, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C1-C4 haloalkyl, C2-C4 alkylcarbonyl, C2-C4 haloalkylcarbonyl, C2- C4 alkoxycarbonyl, C2-C4 alkylaminocarbonyl, C3-C7 dialkylaminocarbonyl, C(O)NfCH2Z2CH2^-, C1-C4 alkoxy, C1-C4 haloalkoxy, C2-C6 alkoxyalkyl, S(O)nR12, S(O)2R13, C1-C4 alkylamino and C2-C6 dialkylamino; each A is independently C(R16)2, O, S(O)n or NR15; each A1 is independently C(R17)2;
X1 is O or S;
G is a direct bond, O, S(O)n, NH, N(CH3), CH2, CH2O, OCH2, C(O), C(O)O, OC(O), C(O)NH or NHC(O);
L is a phenyl or 5- or 6-membered heteroaromatic ring optionally substituted with 1 or 2 substituents independently selected from the group consisting of halogen, cyano, nitro, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C1-C4 haloalkyl, C2- C4 alkylcarbonyl, C2-C4 haloalkylcarbonyl, C2-C4 alkoxycarbonyl, C2-C4 alkylaminocarbonyl, C3-C7 dialkylaminocarbonyl, C(O)N-fCH2Z2CH2>, C1-
C4 alkoxy, C1-C4 haloalkoxy, C2-C6 alkoxyalkyl, S(O)nR12, S(O)2R13, C1-C4 alkylamino and C2-C6 dialkylamino; Q1 is phenyl or a 5- or 6-membered heteroaromatic ring, each optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, cyano, nitro, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C1-C4 haloalkyl, C2-C4 alkylcarbonyl, C2-C4 haloalkylcarbonyl, C2-C4 alkoxycarbonyl, C2-C4 alkylaminocarbonyl, C3-C7 dialkylaminocarbonyl,
C(O)N-f CH2Z2CH2^-, C1-C4 alkoxy, C1-C4 haloalkoxy, C2-C6 alkoxyalkyl, S(O)nR12, S(O)2R13, C1-C4 alkylamino, C2-C6 dialkylamino, SF5, Si(CH3)3, CHO, hydroxy, OC(O)R19 and N(R20)C(O)R19;
Q2 is phenyl or a 5- or 6-membered heteroaromatic ring, each optionally substituted with 1 or 2 substituents independently selected from the group consisting of halogen, cyano, nitro, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C1-C4 haloalkyl, C2-C4 alkylcarbonyl, C2-C4 haloalkylcarbonyl, C2-C4 alkoxycarbonyl, C2-C4 alkylaminocarbonyl, C3-C7 dialkylaminocarbonyl, C(O)N-f- CH2Z2CH2^-, C1-C4 alkoxy, C1-C4 haloalkoxy, C2-C6 alkoxyalkyl, S(O)nR12, S(O)2R13, C1-C4 alkylamino and C2-C6 dialkylamino;
R2 is C2-C6 alkyl, C1-C6 haloalkyl, C3-C6 alkenyl, C3-C6 haloalkenyl, C3-C6 alkynyl, C3-C6 haloalkynyl, CH2CO2R21, CR5R6CH2OR21, CR5R6CH2CH2OR21, CR5R6CH2S(O)nR21 or CR5R6CH2CH2S(O)nR21; or
R2 is C3-C6 cycloalkyl or C4-C7 cycloalkylalkyl, each optionally substituted with 1 to 4 substituents selected from the group consisting of halogen, C1-C2 alkyl, 1 cyclopropyl and 1 CF3; or
R2 is CR5R6Q; or
R2 is
Figure imgf000005_0001
R3 is H, C1-C6 alkyl, C1-C6 haloalkyl, C2-C6 alkenyl, C2-C6 haloalkenyl, C2-C6 alkynyl, C2-C6 haloalkynyl or C≡CR10; or
R3 is C3-C6 cycloalkyl or C4-C7 cycloalkylalkyl, each optionally substituted with 1 to 4 substituents independently selected from the group consisting of halogen, C1- C2 alkyl, 1 cyclopropyl and 1 CF3; or R3 is phenyl, naphthalenyl or a 5- or 6-membered heteroaromatic ring, each optionally substituted with 1 or 2 substituents independently selected from the group consisting of halogen, cyano, nitro, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C1-C4 haloalkyl, C2-C4 alkylcarbonyl, C2-C4 haloalkylcarbonyl, C2-C4 alkoxycarbonyl, C2-C4 alkylaminocarbonyl, C3-C7 dialkylaminocarbonyl, C(O)N-f CH2Z2CH2>, C1-C4 alkoxy, C1-C4 haloalkoxy, C2-C6 alkoxyalkyl,
S(O)nR12, S(O)2R13, C1-C4 alkylamino and C2-C6 dialkylamino; R4 is C1-C6 alkyl, C1-C6 haloalkyl, C2-C6 alkenyl, C2-C6 haloalkenyl, C2-C6 alkynyl, C2-C6 haloalkynyl or C≡CR10; or
R4 is C3-C6 cycloalkyl or C4-C7 cycloalkylalkyl, each optionally substituted with 1 to 4 substituents independently selected from the group consisting of halogen, C1- C2 alkyl, 1 cyclopropyl and 1 CF3; or
R4 is phenyl, naphthalenyl or a 5- or 6-membered heteroaromatic ring, each optionally substituted with 1 or 2 substituents independently selected from the group consisting of halogen, cyano, nitro, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C1-C4 haloalkyl, C2-C4 alkylcarbonyl, C2-C4 haloalkylcarbonyl, C2-C4 alkoxycarbonyl, C2-C4 alkylaminocarbonyl, C3-C7 dialkylaminocarbonyl,
C(O)N-f- CH2Z2CH2^-, C1-C4 alkoxy, C1-C4 haloalkoxy, C2-C6 alkoxyalkyl, S(O)nR12, S(O)2R13, C1-C4 alkylamino and C2-C6 dialkylamino; or
R3 and R4 are taken together with the contiguous linking nitrogen and carbon atoms to form an optionally substituted ring R-I
Figure imgf000006_0001
R-2
Z is C(R8a)=C(R8b), S, O or NCH3, provided that the C(R8a)=C(R8b) moiety is oriented so the carbon atom bonded to R8b is connected as R3 in Formula 1; each R5 is independently H, F, Cl, cyano or C1-C4 alkyl; each R6 is independently H, F, Cl or CH3; Q is
Figure imgf000006_0002
Q-I Q-2 Q-3 Q-4 Q-5
Figure imgf000007_0001
Q-6 Q-8 Q-9 Q-IO Q-I l
Figure imgf000007_0002
Q-12 Q-13 Q-14 Q-15 Q-16
ZMs O5 S Or NR14; each R7 is independently H, halogen, cyano, CF3, C^-C 3 alkyl or C3-C6 cycloalkyl;
R8a is H or F; R8b is H, F, CF2H or CF3; each R9a is independently H, halogen, cyano, nitro, Q-C4 alkyl, Q-C4 haloalkyl, C2- C4 alkenyl, C2-C4 haloalkenyl, C2-C4 alkynyl, C2-C4 haloalkynyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C2-C4 alkylcarbonyl, C2-C4 haloalkylcarbonyl, C2- C4 alkoxycarbonyl, C2-C4 haloalkoxycarbonyl, C(O)NH2, C2-C4 alkylaminocarbonyl, C3-C7 dialkylaminocarbonyl, C(O)N-f CH2Z2CH2^, C2-
C4 haloalkylaminocarbonyl, C3-C7 halodialkylaminocarbonyl, SF5, S(O)nR12 or S(O)2R13; or C3-Q cycloalkyl or C4~C7 cycloalkylalkyl, each optionally substituted with 1 to 4 substituents selected from the group consisting of halogen, Q-C2 alkyl, 1 cyclopropyl and 1 CF3; or phenyl or a 5- or 6-membered heteroaromatic ring, each optionally substituted with 1 or 2 substituents independently selected from the group consisting of halogen, cyano, nitro, C^- C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C1-C4 haloalkyl, C2-C4 alkylcarbonyl, C2-C4 haloalkylcarbonyl, C2-C4 alkoxycarbonyl, C2-C4 alkylaminocarbonyl, C3-C7 dialkylaminocarbonyl, C(O)N-f CH2Z2CH2^, C1-C4 alkoxy, C1-C4 haloalkoxy, C2-C6 alkoxyalkyl, S(O)nR12, S(O)2R13, C1-C4 alkylamino and
C2-C6 dialkylamino; each R9b is independently H, halogen, cyano, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 alkoxy or C1-C4 haloalkoxy; or phenyl or pyridinyl, each optionally substituted with 1 or 2 substituents independently selected from the group consisting of halogen, cyano, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, S(O)nR12 and S(O)2R13; each R10 is independently Si(R1 !)3; or phenyl or pyridinyl, each optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, cyano, nitro, SF5, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C1-C4 haloalkyl, C2-C4 alkylcarbonyl, C2-C4 haloalkylcarbonyl, C2-C4 alkoxycarbonyl, C2-C4 alkylaminocarbonyl, C3-C7 dialkylaminocarbonyl,
C(O)N-f CH2Z2CH2^-, C2-C6 alkoxyalkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, S(O)nR12, S(O)2R13, C1-C4 alkylamino and C2-C6 dialkylamino; each R11 is independently C1-C4 alkyl; each R12 is independently C1-C4 alkyl or C1-C4 haloalkyl; each R13 is independently C1-C4 alkylamino, C2-C6 dialkylamino or
-N-f CH2Z2CH2^- ;
R14 is H, C1-C4 alkyl, C1-C4 haloalkyl, C2-C5 alkoxycarbonyl, C2-C5 alkylaminocarbonyl, C3-C7 dialkylaminocarbonyl, C(O)N-^-CH2Z2CH2-)-, S(O)nR12 or S(O)2R13; or phenyl or pyridinyl, each optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, cyano, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, S(O)nR12 and S(O)2R13; each R15 is independently C1-C4 alkyl; each R16 is independently H or C1-C4 alkyl; each R17 is independently H, F or CH3; R18 is H, C1-C6 alkyl, C1-C6 haloalkyl, C3-C6 cycloalkyl, C1-C6 alkoxy, C1-C6 alkylamino or C2-C7 dialkylamino; or phenyl or a 5- or 6-membered heteroaromatic ring, each optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, C1-C4 alkyl, C1- C4 alkoxy, C1-C4 haloalkoxy, S(O)nR12 and S(O)2R13; R18a is phenyl or a 5- or 6-membered heteroaromatic ring, each optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, S(O)nR12 and S(O)2R13; each R19 is independently C1-C4 alkyl; each R20 is independently H or C1-C4 alkyl; each R20a is independently C1-C4 alkyl; each R21 is independently H or C1-C4 alkyl;
R23 is H, C1-C6 alkyl, C1-C6 haloalkyl, C3-C6 alkenyl, C3-C6 haloalkenyl, C3-C6 alkynyl, C3-C6 haloalkynyl or CH2CO2R21; or R23 is C3-C6 cycloalkyl or C4-C7 cycloalkylalkyl, each optionally substituted with 1 to 4 substituents independently selected from the group consisting of halogen, C1-C2 alkyl, 1 cyclopropyl and 1 CF3; or R23 is phenyl or a 5- or 6-membered heteroaromatic ring, each optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, cyano, nitro, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C1-C4 haloalkyl, C2-C4 alkylcarbonyl, C2-C4 haloalkylcarbonyl, C2-C4 alkoxycarbonyl, C2-C4 alkylaminocarbonyl, C3-C7 dialkylaminocarbonyl,
C(O)N-f CH2Z2CH2^-, C1-C4 alkoxy, C1-C4 haloalkoxy, C2-C6 alkoxyalkyl, S(O)nR12, S(O)2R13, C1-C4 alkylamino and C2-C6 dialkylamino; R23a is C1-C6 alkyl, C2-C6 haloalkyl, C3-C6 alkenyl or C3-C6 cycloalkyl; each R24 is independently H, F or CH3; m is 0, 1, 2 or 3; each n is independently 0, 1 or 2; p is 0, 1, 2, 3 or 4; each q is independently 0, 1 or 2; y is 1 or 2; and each Z2 is independently CH2CH2, CH2CH2CH2 or CH2OCH2.
This invention is also directed to such compounds of Formula 1 (including all geometric and stereoisomers) and compositions containing them and their use for controlling invertebrate pests as described above, and further herein, provided that (a) when R2 is CH2CH=CH2, R3 and R4 are taken together to form ring R-2, Z is CH=CH, X is O and Y is O, then R1 is other than H, CH(CH3)2, CH2CH2CH2CH3, CH2CH=CH2 or unsubstituted phenyl; (b) when R1 is H, R3 and R4 are taken together to form ring R-2, Z is CH=CH, X is O and Y is O, then R2 is other than CH2CH=CH2 or CH2C=CH; (c) when R1 is CH2CH3, R3 and R4 are taken together to form ring R-2, Z is CH=CH, X is O and Y is O, then R2 is other than CH2(CH2)3CH3; (d) when R3 is H, R2 and R4 are both cyclohexyl, X is O and Y is O, then R1 is other than CH3; (e) when R1 is H or C1-C3 n-alkyl, R3 and R4 are taken together to form ring R-2, Z is S, X is O and Y is O, then R2 is other than C1-C6 alkyl or C3-C4 alkoxyalkyl; (f) when R2 is cyclopropylmethyl, R3 and R4 are taken together to form ring R-2, Z is S, X is O and Y is O, then R1 is other than CH3, CH2CH3 or CH2CH2CH3; (g) when R1 is unsubstituted phenyl, R3 and R4 are taken together to form ring R-2, Z is S, X is O and Y is O, then R2 is other than C3-C4 alkoxyalkyl; and (h) when R1 is Br, R3 and R4 are taken together to form ring R-2, Z is S, X is O and Y is O, then R2 is other than CH2CH3.
This invention also provides a composition comprising a compound of Formula 1 and at least one additional component selected from the group consisting of surfactants, solid diluents and liquid diluents. In one embodiment, this invention also provides a composition for controlling an invertebrate pest comprising a compound of Formula 1 (i.e. in a biologically effective amount) and at least one additional component selected from the group consisting of surfactants, solid diluents and liquid diluents, said composition optionally further comprising at least one additional biologically active compound or agent (i.e. in a biologically effective amount).
This invention further provides a composition for protecting an animal from an invertebrate parasitic pest comprising a parasiticidally effective amount of a compound of Formula 1 (i.e. in a parasiticidally effective amount) and at least one carrier.
This invention further provides a spray composition for controlling an invertebrate pest comprising a compound of Formula 1 or the compositions described above (i.e. in a biologically effective amount), and a propellant. This invention also provides a bait composition for controlling an invertebrate pest comprising a compound of Formula 1 or the compositions described in the embodiments above (i.e. in a biologically effective amount), one or more food materials, optionally an attractant, and optionally a humectant.
This invention further provides a trap device for controlling an invertebrate pest comprising said bait composition and a housing adapted to receive said bait composition, wherein the housing has at least one opening sized to permit the invertebrate pest to pass through the opening so the invertebrate pest can gain access to said bait composition from a location outside the housing, and wherein the housing is further adapted to be placed in or near a locus of potential or known activity for the invertebrate pest.
This invention provides a method for controlling an invertebrate pest comprising contacting the invertebrate pest or its environment with a biologically effective amount of a compound of Formula 1 (e.g., as a composition described herein). This invention also relates to such method wherein the invertebrate pest or its environment is contacted with a composition comprising a biologically effective amount of a compound of Formula 1 and at least one additional component selected from the group consisting of surfactants, solid diluents and liquid diluents, said composition optionally further comprising a biologically effective amount of at least one additional biologically active compound or agent.
This invention also provides a method for protecting a seed from an invertebrate pest comprising contacting the seed with a biologically effective amount of a compound of Formula 1 (e.g., as a composition described herein). This invention also relates to the treated seed. This invention further provides a method for treating, preventing, inhibiting and/or killing ecto and/or endoparasites comprising administering to and/or on the animal a parasiticidally effective amount of a compound of Formula 1 (e.g., as a composition described herein). This invention also relates to such method wherein a parasiticidally effective amount of a compound of Formula 1 (e.g., as a composition described herein) is administered to the environment (e.g., a stall or blanket) in which an animal resides.
DETAILS OF THE INVENTION
As used herein, the terms "comprises," "comprising," "includes," "including," "has," "having," "contains" or "containing," or any other variation thereof, are intended to cover a non-exclusive inclusion. For example, a composition, a mixture, process, method, article, or apparatus that comprises a list of elements is not necessarily limited to only those elements but may include other elements not expressly listed or inherent to such composition, mixture, process, method, article, or apparatus. Further, unless expressly stated to the contrary, "or" refers to an inclusive or and not to an exclusive or. For example, a condition A or B is satisfied by any one of the following: A is true (or present) and B is false (or not present), A is false (or not present) and B is true (or present), and both A and B are true (or present).
Also, the indefinite articles "a" and "an" preceding an element or component of the invention are intended to be nonrestrictive regarding the number of instances (i.e. occurrences) of the element or component. Therefore "a" or "an" should be read to include one or at least one, and the singular word form of the element or component also includes the plural unless the number is obviously meant to be singular.
As referred to in this disclosure, the term "invertebrate pest" includes arthropods, gastropods and nematodes of economic importance as pests. The term "arthropod" includes insects, mites, spiders, scorpions, centipedes, millipedes, pill bugs and symphylans. The term "gastropod" includes snails, slugs and other Stylommatophora. The term "nematode" includes all of the helminths, such as: roundworms, heartworms, and phytophagous nematodes (Nematoda), flukes (Tematoda), Acanthocephala, and tapeworms (Cestoda).
In the context of this disclosure "invertebrate pest control" means inhibition of invertebrate pest development (including mortality, feeding reduction, and/or mating disruption), and related expressions are defined analogously.
The term "agronomic" refers to the production of field crops such as for food and fiber and includes the growth of corn, soybeans and other legumes, rice, cereal (e.g., wheat, oats, barley, rye, rice, maize), leafy vegetables (e.g., lettuce, cabbage, and other cole crops), fruiting vegetables (e.g., tomatoes, pepper, eggplant, crucifers and cucurbits), potatoes, sweet potatoes, grapes, cotton, tree fruits (e.g., pome, stone and citrus), small fruit (berries, cherries) and other specialty crops (e.g., canola, sunflower, olives).
The term "nonagronomic" refers to other than field crops, such as horticultural crops (e.g., greenhouse, nursery or ornamental plants not grown in a field), residential, agricultural, commercial and industrial structures, turf (e.g., sod farm, pasture, golf course, lawn, sports field, etc.), wood products, stored product, agro-forestry and vegetation management, public health (i.e. human) and animal health (e.g., domesticated animals such as pets, livestock and poultry, undomesticated animals such as wildlife) applications.
Nonagronomic applications include protecting an animal from an invertebrate parasitic pest by administering a parasiticidally effective (i.e. biologically effective) amount of a compound of the invention, typically in the form of a composition formulated for veterinary use, to the animal to be protected. As referred to in the present disclosure and claims, the terms "parasiticidal" and "parasiticidally" refers to observable effects on an invertebrate parasite pest to provide protection of an animal from the pest. Parasiticidal effects typically relate to diminishing the occurrence or activity of the target invertebrate parasitic pest. Such effects on the pest include necrosis, death, retarded growth, diminished mobility or lessened ability to remain on or in the host animal, reduced feeding and inhibition of reproduction. These effects on invertebrate parasite pests provide control (including prevention, reduction or elimination) of parasitic infestation or infection of the animal.
In the above recitations, the term "alkyl", used either alone or in compound words such as "haloalkyl" includes straight-chain or branched alkyl, such as, methyl, ethyl, n-propyl, /-propyl, or the different butyl, pentyl or hexyl isomers. "Alkenyl" includes straight-chain or branched alkenes such as ethenyl, 1-propenyl, 2-propenyl, and the different butenyl, pentenyl and hexenyl isomers. "Alkenyl" also includes polyenes such as 1 ,2-propadienyl and 2,4-hexadienyl. "Alkynyl" includes straight-chain or branched alkynes such as ethynyl, 1-propynyl, 2-propynyl and the different butynyl, pentynyl and hexynyl isomers. "Alkynyl" can also include moieties comprised of multiple triple bonds such as 2,5-hexadiynyl. "Alkoxy" includes, for example, methoxy, ethoxy, n-propyloxy, isopropyloxy and the different butoxy, pentoxy and hexyloxy isomers. "Alkoxyalkyl" denotes alkoxy substitution on alkyl. Examples of "alkoxyalkyl" include CH2OCH3, CH2CH2OCH3, CH2OCH2CH3, CH2OCH2CH2CH2CH3 and CH2CH2OCH2CH3.
"Cycloalkyl" includes, for example, cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. The term "cycloalkylalkyl" denotes cycloalkyl substitution on an alkyl moiety. Examples of "cycloalkylalkyl" include cyclopropylmethyl, cyclopentylethyl, and other cycloalkyl moieties bonded to straight-chain or branched alkyl groups.
The term "halogen", either alone or in compound words such as "haloalkyl", or when used in descriptions such as "alkyl substituted with halogen" includes fluorine, chlorine, bromine or iodine. Further, when used in compound words such as "haloalkyl", or when used in descriptions such as "alkyl substituted with halogen" said alkyl may be partially or fully substituted with halogen atoms which may be the same or different. Examples of "haloalkyl" or "alkyl substituted with halogen" include CF3, CH2Cl, CH2CF3 and CCl2CF3. The terms "haloalkoxy", "haloalkenyl", "haloalkynyl", and the like, are defined analogously to the term "haloalkyl". Examples of "haloalkoxy" include OCF3, OCH2CCl3, OCH2CH2CHF2 and OCH2CF3. Examples of "haloalkenyl" include CH2CH=C(Cl)2 and CH2CH=CHCH2CF3. Examples of "haloalkynyl" include CHCIC≡CH, C≡CCF3, C≡CCC13 and CH2C≡CCH2F.
"Alkylamino" denotes an NH radical substituted with straight-chain or branched alkyl. Examples of "alkylamino" include NHCH2CH3, NHCH2CH2CH3, and NHCH2CH(CH3)2. "Dialkylamino" denotes an N radical substituted independently with two straight-chain or branched alkyl groups. Examples of "dialkylamino" include N(CH3)2, N(CH3CH2CH2)2 and N(CH3)CH2CH3. "Halodialkylamino" denotes one straight-chain or branched alkyl moiety and one straight-chain or branched haloalkyl moiety bonded to an N radical, or two independent straight-chain or branched haloalkyl moieties bonded to an N radical, wherein "haloalkyl" is as defined above. Examples of "halodialkylamino" include
N(CH2CH3)(CH2CH2Cl) and N(CF2CF3)2. "Alkylcarbonyl" denotes a straight-chain or branched alkyl moiety bonded to a C(O) moiety. The chemical abbreviations C(O) and C(=O) as used herein represent a carbonyl moiety. Examples of "alkylcarbonyl" include C(O)CH3, C(O)CH2CH2CH3 and C(O)CH(CH3)2. Examples of "haloalkylcarbonyl" include C(O)CF3, C(O)CCl3, C(O)CH2CF3 and C(O)CF2CF3. "Alkoxycarbonyl" denotes a straight-chain or branched alkyl moiety bonded to a CO2 moiety. The chemical abbreviations CO2 and C(O)O as used herein represent an ester moiety. Examples of "alkoxycarbonyl" include C(O)OCH3, C(O)CH2CH3,
C(O)OCH2CH2CH3 and C(O)OCH(CH3)2.
"Alkylaminocarbonyl" denotes a straight-chain or branched alkyl moiety bonded to a C(O)NH moiety. The chemical abbreviations C(O)NH, and C(O)N as used herein represent an amide moiety (i.e. an aminocarbonyl group). Examples of "alkylaminocarbonyl" include C(O)NHCH3, C(O)NHCH2CH2CH3 and C(O)NHCH(CH3)2. "Dialkylaminocarbonyl" denotes two independent straight-chain or branched alkyl moieties bonded to a C(O)N moiety. Examples of "dialkylaminocarbonyl" include C(O)N(CH3)2 and C(O)N(CH3)(CH2CH3).
The chemical abbreviation C(O)N- (-CH2Z2CH2-)- as used herein represents a dialkylaminocarbonyl moiety wherein the two alkyl groups are connected to form a ring as shown below.
Figure imgf000013_0001
The chemical abbreviation N-^-CH2Z2CH2-)- is defined analogously.
The chemical abbreviation C(=NOR23)R18 as used herein represents both geometric isomers of the oxime moiety as shown below.
Figure imgf000013_0002
When R3 and R4 are taken together with the contiguous linking nitrogen and carbon atoms to form an optionally substituted ring R-2 and Z is C(R8a)=C(R8b), the C(R8a)=C(R8b) moiety is oriented so the carbon atom bonded to R8^ is connected as R3 in Formula 1 as shown below.
Figure imgf000014_0001
The wavy line in the above structures and elsewhere in the disclosure (e.g., X-24 through X-128 and Y-30 through Y-71 preceding Table 1) indicates the attachment position of the molecular fragment to the remainder of the molecule. The total number of carbon atoms in a substituent group is indicated by the "Ci-Cj" prefix where i and j are numbers from 1 to 7. For example, C^-C4 alkyl designates methyl through butyl; C2 alkoxyalkyl designates CH2OCH3; C3 alkoxyalkyl designates, for example, CH3CH(OCH3), CH2CH2OCH3 or CH2OCH2CH3; and C4 alkoxyalkyl designates the various isomers of an alkyl group substituted with an alkoxy group containing a total of four carbon atoms, examples including CH2OCH2CH2CH3 and CH2CH2OCH2CH3.
When a compound is substituted with a substituent bearing a subscript that indicates the number of said substituents can exceed 1, said substituents (when they exceed 1) are independently selected from the group of defined substituents, e.g., (R7)p, p is O, 1, 2, 3 or 4. When a group contains a substituent which can be hydrogen, for example R1 or R3, then when this substituent is taken as hydrogen, it is recognized that this is equivalent to said group being unsubstituted. When a variable group is shown to be optionally attached to a position, for example (Rv)r in U-36 of Exhibit 1 wherein r may be 0, then hydrogen can be at the position even if not recited in the variable group definition. When one or more positions on a group are said to be "not substituted" or "unsubstituted", then hydrogen atoms are attached to take up any free valency.
The term "heteroaromatic ring" denotes an aromatic ring in which at least one atom forming the ring backbone is not carbon, e.g., nitrogen, oxygen or sulfur. Typically a heteroaromatic ring contains no more than 4 nitrogens, no more than 1 oxygen and no more than 1 sulfur. Unless otherwise indicated, heteroaromatic rings can be attached through any available carbon or nitrogen by replacement of a hydrogen on said carbon or nitrogen. "Aromatic" indicates that each of the ring atoms is essentially in the same plane and has a /?-orbital perpendicular to the ring plane, and in which (4n + T) π electrons, where n is a positive integer, are associated with the ring to comply with Hϋckel's rule. The term "heteroaromatic bicyclic ring system" denotes a ring system consisting of two fused rings, in which at least one of the two rings is a heteroaromatic ring as defined above.
When a radical (e.g., cycloalkyl in the definition of R1) is optionally substituted with listed substituents with the number of substituents stated (e.g., "1 to 4"), then the radical may be unsubstituted or substituted with a number of substituents ranging up to the high number stated (e.g., "4"), and the attached substituents are independently selected from the substituents listed. When the substituent list includes a lower limit for a particular substituent (e.g., "1 cyclopropyl"), this accordingly restricts number of instances of that particular substituent among the substituents attached to the radical. Thus in regards to R1, while up to four substituents may be attached to the cycloalkyl radical, only one of the substituents may be cyclopropyl.
When a substituent (e.g., R1) is a 5- or 6-membered nitrogen-containing heteroaromatic ring, it can be attached to the remainder of Formula 1 though any available carbon or nitrogen ring atom, unless otherwise described. As noted above, substituents such as R1 can be (among others) phenyl optionally substituted with one to three substituents selected from a group of substituents as defined in the Summary of the Invention. An example of phenyl optionally substituted with one to three substituents is the ring illustrated as U-I in Exhibit 1, wherein Rv is as defined in the Summary of the Invention (e.g., for R1) and r is an integer from 0 to 3.
As noted above, substituents such as R1 can be (among others) a 5- or 6-membered heteroaromatic ring, optionally substituted with one or more substituents selected from a group of substituents as defined in the Summary of Invention. Examples of a 5- or 6-membered heteroaromatic ring optionally substituted with one or more substituents include the rings U-2 through U-61 illustrated in Exhibit 1 wherein Rv is any substituent as defined in the Summary of the Invention (e.g., for R1) and r is an integer from 0 to 2, limited by the number of available positions on each U group. As U-29, U-30, U-36, U-37, U-38, U-39, U-40, U-41, U-42 and U-43 have only one available position, for these U groups r is limited to the integers 0 or 1 , and r being 0 means that the U group is unsubstituted and a hydrogen is present at the position indicated by (Rv)r.
Exhibit 1
Figure imgf000015_0001
U-I U-2 U-3 U-4 U-5
Figure imgf000015_0002
U-I l U-12 U-13 U-14 U-15
Figure imgf000016_0001
U-16 U-17 U-18 U-19 U-20
Figure imgf000016_0002
U-21 U-22 U-23 U-24 U-25
Figure imgf000016_0003
U-26 U-27 U-28 U-29 U-30
Figure imgf000016_0004
U-31 U-32 U-33 U-34 U-35
Figure imgf000016_0005
U-36 U-37 U-38 U-39 U-40
Figure imgf000016_0006
Figure imgf000016_0007
Figure imgf000016_0008
U-54 U-55
Figure imgf000017_0001
U-61
As noted above, substituents such as R1 can be (among others) an 8-, 9- or 10-membered heteroaromatic bicyclic ring system optionally substituted with up to 3 substituents selected from a group of substituents as defined in the Summary of Invention. Examples of a 8-, 9- or 10-membered heteroaromatic bicyclic ring system optionally substituted with up to 3 substituents include the ring systems H-I through H-23 illustrated in Exhibit 2 wherein Rv is any substituent as defined in the Summary of the Invention (e.g., halogen, cyano, nitro, SF5, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C1-C4 haloalkyl, C2-C4 alkylcarbonyl, C2-C4 haloalkylcarbonyl, C2-C4 alkoxycarbonyl, C2-C4 alkylaminocarbonyl, C3-C7 dialkylaminocarbonyl, C^-C 4 alkoxy, C1-C4 haloalkoxy, C2- Cβ alkoxyalkyl, S(O)nR12, C1-C4 alkylamino and C2-C6 dialkylamino on carbon ring members and methyl on nitrogen ring members) and r is an integer from 0 to 3, limited by the number of available positions on each H group.
Exhibit 2
Figure imgf000017_0002
Figure imgf000018_0001
Although Rv groups are shown in the structures U-I through U-61 and H-I through H-23, it is noted that they do not need to be present since they are optional substituents. The nitrogen atoms that require substitution to fill their valence are substituted with H or Rv. Note that when the attachment point between (Rv)r and the U or H group is illustrated as floating, (Rv)r can be attached to any available carbon atom or nitrogen atom of the U or H group. Note that when the attachment point on the U or H group is illustrated as floating, the U or H group can be attached to the remainder of Formula 1 through any available carbon or nitrogen of the U or H group by replacement of a hydrogen atom. Note that some U groups can only be substituted with less than 2 Rv groups (e.g., U-2 through U-5, U-7 through U-48, and U-52 through U-61).
A wide variety of synthetic methods are known in the art to enable preparation of aromatic and nonaromatic heterocyclic rings and ring systems; for extensive reviews see the eight volume set of Comprehensive Heterocyclic Chemistry, A. R. Katritzky and C. W. Rees editors-in-chief, Pergamon Press, Oxford, 1984 and the twelve volume set of Comprehensive Heterocyclic Chemistry II, A. R. Katritzky, C. W. Rees and E. F. V. Scriven editors-in-chief, Pergamon Press, Oxford, 1996.
The compounds of Formula 1 are mesoionic inner salts. "Inner salts", also known in the art as "zwitterions", are electrically neutral molecules but carry formal positive and negative charges on different atoms in each valence bond structure according to valence bond theory. Furthermore the molecular structure of the compounds of Formula 1 can be represented by the six valence bond structures shown below, each placing the formal positive and negative charges on different atoms. Because of this resonance, the compounds of Formula 1 are also described as "mesoionic". Although for sake of simplicity, the molecular structure of Formula 1 is depicted as a single valence bond structure in the present disclosure and claims, this particular valence bond structure is to be understood as representative of all six valence bond structures relevant to bonding in molecules of compounds of Formula 1. Therefore reference to Formula 1 in the present disclosure and claims relates to all six applicable valence bond structures and other (e.g., molecular orbital theory) structures unless otherwise specified.
Figure imgf000019_0001
Figure imgf000019_0002
Compounds of this invention can exist as one or more stereoisomers. The various stereoisomers include enantiomers, diastereomers, atropisomers and geometric isomers. For example, substituents and other molecular constituents such as R1 may contain chiral centers. One skilled in the art will appreciate that one stereoisomer may be more active and/or may exhibit beneficial effects when enriched relative to the other stereoisomer(s) or when separated from the other stereoisomer(s). Additionally, the skilled artisan knows how to separate, enrich, and/or to selectively prepare said stereoisomers. This invention comprises racemic mixtures as well as enriched and essentially pure stereoconfigurations at these chiral centers. Compounds of this invention can exist as one or more conformational isomers due to restricted bond rotation caused by steric hinderance. For example, a compound of Formula 1 wherein R1 is phenyl substituted in the ortho-position with a sterically demanding alkyl group (e.g., isopropyl) may exist as two rotamers due to restricted rotation about the R1- pyrimidinium ring bond. This invention comprises mixtures of conformational isomers. In addition, this invention includes compounds that are enriched in one conformer relative to others.
Compounds of Formula 1 can exist in the solid phase as polymorphs (i.e. different crystalline forms). The term "polymorph" refers to a particular crystalline form of a chemical compound that can crystallize in different crystalline forms, these forms having different arrangements and/or conformations of the molecules in the crystal lattice. Although polymorphs can have the same chemical composition, they can also differ in composition due the presence or absence of co-crystallized water or other molecules, which can be weakly or strongly bound in the lattice. Polymorphs can differ in such chemical, physical and biological properties as crystal shape, density, hardness, color, chemical stability, melting point, hygroscopicity, suspensibility, dissolution rate and biological availability. One skilled in the art will appreciate that a polymorph of a compound of Formula 1 can exhibit beneficial effects (e.g., suitability for preparation of useful formulations) relative to another polymorph or a mixture of polymorphs of the same compound of Formula 1. Preparation and isolation of a particular polymorph of a compound of Formula 1 can be achieved by methods known to those skilled in the art including, for example, crystallization using selected solvents and temperatures. This invention comprises both individual polymorphs and mixtures of polymorphs, including mixtures enriched in one polymorph relative to others.
Embodiments of the present invention as described in the Summary of the Invention include those described below. In the following Embodiments reference to "a compound of
Formula 1" includes the definitions of substituents specified in the Summary of the
Invention unless further defined in the Embodiments. The compounds of Formulae Ir and
Is are various subsets of Formula 1.
Embodiment 1. A compound of Formula 1 wherein X is O. Embodiment 2. A compound of Formula 1 wherein X is S.
Embodiment 3. A compound of Formula 1 or Embodiments 1 or 2 wherein Y is O. Embodiment 4. A compound of Formula 1 or Embodiments 1 or 2 wherein Y is S. Embodiment 5. A compound of Formula 1 or any of Embodiments 1-4 wherein R1 is H or halogen. Embodiment 6. A compound of Formula 1 or any of Embodiments 1-4 wherein R1 is phenyl or a 6-membered hetero aromatic ring, each optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, cyano, nitro, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C1-C4 haloalkyl, C2- C4 haloalkenyl, C2-C4 alkylcarbonyl, C2-C4 haloalkylcarbonyl, C2-C4 alkoxycarbonyl, C2-C4 alkylaminocarbonyl, C3-C7 dialkylaminocarbonyl,
C(O)N-f- CH2Z2CH2^-, C1-C4 alkoxy, C1-C4 haloalkoxy, C2-C6 alkoxyalkyl, S(O)nR12, S(O)2R13, C1-C4 alkylamino, C2-C6 dialkylamino, SF5, Si(CH3)3, CHO, hydroxy, OC(O)R19 and N(R2O)C(O)R19.
Embodiment 7. A compound of Embodiment 6 wherein R1 is phenyl or pyridinyl, each optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, cyano, nitro, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C1-C4 haloalkyl, C2-C4 haloalkenyl, C2-C4 alkylcarbonyl, C2-C4 haloalkylcarbonyl, C2-C4 alkoxycarbonyl, C2-C4 alkylaminocarbonyl, C3-C7 dialkylaminocarbonyl, C(O)N-f CH2Z2CH2^-, C1-C4 alkoxy, C1-C4 haloalkoxy, C2-C6 alkoxyalkyl, S(O)nR12, S(O)2R13, C1-C4 alkylamino, C2-C6 dialkylamino, SF5, Si(CH3)3, CHO, hydroxy, OC(O)R19 and N(R20)C(O)R19. Embodiment 8. A compound of Embodiment 7 wherein R1 is phenyl or pyridinyl, each optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, cyano, C1-C4 alkyl, C1-C4 haloalkyl, C2-C4 alkylcarbonyl, C2-C4 alkoxycarbonyl, C2-C4 alkylaminocarbonyl, C3-C7 dialkylaminocarbonyl, C(O)N-f CH2Z2CH2^-, C1-C4 alkoxy, C1-C4 haloalkoxy, C2-C6 alkoxyalkyl, S(O)nR12 and S(O)2R13. Embodiment 9. A compound of Formula 1 or any of Embodiments 1-4 wherein
RMs
Figure imgf000021_0001
Embodiment 10. A compound of Formula 1 or any of Embodiments 1-4 wherein R1 is
C(Xi)R18 or C(=NOR23)R18. Embodiment 11. A compound of Embodiment 10 wherein R1 is C(X^R18.
Embodiment 12. A compound of Formula 1 or any of Embodiments 1-11 wherein X1 is
O. Embodiment 13. A compound of Formula 1 or any of Embodiments 1-11 wherein X1 is
S. Embodiment 14. A compound of Embodiment 10 wherein R1 is C(=NOR23)R18.
Embodiment 15. A compound of Formula 1 or any of Embodiments 1-4 wherein R1 is an 8- to 10-membered heteroaromatic bicyclic ring system optionally substituted on carbon ring members with up to 3 substituents independently selected from the group consisting of halogen, cyano, nitro, SF5, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C1-C4 haloalkyl, C2-C4 alkylcarbonyl, C2-C4 haloalkylcarbonyl, C2-C4 alkoxycarbonyl, C2-C4 alkylaminocarbonyl, C3-C7 dialkylaminocarbonyl, C(O)N-f CH2Z2CH2^-, C1-C4 alkoxy, C1-C4 haloalkoxy, C2-C6 alkoxyalkyl, S(O)nR12, S(O)2R13, C1-C4 alkylamino, C2-C6 dialkylamino, Si(CH3)3, CHO, hydroxy, OC(O)R19 and N(R20)C(O)R19, and optionally substituted on nitrogen ring members with methyl.
Embodiment 16. A compound of Formula 1 or any of Embodiments 1-4 wherein R1 is phenyl or a 5- or 6-membered heteroaromatic ring, each substituted with GQ1 and further optionally substituted with 1 or 2 substituents independently selected from the group consisting of halogen, cyano, nitro, SF5, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C1-C4 haloalkyl, C2-C4 alkylcarbonyl, C2-C4 haloalkylcarbonyl, C2-C4 alkoxycarbonyl, C2-C4 alkylaminocarbonyl, C3-C7 dialkylaminocarbonyl, C(O)N-f CH2Z2CH2^-, C1-C4 alkoxy, C1-C4 haloalkoxy, C2-C6 alkoxyalkyl, S(O)nR12, S(O)2R13, C1-C4 alkylamino, C2-C6 dialkylamino, Si(CH3)3, CHO, hydroxy, OC(O)R19 and N(R20)C(O)R19.
Embodiment 17. A compound of Embodiment 16 wherein R1 is phenyl or pyridinyl, each substituted with GQ1 and further optionally substituted with 1 or 2 substituents independently selected from the group consisting of halogen, cyano, SF5, C1-C4 alkyl, C1-C4 haloalkyl, C2-C4 alkylcarbonyl, C2-C4 alkoxycarbonyl, C2-C4 alkylaminocarbonyl, C3-C7 dialkylaminocarbonyl, C(O)N-f CH2Z2CH2^-, C1-C4 alkoxy, C1-C4 haloalkoxy, C2-C6 alkoxyalkyl, S(O)nR12 and S(O)2R13.
Embodiment 18. A compound of Formula 1 or any of Embodiments 1-17 wherein Q1 is phenyl or pyridinyl, each optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, cyano, C1-C4 alkyl, C1-C4 haloalkyl, C2-C4 alkylcarbonyl, C2-C4 alkoxycarbonyl, C2-C4 alkylaminocarbonyl, C3-C7 dialkylaminocarbonyl, C(O)N-f CH2Z2CH2^, C1-
C4 alkoxy, C1-C4 haloalkoxy, C2-C6 alkoxyalkyl, S(O)nR12 and S(O)2R13.
Embodiment 19. A compound of Formula 1 or any of Embodiments 1-4 wherein R1 is selected from Embodiments 5, 6, 9, 10, 15 and 16.
Embodiment 20. A compound of Formula 1 or any of Embodiments 1-19 wherein R2 is C2-C6 alkyl, C1-C6 haloalkyl, CH2CO2R21, CR5R6CH2OR21,
CR5R6CH2CH2OR21, CR5R6CH2S(O)nR21 or CR5R6CH2CH2S(O)nR21.
Embodiment 21. A compound of Formula 1 or any of Embodiments 1-19 wherein R2 is C3-C6 cycloalkyl or C4-C7 cycloalkylalkyl, each optionally substituted with 1 to 4 substituents selected from the group consisting of halogen, C1-C2 alkyl, 1 cyclopropyl and 1 CF3.
Embodiment 22. A compound of Formula 1 or any of Embodiments 1-19 wherein R2 is CR5R6Q.
Embodiment 22a. A compound of Formula 1 or any of Embodiments 1-19 wherein R2 is selected from Embodiments 20, 21 and 22. Embodiment 23. A compound of Embodiment 20 wherein R2 is C2-C6 alkyl, C1-C6 haloalkyl or CR5R6CH2OR21.
Embodiment 24. A compound of Embodiment 21 wherein R2 is C4-C7 cycloalkylalkyl optionally substituted with 1 to 4 substituents selected from the group consisting of halogen, C1-C2 alkyl, 1 cyclopropyl and 1 CF3. Embodiment 24a. A compound of Formula 1 or any of Embodiments 1-19 wherein R2 is selected from Embodiments 23 and 24.
Embodiment 25. A compound of Formula 1 or any of Embodiments 1-24 wherein G is a direct bond. Embodiment 26. A compound of Formula 1 or any of Embodiments 1-25 wherein R3 is
H, C1-C6 alkyl, C1-C6 haloalkyl, C2-C6 alkenyl, C2-C6 haloalkenyl, C2-C6 alkynyl, C2-C6 haloalkynyl or C≡CR10.
Embodiment 27. A compound of Formula 1 or any of Embodiments 1-25 wherein R3 is C3-C6 cycloalkyl or C4-C7 cycloalkylalkyl, each optionally substituted with 1 to
4 substituents independently selected from the group consisting of halogen, C1-
C2 alkyl, 1 cyclopropyl and 1 CF3. Embodiment 28. A compound of Embodiment 26 wherein R3 is C1-C6 alkyl or C1-C6 haloalkyl. Embodiment 29. A compound of Embodiment 28 wherein R3 is CH3.
Embodiment 29a. A compound of Formula 1 or any of Embodiments 1-29 wherein R4 is C1-C6 alkyl, C1-C6 haloalkyl, C2-C6 alkenyl, C2-C6 haloalkenyl, C2-C6 alkynyl, C2-C6 haloalkynyl or C≡CR10.
Embodiment 29b. A compound of Formula 1 or any of Embodiments 1-29 wherein R4 is C3-C6 cycloalkyl or C4-C7 cycloalkylalkyl, each optionally substituted with 1 to 4 substituents independently selected from the group consisting of halogen,
C1-C2 alkyl, 1 cyclopropyl and 1 CF3. Embodiment 29c. A compound of Embodiment 29a wherein R4 is C1-C6 alkyl or C1-
C6 haloalkyl. Embodiment 29d. A compound of Embodiment 29c wherein R4 is CH3.
Embodiment 30. A compound of Formula 1 or any of Embodiments 1-25 wherein R3 and R4 are taken together with the contiguous linking nitrogen and carbon atoms to form an optionally substituted ring R-I
Figure imgf000023_0001
R-2 Embodiment 31. A compound of Embodiment 30 wherein R3 and R4 are taken together with the contiguous linking nitrogen and carbon atoms to form an optionally substituted ring R-I.
Embodiment 32. A compound of Embodiment 30 wherein R3 and R4 are taken together with the contiguous linking nitrogen and carbon atoms to form an optionally substituted ring R-2. Embodiment 32a. A compound of Formula 1 or any of Embodiments 1-25 wherein R3 is selected from Embodiments 26 and 27, and R4 is selected from Embodiments
29a and 29b; or R3 and R4 are taken together with the contiguous linking nitrogen and carbon atoms to form an optionally substituted ring as described in
Embodiment 30. Embodiment 32b. A compound of Formula 1 or any of Embodiments l-32a wherein m is 2 or 3.
Embodiment 32c. A compound of Formula 1 or any of Embodiments 1-32b wherein p is O.
Embodiment 32d. A compound of Formula 1 or any of Embodiments l-32c wherein Z is C(R8a)=C(R8b) or S, provided that the C(R8a)=C(R8b) moiety is oriented so the carbon atom bonded to R8b is connected as R3 in Formula 1. Embodiment 33. A compound of Embodiment 32d wherein Z is CH=CH or CH=CF, provided that the CH=CF moiety is oriented so the carbon atom bonded to F is connected as R3 in Formula 1.
Embodiment 34. A compound of Embodiment 32d wherein Z is S. Embodiment 35. A compound of Formula 1 or any of Embodiments 1-34 wherein each
R5 is independently H or Q-C 4 alkyl. Embodiment 36. A compound of Embodiment 35 wherein each R5 is independently H or methyl. Embodiment 37. A compound of Formula 1 or any of Embodiments 1-36 wherein R6 is
H.
Embodiment 38. A compound of Formula 1 or any of Embodiments 1-37 wherein Q is Q-I, Q-5, Q-6 or Q-9.
Embodiment 39. A compound of Embodiment 38 wherein Q is Q-I, Q-5 or Q-9. Embodiment 40. A compound of Embodiment 38 wherein Q is Q-I. Embodiment 41. A compound of Embodiment 38 wherein Q is Q-5. Embodiment 42. A compound of Embodiment 38 wherein Q is Q-6. Embodiment 43. A compound of Embodiment 38 wherein Q is Q-9.
Embodiment 44. A compound of any of Embodiments 38, 39, 41 or 43 wherein Z1 is O. Embodiment 45. A compound of any of Embodiments 38, 39, 41 or 43 wherein Z1 is S. Embodiment 46. A compound of any of Embodiments 38, 39, 41 or 43 wherein Z1 is
NR14. Embodiment 47. A compound of Formula 1 or any of Embodiments 1-46 wherein each
R9a is independently H, halogen, cyano, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 alkoxy, C ^C4 haloalkoxy, SF5 or S(O)nR12; or C3-C6 cycloalkyl or C4-C7 cycloalkylalkyl, each optionally substituted with 1 to 4 substituents selected from the group consisting of halogen, C1-C2 alkyl, 1 cyclopropyl and 1 CF3. Embodiment 48. A compound of Embodiment 47 wherein each R9a is independently H, halogen, cyano, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, SF5 or S(O)nR12.
Embodiment 49. A compound of Embodiment 47 wherein each R9a is independently
C3-C6 cycloalkyl or C4-C7 cycloalkylalkyl, each optionally substituted with 1 to
4 substituents selected from the group consisting of halogen, C1-C2 alkyl, 1 cyclopropyl and 1 CF3. Embodiment 50. A compound of Formula 1 or any of Embodiments 1-49 wherein each
R9b is independently H, halogen, cyano, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 alkoxy or C1-C4 haloalkoxy. Embodiment 51. A compound of Formula Ir
Figure imgf000025_0001
Ir wherein X is O or S; Y is O or S;
R1 is H, halogen, C1-Cg alkyl, C1-Cg haloalkyl, C2-Cg alkenyl, C2-Cg haloalkenyl, C2-C6 alkynyl, C2-C6 haloalkynyl or C≡CR10; or
R1 is C3-Cg cycloalkyl or C4-C7 cycloalkylalkyl, each optionally substituted with 1 to 4 substituents independently selected from the group consisting of halogen, C1- C2 alkyl, 1 cyclopropyl and 1 CF3; or
R1 is phenyl, naphthalenyl or a 5- or 6-membered heteroaromatic ring, each optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, cyano, nitro, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C1-C4 haloalkyl, C2-C4 alkylcarbonyl, C2-C4 haloalkylcarbonyl, C2-C4 alkoxycarbonyl, C2-C4 alkylaminocarbonyl, C3-C7 dialkylaminocarbonyl, C1- C4 alkoxy, C1-C4 haloalkoxy, C2-C6 alkoxyalkyl, S(O)nR12, C1-C4 alkylamino and C2-C6 dialkylamino; or
RMs
Figure imgf000026_0001
each A is independently C(R16)2, O, S or NR15; each A1 is independently C(R17)2;
R2 is C2-C6 alkyl, C1-C6 haloalkyl, C3-C6 alkenyl, C3-C6 haloalkenyl, C3-C6 alkynyl, C3-C6 haloalkynyl or C2-C6 alkoxyalkyl; or
R2 is C3-C6 cycloalkyl or C4-C7 cycloalkylalkyl, each optionally substituted with 1 to
4 substituents selected from the group consisting of halogen, Q-C2 alkyl, 1 cyclopropyl and 1 CF3; or R2 is CR5R6Q; R3 is H, C1-C6 alkyl, C1-C6 haloalkyl, C2-C6 alkenyl, C2-C6 haloalkenyl, C2-C6 alkynyl, C2-C6 haloalkynyl or C≡CR10; or R3 is C3-C6 cycloalkyl or C4-C7 cycloalkylalkyl, each optionally substituted with 1 to
4 substituents independently selected from the group consisting of halogen, C1-
C2 alkyl, 1 cyclopropyl and 1 CF3; or R3 is phenyl, naphthalenyl or a 5- or 6-membered heteroaromatic ring, each optionally substituted with 1 or 2 substituents independently selected from the group consisting of halogen, cyano, nitro, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl,
C1-C4 haloalkyl, C2-C4 alkylcarbonyl, C2-C4 haloalkylcarbonyl, C2-C4 alkoxycarbonyl, C2-C4 alkylaminocarbonyl, C3-C7 dialkylaminocarbonyl, C1- C4 alkoxy, C1-C4 haloalkoxy, C2-C6 alkoxyalkyl, S(O)nR12, C1-C4 alkylamino and C2-C6 dialkylamino; R4 is C1-C6 alkyl, C1-C6 haloalkyl, C2-C6 alkenyl, C2-C6 haloalkenyl, C2-C6 alkynyl, C2-C6 haloalkynyl or C≡CR10; or
R4 is C3-C6 cycloalkyl or C4-C7 cycloalkylalkyl, each optionally substituted with 1 to 4 substituents independently selected from the group consisting of halogen, C1-
C2 alkyl, 1 cyclopropyl and 1 CF3; or R4 is phenyl, naphthalenyl or a 5- or 6-membered heteroaromatic ring, each optionally substituted with 1 or 2 substituents independently selected from the group consisting of halogen, cyano, nitro, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C1-C4 haloalkyl, C2-C4 alkylcarbonyl, C2-C4 haloalkylcarbonyl, C2-C4 alkoxycarbonyl, C2-C4 alkylaminocarbonyl, C3-C7 dialkylaminocarbonyl, C1- C4 alkoxy, C1-C4 haloalkoxy, C2-C6 alkoxyalkyl, S(O)nR12, C1-C4 alkylamino and C2-C6 dialkylamino; or
R3 and R4 are taken together with the contiguous linking nitrogen and carbon atoms to form an optionally substituted ring R-I
Figure imgf000027_0001
R-2
Z is C(R8)=C(R8) or S; R5 is H, F, Cl, cyano or C1-C4 alkyl; R6 is H, F, Cl or CH3;
Q is
Figure imgf000027_0002
Figure imgf000027_0003
or ;
Q-5a Q-6a Q-8a
Z1 is O, S or NR14;
R7 is H, halogen, cyano, CF3, C1-C3 alkyl or C3-Cg cycloalkyl; each R8 is independently H or F; each R9 is independently H, halogen, cyano, nitro, C1-C4 alkyl, C1-C4 haloalkyl, C2- C4 alkenyl, C2-C4 haloalkenyl, C2-C4 alkynyl, C2-C4 haloalkynyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C2-C4 alkylcarbonyl, C2-C4 haloalkylcarbonyl, C2- C4 alkoxycarbonyl, C2-C4 haloalkoxycarbonyl, C(O)NH2, C2-C4 alkylaminocarbonyl, C3-C7 dialkylaminocarbonyl, C2-C4 haloalkylaminocarbonyl, C3-C7 halodialkylaminocarbonyl or S(O)nR12; or each R9 is independently C3-C6 cycloalkyl or C4-C7 cycloalkylalkyl, each optionally substituted with 1 to 4 substituents selected from the group consisting of halogen, C1-C2 alkyl, 1 cyclopropyl and 1 CF3; or each R9 is independently phenyl or a 5- or 6-membered heteroaromatic ring, each optionally substituted with 1 or 2 substituents independently selected from the group consisting of halogen, cyano, nitro, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C1-C4 haloalkyl, C2-C4 alkylcarbonyl, C2-C4 haloalkylcarbonyl, C2-
C4 alkoxycarbonyl, C2-C4 alkylaminocarbonyl, C3-C7 dialkylaminocarbonyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C2-C6 alkoxyalkyl, S(O)nR12, C1-C4 alkylamino and C2-C6 dialkylamino; each R10 is independently Si(R1^3; or phenyl optionally substituted with halogen, cyano, nitro, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C1-C4 haloalkyl, C2-
C4 alkylcarbonyl, C2-C4 haloalkylcarbonyl, C2-C4 alkoxycarbonyl, C2-C4 alkylaminocarbonyl, C3-C7 dialkylaminocarbonyl, C2-C6 alkoxyalkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, S(O)nR12, C1-C4 alkylamino or C2-C6 dialkylamino; each R11 is independently C1-C4 alkyl; each R12 is independently C1-C4 alkyl or C1-C4 haloalkyl;
R14 is C1-C4 alkyl; each R15 is independently C1-C4 alkyl; each R16 is independently H or C1-C4 alkyl; each R17 is independently H or F; m is 1, 2 or 3; each n is independently 0, 1 or 2; p is 0, 1, 2, 3 or 4; each r is independently 0, 1 or 2; and v is 1 or 2; provided that (a) when R2 is CH2CH=CH2, R3 and R4 are taken together to form ring R-2, Z is CH=CH, X is O and Y is O, then R1 is other than H, CH(CH3)2, CH2CH2CH2CH3, CH2CH=CH2 or unsubstituted phenyl; (b) when R1 is H, R3 and R4 are taken together to form ring R-2, Z is CH=CH, X is O and Y is O, then R2 is other than CH2CH=CH2 or CH2C=CH; (c) when R1 is CH2CH3, R3 and
R4 are taken together to form ring R-2, Z is CH=CH, X is O and Y is O, then R2 is other than CH2(CH2)3CH3; (d) when R3 is H, R2 and R4 are both cyclohexyl, X is O and Y is O, then R1 is other than CH3; (e) when R1 is H or C1-C3 n-alkyl, R3 and R4 are taken together to form ring R-2, Z is S, X is O and Y is O, then R2 is other than C1-C6 alkyl or C3-C4 alkoxyalkyl; (f) when R2 is cyclopropylmethyl, R3 and R4 are taken together to form ring R-2, Z is S, X is O and Y is O, then R1 is other than CH3, CH2CH3 or CH2CH2CH3; (g) when R1 is unsubstituted phenyl, R3 and R4 are taken together to form ring R-2, Z is S, X is
O and Y is O, then R2 is other than C3-C4 alkoxyalkyl; and (h) when R1 is Br, R3 and R4 are taken together to form ring R-2, Z is S, X is O and Y is O, then R2 is other than CH2CH3.
Embodiment 52. A compound of Embodiment 51 wherein X is O. Embodiment 53. A compound of Embodiment 51 wherein Y is O.
Embodiment 54. A compound of Embodiment 51 wherein R1 is phenyl, naphthalenyl or a 5- or 6-membered heteroaromatic ring, each optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, cyano, nitro, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C1-C4 haloalkyl, C2-C4 alkylcarbonyl, C2-C4 haloalkylcarbonyl, C2-C4 alkoxycarbonyl, C2-C4 alkylaminocarbonyl, C3-C7 dialkylaminocarbonyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C2-C6 alkoxyalkyl, S(O)nR12, C1-C4 alkylamino and C2-C6 dialkylamino.
Embodiment 55. A compound of Embodiment 54 wherein R1 is phenyl optionally substituted with 1 or 2 substituents independently selected from the group consisting of halogen, cyano, C1-C2 haloalkyl, C1-C2 alkoxy and C1-C2 haloalkoxy. Embodiment 56. A compound of Embodiment 54 wherein R1 is 2-, 3- or 4-pyridinyl optionally substituted with halogen, cyano, C1-C2 haloalkyl, C1-C2 alkoxy or C1-C2 haloalkoxy.
Embodiment 57. A compound of Formula Ir wherein R1 is
Figure imgf000029_0001
Embodiment 58. A compound of Embodiment 51 wherein R2 is C2-C6 alkyl, C1-C6 haloalkyl, C3-C6 alkenyl or C3-C6 haloalkenyl. Embodiment 59. A compound of Embodiment 51 wherein R2 is CH2CF3 or CR5R6Q.
Embodiment 60. A compound of Embodiment 59 wherein R2 is CR5R6Q. Embodiment 61. A compound of Embodiment 59 wherein R2 is CH2CF3. Embodiment 62. A compound of Embodiment 51 or Embodiment 60 wherein R5 is H or
CH3. Embodiment 63. A compound of Embodiment 51 or Embodiment 60 wherein R6 is H. Embodiment 64. A compound of Embodiment 51 wherein Q is Q-Ia, Q-2a, Q-3a, Q-4a or Q-5a.
Embodiment 65. A compound of Embodiment 64 wherein Q is Q-Ia or Q-5a. Embodiment 66. A compound of Embodiment 51 wherein R9 is F or Cl. Embodiment 67. A compound of Embodiment 51 wherein R3 and R4 are taken together with the contiguous linking nitrogen and carbon atoms to form ring R-2
Figure imgf000030_0001
R-2
Embodiment 68. A compound of Embodiment 51 or Embodiment 67 wherein Z is
CH=CH. Embodiment 69. A compound of Embodiment 51 or Embodiment 67 wherein Z is S.
Embodiment 70. A compound of Formula Is
Figure imgf000030_0002
Is wherein X is O or S;
Y is O or S; R1 is H, halogen, C^-C6 alkyl, C^-C6 haloalkyl, C2-C6 alkenyl, C2-C6 haloalkenyl,
C2-C6 alkynyl, C2-C6 haloalkynyl or C≡CR10; or
R1 is C3~C6 cycloalkyl or C4-C7 cycloalkylalkyl, each optionally substituted with 1 to 4 substituents independently selected from the group consisting of halogen, C^-
C2 alkyl, 1 cyclopropyl and 1 CF3; or
R1 is phenyl, naphthalenyl or a 5- or 6-membered heteroaromatic ring, each optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, cyano, nitro, Q-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C1-C4 haloalkyl, C2-C4 alkylcarbonyl, C2-C4 haloalkylcarbonyl, C2-C4 alkoxycarbonyl, C2-C4 alkylaminocarbonyl, C3-C7 dialkylaminocarbonyl, C^- C4 alkoxy, C1-C4 haloalkoxy, C2-C6 alkoxyalkyl, S(O)nR12, C1-C4 alkylamino and C2-C6 dialkylamino; or RMs
Figure imgf000031_0001
each A is independently C(R16)2, O, S or NR15; each A1 is independently C(R17)2; R2 is C2-C6 alkyl, C1-C6 haloalkyl, C3-C6 alkenyl, C3-C6 haloalkenyl, C3-C6 alkynyl, C3-C6 haloalkynyl or C2-C6 alkoxyalkyl; or
R2 is C3-C6 cycloalkyl or C4-C7 cycloalkylalkyl, each optionally substituted with 1 to 4 substituents selected from the group consisting of halogen, C1-C2 alkyl, 1 cyclopropyl and 1 CF3; or R2 is CR5R6Q; R3 is H, C1-C6 alkyl, C1-C6 haloalkyl, C2-C6 alkenyl, C2-C6 haloalkenyl, C2-C6 alkynyl, C2-C6 haloalkynyl or C≡CR10; or R3 is C3-C6 cycloalkyl or C4-C7 cycloalkylalkyl, each optionally substituted with 1 to
4 substituents independently selected from the group consisting of halogen, C1- C2 alkyl, 1 cyclopropyl and 1 CF3; or R3 is phenyl, naphthalenyl or a 5- or 6-membered heteroaromatic ring, each optionally substituted with 1 or 2 substituents independently selected from the group consisting of halogen, cyano, nitro, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl,
C1-C4 haloalkyl, C2-C4 alkylcarbonyl, C2-C4 haloalkylcarbonyl, C2-C4 alkoxycarbonyl, C2-C4 alkylaminocarbonyl, C3-C7 dialkylaminocarbonyl, C1- C4 alkoxy, C1-C4 haloalkoxy, C2-C6 alkoxyalkyl, S(O)nR12, C1-C4 alkylamino and C2-C6 dialkylamino; R4 is C1-C6 alkyl, C1-C6 haloalkyl, C2-C6 alkenyl, C2-C6 haloalkenyl, C2-C6 alkynyl, C2-C6 haloalkynyl or C≡CR10; or
R4 is C3-C6 cycloalkyl or C4-C7 cycloalkylalkyl, each optionally substituted with 1 to 4 substituents independently selected from the group consisting of halogen, C1- C2 alkyl, 1 cyclopropyl and 1 CF3; or R4 is phenyl, naphthalenyl or a 5- or 6-membered heteroaromatic ring, each optionally substituted with 1 or 2 substituents independently selected from the group consisting of halogen, cyano, nitro, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C1-C4 haloalkyl, C2-C4 alkylcarbonyl, C2-C4 haloalkylcarbonyl, C2-C4 alkoxycarbonyl, C2-C4 alkylaminocarbonyl, C3-C7 dialkylaminocarbonyl, C1- C4 alkoxy, C1-C4 haloalkoxy, C2-C6 alkoxyalkyl, S(O)nR12, C1-C4 alkylamino and C2-C6 dialkylamino; or R3 and R4 are taken together with the contiguous linking nitrogen and carbon atoms to form an optionally substituted ring R-I
Figure imgf000032_0001
R-I or an optionally substituted aromatic ring R-2
Figure imgf000032_0002
R-2
Z is C(R8)=C(R8);
R5 is H, F, Cl, cyano or C1-C4 alkyl;
R6 is H, F, Cl and CH3;
Q is
Figure imgf000032_0003
Q-5a Q-6a
Z1 is O, S or NR14;
R7 is H, halogen, cyano, CF3, C1-C3 alkyl or C3-C^ cycloalkyl; each R8 is independently H or F; each R9 is independently H, halogen, cyano, nitro, C1-C4 alkyl, C1-C4 haloalkyl, C2- C4 alkenyl, C2-C4 haloalkenyl, C2-C4 alkynyl, C2-C4 haloalkynyl, C ^C4 alkoxy, C1-C4 haloalkoxy, C2-C4 alkylcarbonyl, C2-C4 haloalkylcarbonyl, C2- C4 alkoxycarbonyl, C2-C4 haloalkoxycarbonyl, C(O)NH2, C2-C4 alkylaminocarbonyl, C3-C7 dialkylaminocarbonyl, C2-C4 haloalkylaminocarbonyl, C3-C7 halodialkylaminocarbonyl or S(O)nR12; or each R9 is independently C3-C6 cycloalkyl or C4-C7 cycloalkylalkyl, each optionally substituted with 1 to 4 substituents selected from the group consisting of halogen, C1-C2 alkyl, 1 cyclopropyl and 1 CF3; each R10 is independently Si(R^)3; or phenyl optionally substituted with halogen, cyano, nitro, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C1-C4 haloalkyl, C2-
C4 alkylcarbonyl, C2-C4 haloalkylcarbonyl, C2-C4 alkoxycarbonyl, C2-C4 alkylaminocarbonyl, C3-C7 dialkylaminocarbonyl, C2-C6 alkoxyalkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, S(O)nR12, C1-C4 alkylamino and C2-C6 dialkylamino; each R11 is independently C1-C4 alkyl; each R12 is independently C1-C4 alkyl or C1-C4 haloalkyl;
R14 is C1-C4 alkyl; each R15 is independently C1-C4 alkyl; each R16 is independently H or C1-C4 alkyl; each R17 is independently H or F; m is 1, 2 or 3; each n is independently 0, 1 or 2; p is 0, 1, 2, 3 or 4; each r is independently 0, 1 or 2; and v is 1 or 2; provided that (a) when R2 is CH2CH=CH2, R3 and R4 are taken together to form carbocyclic ring R-2, Z is CH=CH, X is O and Y is O, then R1 is other than H, CH(CH3)2, CH2CH2CH2CH3, CH2CH=CH2 or unsubstituted phenyl; (b) when R1 is H, R3 and R4 are taken together to form carbocyclic ring R-2, Z is CH=CH, X is O and Y is O, then R2 is other than CH2CH=CH2 or CH2C=CH;
(c) when R1 is CH2CH3, R3 and R4 are taken together to form carbocyclic ring R-2, Z is CH=CH, X is O and Y is O, then R2 is other than CH2(CH2)3CH3; and
(d) when R3 is H, R2 and R4 are both cyclohexyl, X is O and Y is O, then R1 is other than CH3. Embodiment 71. A compound of Embodiment 70 wherein X is O.
Embodiment 72. A compound of Embodiment 70 wherein Y is O. Embodiment 73. A compound of Embodiment 70 wherein R1 is phenyl, naphthalenyl or a 5- or 6-membered heteroaromatic ring, each optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, cyano, nitro, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C1-C4 haloalkyl, C2-C4 alkylcarbonyl, C2-C4 haloalkylcarbonyl, C2-C4 alkoxycarbonyl, C2-C4 alkylaminocarbonyl, C3-C7 dialkylaminocarbonyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C2-C6 alkoxyalkyl, S(O)nR12, C1-C4 alkylamino and C2-C6 dialkylamino.
Embodiment 74. A compound of Embodiment 73 wherein R1 is phenyl optionally substituted with 1 or 2 substituents independently selected from the group consisting of halogen, cyano, C1-C2 haloalkyl, C1-C2 alkoxy and C1-C2 haloalkoxy. Embodiment 75. A compound of Embodiment 73 wherein R1 is 2-, 3- or 4-pyridinyl optionally substituted with halogen, cyano, C1-C2 haloalkyl, C1-C2 alkoxy and C1-C2 haloalkoxy. Embodiment 76. A compound of Embodiment 70 wherein R1 is
Figure imgf000034_0001
Embodiment 77. A compound of Formula Is wherein R2 is C2-C6 alkyl, C1-C6 haloalkyl, C3-C6 alkenyl or C3-C6 haloalkenyl.
Embodiment 78. A compound of Embodiment 70 wherein R2 is CH2CF3 or CR5R6Q. Embodiment 79. A compound of Embodiment 78 wherein R2 is CR5R6Q.
Embodiment 80. A compound of Embodiment 78 wherein R2 is CH2CF3. Embodiment 81. A compound of Embodiment 70 or Embodiment 79 wherein R5 is H or
CH3.
Embodiment 82. A compound of Embodiment 70 or Embodiment 79 wherein R6 is H. Embodiment 83. A compound of Embodiment 70 wherein Q is Q-Ia, Q-2a, Q-3a, Q-4a or Q-5a.
Embodiment 84. A compound of Embodiment 83 wherein Q is Q-Ia or Q-5a. Embodiment 85. A compound of Embodiment 70 wherein R9 is F or Cl. Embodiment 86. A compound of Embodiment 70 wherein R3 and R4 are taken together with the contiguous linking nitrogen and carbon atoms to form an optionally substituted aromatic ring R-2
Figure imgf000034_0002
R-2
Embodiment 87. A compound of Embodiment 70 or Embodiment 86 wherein Z is CH=CH. Of note are compounds of Formulae 1, Ir and Is or any one of Embodiments 1-87 wherein X and Y are O, a composition comprising said compound, and its use for controlling an invertebrate pest.
Embodiments of this invention, including Embodiments 1-87 above as well as any other embodiments described herein, can be combined in any manner, and the descriptions of variables in the embodiments pertain not only to the compounds of Formulae 1, Ir and Is but also to the starting compounds and intermediate compounds useful for preparing the compounds of Formulae 1, Ir and Is. In addition, embodiments of this invention, including
Embodiments 1-87 above as well as any other embodiments described herein, and any combination thereof, pertain to the compositions and methods of the present invention.
Combinations of Embodiments 1-50 are illustrated by: Embodiment A. A compound of Formula 1 wherein X is O; Y is O; R1 is H or halogen; or
R1 is phenyl or a 6-membered heteroaromatic ring, each optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, cyano, nitro, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C1-C4 haloalkyl, C2- C4 haloalkenyl, C2-C4 alkylcarbonyl, C2-C4 haloalkylcarbonyl, C2-C4 alkoxycarbonyl, C2-C4 alkylaminocarbonyl, C3-C7 dialkylaminocarbonyl,
C(O)N-f- CH2Z2CH2^-, C1-C4 alkoxy, C1-C4 haloalkoxy, C2-C6 alkoxyalkyl, S(O)nR12, S(O)2R13, C1-C4 alkylamino, C2-C6 dialkylamino, SF5, Si(CH3)3, CHO, hydroxy, OC(O)R19 and N(R20)C(O)R19; or RMs
Figure imgf000035_0001
R1 is C(Xi)R18 or C(=NOR23)R18; or
R1 is an 8- to 10-membered heteroaromatic bicyclic ring system optionally substituted on carbon ring members with up to 3 substituents independently selected from the group consisting of halogen, cyano, nitro, SF5, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C1-C4 haloalkyl, C2-C4 alkylcarbonyl, C2-C4 haloalkylcarbonyl, C2-C4 alkoxycarbonyl, C2-C4 alkylaminocarbonyl, C3-C7 dialkylaminocarbonyl, C(O)N-f CH2Z2CH2^-, C1-C4 alkoxy, C1-C4 haloalkoxy, C2-C6 alkoxyalkyl, S(O)nR12, S(O)2R13, C1-C4 alkylamino, C2-C6 dialkylamino, Si(CH3)3, CHO, hydroxy, OC(O)R19 and N(R20)C(O)R19, and optionally substituted on nitrogen ring members with methyl; or R1 is phenyl or a 5- or 6-membered heteroaromatic ring, each substituted with GQ1, each optionally substituted with 1 Q2 and each optionally substituted with 1 or 2 substituents independently selected from the group consisting of halogen, cyano, nitro, SF5, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C1-C4 haloalkyl, C2-C4 alkylcarbonyl, C2-C4 haloalkylcarbonyl, C2-C4 alkoxycarbonyl, C2-C4 alkylaminocarbonyl, C3-C7 dialkylaminocarbonyl, C(O)N-f CH2Z2CH2^, C1- C4 alkoxy, C1-C4 haloalkoxy, C2-C6 alkoxyalkyl, S(O)nR12, S(O)2R13, C1-C4 alkylamino, C2-C6 dialkylamino, Si(CH3)3, CHO, hydroxy, OC(O)R19 and N(R20)C(O)R19; G is a direct bond;
Q1 is phenyl or a 5- or 6-membered heteroaromatic ring, each optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, cyano, nitro, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C1-C4 haloalkyl, C2-C4 alkylcarbonyl, C2-C4 haloalkylcarbonyl, C2-C4 alkoxycarbonyl, C2-C4 alkylaminocarbonyl, C3-C7 dialkylaminocarbonyl,
C(O)N-f- CH2Z2CH2^-, C1-C4 alkoxy, C1-C4 haloalkoxy, C2-C6 alkoxyalkyl, S(O)nR12, S(O)2R13, C1-C4 alkylamino, C2-C6 dialkylamino, SF5, Si(CH3)3, CHO, hydroxy, OC(O)R19 and N(R20)C(O)R19; R2 is C2-C6 alkyl, C1-C6 haloalkyl, CH2CO2R21, CR5R6CH2OR21, CR5R6CH2CH2OR21, CR5R6CH2S(O)nR21 or CR5R6CH2CH2S(O)nR21; or
R2 is C3-C6 cycloalkyl or C4-C7 cycloalkylalkyl, each optionally substituted with 1 to 4 substituents selected from the group consisting of halogen, C1-C2 alkyl, 1 cyclopropyl and 1 CF3; or R2 is CR5R6Q; R3 is H, C1-C6 alkyl, C1-C6 haloalkyl, C2-C6 alkenyl, C2-C6 haloalkenyl, C2-C6 alkynyl, C2-C6 haloalkynyl or C≡CR10; or
R3 is C3-C6 cycloalkyl or C4-C7 cycloalkylalkyl, each optionally substituted with 1 to 4 substituents independently selected from the group consisting of halogen, C1- C2 alkyl, 1 cyclopropyl and 1 CF3; R4 is C1-C6 alkyl, C1-C6 haloalkyl, C2-C6 alkenyl, C2-C6 haloalkenyl, C2-C6 alkynyl, C2-C6 haloalkynyl or C≡CR10; or
R4 is C3-C6 cycloalkyl or C4-C7 cycloalkylalkyl, each optionally substituted with 1 to 4 substituents independently selected from the group consisting of halogen, C1- C2 alkyl, 1 cyclopropyl and 1 CF3; or R3 and R4 are taken together with the contiguous linking nitrogen and carbon atoms to form an optionally substituted ring R-I
Figure imgf000037_0001
R-I or ring R-2
Figure imgf000037_0002
R-2
Z is C(R8a)=C(R8b) or S, provided that the C(R8a)=C(R8b) moiety is oriented so the carbon atom bonded to R8b is connected as R3 in Formula 1; each R5 is independently H, F, Cl, cyano or Q-C4 alkyl; each R6 is independently H, F, Cl or CH3; and Q is
Figure imgf000037_0003
Q-I Q-5 Q-6 Q-9
Embodiment B. A compound of Embodiment A wherein
X is O; and Y is O. Embodiment C. A compound of Embodiment B wherein
R3 is C1-C6 alkyl or C1-C6 haloalkyl; and R4 is C1-C6 alkyl or C1-C6 haloalkyl.
Embodiment D. A compound of Embodiment C wherein R3 is CH3; and R4 is CH3.
Embodiment E. A compound of Embodiment B wherein R3 and R4 are taken together with the contiguous linking nitrogen and carbon atoms to form an optionally substituted ring R-I; m is 2 or 3; and p is 0. Embodiment F. A compound of Embodiment B wherein R3 and R4 are taken together with the contiguous linking nitrogen and carbon atoms to form an optionally substituted ring R-2; and
Z is CH=CH or CH=CF, provided that the CH=CF moiety is oriented so the carbon atom bonded to F is connected as R3 in Formula 1.
Embodiment G. A compound of Embodiment B wherein R3 and R4 are taken together with the contiguous linking nitrogen and carbon atoms to form an optionally substituted ring R-2; and Z is S. Embodiment H. A compound of any one of Embodiments C-G wherein
R1 is H or halogen.
Embodiment I. A compound of any one of Embodiments C-G wherein R1 is phenyl or pyridinyl, each optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, cyano, nitro, C1- C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C1-C4 haloalkyl, C2-C4 haloalkenyl,
C2-C4 alkylcarbonyl, C2-C4 haloalkylcarbonyl, C2-C4 alkoxycarbonyl, C2-C4 alkylaminocarbonyl, C3-C7 dialkylaminocarbonyl, C(O)N-f- CH2Z2CH2^, C1- C4 alkoxy, C1-C4 haloalkoxy, C2-C6 alkoxyalkyl, S(O)nR12, S(O)2R13, C1-C4 alkylamino, C2-C6 dialkylamino, SF5, Si(CH3)3, CHO, hydroxy, OC(O)R19 and N(R20)C(O)R19.
Embodiment J. A compound of Embodiment I wherein R1 is phenyl or pyridinyl, each optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, cyano, C1-C4 alkyl, C1-C4 haloalkyl, C2-C4 alkylcarbonyl, C2-C4 alkoxycarbonyl, C2-C4 alkylaminocarbonyl, C3-C7 dialkylaminocarbonyl, C(O)N-f CH2Z2CH2^, C1-
C4 alkoxy, C1-C4 haloalkoxy, C2-C6 alkoxyalkyl, S(O)nR12 and S(O)2R13. Embodiment K. A compound of any one of Embodiments C-G wherein R1 is C(Xi)R18 or C(=NOR23)R18; and X1 is O. Embodiment L. A compound of any one of Embodiments C-G wherein
R1 is phenyl or pyridinyl, each substituted with GQ1 and further optionally substituted with 1 or 2 substituents independently selected from the group consisting of halogen, cyano, nitro, SF5, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C1-C4 haloalkyl, C2-C4 alkylcarbonyl, C2-C4 haloalkylcarbonyl, C2-C4 alkoxycarbonyl, C2-C4 alkylaminocarbonyl, C3-C7 dialkylaminocarbonyl,
C(O)N-f CH2Z2CH2>, C1-C4 alkoxy, C1-C4 haloalkoxy, C2-C6 alkoxyalkyl, S(O)nR12, S(O)2R13, C1-C4 alkylamino, C2-C6 dialkylamino, Si(CH3)3, CHO, hydroxy, OC(O)R19 and N(R20)C(O)R19. Embodiment M. A compound of Embodiment L wherein
R1 is phenyl or pyridinyl, each substituted with GQ1 and further optionally substituted with 1 or 2 substituents independently selected from the group consisting of halogen, cyano, SF5, C1-C4 alkyl, C1-C4 haloalkyl, C2-C4 alkylcarbonyl, C2- C4 alkoxycarbonyl, C2-C4 alkylaminocarbonyl, C3-C7 dialkylaminocarbonyl,
C(O)N-f CH2Z2CH2^-, C1-C4 alkoxy, C1-C4 haloalkoxy, C2-C6 alkoxyalkyl, S(O)nR12 and S(O)2R13; and Q1 is phenyl or pyridinyl, each optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, cyano, C1-C4 alkyl, C1-C4 haloalkyl, C2-C4 alkylcarbonyl, C2-C4 alkoxycarbonyl, C2-C4 alkylaminocarbonyl, C3-C7 dialkylaminocarbonyl, C(O)N-f CH2Z2CH2^, C1- C4 alkoxy, C1-C4 haloalkoxy, C2-C6 alkoxyalkyl, S(O)nR12 and S(O)2R13. Embodiment N. A compound of any one of Embodiments C-G wherein
R2 is C2-C6 alkyl, C1-C6 haloalkyl or CR5R6CH2OR21; or R2 is C4-C7 cycloalkylalkyl optionally substituted with 1 to 4 substituents selected from the group consisting of halogen, C1-C2 alkyl, 1 cyclopropyl and 1 CF3. Embodiment O. A compound of any one of Embodiments C-G wherein
R2 is CR5R6Q.
Embodiment P. A compound of Embodiment O wherein Q is Q-I, Q-5, Q-6 or Q-9;
R5 is H or methyl; R6 is H; each R9a is independently H, halogen, cyano, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, SF5 or S(O)nR12; or C3-C6 cycloalkyl or C4-C7 cycloalkylalkyl, each optionally substituted with 1 to 4 substituents selected from the group consisting of halogen, C1-C2 alkyl, 1 cyclopropyl and 1 CF3; and each R9b is independently H, halogen, cyano, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 alkoxy or C1-C4 haloalkoxy.
Combinations of Embodiments 51-69 are illustrated by: Embodiment Al . A compound of Formula Ir
Figure imgf000039_0001
Ir wherein X is O; Y is O; and
R3 and R4 are taken together with the contiguous linking nitrogen and carbon atoms to form ring R-2
Figure imgf000040_0001
R-2
Embodiment B 1. A compound of Embodiment Al wherein
R1 is phenyl, naphthalenyl or a 5- or 6-membered heteroaromatic ring, each optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, cyano, nitro, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl,
C1-C4 haloalkyl, C2-C4 alkylcarbonyl, C2-C4 haloalkylcarbonyl, C2-C4 alkoxycarbonyl, C2-C4 alkylaminocarbonyl, C3-C7 dialkylaminocarbonyl, C1- C4 alkoxy, C1-C4 haloalkoxy, C2-C6 alkoxyalkyl, S(O)nR12, C1-C4 alkylamino and C2-C6 dialkylamino; or R1 is
Figure imgf000040_0002
Embodiment C 1. A compound of Embodiment B 1 wherein
R2 is C2-C6 alkyl, C1-C6 haloalkyl, C3-C6 alkenyl or C3-C6 haloalkenyl; or
R2 is CR5R6Q; and Q is Q-Ia, Q-2a, Q-3a, Q-4a or Q-5a.
Embodiment D 1. A compound of Embodiment C 1 wherein
Z is CH=CH;
R1 is phenyl optionally substituted with 1 or 2 substituents independently selected from the group consisting of halogen, cyano, C1-C2 haloalkyl, C1-C2 alkoxy and C1- C2 haloalkoxy;
R2 is CH2CF3 or CR5R6Q;
R5 is H or CH3;
Q is Q-Ia or Q-5a;
R6 is H; R9 is F or Cl; and r is 1. Embodiment E 1. A compound of Embodiment C 1 wherein Z is S;
R1 is phenyl optionally substituted with 1 or 2 substituents independently selected from the group consisting of halogen, cyano, C^-C2 haloalkyl, C^-C2 alkoxy and C^- C2 haloalkoxy;
R2 is CH2CF3 or CR5R6Q; R5 is H or CH3; Q is Q-Ia or Q-5a; R6 is H; R9 is F or Cl; and r is 1.
Combinations of Embodiments 70-87 are illustrated by: Embodiment A2. A compound of Formula Is
Figure imgf000041_0001
ls wherein X is O; Y is O; and
R3 and R4 are taken together with the contiguous linking nitrogen and carbon atoms to form an optionally substituted aromatic ring R-2
Figure imgf000041_0002
R-2
Embodiment B2. A compound of Embodiment A2 wherein
R1 is phenyl, naphthalenyl or a 5- or 6-membered heteroaromatic ring, each optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, cyano, nitro, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl,
C1-C4 haloalkyl, C2-C4 alkylcarbonyl, C2-C4 haloalkylcarbonyl, C2-C4 alkoxycarbonyl, C2-C4 alkylaminocarbonyl, C3-C7 dialkylaminocarbonyl, C^- C4 alkoxy, C1-C4 haloalkoxy, C2-C6 alkoxyalkyl, S(O)nR12, C1-C4 alkylamino and C2-C6 dialkylamino; or RMs
Figure imgf000042_0001
Embodiment C2. A compound of Embodiment B2 wherein
R2 is C2-C6 alkyl, C1-C6 haloalkyl, C3-C6 alkenyl or C3-C6 haloalkenyl; or
R2 is CR5R6Q; and
Q is Q-Ia, Q-2a, Q-3a, Q-4a or Q-5a.
Embodiment D2. A compound of Embodiment C2 wherein Z is CH=CH;
R1 is phenyl optionally substituted with 1 or 2 substituents independently selected from the group consisting of halogen, cyano, C1-C2 haloalkyl, C1-C2 alkoxy and C1- C2 haloalkoxy; R2 is CH2CF3 or CR5R6Q; R5 is H or CH3;
Q is Q-Ia or Q-5a; R6 is H;
R9 is F or Cl; and r is 1.
Specific embodiments include compounds of Formula 1 selected from the group consisting of:
3-(2,4-difluorophenyl)-2-hydroxy-4-oxo-l-(2,2,2-trifluoroethyl)-4H- pyrido[l,2-α]pyrimidinium inner salt;
3-(4-fluorophenyl)-2-hydroxy-4-oxo-l-(2,2,2-trifluoroethyl)-4H-pyrido[l,2- αjpyrimidinium inner salt; l-[(6-chloro-3-pyridinyl)methyl]-3-(2,4-difluorophenyl)-2-hydroxy-4-oxo- 4H-pyrido[l,2-α]pyrimidinium inner salt; l-[(6-chloro-3-pyridinyl)methyl]-3-(4-fluorophenyl)-2-hydroxy-4-oxo-4H- pyrido[l,2-α]pyrimidinium inner salt;
3-(3-chlorophenyl)-l-[(2-chloro-5-thiazolyl)methyl]-2-hydroxy-4-oxo-4H- pyrido[l,2-α]pyrimidinium inner salt; l-[(2-chloro-5-thiazolyl)methyl]-2-hydroxy-4-oxo-3-[3- (trifluoromethyl)phenyl]-4H-pyrido[l,2-α]pyrimidinium inner salt; l-[(2-chloro-5-thiazolyl)methyl]-2-hydroxy-4-oxo-3-[3- (trifluoromethoxy)phenyl]-4H-pyrido[l,2-α]pyrimidinium inner salt; l-[(2-chloro-5-thiazolyl)methyl]-3-(4-fluorophenyl)-2-hydroxy-4-oxo-4H- pyrido[l,2-α]pyrimidinium inner salt;
1 -[(2-chloro-5-thiazolyl)methyl]-2-hydroxy-4-oxo-3-phenyl-4H-pyrido[ 1 ,2- αjpyrimidinium inner salt; l-[(2-chloro-5-thiazolyl)methyl]-3-(2,4-difluorophenyl)-2-hydroxy-4-oxo-
4H-pyrido[l,2-α]pyrimidinium inner salt; l-[(2-chloro-5-thiazolyl)methyl]-2-hydroxy-3-(4-methoxyphenyl)-4-oxo-4H- pyrido[l,2-α]pyrimidinium inner salt; l-[(2-chloro-5-thiazolyl)methyl]-2-hydroxy-3-(3-methoxyphenyl)-4-oxo-4H- pyrido[l,2-α]pyrimidinium inner salt; l-[(6-fluoro-3-pyridinyl)methyl]-3-(4-fluorophenyl)-2-hydroxy-4-oxo-4H- pyrido[l,2-α]pyrimidinium inner salt;
3-(3-bromophenyl)-l-[(2-chloro-5-thiazolyl)methyl]-2-hydroxy-4-oxo-4H- pyrido[l,2-α]pyrimidinium inner salt;
3 -(3 -bromophenyl)- 1 -[(6-chloro-3 -pyridinyl)methyl] -2-hydroxy-4-oxo-4H- pyrido[l,2-α]pyrimidinium inner salt; l-[(6-chloro-3-pyridinyl)methyl]-2-hydroxy-4-oxo-3-[3-
(trifluoromethoxy)phenyl]-4H-pyrido[l,2-α]pyrimidinium inner salt; l-[(2-chloro-5-thiazolyl)methyl]-2-hydroxy-4-oxo-3-[4-(trifluoromethyl)-2- pyridinyl]-4H-pyrido[l,2-α]pyrimidinium inner salt; l-[(2-chloro-5-thiazolyl)methyl]-3-(2-cyanophenyl)-2-hydroxy-4-oxo-4H- pyrido[l,2-α]pyrimidinium inner salt;
8-[(6-chloro-3-pyridinyl)methyl]-7-hydroxy-5-oxo-6-phenyl-5H-thiazolo[3,2- αjpyrimidinium inner salt;
8-[(6-chloro-3-pyridinyl)methyl]-6-(4-fluorophenyl)-7-hydroxy-5-oxo-5H- thiazolo[3,2-α]pyrimidinium inner salt;
8-[(6-chloro-3-pyridinyl)methyl]-7-hydroxy-5-oxo-6-[3-
(trifluoromethoxy)phenyl]-5H-thiazolo[3,2-α]pyrimidinium inner salt;
8-[(2-chloro-5-thiazolyl)methyl]-7-hydroxy-5-oxo-6-phenyl-5H-thiazolo[3,2- αjpyrimidinium inner salt;
8-[(2-chloro-5-thiazolyl)methyl]-6-(4-fluorophenyl)-7-hydroxy-5-oxo-5H- thiazolo[3,2-α]pyrimidinium inner salt;
8-[(2-chloro-5-thiazolyl)methyl]-7-hydroxy-5-oxo-6-[3-
(trifluoromethoxy)phenyl]-5H-thiazolo[3,2-α]pyrimidinium inner salt;
3-[3-(6-chloro-3-pyridinyl)phenyl]-l-[(2-chloro-5-thiazolyl)methyl]-2- hydroxy-4-oxo-4H-pyrido[l,2-α]pyrimidinium inner salt;
1 -[(6-fluoro-3 -pyridinyl)methyl] -2-hydroxy-4-oxo-3 - [3 -
(trifluoromethoxy)phenyl]-4H-pyrido[l,2-α]pyrimidinium inner salt; 3-(5-chloro-2-fluorophenyl)-l-[(2-chloro-5-thiazolyl)methyl]-2-hydroxy-4- oxo-4H-pyrido[l,2-α]pyrimidinium inner salt;
1 -[(2-chloro-5 -thiazolyl)methyl]-3 - [2-chloro-5 -(trifluoromethoxy)phenyl] -2- hydroxy-4-oxo-4H-pyrido[l,2-α]pyrimidinium inner salt;
3-(4-fluorophenyl)-2-hydroxy- 1 -[( 1 -methyl- lH-pyrazol-4-yl)methyl]-4-oxo-
4H-pyrido[l,2-α]pyrimidinium inner salt;
2-hydroxy- 1 -[(1 -methyl- lH-pyrazol-4-yl)methyl]-4-oxo-3-phenyl-4H- pyrido[l,2-α]pyrimidinium inner salt; l-[(2-chloro-5-thiazolyl)methyl]-3-(3,5-dimethoxyphenyl)-2-hydroxy-4-oxo-
4H-pyrido[l,2-α]pyrimidinium inner salt; l-[(2-chloro-5-thiazolyl)methyl]-3-[2-fluoro-5-(trifluoromethoxy)phenyl]-2- hydroxy-4-oxo-4H-pyrido[l,2-α]pyrimidinium inner salt;
3-(2-chloro-4-pyridinyl)-l-[(2-chloro-5-thiazolyl)methyl]-2-hydroxy-4-oxo-
4H-pyrido[l,2-α]pyrimidinium inner salt; l-[(2-chloro-5-thiazolyl)methyl]-3-(2-fluoro-5-bromophenyl)-2-hydroxy-4- oxo-4H-pyrido[l,2-α]pyrimidinium inner salt; l-[(2-chloro-5-thiazolyl)methyl]-2-hydroxy-4-oxo-3-(2,4,5-trifluorophenyl)-
4H-pyrido[l,2-α]pyrimidinium inner salt;
3 -[3 -bromo-5 -(trifluoromethoxy)phenyl] - 1 - [(2-chloro-5 -thiazolyl)methyl] -2- hydroxy-4-oxo-4H-pyrido[l,2-α]pyrimidinium inner salt;
3 -[3 -bromo-5 -(trifluoromethyl)phenyl] - 1 - [(2-chloro-5 -thiazolyl)methyl] -2- hydroxy-4-oxo-4H-pyrido[l,2-α]pyrimidinium inner salt; l-[(2-chloro-5-thiazolyl)methyl]-3-[2-fluoro-5-(trifluoromethyl)phenyl]-2- hydroxy-4-oxo-4H-pyrido[l,2-α]pyrimidinium inner salt; l-[(2-chloro-5-thiazolyl)methyl]-2-hydroxy-3-(2-methoxyphenyl)-4-oxo-4H- pyrido[l,2-α]pyrimidinium inner salt; l-[(2-chloro-5-thiazolyl)methyl]-3-(2-fluorophenyl)-2-hydroxy-4-oxo-4H- pyrido[l,2-α]pyrimidinium inner salt; l-[(6-chloro-3-pyridinyl)methyl]-3-(2-fluorophenyl)-2-hydroxy-4-oxo-5H- thiazolo[3,2-α]pyrimidinium inner salt;
2-hydroxy-4-oxo-3-phenyl-l-(2,2,2-trifluoroethyl)-4H-pyrido[l,2- αjpyrimidinium inner salt;
3 -[(6-chloro-3 -pyridinyl)methyl] -5 -(4-fluorophenyl)-3 ,6-dihydro-4-hydroxy- l,2-dimethyl-6-oxopyrimidinium inner salt; l-[(2-chloro-5-thiazolyl)methyl]-3-[3-(6-fluoro-3-pyridinyl)-5-
(trifluoromethyl)phenyl]-2-hydroxy-4-oxo-4H-pyrido[l,2-α]pyrimidinium inner salt;
1 -[ 1 -(6-chloro-3-pyridinyl)ethyl]-3-(4-fluorophenyl)-2-hydroxy-4-oxo-4H- pyrido[l,2-α]pyrimidinium inner salt; l-[(2-chloro-5-thiazolyl)methyl]-3-(ethoxycarbonyl)-2-hydroxy-4-oxo-4H- pyrido[l,2-α]pyrimidinium inner salt;
3 -benzoyl- l-[(2-chloro-5 -thiazolyl)methyl]-2-hydroxy-4-oxo-4H-pyrido[ 1,2- αjpyrimidinium inner salt;
3 -(2,4-difluorophenyl)- 1 - [(6-fluoro-3 -pyridinyl)methyl] -2-hydroxy-4-oxo-
4H-pyrido[l,2-α]pyrimidinium inner salt;
1 -[(6-chloro-3 -pyridinyl)methyl] -2-hydroxy-3 -(3 -methoxyphenyl)-4-oxo-4H- pyrido[l,2-α]pyrimidinium inner salt; l-[(6-chloro-3-pyridinyl)methyl]-3-(2,3-difluorophenyl)-2-hydroxy-4-oxo-
4H-pyrido[l,2-α]pyrimidinium inner salt;
1 -[(6-chloro-3 -pyridinyl)methyl] -3 -(2-fluoro-3 -methoxyphenyl)-2-hydroxy-4- oxo-4H-pyrido[l,2-α]pyrimidinium inner salt;
3 -(3 ,5 -dimethoxyphenyl)- 1 - [(6-fluoro-3 -pyridinyl)methyl] -2-hydroxy-4-oxo-
4H-pyrido[l,2-α]pyrimidinium inner salt;
1 -[(6-fluoro-3 -pyridinyl)methyl] -2-hydroxy-4-oxo-3 - [3 -
(trifluoromethyl)phenyl]-4H-pyrido[l,2-α]pyrimidinium inner salt;
3-(4-fluorophenyl)-2-hydroxy-l-[(2-methyl-5-thiazolyl)methyl]-4-oxo-4H- pyrido[l,2-α]pyrimidinium inner salt;
2-hydroxy-4-oxo-3 -phenyl- 1 - [(5 -thiazolyl)methyl]-4H-pyrido [ 1 ,2- αjpyrimidinium inner salt;
3-(4-fluorophenyl)-2-hydroxy-4-oxo- 1 -[(5-thiazolyl)methyl]-4H-pyrido[ 1 ,2- αjpyrimidinium inner salt;
3 -(2-fluorophenyl)- 1 -[(6-fluoro-3 -pyridinyl)methyl] -2-hydroxy-4-oxo-4H- pyrido[l,2-α]pyrimidinium inner salt;
1 -[(6-chloro-3 -pyridinyl)methyl] -3 - [2-chloro-5 -(trifluoromethyl)phenyl] -2- hydroxy-4-oxo-4H-pyrido[l,2-α]pyrimidinium inner salt;
3 -(2-fluoro-4-cyanophenyl)- 1 - [(6-fluoro-3 -pyridinyl)methyl]-2-hydroxy-4- oxo-4H-pyrido[l,2-α]pyrimidinium inner salt;
1 -[(6-fluoro-3 -pyridinyl)methyl] -3 -[2-fluoro-5 -(trifluoromethyl)phenyl] -2- hydroxy-4-oxo-4H-pyrido[l,2-α]pyrimidinium inner salt; and l-[(2-chloro-5-thiazolyl)methyl]-2-hydroxy-4-oxo-3-[3-(6-trifluoromethyl-3- pyridinyl)phenyl]-4H-pyrido[l,2-α]pyrimidinium inner salt.
Of note is that compounds of this invention are characterized by favorable metabolic and/or soil residual patterns and exhibit activity controlling a spectrum of agronomic and nonagronomic invertebrate pests. Of particular note, for reasons of invertebrate pest control spectrum and economic importance, protection of agronomic crops from damage or injury caused by invertebrate pests by controlling invertebrate pests are embodiments of the invention. Compounds of this invention because of their favorable translocation properties or systemicity in plants also protect foliar or other plant parts which are not directly contacted with a compound of Formula 1 or a composition comprising the compound.
Also noteworthy as embodiments of the present invention are compositions comprising a compound of any of the preceding Embodiments, as well as any other embodiments described herein, and any combinations thereof, and at least one additional component selected from the group consisting of a surfactant, a solid diluent and a liquid diluent, said compositions optionally further comprising at least one additional biologically active compound or agent.
Further noteworthy as embodiments of the present invention are compositions for controlling an invertebrate pest comprising a biologically effective amount of a compound of any of the preceding Embodiments, as well as any other embodiments described herein, and any combinations thereof, and at least one additional component selected from the group consisting of a surfactant, a solid diluent and a liquid diluent, said compositions optionally further comprising a biologically effective amount of at least one additional biologically active compound or agent. Embodiments of the invention also include a composition for protecting an animal comprising a compound (i.e. in a parasiticidally effective amount) of any of the preceding Embodiments and a carrier.
Embodiments of the invention further include methods for controlling an invertebrate pest comprising contacting the invertebrate pest or its environment with a biologically effective amount of a compound of any of the preceding Embodiments (e.g., as a composition described herein). Of particular note is a method for protecting an animal comprising administering to the animal a parasiticidally effective amount of a compound of any of the preceding Embodiments (e.g., as a composition described herein).
Embodiments of the invention also include a composition comprising a compound of any of the preceding Embodiments, in the form of a soil drench liquid formulation. Embodiments of the invention further include methods for controlling an invertebrate pest comprising contacting the soil with a liquid composition as a soil drench comprising a biologically effective amount of a compound of any of the preceding Embodiments.
Embodiments of the invention also include a spray composition for controlling an invertebrate pest comprising a biologically effective amount of a compound of any of the preceding Embodiments and a propellant. Embodiments of the invention further include a bait composition for controlling an invertebrate pest comprising a biologically effective amount of a compound of any of the preceding Embodiments, one or more food materials, optionally an attractant, and optionally a humectant. Embodiments of the invention also include a device for controlling an invertebrate pest comprising said bait composition and a housing adapted to receive said bait composition, wherein the housing has at least one opening sized to permit the invertebrate pest to pass through the opening so the invertebrate pest can gain access to said bait composition from a location outside the housing, and wherein the housing is further adapted to be placed in or near a locus of potential or known activity for the invertebrate pest.
Embodiments of the invention also include a method for protecting a seed from an invertebrate pest comprising contacting the seed with a biologically effective amount of a compound of any of the preceding Embodiments (e.g., as a composition described herein).
Embodiments of the invention also include methods for protecting an animal from an invertebrate parasitic pest comprising administering to the animal a parasiticidally effective amount of a compound of any of the preceding Embodiments.
Embodiments of the invention also include methods for controlling an invertebrate pest comprising contacting the invertebrate pest or its environment with a biologically effective amount of a compound of Formula 1, an JV-oxide or a salt thereof, (e.g., as a composition described herein), provided that the methods are not methods of medical treatment of a human or animal body by therapy.
This invention also relates to such methods wherein the invertebrate pest or its environment is contacted with a composition comprising a biologically effective amount of a compound of Formula 1, an JV-oxide or a salt thereof, and at least one additional component selected from the group consisting of surfactants, solid diluents and liquid diluents, said composition optionally further comprising a biologically effective amount of at least one additional biologically active compound or agent, provided that the methods are not methods of medical treatment of a human or animal body by therapy.
One or more of the following methods and variations as described in Schemes 1-19 can be used to prepare the compounds of Formula 1. The definitions of R1, R2, R3, R4, R9, R10, R18, R23, X and Y in the compounds of Formulae 1-22 below are as defined above in the Summary of the Invention unless otherwise noted. Formulae Ia-Il are various subsets of Formula 1, and all substituents for Formulae Ia-Il are as defined above for Formula 1 unless otherwise indicated. Ambient or room temperature is defined as about 20-25 0C.
Compounds of Formula Ia (i.e. Formula 1 wherein X and Y are O) can be prepared by condensation of appropriately substituted compounds of Formula 2 with optionally substituted malonic acids (3a) in the presence of condensing agents as shown in Scheme 1. Condensing agents can be carbodiimides such as dicyclohexyl carbodiimide (see, for example, Koch, A. et al. Tetrahedron 2004, 60, 10011-10018) or other agents well known in the art to form amide bonds with or without activating agents such as JV-hydroxybenzotriazole as described in Science of Synthesis 2005, 21, 17-25 and Tetrahedron 2005, 61, 10827-10852. This reaction is typically carried out in an inert organic solvent, such as dichloromethane or 1 ,2-dichloroethane, at temperatures from about 0 to about 80 0C for a period of 10 min to several days.
Scheme 1
Figure imgf000048_0001
Compounds of Formula Ia can also be prepared by the condensation of compounds of Formula 2 with malonic acid esters (3b) wherein R is a C1-C5 alkyl group, preferably a C^- C4 alkyl group, as shown in Scheme 2. These reactions can be performed neat or in the presence of inert solvents as described in Bulletin of the Chemical Society of Japan 1999, 72(3), 503-509. Inert solvents include, but are not limited to, high boiling hydrocarbons such as mesitylene, tetralin or cymene, or high boiling ethers such as diphenyl ether. Typical temperatures range from 50 to 250 0C. Of note are temperatures from 150 to 200 0C, which typically provide rapid reaction times and high yields. These reactions can also be performed in microwave reactors within the same temperature ranges. Typical reaction times range from 5 min to several hours.
Compounds of the Formula 3a can be prepared by a variety of methods known in the art, for example by base hydrolysis of compounds of Formula 3b. Compounds of Formula 3b can be prepared by arylation of malonate esters catalyzed by palladium (J. Org. Chem 2002, 67, 541-555) or copper (Org. Lett. 2002, 4, 269-272 and Org. Lett. 2005, 7, 4693- 4695).
Scheme 2
Figure imgf000048_0002
2 3b (R iS C1-C5 alkyl) la
Compounds of Formula Ia can also be prepared by treatment of compounds of
Formula 2 with activated esters of Formula 3c wherein LvO is an activated leaving group as shown in Scheme 3. Examples of Lv preferred for ease of synthesis or reactivity are 2,4,6- trichlorophenyl, pentachlorophenyl or pentafluorophenyl as described in Archiv der Pharmazie (Weinheim, Germany) 1991, 324, 863-6. Other activated esters are well known in the art and include, but are not limited to, iV-hydroxysuccinimide esters (see, for example, J. Am. Chem. Soc. 2002, 124, 6872-6878). Typical temperatures range from 50 to 200 0C. Of note are temperatures from 50 to 150 0C, which typically provide rapid reaction times and high yields. These reactions can be performed with or without solvent, such as toluene, and in microwave reactors within the same temperature ranges. Typical reaction times range from 5 min to 2 h.
Scheme 3
Figure imgf000049_0001
Compounds of the Formula 3c can be prepared, for example, from compounds of
Formula 3a (see, for example, J. Het. Chem. 1980, 17, 337).
Compounds of Formula Ia can also be prepared by condensation of compounds of Formula 2 with compounds of Formulas 3d or 3e, or by condensation of compounds of Formula 2 with mixtures of compounds of Formulae 3d and 3e as shown in Scheme 4. These reactions are typically performed in an inert solvent, such as dichloromethane, and optionally in the presence of two or more equivalents of an acid acceptor (see, for example, Zeitschrift fiir Naturforschung, Teil B: Anorganische Chemie, Organische Chemie 1982, 37B(2), 222-33). Typical acid acceptors include, but are not limited to, triethylamine, JV,JV-diisopropylethylamine, pyridine and substituted pyridines. Scheme 4
Figure imgf000049_0002
3e Compounds of Formula Ib (i.e. Formula Ia wherein R1 is H) can be prepared by condensation of compounds of Formula 2 with carbon suboxide (3f) (see, for example, J. Org. Chem. 1972, 37(9), 1422-5) as shown in Scheme 5. The reactions are typically performed in an inert solvent such as ether and can include the use of a catalyst such as AlCl3.
Scheme 5
Figure imgf000050_0001
Ib
Compounds of Formula 2 can be prepared in a variety of ways known in the art; see, for example, Patai, S. The Chemistry of Functional Groups: The Chemistry of Amidines and Imidates; Wiley: Chichester, UK, 1975; The Chemistry of Amidines and Imidates; Patai, S.; Rappoport, Z., Eds.; Wiley: Chichester, UK, 1991; Vol. 2; Mega, T. et al. Bulletin of the Chemical Society of Japan 1988, 61(12), 4315-21; Ife, R. et al. European Journal of Medicinal Chemistry 1989, 24(3), 249-57; Wagaw, S.; Buchwald, S. Journal of Organic Chemistry 1996, 61(21), 7240-7241; Shen, Q. et al. Angewandte Chemie, International Edition 2005, 44(9), 1371-1375; and Okano, K. et al. Organic Letters 2003, 5(26), 4987- 4990.
Compounds of Formula Ia wherein R1 is CR24=C(R24)R10, optionally substituted phenyl, naphthalenyl, a 5- or 6-membered heteroaromatic ring or an 8- to 10-membered heteroaromatic bicyclic ring system can be prepared from compounds of Formula Id (i.e. Formula 1 wherein R1 is Cl, Br or I, preferably wherein R1 is Br or I) and compounds of Formula 4 wherein M with R1 forms a boronic acid, boronic acid ester or trifluoroborate salt, or M is trialkylstannyl or zinc and R1 is CR24=C(R24)R10, optionally substituted phenyl, naphthalenyl, a 5- or 6-membered heteroaromatic ring or an 8- to 10-membered heteroaromatic bicyclic ring system as shown in Scheme 6. Scheme 6
Figure imgf000050_0002
Id Ia Compounds of Formula Ie (i.e. Formula Ia wherein R2 is CR5R6Q, and Q is a heterocycle substituted with a phenyl or a 5- or 6-membered heteroaromatic ring) can be prepared from compounds of Formula If and compounds of Formula 4a wherein M with R9c forms a boronic acid, boronic acid ester or trifluoroborate salt, or M is trialkylstannyl or zinc and R9c is a phenyl or a 5- or 6-membered heteroaromatic ring as shown in Scheme 7.
Scheme 7
Figure imgf000051_0001
If Ie
Compounds of Formula Ig (i.e. Formula Ia wherein R1 is phenyl or pyridyl substituted with GQ1 and G is a direct bond) can be prepared from compounds of Formula Ih (i.e. Formula Ia wherein R1 is phenyl substituted with Br or I) and compounds of Formula 4b wherein M with Q1 forms a boronic acid, boronic acid ester or trifluoroborate salt, or M is trialkylstannyl or zinc, and Q1 is a phenyl or 5- or 6-membered heteroaromatic ring) as shown in Scheme 8.
Scheme 8
Figure imgf000051_0002
Ih Ig
The reactions of Schemes 6, 7 and 8 are typically carried out in the presence of a palladium catalyst and a base optionally under an inert atmosphere. The palladium catalysts used for the reactions of Schemes 6, 7 and 8 typically comprises palladium in a formal oxidation state of either 0 (i.e. Pd(O)) or 2 (i.e. Pd(II)). A wide variety of such palladium- containing compounds and complexes are useful as catalysts for these reactions. Examples of palladium-containing compounds and complexes useful as catalysts in the methods of Schemes 7, 8 and 9 include PdCl2(PPh3)2 (bis(triphenylphosphine)palladium (II) dichloride), Pd(PPh3)4 (tetrakis(triphenylphosphine)palladium(O)), Pd(C5H7O2)2 (palladium(II) acetyl- acetonate), Pd2(dba)3 (tris(dibenzylideneacetone)dipalladium(O)), and [l,l'-bis(diphenyl- phosphino)ferrocene]dichloropalladium(II). The methods of Schemes 6, 7 and 8 are generally conducted in a liquid phase, and therefore to be most effective the palladium catalyst preferably has good solubility in the liquid phase. Useful solvents include, for example, water, ethers such as 1 ,2-dimethoxyethane, amides such as N^/V-dimethyl- acetamide, and non-halogenated aromatic hydrocarbons such as toluene.
The methods of Schemes 6, 7 and 8 can be conducted over a wide range of temperatures, ranging from about 25 to about 200 0C. Of note are temperatures from about 60 to about 150 0C, which typically provide fast reaction times and high product yields. The general methods and procedures for Stille, Negishi and Suzuki couplings with aryl iodides, bromides or chlorides and an aryl tin, aryl zinc or aryl boronic acid respectively are well known in the literature; see, for example, E. Negishi, Handbook of Organopalladium Chemistry for Organic Synthesis, Wiley-Interscience, 2002, New York, New York.
Compounds of Formula Ia wherein R1 is optionally substituted phenyl, naphthalenyl, a 5- or 6-membered heteroaromatic ring or an 8- to 10-membered heteroaromatic bicyclic ring system can be prepared from compounds of Formula Ib (i.e. Formula Ia wherein R1 is H) and compounds of Formula 5 wherein X1 is Cl, Br or I (preferably wherein X1 is Br or I) as shown in Scheme 9.
Scheme 9
Cu source and Ligand
Figure imgf000052_0002
Figure imgf000052_0001
Ib Ia These reactions are typically carried out in the presence of a copper catalyst optionally under an inert atmosphere. The copper catalysts used for the present method typically comprise copper in metallic form (e.g., as a powder) or copper in a formal oxidation state of 1 (i.e. Cu(I)). Examples of copper-containing compounds useful as catalysts in the method of Scheme 9 include, but are not limited to, Cu, CuI, CuBr, CuCl. Useful solvents for the method of Scheme 9 include, for example, ethers such as 1,4-dioxane, amides such as JV,iV-dimethylacetamide and dimethyl sulfoxide.
The method of Scheme 9 can be conducted over a wide range of temperatures from 25 to 200 0C. Of note are temperatures from 40 to 150 0C. The method of Scheme 9 can be conducted in the presence of a ligand. A wide variety of such copper-binding compounds are useful as ligands for the present method. Examples of useful ligands include, but are not limited to, 1,10-phenanthroline, N,Λ/-dimethylethylenediamine, L-proline and 2-picolinic acid. The general methods and procedures for copper-catalyzed Ullmann-type coupling reactions are well known in the literature; see, for example, Xie, Ma, et al. Org. Lett. 2005, 7, 4693-4695.
Compounds of Formula Ii can be prepared from compounds of Formula Ib by carbonylation with compounds of Formula 6 as shown in Scheme 10. Examples of carbonylation agents of Formula 6 useful in the method of Scheme 10 include, but are not limited to, aliphatic or aromatic carboxylic acids, acid anhydrides, acid halides, isocyanates and isothiocyanates. Typically the reaction is performed in an inert solvent, more typically a polar solvent such as JV,iV-dimethylacetamide or l-methyl-2-pyrrolidinone. The reaction is typically performed at temperatures from 0 to 180 0C, more typically at ambient temperature to 150 0C. Microwave irradiation can be advantageous in heating the reaction mixture.
Scheme 10
Figure imgf000053_0001
Ib R18aNC(O) or R18aNC(S) Ii
Ra is R18 or NHR18a
Compounds of the Formula Ij can be prepared by reacting compounds of Formula Ii with an alkoxyamine salt of the Formula 7, where X3 is a counterion such as halide or oxalate, as shown in Scheme 11. The reaction can be run in an alcoholic solvent such as ethanol or propanol at temperatures ranging from 80 0C to the reflux temperature of the solvent in 3 to 24 hours.
Scheme 11
Figure imgf000053_0002
Ii Ij
Compounds of Formula Ia wherein R1 is C(=NNR20R23)R18, C(=NNR20C(O)R23)R18, C(=NNR20C(O)OR23a)R18 or C(=NNR20C(O)NR20R23)R18 can be prepared from compounds of Formula Ii and the appropriately substituted hydrazine by the method shown in Scheme 11.
Compounds of Formula Ia wherein R1 is C2-C6 alkynyl, C2-C6 haloalkynyl or C≡CR10 can be prepared from compounds of Formula Id (i.e. Formula Ia wherein R1 is Cl, Br or I) and substituted alkynes of Formula 8 by a Sonigashira coupling reaction as shown in Scheme 12. Sonigashira couplings are well known in the literature. See, for example, K. Sonogashira, Sonogashira Alkyne Synthesis VoI 2, p. 493 in E. Negishi, Handbook of Organopalladium Chemistry for Organic Synthesis, Wiley-Interscience, 2002, New York, New York.
Scheme 12
Figure imgf000054_0001
Compounds of Formula Id can be prepared from compounds of Formula Ib by halogenation using, for example, liquid bromine or JV-halosuccinimides (9) as shown in Scheme 13. Typically the reaction is performed in an inert solvent, more typically a halogenated solvent such as methylene chloride or 1,2-dichloroethane. The reaction is typically performed at temperatures from 0 to 80 0C, more typically at ambient temperature.
Scheme 13
Figure imgf000054_0002
Compounds of Formula Ik (i.e. Formula Ia wherein R3 and R4 are taken together to form an optionally substituted carbocyclic ring R-I wherein m is 2) can be prepared from compounds of Formula 11 (i.e. Formula 1 wherein R3 and R4 are taken together to form an optionally substituted aromatic ring R-2 wherein Z is CH=CH) by reduction using hydrogen in the presence of a platinum group metal or metal oxide catalyst as shown in Scheme 14. Typically the platinum group metal is platinum or palladium or their oxides and the reduction is performed in an inert solvent (see, for example, Kappe, Thomas, et al. Heterocycles 1995, 40, 681-9). Suitable solvents include, but are not limited to, methanol, ethanol, tetrahydrofuran and methyl t-butyl ether. The reaction is typically performed at ambient temperature and at approximately 100 kPa of pressure.
Scheme 14
Figure imgf000055_0001
Compounds of Formula 11 can be prepared from compounds of Formula 2 (wherein R3 and R4 are taken together with the contiguous linking nitrogen and carbon atoms to form ring R-I and Z is CH=CH) by the methods shown in Schemes 1 through 5.
Compounds of Formula Ia can also be prepared by alkylation of compounds of Formula 10 using appropriately substituted alkylating agents and bases such as potassium carbonate as shown in Scheme 15 (see, for example, Kappe, T. et al. Monatschefte fur Chemie 1971, 102, 412-424 and Urban, M. G.; Arnold,W. Helvetica Chimica Acta 1970, 53, 905-922). Alkylating agents include, but are not limited to, alkyl chlorides, bromides, iodides and sulfonate esters. A wide variety of bases and solvents can be employed in the method of Scheme 15, and these bases and solvents are well known in the art.
Scheme 15
Figure imgf000055_0002
10 Ia
Compounds of Formula 10 can be prepared from compounds of Formula 2a by methods analogous to those shown in Schemes 1 through 5. Compounds of Formula 2a are commercially available or can be prepared by general methods well known in the art.
Figure imgf000055_0003
2a One skilled in the art will appreciate that compounds of Formula 2 wherein R3 and R4 are taken together to form ring R-2 and wherein Ra is the subset of R2 substituents containing a terminal CH2 group can be prepared by general methods well known in the art. For example, Scheme 16 illustrates a method wherein a compound of Formula 12 is acylated with a compound of Formula 13 in the presence of an appropriate base. The resulting intermediate of Formula 14 is reduced with an appropriate reagent such as diborane to provide the compound of Formula 11.
Scheme 16 bbaassee
Figure imgf000056_0001
Figure imgf000056_0002
Figure imgf000056_0003
11 Compounds of Formula 11a (compounds of Formula 11 where Z is CH=CH) can be prepared by direct displacement reaction of alpha-halopyridine compounds of Formula 15 by suitable amines of Formula 16 as shown in Scheme 17. Examples of alpha-halopyridine compounds useful in the method of Scheme 17 include, but are not limited to, 2- fluoropyridine and 2-chloropyridine. Examples of suitable amines include, but are not limited to, 2,2,2-trifluoroethylamine and 5-aminomethyl-2-chloropyridine. Typically the reaction is performed in an inert solvent, more typically a polar solvent such as JV,iV-dimethylacetamide or l-methyl-2-pyrrolidinone. The reaction is typically performed at temperatures from 0 to 250 0C, more typically at ambient temperature to 150 0C. Alternatively, the reaction can be performed in a sealed tube in a laboratory microwave reactor; typical reaction temperatures are from 200 to 240 0C. The hydrochloride salts of the compounds of Formula 15 are suitable starting materials for this method.
Scheme 17
Figure imgf000056_0004
X is halogen Compounds of Formula 11 can be prepared by reductive amination reaction between amines of Formula 12 and suitable aldehydes of Formula 17. These reactions are either performed in one-pot or by stepwise reaction via the imine intermediate of Formula 18 as shown in Scheme 18. Examples of amine compounds useful in the method of Scheme 18 include, but are not limited to, 2-aminopyridine and 2-aminothiazole. Examples of suitable aldehydes in the method of Scheme 18 include, but are not limited to, 6- chloronicotinaldehyde. Examples of suitable reducing agents in the method of Scheme 18 include, but are limited to, sodium borohydride, zinc borohydride and sodium cyanoborohydride. General methods and procedures for reductive amination reactions are well known in the literature; see, for example, Abdel-Magid, et al. J. Org. Chem. 1996, 61(11), 3849-3862.
Scheme 18
Figure imgf000057_0001
12 17
18 reducing
Z is C(R8)=C(R8), agent S, O or NCH3
Figure imgf000057_0002
11
An alternative method for the preparation of compounds of Formula 11 is shown in Scheme 19. In the method of Scheme 19, compounds of Formula 12 are protected with suitable protecting groups such as, but not limited to, te/t-butoxycarbonyl, acetyl or formyl to form the intermediate of Formula 20 wherein PG is a protecting group. The compound of Formula 20 is then alkylated with an appropriate reagent of Formula 21 (wherein Ra is the subset of R2 substituients containing a terminal CH2 group and X5 is a leaving group such as a halogen) to give an intermediate of Formula 22. The protecting group is removed to provide a compound of Formula 11. Conditions for the formation and removal of protecting groups on an amine function are known in the literature (see, for example, Greene, T. W.; Wuts, P. G. M. Protective Groups in Organic Synthesis, 2nd ed.; Wiley: New York, 1991). Scheme 19
Figure imgf000058_0001
S, O or NCH3
Figure imgf000058_0002
Compounds of Formula 1 wherein X and/or Y are S can be prepared from corresponding compounds of Formula Ia by general methods known in the art involving treatment with thionating reagents such as P4S10 or Lawessen's Reagent (2,4-bis-(4- methoxyphenyl)-l,3-dithia-2,4-diphosphetane 2,4-disulfϊde). Alternatively, malonic acids of Formula 3a can be treated with P2S6(CH3)2 as described in J. Am. Chem. Soc. 1988, 110 (4), 1316-1318. The resulting malonic acid sulfur derivatives can then be used to prepare the compounds of Formula 1 wherein X and/or Y are S by the method of Scheme 1. Schemes 1 through 19 illustrate methods to prepare compounds of Formula 1 having a variety of substituents noted for R1, R2, R3 and R4. Compounds of Formula 1 having R1, R2, R3 and R4 substituents other than those particularly noted for Schemes 1 through 19 can be prepared by general methods known in the art of synthetic organic chemistry, including methods analogous to those described for Schemes 1 to 19. Examples of intermediates useful in the preparation of compounds of this invention are shown in Tables 1-1 through 1-19. The following abbreviations are used in the Tables which follow: Me means methyl, Et means ethyl and C(O)O(2,4,6-trichlorophenyl) means
Figure imgf000058_0003
. TABLE I-I
Figure imgf000059_0001
Rx is C(O)OH and RJ is H
Ra ώ R£ R£
H H H H H
F H H H H
H F H H H
H H F H H
OMe H H H H
H OMe H H H
H H OMe H H
F F H H H
F H F H H
F H H F H
F H H H F
Cl H H H H
H Cl H H H
H H Cl H H
H Br H H H
H I H H H
H Cl H Cl H
H Cl H Br H
H Cl H OCF3 H
H Cl H CF3 H
H Br H Br H
H Br H OCF3 H
H Br H CF3 H
H H cyano H H
F H cyano H H
H OCF3 H H H
H CF3 H H H
H SCF3 H H H Ra ώ R£ S^ Ef
F H H Cl H
F H H Br H
F H H OCF3 H
F H H CF3 H
F H H OMe H
F H H SCF3 H
Cl H H OCF3 H
Cl H H CF3 H
H H H SF5 H
Cl H H SF5 H
H OCF2H H H H
H H OCF2H H H
F F H F H
F H F H F
F H F H
F F F H H
H OMe H OMe H
F OMe H H H
OMe H H Cl H
OMe H H Br H
OMe H H OCF3 H
OMe H H CF3 H
H CF3 H CF3 H
Me H H H H
H Me H H H
H H Me H H
H 6-fluoro-3 -pyridinyl H H H
H 6-chloro-3 -pyridinyl H H H
H 6-bromo-3 -pyridinyl H H H
H 6-trifluoromethyl-3 -pyridinyl H H H
Figure imgf000060_0001
H 6-fluoro-3 -pyridinyl H OMe H
H 6-chloro-3 -pyridinyl H OMe H
H 6-bromo-3 -pyridinyl H OMe H
H 6-trifluoromethyl-3 -pyridinyl H OMe H Ra ώ R£ S^ Ef
H 6- fluoro 3 -pyridinyl H CF3 H
H 6-chloro-3 -pyridinyl H CF3 H
H 6-bromo-3 -pyridinyl H CF3 H
H 6-trifluoromethyl-3 -pyridinyl H CF3 H
H 6-fluoro-3 -pyridinyl H Br H
H 6-chloro-3 -pyridinyl H Br H
H 6-bromo-3 -pyridinyl H Br H
H 6-trifluoromethyl-3 -pyridinyl H Br H
H 6-fluoro-3 -pyridinyl H Cl H
H 6-chloro3 -pyridinyl H Cl H
H 6-bromo-3 -pyridinyl H Cl H
H 6-trifluoromethyl-3 -pyridinyl H Cl H
H 6-fluoro-3 -pyridinyl OMe H H
H 6-chloro-3 -pyridinyl OMe H H
H 6-bromo-3 -pyridinyl OMe H H
H 6-trifluoromethyl-3 -pyridinyl OMe H H
H 6-fluoro-3 -pyridinyl F H H
H 6-chloro-3 -pyridinyl F H H
H 6-bromo-3 -pyridinyl F H H
H 6-trifluoromethyl-3 -pyridinyl F H H
SCF3 H H Cl H
SCF3 H H Br H
SCF3 H H OCF3 H
SCF3 H H CF3 H
SCF3 H H SCF3 H
SCF3 H H 6-trifluoromethyl-3 -pyridinyl H
SCF3 H H 6-fluoro-3 -pyridinyl H
SCF3 H H 6- chloro 3 -pyridinyl H
SCF3 H H 6-bromo-3 -pyridinyl H
TABLE 1-2 Table 1-2 is constructed the same as Table 1-1, except that Rx is C(O)OMe and Ry is H.
TABLE 1-3 Table 1-3 is constructed the same as Table 1-1, except that Rx is C(O)OEt and Ry is H.
TABLE 1-4 Table 1-4 is constructed the same as Table 1-1, except that Rx is C(O)OH and Ry is C(O)OH. TABLE 1-5
Table 1-5 is constructed the same as Table 1-1, except that Rx is C(O)OH and Ry is C(O)OMe.
TABLE 1-6 Table 1-6 is constructed the same as Table I- 1 , except that Rx is C(O)OH and RY is C(O)OEt.
TABLE 1-7
Table 1-7 is constructed the same as Table 1-1, except that Rx is C(O)OH and Ry is C(O)OC(CH3)3.
TABLE 1-8 Table 1-8 is constructed the same as Table 1-1, except that Rx is C(O)Cl and Ry is C(O)Cl.
TABLE 1-9
Table 1-9 is constructed the same as Table 1-1, except that Rx is C(O)OMe and Ry is C(O)OMe.
TABLE I-10 Table I- 10 is constructed the same as Table 1-1, except that Rx is C(O)OEt and Ry is C(O)OEt.
TABLE I-I l
Table 1-11 is constructed the same as Table 1-1, except that Rx is C(O)OC(CH3)3 and Ry is C(O)OC(CH3)3. TABLE 1-12
Table 1-12 is constructed the same as Table 1-1, except that Rx is C(O)O(2,4,6- trichlorophenyl) and Ry is C(O)O(2,4,6-trichlorophenyl).
TABLE I- 12a
Table I- 12a is constructed the same as Table 1-1, except that Rx is H and Ry is C(O)OC(CH3)3.
TABLE 1-13
Figure imgf000062_0001
gy gy
H C(O)OH C(O)OMe C(O)OMe H C(O)OMe C(O)OEt C(O)OEt R-. Ry R* gy
H C(O)OEt C(O)OC(CH3)3 C(O)OC(CH3)3
C(O)OH C(O)OH C(O)OH C(O)OMe
C(O)Cl C(O)Cl C(O)OH C(O)OEt
C(O)O(2,4,6-trichlorophenyl) C(O)O(2,4,6-trichlorophenyl) C(O)OH C(O)OC(CH3)3
H C(O)OC(CH3)3
TABLE 1-14
Figure imgf000063_0001
gy SΞ gy
H C(O)OH C(O)OMe C(O)OMe
H C(O)OMe C(O)OEt C(O)OEt
H C(O)OEt C(O)OC(CH3)3 C(O)OC(CH3)3
C(O)OH C(O)OH C(O)OH C(O)OMe
C(O)Cl C(O)Cl C(O)OH C(O)OEt
C(O)O(2,4,6-trichlorophenyl) C(O)O(2,4,6-trichlorophenyl) C(O)OH C(O)OC(CH3)3
H C(O)OC(CH3)3
TABLE 1-15
Figure imgf000063_0002
gy gΞ gy
H C(O)OH C(O)OMe C(O)OMe
H C(O)OMe C(O)OEt C(O)OEt
H C(O)OEt C(O)OC(CH3)3 C(O)OC(CH3)3
C(O)OH C(O)OH C(O)OH C(O)OMe
C(O)Cl C(O)Cl C(O)OH C(O)OEt R^ Ry gf gy
C(O)O(2,4,6-trichlorophenyl) C(O)O(2,4,6-trichlorophenyl) C(O)OH C(O)OC(CH3)3 H C(O)OC(CH3)3
TABLE 1-16
Figure imgf000064_0001
SΞ gy SΞ gy
H C(O)OH C(O)OMe C(O)OMe
H C(O)OMe C(O)OEt C(O)OEt
H C(O)OEt C(O)OC(CH3)3 C(O)OC(CH3)3
C(O)OH C(O)OH C(O)OH C(O)OMe
C(O)Cl C(O)Cl C(O)OH C(O)OEt
C(O)O(2,4,6-trichlorophenyl) C(O)O(2,4,6-trichlorophenyl) C(O)OH C(O)OC(CH3)3
H C(O)OC(CH3)3
TABLE 1-17
Figure imgf000064_0002
gy gΞ gy
H C(O)OH C(O)OMe C(O)OMe
H C(O)OMe C(O)OEt C(O)OEt
H C(O)OEt C(O)OC(CH3)3 C(O)OC(CH3)3
C(O)OH C(O)OH C(O)OH C(O)OMe
C(O)Cl C(O)Cl C(O)OH C(O)OEt
C(O)O(2,4,6-trichlorophenyl) C(O)O(2,4,6-trichlorophenyl) C(O)OH C(O)OC(CH3)3
H C(O)OC(CH3)3 TABLE 1-18
Figure imgf000065_0001
Si- SZ s± SZ
H CF3 H CH2CHFCF2Cl
Me CF3 Me CH2CHFCF2Cl
H Et H cyclopropyl
Me Et Me cyclopropyl
H 3-pyridinyl H 6-methyl-3 -pyridinyl
Me 3-pyridinyl Me 6-methyl-3 -pyridinyl
H 6-fluoro-3 -pyridinyl H 6-chloro-3 -pyridinyl
Me 6-fluoro-3 -pyridinyl Me 6-chloro-3 -pyridinyl
H 6-bromo-3 -pyridinyl H 5 -thiazolyl
Me 6-bromo-3 -pyridinyl Me 5 -thiazolyl
H 2 -methyl- 5 -thiazolyl H 2 - fluoro- 5 -thiazolyl
Me 2 -methyl- 5 -thiazolyl Me 2 - fluoro- 5 -thiazolyl
H 2 - chloro 5 -thiazolyl H 2-bromo-5-thiazolyl
Me 2-chloro-5-thiazolyl Me 2-bromo-5-thiazolyl
H 1 -methyl-4-pyrazolyl H 3-methyl-5-isoxazoly~
Me 1 -methyl-4-pyrazolyl Me 3-methyl-5-isoxazoly~
TABLE 1-19
Figure imgf000065_0002
SΞ SZ SΞ SZ
H CF3 H CH2CHFCF2Cl
Me CF3 Me CH2CHFCF2Cl
H Et H cyclopropyl
Me Et Me cyclopropyl
H 3-pyridinyl H 6-methyl-3 -pyridinyl
Me 3-pyridinyl Me 6-methyl-3 -pyridinyl Rf- Ry Si- EZ
H 6-fluoro-3 -pyridinyl H 6-chloro-3 -pyridinyl
Me 6-fluoro-3 -pyridinyl Me 6-chloro-3 -pyridinyl
H 6-bromo-3 -pyridinyl H 5 -thiazolyl
Me 6-bromo-3 -pyridinyl Me 5 -thiazolyl
H 2 -methyl- 5 -thiazolyl H 2 - fluoro- 5 -thiazolyl
Me 2 -methyl- 5 -thiazolyl Me 2 - fluoro- 5 -thiazolyl
H 2 - chloro 5 -thiazolyl H 2-bromo-5-thiazolyl
Me 2-chloro-5-thiazolyl Me 2-bromo-5-thiazolyl
H 1 -methyl-4-pyrazolyl H 3-methyl-5-isoxazoly~
Me 1 -methyl-4-pyrazolyl Me 3-methyl-5-isoxazoly~
It is recognized that some reagents and reaction conditions described above for preparing compounds of Formula 1 may not be compatible with certain functionalities present in the intermediates. In these instances, the incorporation of protection/deprotection sequences or functional group interconversions into the synthesis will aid in obtaining the desired products. The use and choice of the protecting groups will be apparent to one skilled in chemical synthesis (see, for example, Greene, T. W.; Wuts, P. G. M. Protective Groups in Organic Synthesis, 2nd ed.; Wiley: New York, 1991). One skilled in the art will recognize that, in some cases, after the introduction of a given reagent as it is depicted in any individual scheme, it may be necessary to perform additional routine synthetic steps not described in detail to complete the synthesis of compounds of Formula 1. One skilled in the art will also recognize that it may be necessary to perform a combination of the steps illustrated in the above schemes in an order other than that implied by the particular sequence presented to prepare the compounds of Formula 1. One skilled in the art will also recognize that compounds of Formula 1 and the intermediates described herein can be subjected to various electrophilic, nucleophilic, radical, organometallic, oxidation, and reduction reactions to add substituents or modify existing substituents.
Without further elaboration, it is believed that one skilled in the art using the preceding description can utilize the present invention to its fullest extent. The following Synthesis Examples are, therefore, to be construed as merely illustrative, and not limiting of the disclosure in any way whatsoever. Steps in the following Synthesis Examples illustrate a procedure for each step in an overall synthetic transformation, and the starting material for each step may not have necessarily been prepared by a particular preparative run whose procedure is described in other Examples or Steps. Ambient or room temperature is defined as about 20-25 0C. Percentages are by weight except for chromatographic solvent mixtures or where otherwise indicated. Parts and percentages for chromatographic solvent mixtures are by volume unless otherwise indicated. 1H NMR spectra are reported in ppm downfϊeld from tetramethylsilane; "s" means singlet, "d" means doublet, "dd" means doublet of doublets, "ddd" means doublet of doublet of doublets, "t" means triplet, "m" means multiplet, and "br s" means broad singlet. For mass spectral data, the numerical value reported is the molecular weight of the parent molecular ion (M) formed by addition of H+ (molecular weight of 1) to the molecule to give a M+l peak observed by mass spectrometry using atmospheric pressure chemical ionization (AP+).
SYNTHESIS EXAMPLE 1
Preparation of 2-hydroxy-4-oxo-3-phenyl-l-(2,2,2-trifluoroethyl)-4H-pyrido[l,2-α]- pyrimidinium inner salt
A mixture of diethyl phenylmalonate (0.62 g, 2.7 mmol) and 7V-(2,2,2-trifluoroethyl)-
2-pyridinamine (0.87 g, 2.7 mmol, prepared by the method of Bissell, E. R.; Swanslger, R.
W. J. Chem. Eng. Data. 1981, 26, 234-235) was heated to 180 0C for 2 h. After cooling, the reaction mixture was purified by chromatography on silica gel by elution with ethyl acetate to provide the title compound (compound number 7), a compound of this invention, as a yellow solid (45 mg).
1H NMR (CDCl3) δ 9.61 (dd, IH), 8.17 (ddd, IH), 7.74 (d, 2H), 7.55 (d, IH), 7.45 (t, IH),
7.39 (m, 2H), 7.21-7.25 (m, IH), 5.10 (br s, 2H).
SYNTHESIS EXAMPLE 2 Preparation of l-[(2-chloro-5-thiazolyl)methyl]-2-hydroxy-4-oxo-4H-pyrido[l,2-α]- pyrimidinium inner salt and l-[(2-chloro-5-thiazolyl)methyl]-2-hydroxy-4-oxo-3-(2,2,2- trifluoroacetyl)-4H-pyrido[l,2-α]pyrimidinium inner salt
Step A: Preparation of 1 , 1 -dimethylethyl 7V-[(2-chloro-5-thiazolyl)methyl]-7V-2- pyridinylcarbamate (alternatively named 2-chlorothiazol-5-ylmethyl)pyridin- 2-yl-carbamic acid t-butyl ester)
Sodium hydride in mineral oil (60%, 2.22 g, 55.6 mmol) was added portionwise to a solution of 1,1 -dimethylethyl JV-2-pyridinylcarbamate (9.0 g, 46.3 mmol, prepared by the method of Krein, D. M.; Lowary, T. L. J. Org. Chem. 2002, 67, 4965-4967) in NJSf- dimethylformamide (40 mL) in a round bottom flask cooled to 0 0C in an ice/water bath. The suspension was stirred vigorously for an additional 30 min, followed by the addition of 2-chloro-5-(chloromethyl)thiazole (7.4 g, 55.6 mmol). The reaction mixture was gradually warmed to room temperature and stirred for 16-24 h. Water (200 mL) was then added, and the reaction mixture was extracted three times with 50 mL of ethyl acetate. The combined organic extracts were washed four times with 20 mL of water, dried over Na2SC>4, and concentrated under reduced pressure. The resulting residue was purified by chromatography on silica gel by elution with ethyl acetate/hexane to provide the title compound as an amber oil (9.3 g). 1H NMR (CDCl3) δ 8.40 (d, IH), 7.78 (d, IH), 7.64 (t, IH), 7.49 (s, IH), 7.03 (t, IH), 5.18 (s, 2H), 1.54 (s, 9 H).
Step B: Preparation of Λ/-[(chloro-5-thiazolyl)methyl]-2-pyridinamine (alternatively named (2-chlorothiazol-5 -ylmethyl)-pyridin-2-yl-amine) Trifluoroacetic acid (13.2 mL, 171 mmol) was added to a solution of 1,1-dimethylethyl
Λ/-[(2-chloro-5-thiazolyl)methyl]-Λ/-2-pyridinylcarbamate (i.e. the product of Step A) (9.3 g, 28.5 mmol) in dichloromethane: water (60 mL:8 mL) in a round bottom flask, and the mixture was stirred for 66 h. The reaction mixture was then cooled to 0 0C and neutralized with 3 M NaOH to approximately pH 12 before being extracted twice with 100 mL of ethyl acetate. The organic layers were combined, dried over Na2SOφ and concentrated under reduced pressure to provide the title compound as a tan solid (5.0 g).
1H NMR (CDCl3) δ 8.19 (d, IH), 7.43 (m, 2H), 7.65 (t, IH), 6.42 (d, IH), 4.80 (s, NH), 4.67 (d, 2H).
Step C: Preparation of l-[(2-chloro-5-thiazolyl)methyl]-2-hydroxy-4-oxo-4H- pyrido [ 1 ,2-α]pyrimidinium inner salt
A solution of dicyclohexylcarbodiimide (1.0 M in dichloromethane, 26.6 mL, 26.6 mmol) was added to a solution of Λ/-[(chloro-5-thiazolyl)methyl]-2-pyridinamine (i.e. the product of Step B) (3.0 g, 13.3 mmol) and malonic acid (1.38 g, 13.3 mmol) in dichloromethane (30 mL) in a round bottom flask. The reaction mixture was stirred at room temperature for 16-24 h. The reaction mixture was then filtered through a pad of Celite® diatomaceaus filter aid, and the filtration cake was washed with dichloromethane. The combined organic phases were concentrated under reduced pressure, and the resulting residue was purified by chromatography on silica gel by elution with ethyl acetate/hexane to provide the title compound (compound number 125), a compound of this invention, as a pale yellow solid (2.90 g).
1H NMR (CD3S(O)CD3) δ 9.20 (d, IH), 8.36 (t, IH), 8.11 (d, IH), 7.95 (s, IH), 7.52 (t, IH), 5.56 (s, 2H), 4.98 (s, IH).
Step D: Preparation of l-[(2-chloro-5-thiazolyl)methyl]-2-hydroxy-4-oxo-3-(2,2,2- trifluoroacetyl)-4H-pyrido[l,2-α]pyrimidinium inner salt 1 -[(2-Chloro-5-thiazolyl)methyl]-2-hydroxy-4-oxo-4H-pyrido[ 1 ,2-α]pyrimidinium inner salt (i.e. the product of Step C) (300 mg, 1.02 mmol), l,4-diazabicyclo[2.2.2]octane (11.5 mg, 0.102 mmol), and trifluoroacetic anhydride (0.14 mL, 1.02 mmol) were dissolved in JV-methyl-2-pyrrolidinone (3 mL), and the reaction mixture was stirred at room temperature for 1 h. The mixture was diluted with dichloromethane (30 mL), washed with water (10 mL), saturated aqueous sodium bicarbonate (10 mL) and water (10 mL x 4 times), concentrated and triturated with diethyl ether to yield the title compound (compound number 702), a compound of this invention, as a solid (98 mg). 1H NMR (CD3COCD3) δ 9.38 (d, IH), 8.58 (t, IH), 8.22 (d, IH), 7.94 (s, IH), 7.70 (t, IH), 5.71 (br s, 2H).
SYNTHESIS EXAMPLE 3
Preparation of l-[(6-chloro-3-pyridinyl)methyl]-3-[2-fluoro-5-(trifluoromethoxy)phenyl]- 2-hydroxy-4-oxo-4H-pyrido [ 1 ,2-α]pyrimidinium inner salt, 1 - [(6-chloro-3 - pyridinyl)methyl]-2-hydroxy-4-oxo-4H-pyrido[l,2-α]pyrimidinium inner salt and l-[(6- chloro-3-pyridinyl)methyl]-2-hydroxy-3-iodo-4-oxo-4H-pyrido[l,2-α]pyrimidinium inner salt
Step A: Preparation of 6-chloro-Λ/-2-pyridinyl-3-pyridinemethanamine A mixture of 2-fluoropyridine (1.4 g, 15 mmol) and 6-chloro-3-pyridinemethanamine
(alternatively named 5-aminomethyl-2-chloropyridine) (2.55 g, 18 mmol) in N- methylpyrrolidinone (5 mL) was heated at 230 0C in a microwave reactor for 30 min. This reaction was repeated four times using the same amounts of starting materials for each repetition. All five of the reaction mixtures were then poured into saturated aqueous sodium bicarbonate solution and extracted into ethyl acetate. The organic layer was washed with saturated aqueous sodium bicarbonate solution, dried over Na2SC^, and concentrated under reduced pressure. The crude product was then purified by chromatography on silica gel using 10% ethyl acetate in hexanes as the eluent to provide the title compound as an oil (5.1 g)- 1H NMR (CDCl3) δ 8.38 (s, IH), 8.1 (m, IH), 7.67 (d, IH), 7.42 (dd, IH), 7.28 (d, IH), 6.63
(m, IH), 6.38 (d, IH), 4.88 (s, IH), 4.56 (d, 2H).
Step B: Preparation of l-[(6-chloro-3-pyridinyl)methyl]-2-hydroxy-4-oxo-4H- pyrido[l,2-α]pyrimidinium inner salt A solution of dicyclohexylcarbodiimide (4.12 g, 20 mmol in 10 mL of dichloromethane) was added to a solution of 6-chloro-Λ/-2-pyridinyl-3-pyridinemethanamine (i.e. the product of Step A) (2.19 g, 10 mmol) and malonic acid (1.04 g, 10 mmol) in dichloromethane (10 mL) in a round bottom flask. The reaction mixture was stirred at room temperature for 16-24 h. The reaction mixture was then filtered, and the filtration cake was washed with diethyl ether. The filtrate was concentrated under reduced pressure, and the resulting residue was washed with methanol to provide the title compound (compound number 611), a compound of this invention, as a pale yellow solid (2.54 g). 1H NMR (acetone-^) δ 9.32 (d, IH), 8.52 (s, IH), 8.29 (dd, IH), 7.79 (m, 2H), 7.52 (t, IH), 7.42 (d, IH), 5.63 (s, 2H), 5.03 (s, IH). Step C: Preparation of l-[(6-chloro-3-pyridinyl)methyl]-2-hydroxy-3-iodo-4-oxo-4H- pyrido[l,2-α]pyrimidinium inner salt iV-iodosuccinimide (1.12 g, 5 mmol) was added to a solution of l-[(6-chloro-3- pyridinyl)methyl]-2-hydroxy-4-oxo-4H-pyrido[l,2-α]pyrimidinium inner salt (i.e. the product of Step B) (1.4 g, 5 mmol) in N,N-dimethylformamide (10 mL) and stirred for 5 min. Water was added, and the mixture was extracted with dichloromethane. The combined organic phases were washed repeatedly with water, dried over Na2SO4, and concentrated under reduced pressure. The resulting crude product (compound number 118), a compound of this invention, (1.8 g) was used in the next step without further purification. 1H NMR (CDCl3) δ 9.49 (d, IH), 8.45 (d, IH), 8.12 (dd, IH), 7.40 (m, 2H), 7.32 (d, IH), 5.50 (s, 2H).
Step D: Preparation of l-[(6-chloro-3-pyridinyl)methyl]-3-[2-fluoro-5-
(trifluoromethoxy)phenyl]-2-hydroxy-4-oxo-4H-pyrido[l,2-α]pyrimidinium inner salt l-[(6-Chloro-3-pyridinyl)methyl]-2-hydroxy-3-iodo-4-oxo-4H-pyrido[l,2- αjpyrimidinium inner salt (i.e. the product of Step C) (206 mg, 0.5 mmol), 2-fluoro-5- (trifluoromethoxy)benzeneboronic acid (224 mg, 1 mmol) and bis(triphenylphosphino)- palladium dichloride (35 mg, 0.005 mmol) were dissolved in dioxane (2 mL). Aqueous sodium carbonate solution (2 N, 1 mL) was added, and the reaction mixture was heated in a microwave reactor for 10 min at 160 0C. The cooled reaction mixture was poured directly onto a silica gel column and eluted successively with hexanes, 30% ethyl acetate in hexanes, 50% ethyl acetate in hexanes, and finally ethyl acetate to yield the title compound (compound number 58), a compound of this invention, as a solid (20 mg). 1H NMR (CDCl3) 5 9.53 (d, IH), 8.49 (s, IH), 8.11 (dd, IH), 7.69 (d, IH), 7.50 (d, IH), 7.41 (m, 2H), 7.34 (d, IH), 7.16 (d, 2H), 7.58 (br s, 2H).
SYNTHESIS EXAMPLE 4
Preparation of 2-hydroxy-4-oxo-3-phenyl- 1 -(2-propen- 1 -yl)-4H-pyrido[ 1 ,2-α]pyrimidinium inner salt
Λ/-2-propen-l-yl-2-pyridinamine (670 mg, 5 mmol) and l,3-bis(2,4,6-trichlorophenyl) 2-phenylpropanedioate (3.0 g, 6 mmol) were dissolved in dioxane (3 mL) and heated at
60 0C for 15 min. The reaction mixture was then poured onto a silica gel column, which was eluted with 50% ethyl acetate in hexanes to provide the title compound (compound number
122), a compound of this invention, as a solid (14 mg).
1H NMR (CDCl3) δ 9.52 (d, IH), 8.04 (dd, IH), 7.76 (d, IH), 7.2-7.45 (m, 6H), 5.95 (m, IH), 5,34 (d, IH), 5.30 (d, IH), 5.01 (d, 2H). SYNTHESIS EXAMPLE 5
Preparation of 2-hydroxy-4-oxo-3-phenyl-l-(2,2,2-trifluoroethyl)-4H-pyrido[l,2-α]- pyrimidinium inner salt
Step A: Preparation of Λ/-(2,2,2-trifluoroethyl)-2-pyridinamine A mixture of 2-fluoropyridine (2.00 g, 20.6 mmol) and 2,2,2-trifluoroethylamine hydrogen chloride (5.00 g, 36.9 mmol) was heated to 220 0C for 30 min in a microwave reactor. The same reaction was repeated 5 times. The reaction mixtures from all 6 reactions were cooled, combined and diluted with ethyl acetate (150 mL). The organic mixture was neutralized by washing with saturated aqueous sodium bicarbonate, water (30 mL) and brine (30 mL). The organic phase was dried over Na2SC^ and concentrated, and the resulting residue was purified by chromatography on silica gel using 80% ethyl acetate/hexane as eluant to give the title compound as a white solid (17.0 g).
1H NMR (CDCl3) δ 8.15 (d, IH), 7.45 (dd, IH), 6.69 (dd, IH), 6.49 (d, IH), 4.58 (br s, IH), 4.11 (q, 2H). Step B: Preparation of l,3-bis(2,4,6-trichlorophenyl) 2-phenylpropanedioate
To a slurry of phenylmalonic acid (5.00 g, 27.8 mmol) in dichloromethane (7 mL) at room temperature was added a drop of N,Λ/-dimethylformamide, followed by the dropwise addition of oxalyl chloride (9.09 g, 71.6 mmol) at such a rate to keep gas evolution under control. The reaction mixture was stirred for an additional hour at room temperature, during which time the reaction mixture clarified. 2,4,6-Trichlorophenol (15 g, 76 mmol) was added, and the reaction mixture was stirred at room temperature for 18 h. The reaction mixture was concentrated under vacuum, and methanol (100 mL) was added to the residue, which resulted in precipitation of a large amount of solid. The solid was collected by filtration, rinsed with methanol (80 mL) and air dried to give the title product as a white solid (13 g).
1H NMR (CDCl3) δ 7.64-7.62 (m, 2H), 7.46-7.43 (m, 3H), 7.36 (s, 4H), 5.32 (s, IH).
Step C: Preparation of 2-hydroxy-4-oxo-3-phenyl-l-(2,2,2-trifluoroethyl)-
4H-pyrido[l,2-α]-pyrimidinium inner salt A solution of Λ/-(2,2,2-trifluoroethyl)-2-pyridinamine (i.e. the product of Step A) (2.00 g, 11.4 mmol) and l,3-bis(2,4,6-trichlorophenyl) 2-phenylpropanedioate (i.e. the product of Step B) (6.40 g, 11.9 mmol) in toluene (40 mL) was refluxed for 1 h. The reaction mixture was cooled in an ice-water bath with stirring for 2 h. The solid that precipitated was collected by filtration, rinsed with diethyl ether and air dried to give the title compound (compound number 7), a compound of this invention, as a yellow solid (3.44 g). 1H NMR (CD3S(O)CD3) δ 9.37 (d, IH), 8.42 (m, IH), 8.11 (d, IH), 7.66 (d, 2H), 7.61 (m, IH), 7.32 (t, 2H), 7.18 (t, IH), 5.35 (q, 2H). SYNTHESIS EXAMPLE 6
Preparation of 8-[(6-chloro-3-pyridinyl)methyl]-7-hydroxy-5-oxo-6-[3- (trifluoromethoxy)phenyl] -5H-thiazolo [3 ,2-α]pyrimidinium inner salt
Step A: Preparation of Λ/-[(6-chloro-3-pyridinyl)methylene]-2-thiazolamine 2-Aminothiazole (0.75 g, 7.5 mmol) was added to 2-chloropyridine-6-carboxaldehyde
(1.0 g, 7.1 mmol) in dichloromethane (25 mL) at room temperature. The suspension was stirred an additional 10 min and then concentrated to dryness under vacuum. The resulting residue was heated to 90 0C on a rotory evaporator with a non-returning bump trap to facilitate water removal. After 30 min the resultant yellow solid was checked by NMR to verify reaction completion (by disappearence of the characteristic aldehyde peak at 10.10 ppm (s, IH)). The title compound was obtained as a yellow solid (1.55 g) and used in the next step without further purification.
1H NMR (CDCl3) δ 9.10 (s, IH), 8.84 (d, IH), 8.35-8.32 (dd, IH), 7.72-7.70 (d, IH), 7.48- 7.46 (d, IH), 7.32-7.31 (d, IH). Step B : Preparation of 6-chloro-iV-2-thiazolyl-3 -pyridinemethanamine
Λ/-[(6-chloro-3-pyridinyl)methylene]-2-thiazolamine (i.e. the product of Step A) (0.55 g, 2.46 mmol) was added portionwise to a stirred excess of sodium borohydride (0.45 g, 11.8 mmol) in methanol (30 mL). Additional portions of sodium borohydride (2 x 1 equivalent) were added during the addition of the imine to maintain an exothermic reaction. After addition was complete, the reaction mixture was allowed to stir for 5 min at ambient temperature. The excess reducing agent was quenched by adding glacial acetic acid until gas evolution ceased. The clear reaction mixture was concentrated, and the resulting residue was partitioned between saturated aqueous sodium carbonate and ethyl acetate. The aqueous phase was extracted with ethyl acetate (3 x 30 mL), and the combined organic phases were washed with brine, dried (MgSC^) and concentrated to give the title compound as a tan powder (0.55 g).
1H NMR (CDCl3) δ 8.39 (d, IH), 7.71-7.68 (dd, IH), 7.30-7.28 (d, IH), 6.98 (d, IH), 6.48 (d, IH), 4.48 (s, 2H).
Step C : Preparation of 2- [3 -(trifluoromethoxy)phenyl]propanedioic acid Diethyl 3-trifluoromethoxyphenylmalonate (3.00 g, 9.38 mmol) was stirred in an aqueous sodium hydroxide solution (15 g, 20% by weight) at 65 0C for 10 min. The reaction mixture was then cooled in an ice bath, and ice (7 g) was added to the reaction mixture, followed by 6 N hydrochloric acid to adjust the pH to about 2. The aqueous mixture was saturated with sodium chloride and extracted with ethyl acetate three times. The combined organic phases were dried (MgSC^) and concentrated to give a solid, which was triturated with a mixture of 33% diethyl ether/hexane to give the title compound as a white solid (2.24 g)- 1H NMR (CD3C(O)CD3) δ 11.51 (br s, 2H), 7.54-7.51 (m, 3H), 7.35-7.30 (m, IH), 4.91 (s, IH).
Step D: Preparation of 8-[(6-chloro-3-pyridinyl)methyl]-7-hydroxy-5-oxo-6-[3-
(trifluoromethoxy)phenyl]-5H-thiazolo[3,2-α]pyrimidinium inner salt Oxalyl chloride (1.0 mL, 11 mmol) was added dropwise at ambient temperature to a slurry of 2-[3-(trifluoromethoxy)phenyl]propanedioic acid (i.e. the product of Step C) (0.17 g, 0.66 mmol) in dichloromethane (0.2 mL) containing a catalytic amount of Λ/,Λ/-dimethylformamide. The reaction mixture was stirred for an additional 10 min during which time gas evolution ceased. The reaction mixture was briefly concentrated under vacuum at ambient temperature. The resultant oil was taken up in dichloromethane (2 mL) and added to a solution of 6-chloro-Λ/-2-thiazolyl-3-pyridinemethanamine (i.e. the product of Step B) (0.23 g, 1.02 mmol) and triethylamine (0.40 g, 3.37 mmol) in dichloromethane (4 mL) at 0 0C. After stirring for 15 min, the reaction mixture was concentrated, and the resultant residue was purified by chromatography on silica gel using 50-100% ethyl acetate/hexane as eluant to give the title compound (compound number 138), a compound of this invention, as a solid (0.19 g).
1H NMR (CDCl3) δ 8.50 (s, IH), 8.25 (d, IH), 7.87 (d, IH), 7.75 (d, IH), 7.70 (s, IH), 7.41- 7.35 (m, 2H), 7.08 (d, IH), 7.03 (d, IH), 5.29 (s, 2H).
SYNTHESIS EXAMPLE 7 Preparation of 2-hydroxy-4-oxo- 1 -propyl-3 - [2-(trifluoromethyl)phenyl] -4H-pyrido [ 1 ,2-a]- pyrimidinium inner salt and 2-hydroxy-4-oxo-l-propyl-4H-pyrido[l,2-α]-pyrimidinium inner salt
Step A: Preparation of 2-hydroxy-4-oxo-l-propyl-4H-pyrido[l,2-α]-pyrimidinium inner salt A solution of dicyclohexylcarbodiimide (15.63 g in 45 mL of dichloromethane, 75.76 mmol) was added to a solution of JV-propyl-2-aminopyridine (5.16 g, 37.8 mmol) and malonic acid (3.94 g, 37.8 mmol) in dichloromethane (90 mL). The reaction mixture was stirred at room temperature for 24 h. The reaction mixture was then filtered through a pad of Celite®, and the filtration cake was washed with dichloromethane. The combined organic phases were concentrated, and the resulting residue was purified by chromatography on silica gel using 50-100% ethyl acetate/hexane as eluant to give the title compound (compound number 609), a compound of this invention, as a pale yellow solid (5.60 g). 1H NMR (CDCl3) δ 9.40 (d, IH), 8.15 (t, IH), 7.42 (d, IH), 7.30 (t, IH), 5.38 (s, IH), 4.24 (t, 2H), 1.88 (m, 2H), 1.06 (t, 3H). Step B: Preparation of 2-hydroxy-4-oxo-l-propyl-3-[2-(trifluoromethyl)phenyl]-
4H-pyrido[l,2-α]-pyrimidinium inner salt
2-Ηydroxy-4-oxo-l-propyl-4H-pyrido[l,2-α]pyrimidinium inner salt (i.e. the product of Step A) (500 mg, 2.45 mmol), l-iodo-2-(trifluoromethyl)benzene (0.34 rnL, 2.45 mmol), copper iodide (46.6 mg, 0.245 mmol), 1,10-phenanthroline (44.1 mg, 0.245 mmol) and cesium carbonate (798 mg, 2.45 mmol) were combined in N,Λ/-dimethylformamide (3 mL).
The reaction mixture was heated at 118 0C under nitrogen for 24 h. The reaction mixture was cooled and concentrated, and the resulting residue was purified by reverse phase liquid chromatography on a XTerra® Cl 8 OBD column (5 micron particle, 30 x 100 mm, manufactured by Waters) using a gradient of 30-90% (1 :1 acetonitrile/methanol)/water to provide the title compound (compound number 308), a compound of this invention, as a solid (20 mg).
1H NMR (CDCl3) δ 9.44 (d, IH), 8.13 (t, IH), 7.75 (d, IH), 7.58 (t, IH), 7.42-7.52 (m, 3H), 7.35 (t, IH), 4.42-4.35 (m, IH), 4.24-4.18 (m, IH), 1.80 (q, 2H), 1.05 (t, 3H). SYNTHESIS EXAMPLE 8
Preparation of 2-hydroxy-3-iodo-l-[[2-(3-methoxyphenyl)-5-thiazolyl]methyl]-4-oxo- 4H-pyrido[l,2-α]-pyrimidinium inner salt
Step A: Preparation of l-[(2-chloro-5-thiazolyl)methyl]-2-hydroxy-3-iodo-4-oxo-
4H-pyrido[l,2-α]-pyrimidinium inner salt TV-iodosuccinimide (2.19 g, 9.76 mmol) was added to a solution of l-[(2-chloro-5- thiazolyl)methyl]-2-hydroxy-4-oxo-4H-pyrido[l,2-α]pyrimidinium inner salt (i.e. the product of Example 2, Step C) (2.9 g, 9.76 mmol) in Λ/,Λ/-dimethylformamide (30 mL), and the mixture was stirred for 5 min. Water was added, and the mixture was extracted with ethyl acetate. The combined organic phases were washed several times with water, dried over Na2SC>4 and concentrated under reduced pressure. The resulting crude product (compound number 608) (1.2 g), a compound of this invention, was used in the next step without further purification.
1H NMR (CD3COCD3) δ 9.36 (d, IH), 8.45(t, IH), 8.20 (d, IH), 7.94 (s, IH), 7.58 (t, IH), 5.77 (s, 2H). Step B : Preparation of 2-hydroxy-3 -iodo- 1 - [ [2-(3 -methoxyphenyl)-5 - thiazolyl]methyl]-4-oxo-4H-pyrido[l,2-α]-pyrimidinium inner salt 1 -[(2-chloro-5-thiazolyl)methyl]-2-hydroxy-3-iodo-4-oxo-4H-pyrido[ 1 ,2-a]- pyrimidinium inner salt (i.e. the product of Step A) (250 mg, 0.59 mmol), 3-methoxybenzeneboronic acid (89 mg, 0.59 mmol) and bis(triphenylphosphine)- palladium(II) dichloride (20 mg, 0.029 mmol) were dissolved in dioxane (3 mL). Aqueous sodium carbonate solution (2 N, 1 mL) was added, and the reaction mixture was heated in a microwave reactor for 15 min at 150 0C. The cooled reaction mixture was poured directly onto a silica gel column and eluted successively with hexanes, 30% ethyl acetate in hexanes, 50% ethyl acetate in hexanes, and finally ethyl acetate to yield the title compound (compound number 613), a compound of this invention, as a solid (35 mg). 1H NMR (CD3COCD3) δ 9.38 (d, IH), 8.43 (t, IH), 8.20 (d, IH), 8.13 (s, IH), 7.58 (t, IH), 7.50 (m, 2H), 7.39 (t, IH), 7.02 (d, IH), 5.88 (br s, 2H), 3.86 (s, 3H).
SYNTHESIS EXAMPLE 9
Preparation of 2-hydroxy-4-oxo- 1 -(2,2,2-trifluoroethyl)-3-[2,2,2-trifluoro-l - (methoxyimino)ethyl]-4H-pyrido[l,2-α]-pyrimidinium inner salt, 2-hydroxy-4-oxo-l -(2,2,2- trifluoroethyl)-4H-pyrido[l,2-α]-pyrimidinium inner salt and 2-hydroxy-4-oxo-3-(2,2,2- trifluoroacetyl)-l-(2,2,2-trifluoroethyl)-4H-pyrido[l,2-α]-pyrimidinium inner salt
Step A: Preparation of 2-hydroxy-4-oxo-l-(2,2,2-trifluoroethyl)-4H-pyrido[l,2-α]- pyrimidinium inner salt A solution of dicyclohexylcarbodiimide (1.0 M in dichloromethane, 108 mL, 108 mmol) was added to a solution of Λ/-(2,2,2-trifluoroethyl)-2-pyridinamine (i.e. the product of Example 5, Step A) (9.51 g, 54.0 mmol) and malonic acid (5.62 g, 54.0 mmol) in dichloromethane (190 mL). The reaction mixture was stirred at room temperature for 24 h.
The reaction mixture was then filtered through a pad of Celite®, and the filtration cake washed with dichloromethane. The combined organic phases were concentrated under reduced pressure, and the resulting residue was purified by chromatography on silica gel using 50-100% ethyl acetate/hexane as eluant to give the title compound (compound number
610), a compound of this invention, as a pale yellow solid (7.0 g).
1H NMR (CD3S(O)CD3) 5 9.22 (d, IH), 8.42 (t, IH), 8.11 (d, IH), 7.59 (t, IH), 5.25 (q,
2H), 4.96 (s, IH).
Step B: Preparation of 2-hydroxy-4-oxo-3-(2,2,2-trifiuoroacetyl)-l-(2,2,2- trifluoroethyl)-4H-pyrido[ 1 ,2-α]-pyrimidinium inner salt
2-Ηydroxy-4-oxo-l-(2,2,2-trifluoroethyl)-4H-pyrido[l,2-α]-pyrimidinium inner salt (i.e. the product of Step A) (1.12 g, 4.57 mmol), l,4-diazabicyclo[2.2.2]octane (132.0 mg, 1.12 mmol) and trifluoroacetic anhydride (1.50 mL, 10.92 mmol) were dissolved in l-methyl-2-pyrrolidinone (10 mL), and the reaction mixture was stirred at room temperature for 18 h. The mixture was diluted with ethyl acetate (250 mL), washed with saturated aqueous sodium bicarbonate (150 mL) water (3 x 100 mL), and concentrated. The residue was triturated with diethyl ether to yield the title compound (compound number 711), a compound of this invention, as a solid (1.10 g).
1H NMR (CD3S(O)CD3) 5 9.25 (d, IH), 8.58 (t, IH), 8.10 (d, IH), 7.65 (t, IH), 5.25 (q, 2H). Step C: Preparation of 2-hydroxy-4-oxo-l-(2,2,2-trifluoroethyl)-3-[2,2,2-trifluoro-l-
(methoxyimino)ethyl]-4H-pyrido[l,2-α]-pyrimidinium inner salt
A solution of 2-hydroxy-4-oxo-3-(2,2,2-trifluoroacetyl)-l-(2,2,2-trifluoroethyl)-
4H-pyrido[l,2-α]-pyrimidinium inner salt (i.e. the product of Step B) (75 mg, 0.22 mmol) and methoxyamine hydrochloride (62 mg, 0.74 mmol) in ethanol (7 mL) was refluxed for 3 h. The solvent was concentrated under vacuum, and ethyl acetate (60 mL) was added. The organic phase was washed successively with a solution of dilute sodium hydroxide (3 mL of
1 N NaOH and 30 mL water) and water (20 mL). The organic phase was then filtered through a Chem Elut™ cartridge (manufactured by Varian) prepacked with Celite® and concentrated to a crude oil. The resultant residue was purified by preparative thin layer chromatography on an Analtech Uniplate™ (20 x 20 cm, 2000 microns layer of silica gel) eluted with ethyl acetate to provide the title compound (compound number 637), a compound of this invention, as a thick oil (53 mg, 1 :1 mixture of E and Z isomers). 1H NMR (CDCl3) δ 9.49 (d, 0.5H), 9.47 (d, 0.5H), 8.23 (t, IH), 7.61 (d, IH), 7.50 (m, IH), 5.00 (m, 2H), 4.10 (s, 1.5H), 4.04 (s, 1.5H)
SYNTHESIS EXAMPLE 10
Preparation of 1 -[(6-chloro-3-pyridinyl)methyl]-4-hydroxy-2-imino-3-(2-methoxyphenyl)- 2H-pyrido[l,2-α]pyrimidinium inner salt
Step A: Preparation of phenyl α-cyano-2-methoxybenzeneacetate To a slurry of sodium hydride (3.39 g of 60% in mineral oil, 84.9 mmol) in tetrahydrofuran (200 mL) at room temperature was added 2-(2-methoxyphenyl)acetonitrile (10.0 g, 67.9 mmol) dropwise. The reaction mixture was then heated to reflux and the gray suspension turned dark red over 30 min. Diphenyl carbonate (18.2 g, 84.9 mmol) was added portionwise, and the reaction suspension was heated at reflux for an additional 18 h. The reaction mixture was cooled, poured into 1 N HCl (200 mL) and extracted with ethyl acetate (3 x 200 mL). The organic phases were combined, dried over magnesium sulfate, filtered and concentrated onto Celite® under reduced pressure. The resultant residue was purified by chromatography on silica gel using 10-90% ethyl acetate/hexane as eluant to give the title compound as a light yellow solid (14.3 g). 1H NMR (CD3S(O)CD3) δ 7.48-7.44 (m, 3H), 7.31 (t, IH), 7.19-7.03 (m, 4H), 6.75 (d, IH), 5.97 (s, IH), 3.93 (s, 3H).
Step B: Preparation of l-[(6-chloro-3-pyridinyl)methyl]-4-hydroxy-2-imino-3-(2- methoxyphenyl)-2H-pyrido[l,2-α]pyrimidinium inner salt
To a solution containing 6-chloro-N-2-pyridinyl-3-pyridinemethanamine (0.82 g, 3.74 mmol) in xylene (100 mL) under nitrogen was added phenyl α-cyano-2- methoxybenzeneacetate (i.e. the product of Step A) (1.00 g, 3.74 mmol). The reaction mixture was heated to reflux for 24 h. The mixture was cooled, Celite® was added, and the xylene was evaporated under reduced pressure. The resultant residue was purified by chromatography on silica gel using a gradient of 100% ethyl acetate to 1% triethylamine/40% methanol/59% ethyl acetate as eluant to give the title compound (compound number 662), a compound of this invention, as a cream solid (4.7 mg). MS (AP+) = 393.
1H NMR (CD3COCD3) δ 8.47 (d, IH), 8.28 (s, IH), 7.83 (t, IH), 7.76 (d, IH), 7.38-7.27 (m, 5H), 6.94-6.88 (m, 2H), 5.71 (s, NH), 5.62 (s, 2 H), 3.64 (s, 3H).
SYNTHESIS EXAMPLE 11
Preparation of 1 -[(6-chloro-3-pyridinyl)methyl]-2-hydroxy-4-oxo-3-phenyl-4H- pyrido [ 1 ,2-α]pyrimidinium inner salt
Step A: Preparation of Λ/-[(6-chloro-3-pyridinyl)methyl]-2-phenyl-JV-(2- pyridinyl)malonamic acid ethyl ester
2-Phenylmalonic acid monoethyl ester was prepared following the procedure in Journal of Organic Chemistry 2000, 65, 5834-5836. 2-Phenylmalonic acid monoethyl ester (1.02 g, 5.0 mmol) was dissolved in anhydrous dichloromethane (10 mL), and oxalyl chloride (0.52 mL, 6.0 mmol) was added, followed by one drop of Λf,Λ/-dimethylformamide. The reaction mixture was stirred for 30 min, then concentrated, redissolved in anhydrous dichloromethane (5 mL) and added to a solution of 6-chloro-iV-2-pyridinyl-3- pyridinemethanamine (i.e. the product of Example 3, Step A) (1.1 g, 5.0 mmol) and triethyl amine (0.83 mL, 6.0 mmol) in anhydrous dichloromethane (5 mL) at 0 0C. The stirred reaction mixture was allowed to warm to room temperature over 30 min. The reaction mixture was poured onto a silica gel cartridge (Bond Elute® manufactured by Varian) and purified using a gradient of 0-50% ethyl acetate/hexanes. A mixture of desired product and starting amine was isolated (1.3 g of 33 mol% recovered amine/67 mol% desired product). 2-Phenylmalonic acid monoethyl ester (0.54 g, 2.6 mmol) was dissolved in anhydrous dichloromethane (3 mL), and oxalyl chloride (0.26 mL, 3.0 mmol) was added, followed by one drop of Λ/,Λ/-dimethylformamide. The reaction mixture was stirred until gas evolution ceased and then concentrated, redissolved in anhydrous dichloromethane (3 mL) and added to the mixture of recovered amine and desired product isolated previously. The reaction mixture was stirred for 30 min and then concentrated, and the crude residue was chromatographed as already described to give the title compound as a solid (0.9 g). 1H NMR (CDCl3) δ 8.50 (m, 1Η), 8.18 (s, 1Η), 7.60-7.75 (m, 2Η), 7.2-7.3 (m, 5H), 7.13 (m, 2H), 6.87 (s, IH), 5.13-4.88 (dd, 2H), 4.86 (s, IH), 4.16 (m, 2H), 1.22 (t, 3H).
Step B: Preparation of l-[(6-chloro-3-pyridinyl)methyl]-2-hydroxy-4-oxo-3-phenyl- 4H-pyrido [ 1 ,2-α]pyrimidinium inner salt
Λ/-[(6-chloro-3-pyridinyl)methyl]-2-phenyl-Λ/-(2-pyridinyl)malonamic acid ethyl ester (i.e. the product of Step A) (200 mg, 0.49 mmol) was added to tetralin (0.5 mL) and heated at 200 0C for 30 min. The reaction mixture was cooled and concentrated, and the resulting residue was purified by chromatography on silica gel using 50-100% ethyl acetate/hexane as eluant to give the title compound (compound number 59), a compound of this invention, as a solid (15 mg).
1H NMR (CDCl3) δ 9.55 (dd, IH), 8.47 (d, IH), 8.04 (m, IH), 7.98 (d, 2H), 7.70 (dd, IH), 7.2-7.4 (m, 6H), 5.58 (s, 2H).
By the procedures described herein together with methods known in the art, the following compounds of Tables 1 to 8 can be prepared. Abbreviations used in Tables 1 to 8 are shown below as X-I through X- 128 and Y-I through Y-71.
isopropyl isobutyl cyclopropyl cyclobutyl cyclopentyl
X-I X-2 X-3 X-4 X-5
cyclohexyl CF3 CH2CF3 C2F5 C(CF3)2F
X-6 X-7 X-8 X-9 X-IO
4-fluoro-l-
1 -naphthalenyl 2 -naphthalenyl C(O)Me C(O)CF3 naphthalenyl
X-I l X-12 X-13 X-14 X-15
C(O)Ph C(O)OMe C(O)OEt C(O)NHMe C(O)NHPh
X-16 X-17 X-18 X-19 X-20
C(O)NH(3-
C(S)NHPh C(=NOEt)CF3 methoxyphenyl)
X-21 X-22 X-23
Figure imgf000078_0001
X-24 X-25 X-26 X-27
Figure imgf000078_0002
X-28 X-29 X-30 X-31
Figure imgf000079_0001
X-32 X-33 X-34 X-35
Figure imgf000079_0002
X-36 X-37 X-38 X-39
Figure imgf000079_0003
X-40 X-41 X-42
Abbreviations X-50 to X- 128 pertain to the substituted phenyl ring as shown below. Blank entries in the table denote a hydrogen atom.
Figure imgf000079_0004
Ra Rb Rc Rd Re
X-50 F
X-51 OMe
X-52 Cl
X-53 F
X-54 OMe
X-55 Cl
X-56 F
X-57 OMe Ra Rb Rc Rd Re
X-58 Cl
X-59 CF3
X-60 OCF3
X-61 SCF3
X-62 SF5
X-63 Br
X-64 cyano
X-65 F CF3
X-66 F OCF3
X-67 F SCF3
X-68 F Br
X-69 S(O)CF3
X-70 S(O)CF3
X-71 S(O)CF3
X-72 Cl cyano
X-73 Cl CF3
X-74 Cl OCF3
X-75 Cl SCF3
X-76 Cl Br
X-77 Cl CF3
X-78 Cl OCF3
X-79 Cl SCF3
X-80 Cl Br
X-81 Br CF3
X-82 Br OCF3
X-83 Br SCF3
X-84 Br Br
X-85 F CF3
X-86 F OCF3
X-87 F SCF3
X-88 F Br
X-89 F F F
X-90 F F F
X-91 F CF3
X-92 F OCF3
X-93 F CF3
X-94 F OCF3 Ra Rb Rc Rd Re
X-95 F F
X-96 OCHF2
X-97 OCHF2
X-98 OCHF2
X-99 SCHF2
X-IOO SCHF2
X-IOl SCHF2
X- 102 F F
X-103 F F
X- 104 F F
X- 105 CF3 CF3
X-106 F OMe
X-107 OMe OMe
X-108 F OMe
X- 109 F OMe
X-IlO OMe CF3 x-i i i OMe OCF3
X-112 OMe Cl
X-113 OMe Br
X-114 OMe CF3
X-115 OMe OCF3
X-116 OMe Cl
X-117 OMe Br
X-118 OMe F
X-119 OMe OMe
X-120 OMe F
Figure imgf000081_0001
Figure imgf000082_0001
X-126 OCHF2
X- 127
OCHF2
X-128 OCHF2
methyl ethyl «-propyl «-butyl
Y-I Y-2 Y-3 Y-4
CHF2 CH2CH2CF3 CH2CH2CF2Cl isopropyl
Y-5 Y-6 Y-7 Y-8
5-butyl z'-butyl CH2CH2OCH3 CH2C(O)OCH3
Y-9 Y-IO Y-I l Y-12
CH2CH2SCH3 CH2CH2S(O)CH3 CH2CH=CH2 CH2C≡CH
Y-13 Y-14 Y-15 Y-16
cyclopropyl cyclobutyl CH2CF3 CH(CH3)CF3
Y-17 Y-18 Y-19 Y-20
CH2CF2CF3 CH2CH2CHFCF2CI
Y-21 Y-22
Figure imgf000082_0002
Y-30 Y-31 Y-32 Y-33
Figure imgf000083_0001
Y-34 Y-35 Y-36 Y-37
Figure imgf000083_0002
Y-38 Y-39 Y-40 Y-41
Figure imgf000083_0003
Y-42 Y-43 Y-44 Y-45
Figure imgf000083_0004
Y-46 Y-47 Y-48 Y-49
Figure imgf000083_0005
Y-50 Y-51 Y-52 Y-53
Figure imgf000084_0001
Y-54 Y-55 Y-56 Y-57
Figure imgf000084_0002
Y-58 Y-59 Y-60 Y-61
Figure imgf000084_0003
Y-62 Y-63 Y-64 Y-65
Figure imgf000084_0004
Y-66 Y-67 Y-68 Y-69
Figure imgf000084_0005
Y-70 Y-71 TABLE 1
Figure imgf000085_0001
R2 is Y-I
Figure imgf000085_0002
R2 is Y-3
Figure imgf000086_0001
Figure imgf000087_0001
Figure imgf000088_0001
R2 is Y-9
Figure imgf000088_0002
Figure imgf000089_0001
R2isY-12
Figure imgf000090_0001
Figure imgf000091_0001
Figure imgf000092_0001
R2isY-19
Figure imgf000093_0001
Figure imgf000094_0001
Figure imgf000095_0001
R2 is Y-33
Figure imgf000096_0001
Figure imgf000097_0001
Figure imgf000098_0001
R2 is Y-40
Figure imgf000099_0001
Figure imgf000100_0001
Figure imgf000101_0001
R2 is γ_47
Figure imgf000102_0001
Figure imgf000103_0001
Figure imgf000104_0001
R2 is Y-54
Figure imgf000105_0001
Figure imgf000106_0001
Figure imgf000107_0001
R2isY-61
Figure imgf000108_0001
Figure imgf000109_0001
Figure imgf000110_0001
R2 is Y-68
Figure imgf000111_0001
Figure imgf000112_0001
TABLE 2
Table 2 is constructed the same as Table 1 , except that the chemical structure under the Table 1 heading is replaced with the following structure:
Figure imgf000113_0001
For example, the first compound in Table 2 is the structure shown immediately above wherein R1 is X-I and R2 is Y-I as defined for Table 1.
TABLE 3
Table 3 is constructed the same as Table 1 , except that the chemical structure under the Table 1 heading is replaced with the following structure:
Figure imgf000113_0002
For example, the first compound in Table 3 is the structure shown immediately above wherein R1 is X-I and R2 is Y-I as defined for Table 1.
TABLE 4
Table 4 is constructed the same as Table 1 , except that the chemical structure under the Table 1 heading is replaced with the following structure:
Figure imgf000113_0003
For example, the first compound in Table 4 is the structure shown immediately above wherein R1 is X-I and R2 is Y-I as defined for Table 1. TABLE 5
Table 5 is constructed the same as Table 1 , except that the chemical structure under the Table 1 heading is replaced with the following structure:
Figure imgf000114_0001
For example, the first compound in Table 5 is the structure shown immediately above wherein R1 is X-I and R2 is Y-I as defined for Table 1.
TABLE 6
Table 6 is constructed the same as Table 1 , except that the chemical structure under the Table 1 heading is replaced with the following structure:
Figure imgf000114_0002
For example, the first compound in Table 6 is the structure shown immediately above wherein R1 is X-I and R2 is Y-I as defined for Table 1.
Figure imgf000114_0003
R2 is Y-3
Figure imgf000114_0004
R2isY-19
Figure imgf000115_0001
Figure imgf000116_0001
R2 is Y-38
Figure imgf000117_0001
Figure imgf000118_0001
R2 is Y-65
Figure imgf000119_0001
Figure imgf000120_0002
TABLE 8
Table 8 is constructed the same as Table 7, except that the chemical structure under the Table 7 heading is replaced with the following structure:
Figure imgf000120_0001
For example, the first compound in Table 8 is the structure shown immediately above wherein R1 is X- 15 and R2 is Y-3 as defined for Table 7.
A compound of this invention will generally be used as an invertebrate pest control active ingredient in a composition, i.e. formulation, with at least one additional component selected from the group consisting of surfactants, solid diluents and liquid diluents, which serves as a carrier. The formulation or composition ingredients are selected to be consistent with the physical properties of the active ingredient, mode of application and environmental factors such as soil type, moisture and temperature. Useful formulations include both liquid and solid compositions. Liquid compositions include solutions (including emulsifϊable concentrates), suspensions, emulsions (including microemulsions and/or suspoemulsions) and the like, which optionally can be thickened into gels. The general types of aqueous liquid compositions are soluble concentrate, suspension concentrate, capsule suspension, concentrated emulsion, microemulsion and suspo-emulsion. The general types of nonaqueous liquid compositions are emulsifiable concentrate, microemulsifiable concentrate, dispersible concentrate and oil dispersion.
The general types of solid compositions are dusts, powders, granules, pellets, prills, pastilles, tablets, filled films (including seed coatings) and the like, which can be water-dispersible ("wettable") or water-soluble. Films and coatings formed from film- forming solutions or flowable suspensions are particularly useful for seed treatment. Active ingredient can be (micro)encapsulated and further formed into a suspension or solid formulation; alternatively the entire formulation of active ingredient can be encapsulated (or "overcoated"). Encapsulation can control or delay release of the active ingredient. An emulsifiable granule combines the advantages of both an emulsifiable concentrate formulation and a dry granular formulation. High- strength compositions are primarily used as intermediates for further formulation. Sprayable formulations are typically extended in a suitable medium before spraying. Such liquid and solid formulations are formulated to be readily diluted in the spray medium, usually water. Spray volumes can range from about from about one to several thousand liters per hectare, but more typically are in the range from about ten to several hundred liters per hectare. Sprayable formulations can be tank mixed with water or another suitable medium for foliar treatment by aerial or ground application, or for application to the growing medium of the plant. Liquid and dry formulations can be metered directly into drip irrigation systems or metered into the furrow during planting. Liquid and solid formulations can be applied onto seeds of crops and other desirable vegetation as seed treatments before planting to protect developing roots and other subterranean plant parts and/or foliage through systemic uptake.
The formulations will typically contain effective amounts of active ingredient, diluent and surfactant within the following approximate ranges which add up to 100 percent by weight.
Weight Percent
Active
Ingredient Diluent Surfactant
Water-Dispersible and Water- 0.001-90 0-99.999 0-15 soluble Granules, Tablets and Powders
Oil Dispersions, Suspensions, 1-50 40-99 0-50 Emulsions, Solutions (including Emulsifiable Concentrates)
Dusts 1-25 70-99 0-5
Granules and Pellets 0.001-95 5-99.999 0-15
High Strength Compositions 90-99 0-10 0-2 Solid diluents include, for example, clays such as bentonite, montmorillonite, attapulgite and kaolin, gypsum, cellulose, titanium dioxide, zinc oxide, starch, dextrin, sugars (e.g., lactose, sucrose), silica, talc, mica, diatomaceous earth, urea, calcium carbonate, sodium carbonate and bicarbonate, and sodium sulfate. Typical solid diluents are described in Watkins et al., Handbook of Insecticide Dust Diluents and Carriers, 2nd Ed., Dorland Books, Caldwell, New Jersey.
Liquid diluents include, for example, water, JV,iV-dimethylalkanamides (e.g., Λ/,Λ/-dimethylformamide), limonene, dimethyl sulfoxide, JV-alkylpyrrolidones (e.g., JV-methylpyrrolidinone), ethylene glycol, Methylene glycol, propylene glycol, dipropylene glycol, polypropylene glycol, propylene carbonate, butylene carbonate, paraffins (e.g., white mineral oils, normal paraffins, isoparaffϊns), alkylbenzenes, alkylnaphthalenes, glycerine, glycerol triacetate, sorbitol, triacetin, aromatic hydrocarbons, dearomatized aliphatics, alkylbenzenes, alkylnaphthalenes, ketones such as cyclohexanone, 2-heptanone, isophorone and 4-hydroxy-4-methyl-2-pentanone, acetates such as isoamyl acetate, hexyl acetate, heptyl acetate, octyl acetate, nonyl acetate, tridecyl acetate and isobornyl acetate, other esters such as alkylated lactate esters, dibasic esters and γ-butyrolactone, and alcohols, which can be linear, branched, saturated or unsaturated, such as methanol, ethanol, n-propanol, isopropyl alcohol, n-butanol, isobutyl alcohol, n-hexanol, 2-ethylhexanol, n-octanol, decanol, isodecyl alcohol, isooctadecanol, cetyl alcohol, lauryl alcohol, tridecyl alcohol, oleyl alcohol, cyclohexanol, tetrahydrofurfuryl alcohol, diacetone alcohol and benzyl alcohol. Liquid diluents also include glycerol esters of saturated and unsaturated fatty acids (typically C6-C22), such as plant seed and fruit oils (e.g, oils of olive, castor, linseed, sesame, corn (maize), peanut, sunflower, grapeseed, safflower, cottonseed, soybean, rapeseed, coconut and palm kernel), animal-sourced fats (e.g., beef tallow, pork tallow, lard, cod liver oil, fish oil), and mixtures thereof. Liquid diluents also include alkylated fatty acids (e.g., methylated, ethylated, butylated) wherein the fatty acids can be obtained by hydrolysis of glycerol esters from plant and animal sources, and can be purified by distillation. Typical liquid diluents are described in Marsden, Solvents Guide, 2nd Ed., Interscience, New York, 1950.
The solid and liquid compositions of the present invention often include one or more surfactants. When added to a liquid, surfactants (also known as "surface-active agents") generally modify, most often reduce, the surface tension of the liquid. Depending on the nature of the hydrophilic and lipophilic groups in a surfactant molecule, surfactants can be useful as wetting agents, dispersants, emulsifϊers or defoaming agents.
Surfactants can be classified as nonionic, anionic or cationic. Nonionic surfactants useful for the present compositions include, but are not limited to: alcohol alkoxylates such as alcohol alkoxylates based on natural and synthetic alcohols (which are branched or linear) and prepared from the alcohols and ethylene oxide, propylene oxide, butylene oxide or mixtures thereof; amine ethoxylates, alkanolamides and ethoxylated alkanolamides; alkoxylated triglycerides such as ethoxylated soybean, castor and rapeseed oils; alkylphenol alkoxylates such as octylphenol ethoxylates, nonylphenol ethoxylates, dinonyl phenol ethoxylates and dodecyl phenol ethoxylates (prepared from the phenols and ethylene oxide, propylene oxide, butylene oxide or mixtures thereof); block polymers prepared from ethylene oxide or propylene oxide and reverse block polymers where the terminal blocks are prepared from propylene oxide; ethoxylated fatty acids; ethoxylated fatty esters and oils; ethoxylated methyl esters; ethoxylated tristyrylphenol (including those prepared from ethylene oxide, propylene oxide, butylene oxide or mixtures thereof); fatty acid esters, glycerol esters, lanolin-based derivatives, polyethoxylate esters such as polyethoxylated sorbitan fatty acid esters, polyethoxylated sorbitol fatty acid esters and polyethoxylated glycerol fatty acid esters; other sorbitan derivatives such as sorbitan esters; polymeric surfactants such as random copolymers, block copolymers, alkyd peg (polyethylene glycol) resins, graft or comb polymers and star polymers; polyethylene glycols (pegs); polyethylene glycol fatty acid esters; silicone-based surfactants; and sugar-derivatives such as sucrose esters, alkyl polyglycosides and alkyl polysaccharides.
Useful anionic surfactants include, but are not limited to: alkylaryl sulfonic acids and their salts; carboxylated alcohol or alkylphenol ethoxylates; diphenyl sulfonate derivatives; lignin and lignin derivatives such as lignosulfonates; maleic or succinic acids or their anhydrides; olefin sulfonates; phosphate esters such as phosphate esters of alcohol alkoxylates, phosphate esters of alkylphenol alkoxylates and phosphate esters of styryl phenol ethoxylates; protein-based surfactants; sarcosine derivatives; styryl phenol ether sulfate; sulfates and sulfonates of oils and fatty acids; sulfates and sulfonates of ethoxylated alkylphenols; sulfates of alcohols; sulfates of ethoxylated alcohols; sulfonates of amines and amides such as 7V,iV-alkyltaurates; sulfonates of benzene, cumene, toluene, xylene, and dodecyl and tridecylbenzenes; sulfonates of condensed naphthalenes; sulfonates of naphthalene and alkyl naphthalene; sulfonates of fractionated petroleum; sulfosuccinamates; and sulfosuccinates and their derivatives such as dialkyl sulfosuccinate salts.
Useful cationic surfactants include, but are not limited to: amides and ethoxylated amides; amines such as JV-alkyl propanediamines, tripropylenetriamines and dipropylenetetramines, and ethoxylated amines, ethoxylated diamines and propoxylated amines (prepared from the amines and ethylene oxide, propylene oxide, butylene oxide or mixtures thereof); amine salts such as amine acetates and diamine salts; quaternary ammonium salts such as quaternary salts, ethoxylated quaternary salts and diquaternary salts; and amine oxides such as alkyldimethylamine oxides and bis-(2-hydroxyethyl)-alkylamine oxides.
Also useful for the present compositions are mixtures of nonionic and anionic surfactants or mixtures of nonionic and cationic surfactants. Nonionic, anionic and cationic surfactants and their recommended uses are disclosed in a variety of published references including McCutcheon 's Emulsifiers and Detergents, annual American and International Editions published by McCutcheon's Division, The Manufacturing Confectioner Publishing Co.; Sisely and Wood, Encyclopedia of Surface Active Agents, Chemical Publ. Co., Inc., New York, 1964; and A. S. Davidson and B. Milwidsky, Synthetic Detergents, Seventh Edition, John Wiley and Sons, New York, 1987.
Compositions of this invention can also contain formulation auxiliaries and additives, known to those skilled in the art as formulation aids (some of which can be considered to also function as solid diluents, liquid diluents or surfactants). Such formulation auxiliaries and additives can control: pH (buffers), foaming during processing (antifoams such polyorganosiloxanes), sedimentation of active ingredients (suspending agents), viscosity (thixotropic thickeners), in-container microbial growth (antimicrobials), product freezing (antifreezes), color (dyes/pigment dispersions), wash-off (film formers or stickers), evaporation (evaporation retardants), and other formulation attributes. Film formers include, for example, polyvinyl acetates, polyvinyl acetate copolymers, polyvinylpyrrolidone-vinyl acetate copolymer, polyvinyl alcohols, polyvinyl alcohol copolymers and waxes. Examples of formulation auxiliaries and additives include those listed in McCutcheon 's Volume 2: Functional Materials, annual International and North American editions published by McCutcheon' s Division, The Manufacturing Confectioner Publishing Co.; and PCT Publication WO 03/024222. The compound of Formula 1 and any other active ingredients are typically incorporated into the present compositions by dissolving the active ingredient in a solvent or by grinding in a liquid or dry diluent. Solutions, including emulsifiable concentrates, can be prepared by simply mixing the ingredients. If the solvent of a liquid composition intended for use as an emulsifiable concentrate is water-immiscible, an emulsifier is typically added to emulsify the active-containing solvent upon dilution with water. Active ingredient slurries, with particle diameters of up to 2,000 μm can be wet milled using media mills to obtain particles with average diameters below 3 μm. Aqueous slurries can be made into finished suspension concentrates (see, for example, U.S. 3,060,084) or further processed by spray drying to form water-dispersible granules. Dry formulations usually require dry milling processes, which produce average particle diameters in the 2 to 10 μm range. Dusts and powders can be prepared by blending and usually grinding (such as with a hammer mill or fluid-energy mill). Granules and pellets can be prepared by spraying the active material upon preformed granular carriers or by agglomeration techniques. See Browning, "Agglomeration", Chemical Engineering, December 4, 1967, pp 147-48, Perry's Chemical Engineer's Handbook, 4th Ed., McGraw-Hill, New York, 1963, pages 8-57 and following, and WO 91/13546. Pellets can be prepared as described in U.S. 4,172,714. Water-dispersible and water-soluble granules can be prepared as taught in U.S. 4,144,050, U.S. 3,920,442 and DE 3,246,493. Tablets can be prepared as taught in U.S. 5,180,587, U.S. 5,232,701 and U.S. 5,208,030. Films can be prepared as taught in GB 2,095,558 and U.S. 3,299,566.
For further information regarding the art of formulation, see T. S. Woods, "The Formulator's Toolbox - Product Forms for Modern Agriculture" in Pesticide Chemistry and Bioscience, The Food-Environment Challenge, T. Brooks and T. R. Roberts, Eds., Proceedings of the 9th International Congress on Pesticide Chemistry, The Royal Society of Chemistry, Cambridge, 1999, pp. 120-133. See also U.S. 3,235,361, Col. 6, line 16 through Col. 7, line 19 and Examples 10-41; U.S. 3,309,192, Col. 5, line 43 through Col. 7, line 62 and Examples 8, 12, 15, 39, 41, 52, 53, 58, 132, 138-140, 162-164, 166, 167 and 169-182; U.S. 2,891,855, Col. 3, line 66 through Col. 5, line 17 and Examples 1-4; Klingman, Weed Control as a Science, John Wiley and Sons, Inc., New York, 1961, pp 81-96; Hance et al, Weed Control Handbook, 8th Ed., Blackwell Scientific Publications, Oxford, 1989; and Developments in formulation technology, PJB Publications, Richmond, UK, 2000.
In the following Examples, all formulations are prepared in conventional ways. Compound numbers refer to compounds in Index Tables A-F. Without further elaboration, it is believed that one skilled in the art using the preceding description can utilize the present invention to its fullest extent. The following Examples are, therefore, to be construed as merely illustrative, and not limiting of the disclosure in any way whatsoever. Percentages are by weight except where otherwise indicated. Example A
High Strength Concentrate
Compound 7 98.5% silica aerogel 0.5% synthetic amorphous fine silica 1.0%
Example B Wettable Powder
Compound 50 65.0% dodecylphenol polyethylene glycol ether 2.0% sodium ligninsulfonate 4.0% sodium silicoaluminate 6.0% montmorillonite (calcined) 23.0%
Example C Granule
Compound 138 10.0% attapulgite granules (low volatile matter, 0.71/0.30 mm; 90.0%
U.S.S. No. 25-50 sieves)
Example D Extruded Pellet
Compound 157 25.0% anhydrous sodium sulfate 10.0% crude calcium ligninsulfonate 5.0% sodium alkylnaphthalenesulfonate 1.0% calcium/magnesium bentonite 59.0% Example E
Emulsifiable Concentrate
Compound 7 10.0% polyoxyethylene sorbitol hexoleate 20.0%
C6-C10 fatty acid methyl ester 70.0%
Example F
Microemulsion
Compound 50 5.0% polyvinylpyrrolidone -vinyl acetate copolymer 30.0% alkylpolyglycoside 30.0% glyceryl monooleate 15.0% water 20.0%
Example G
Seed Treatment
Compound 138 20.00% polyvinylpyrrolidone -vinyl acetate copolymer 5.00% montan acid wax 5.00% calcium ligninsulfonate 1.00% polyoxyethylene/polyoxypropylene block copolymers 1.00% stearyl alcohol (POE 20) 2.00% polyorganosilane 0.20% colorant red dye 0.05% water 65.75%
Example H
Fertilizer Stick
Compound 157 2.50% pyrrolidone-styrene copolymer 4.80% tristyrylphenyl 16-ethoxylate 2.30% talc 0.80% corn starch 5.00%
Nitrophoska® Permanent 15-9-15 slow-release fertilizer 36.00%
(BASF) kaolin 38.00% water 10.60% Compounds of this invention exhibit activity against a wide spectrum of invertebrate pests. These pests include invertebrates inhabiting a variety of environments such as, for example, plant foliage, roots, soil, harvested crops or other foodstuffs, building structures or animal integuments. These pests include, for example, invertebrates feeding on foliage (including leaves, stems, flowers and fruits), seeds, wood, textile fibers or animal blood or tissues, and thereby causing injury or damage to, for example, growing or stored agronomic crops, forests, greenhouse crops, ornamentals, nursery crops, stored foodstuffs or fiber products, or houses or other structures or their contents, or being harmful to animal health or public health. Those skilled in the art will appreciate that not all compounds are equally effective against all growth stages of all pests.
These present compounds and compositions are thus useful agronomically for protecting field crops from phytophagous invertebrate pests, and also nonagronomically for protecting other horticultural crops and plants from phytophagous invertebrate pests. This utility includes protecting crops and other plants (i.e. both agronomic and nonagronomic) that contain genetic material introduced by genetic engineering (i.e. transgenic) or modified by mutagenesis to provide advantageous traits. Examples of such traits include tolerance to herbicides, resistance to phytophagous pests (e.g., insects, mites, aphids, spiders, nematodes, snails, plant-pathogenic fungi, bacteria and viruses), improved plant growth, increased tolerance of adverse growing conditions such as high or low temperatures, low or high soil moisture, and high salinity, increased flowering or fruiting, greater harvest yields, more rapid maturation, higher quality and/or nutritional value of the harvested product, or improved storage or process properties of the harvested products. Transgenic plants can be modified to express multiple traits. Examples of plants containing traits provided by genetic engineering or mutagenesis include varieties of corn, cotton, soybean and potato expressing an insecticidal Bacillus thuringiensis toxin such as YIELD GARD®, KNOCKOUT , STARLINK®, BOLLGARD®, NuCOTN® and NEWLEAF®, and herbicide-tolerant varieties of corn, cotton, soybean and rapeseed such as ROUNDUP READY®, LIBERTY LINK®, IMI , STS and CLEARFIELD , as well as crops expressing JV-acetyltransferase (GAT) to provide resistance to glyphosate herbicide, or crops containing the HRA gene providing resistance to herbicides inhibiting acetolactate synthase (ALS). The present compounds and compositions may interact synergistically with traits introduced by genetic engineering or modified by mutagenesis, thus enhancing phenotypic expression or effectiveness of the traits or increasing the invertebrate pest control effectiveness of the present compounds and compositions. In particular, the present compounds and compositions may interact synergistically with the phenotypic expression of proteins or other natural products toxic to invertebrate pests to provide greater-than-additive control of these pests.
Compositions of this invention can also optionally comprise plant nutrients, e.g., a fertilizer composition comprising at least one plant nutrient selected from nitrogen, phosphorus, potassium, sulfur, calcium, magnesium, iron, copper, boron, manganese, zinc, and molybdenum. Of note are compositions comprising at least one fertilizer composition comprising at least one plant nutrient selected from nitrogen, phosphorus, potassium, sulfur, calcium and magnesium. Compositions of the present invention which further comprise at least one plant nutrient can be in the form of liquids or solids. Of note are solid formulations in the form of granules, small sticks or tablets. Solid formulations comprising a fertilizer composition can be prepared by mixing the compound or composition of the present invention with the fertilizer composition together with formulating ingredients and then preparing the formulation by methods such as granulation or extrusion. Alternatively solid formulations can be prepared by spraying a solution or suspension of a compound or composition of the present invention in a volatile solvent onto a previous prepared fertilizer composition in the form of dimensionally stable mixtures, e.g., granules, small sticks or tablets, and then evaporating the solvent.
Examples of agronomic or nonagronomic invertebrate pests include eggs, larvae and adults of the order Lepidoptera, such as armyworms, cutworms, loopers, and heliothines in the family Noctuidae (e.g., pink stem borer (Sesamia inferens Walker), corn stalk borer (Sesamia nonagrioides Lefebvre), southern armyworm (Spodoptera eridania Cramer), fall armyworm (Spodoptera fugiperda J. E. Smith), beet armyworm (Spodoptera exigua Hϋbner), cotton leafworm (Spodoptera littoralis Boisduval), yellowstriped armyworm (Spodoptera ornithogalli Guenee), black cutworm (Agrotis ipsilon Hufnagel), velvetbean caterpillar (Anticarsia gemmatalis Hϋbner), green fruitworm (Lithophane antennata Walker), cabbage armyworm (Barathra brassicae Linnaeus), soybean looper (Pseudoplusia includens Walker), cabbage looper (Trichoplusia ni Hϋbner), tobacco budworm (Heliothis virescens Fabricius)); borers, casebearers, webworms, coneworms, cabbageworms and skeletonizers from the family Pyralidae (e.g., European corn borer (Ostrinia nubilalis Hϋbner), navel orangeworm (Amyelois transitella Walker), corn root webworm (Crambus caliginosellus Clemens), sod webworms (Pyralidae: Crambinae) such as sod worm (Herpeto gramma licarsisalis Walker), sugarcane stem borer (Chilo infuscatellus Snellen), tomato small borer (Neoleucinodes elegantalis Guenee), green leafroller (Cnaphalocerus medinalis), grape leaffolder (Desmia funeralis Hϋbner), melon worm (Diaphania nitidalis Stoll), cabbage center grub (Helluala hydralis Guenee), yellow stem borer (Scirpophaga incertulas Walker), early shoot borer (Scirpophaga infuscatellus Snellen), white stem borer (Scirpophaga innotata Walker), top shoot borer (Scirpophaga nivella Fabricius), dark- headed rice borer (Chilo polychrysus Meyrick), cabbage cluster caterpillar (Crocidolomia binotalis English)); leafrollers, budworms, seed worms, and fruit worms in the family Tortricidae (e.g., codling moth (Cydia pomonella Linnaeus), grape berry moth (Endopiza viteana Clemens), oriental fruit moth (Grapholita molesta Busck), citrus false codling moth (Cryptophlebia leucotreta Meyrick), citrus borer (Ecdytolopha aurantiana Lima), redbanded leafroller (Argyrotaenia velutinana Walker), obliquebanded leafroller (Choristoneura rosaceana Harris), light brown apple moth (Epiphyas postvittana Walker), European grape berry moth (Eupoecilia ambiguella Hϋbner), apple bud moth (Pandemis pyrusana Kearfott), omnivorous leafroller {Platynota stultana Walsingham), barred fruit-tree tortrix (Pandemis cerasana Hϋbner), apple brown tortrix {Pandemis heparana Denis & Schiffermϋller)); and many other economically important lepidoptera (e.g., diamondback moth (Plutella xylostella Linnaeus), pink bollworm {Pectinophora gossypiella Saunders), gypsy moth (Lymantria dispar Linnaeus), peach fruit borer (Carposina niponensis Walsingham), peach twig borer {Anarsia lineatella Zeller), potato tuberworm (Phthorimaea operculella Zeller), spotted teniform leafminer {Lithocolletis blancardella Fabricius), Asiatic apple leafminer {Lithocolletis ringoniella Matsumura), rice leaffolder (Lerodea eufala Edwards), apple leafminer (Leucoptera scitella Zeller)); eggs, nymphs and adults of the order Blattodea including cockroaches from the families Blattellidae and Blattidae (e.g., oriental cockroach (Blatta orientalis Linnaeus), Asian cockroach (Blatella asahinai Mizukubo), German cockroach (Blattella germanica Linnaeus), brownbanded cockroach (Supella longipalpa Fabricius), American cockroach (Periplaneta americana Linnaeus), brown cockroach {Periplaneta brunnea Burmeister), Madeira cockroach (Leucophaea maderae Fabricius)), smoky brown cockroach (Periplaneta fuliginosa Service), Australian Cockroach {Periplaneta australasiae Fabr.), lobster cockroach (Nauphoeta cinerea Olivier) and smooth cockroach (Symploce pallens Stephens)); eggs, foliar feeding, fruit feeding, root feeding, seed feeding and vesicular tissue feeding larvae and adults of the order Coleoptera including weevils from the families Anthribidae, Bruchidae, and Curculionidae (e.g., boll weevil (Anthonomus grandis Boheman), rice water weevil (Lissorhoptrus oryzophilus Kuschel), granary weevil (Sitophilus granarius Linnaeus), rice weevil (Sitophilus oryzae Linnaeus)), annual bluegrass weevil (Listronotus maculicollis Dietz), bluegrass billbug (Sphenophorus parvulus Gyllenhal), hunting billbug (Sphenophorus venatus vestitus), Denver billbug (Sphenophorus cicatristriatus Fahraeus)); flea beetles, cucumber beetles, rootworms, leaf beetles, potato beetles, and leafminers in the family Chrysomelidae (e.g., Colorado potato beetle (Leptinotarsa decemlineata Say), western corn rootworm (Diabrotica virgifera virgifera LeConte)); chafers and other beetles from the family Scarabaeidae (e.g., Japanese beetle (Popillia japonica Newman), oriental beetle (Anomala orientalis Waterhouse, Exomala orientalis (Waterhouse) Baraud), northern masked chafer (Cyclocephala borealis Arrow), southern masked chafer (Cyclocephala immaculata Olivier or C. lurida Bland), dung beetle and white grub (Aphodius spp.), black turfgrass ataenius (Ataenius spretulus Haldeman), green June beetle (Cotinis nitida Linnaeus), Asiatic garden beetle (Maladera castanea Arrow), May/June beetles (Phyllophaga spp.) and European chafer (Rhizotrogus majalis Razoumowsky)); carpet beetles from the family Dermestidae; wireworms from the family Elateridae; bark beetles from the family Scolytidae and flour beetles from the family Tenebrionidae. In addition, agronomic and nonagronomic pests include: eggs, adults and larvae of the order Dermaptera including earwigs from the family Forfϊculidae (e.g., European earwig (Forβcula auricularia Linnaeus), black earwig (Chelisoches mono Fabricius)); eggs, immatures, adults and nymphs of the orders Hemiptera and Homoptera such as, plant bugs from the family Miridae, cicadas from the family Cicadidae, leafhoppers (e.g. Empoasca spp.) from the family Cicadellidae, bed bugs (e.g., Cimex lectularius Linnaeus) from the family Cimicidae, planthoppers from the families Fulgoroidae and Delphacidae, treehoppers from the family Membracidae, psyllids from the family Psyllidae, whiteflies from the family Aleyrodidae, aphids from the family Aphididae, phylloxera from the family Phylloxeridae, mealybugs from the family Pseudococcidae, scales from the families Coccidae, Diaspididae and Margarodidae, lace bugs from the family Tingidae, stink bugs from the family Pentatomidae, chinch bugs (e.g., hairy chinch bug (Blissus leucopterus hirtus Montandon) and southern chinch bug {Blissus insularis Barber)) and other seed bugs from the family Lygaeidae, spittlebugs from the family Cercopidae squash bugs from the family Coreidae, and red bugs and cotton stainers from the family Pyrrhocoridae. Also included are eggs, larvae, nymphs and adults of the order Acari (mites) such as spider mites and red mites in the family Tetranychidae (e.g., European red mite {Panonychus ulmi Koch), two spotted spider mite (Tetranychus urticae Koch), McDaniel mite (Tetranychus mcdanieli McGregor)); flat mites in the family Tenuipalpidae (e.g., citrus flat mite (Brevipalpus lewisi McGregor)); rust and bud mites in the family Eriophyidae and other foliar feeding mites and mites important in human and animal health, i.e. dust mites in the family Epidermoptidae, follicle mites in the family Demodicidae, grain mites in the family Glycyphagidae; ticks in the family Ixodidae, commonly known as hard ticks (e.g., deer tick {Ixodes scapularis Say), Australian paralysis tick {Ixodes holocyclus Neumann), American dog tick {Dermacentor variabilis Say), lone star tick {Amblyomma americanum Linnaeus)) and ticks in the family Argasidae, commonly known as soft ticks (e.g., relapsing fever tick {Ornithodoros turicata), common fowl tick {Argas radiatus)); scab and itch mites in the families Psoroptidae, Pyemotidae, and Sarcoptidae; eggs, adults and immatures of the order Orthoptera including grasshoppers, locusts and crickets (e.g., migratory grasshoppers (e.g., Melanoplus sanguinipes Fabricius, M. differ entialis Thomas), American grasshoppers (e.g., Schistocerca americana Drury), desert locust {Schistocerca gregaria Forskal), migratory locust {Locusta migratoria Linnaeus), bush locust {Zonocerus spp.), house cricket {Acheta domesticus Linnaeus), mole crickets (e.g., tawny mole cricket {Scapteriscus vicinus Scudder) and southern mole cricket {Scapteriscus borellii Giglio-Tos)); eggs, adults and immatures of the order Diptera including leafminers (e.g., Liriomyza spp. such as serpentine vegetable leafminer {Liriomyza sativae Blanchard)), midges, fruit flies (Tephritidae), frit flies (e.g., Oscinella frit Linnaeus), soil maggots, house flies (e.g., Musca domestica Linnaeus), lesser house flies (e.g., Fannia canicularis Linnaeus, F. femoralis Stein), stable flies (e.g., Stomoxys calcitrans Linnaeus), face flies, horn flies, blow flies (e.g., Chrysomya spp., Phormia spp.), and other muscoid fly pests, horse flies (e.g., Tabanus spp.), bot flies (e.g., Gastrophilus spp., Oestrus spp.), cattle grubs (e.g., Hypoderma spp.), deer flies (e.g., Chrysops spp.), keds (e.g., Melophagus ovinus Linnaeus) and other Brachycera, mosquitoes (e.g., Aedes spp., Anopheles spp., Culex spp.), black flies (e.g., Prosimulium spp., Simulium spp.), biting midges, sand flies, sciarids, and other Nematocera; eggs, adults and immatures of the order Thysanoptera including onion thrips (Thrips tabaci Lindeman), flower thrips {Frankliniella spp.), and other foliar feeding thrips; insect pests of the order Hymenoptera including ants of the Family Formicidae including the Florida carpenter ant (Camponotus floridanus Buckley), red carpenter ant (Camponotus ferrugineus Fabricius), black carpenter ant (Camponotus pennsylvanicus De Geer), white-footed ant (Technomyrmex albipes fr. Smith), big headed ants (Pheidole sp.), ghost ant (Tapinoma melanocephalum Fabricius); Pharaoh ant (Monomorium pharaonis Linnaeus), little fire ant (Wasmannia auropunctata Roger), fire ant (Solenopsis geminata Fabricius), red imported fire ant (Solenopsis invicta Buren), Argentine ant (Iήdomyrmex humilis Mayr), crazy ant (Paratrechina longicornis Latreille), pavement ant (Tetramorium caespitum Linnaeus), cornfield ant (Lasius alienus Fόrster) and odorous house ant (Tapinoma sessile Say). Other Hymenoptera including bees (including carpenter bees), hornets, yellow jackets, wasps, and sawflies (Neodiprion spp.; Cephus spp.); insect pests of the order Isoptera including termites in the Termitidae (e.g., Macrotermes sp., Odontotermes obesus Rambur), Kalotermitidae (e.g., Cryptotermes sp.), and Rhinotermitidae (e.g., Reticulitermes sp., Coptotermes sp., Heterotermes tenuis Hagen) families, the eastern subterranean termite (Reticulitermes flavipes Kollar), western subterranean termite (Reticulitermes hesperus Banks), Formosan subterranean termite (Coptotermes formosanus Shiraki), West Indian drywood termite (Incisitermes immigrans Snyder), powder post termite (Cryptotermes brevis Walker), drywood termite (Incisitermes snyderi Light), southeastern subterranean termite (Reticulitermes virginicus Banks), western drywood termite (Incisitermes minor Hagen), arboreal termites such as Nasutitermes sp. and other termites of economic importance; insect pests of the order Thysanura such as silverfish (Lepisma saccharina Linnaeus) and firebrat (Thermobia domestica Packard); insect pests of the order Mallophaga and including the head louse (Pediculus humanus capitis De Geer), body louse (Pediculus humanus Linnaeus), chicken body louse (Menacanthus stramineus Nitszch), dog biting louse (Trichodectes canis De Geer), fluff louse (Goniocotes gallinae De Geer), sheep body louse (Bovicola ovis Schrank), short-nosed cattle louse (Haematopinus eurysternus Nitzsch), long-nosed cattle louse (Linognathus vituli Linnaeus) and other sucking and chewing parasitic lice that attack man and animals; insect pests of the order Siphonoptera including the oriental rat flea (Xenopsylla cheopis Rothschild), cat flea (Ctenocephalides felis Bouche), dog flea (Ctenocephalides canis Curtis), hen flea (Ceratophyllus gallinae Schrank), sticktight flea (Echidnophaga gallinacea Westwood), human flea (Pulex irritans Linnaeus) and other fleas afflicting mammals and birds. Additional arthropod pests covered include: spiders in the order Araneae such as the brown recluse spider (Loxosceles reclusa Gertsch & Mulaik) and the black widow spider (Latrodectus mactans Fabricius), and centipedes in the order Scutigeromorpha such as the house centipede (Scutigera coleoptrata Linnaeus). Compounds of the present invention also have activity on members of the Classes Nematoda, Cestoda, Trematoda, and Acanthocephala including economically important members of the orders Strongylida, Ascaridida, Oxyurida, Rhabditida, Spirurida, and Enoplida such as but not limited to economically important agricultural pests (i.e. root knot nematodes in the genus Meloidogyne, lesion nematodes in the genus Pratylenchus, stubby root nematodes in the genus Tήchodorus, etc.) and animal and human health pests (i.e. all economically important flukes, tapeworms, and roundworms, such as Strongylus vulgaris in horses, Toxocara canis in dogs, Haemonchus contortus in sheep, Dirofilaria immitis Leidy in dogs, Anoplocephala perfoliata in horses, Fasciola hepatica Linnaeus in ruminants, etc.).
Compounds of the invention show particularly high activity against pests in the order Lepidoptera (e.g., Alabama argillacea Hϋbner (cotton leaf worm), Archips argyrospila Walker (fruit tree leaf roller), A. rosana Linnaeus (European leaf roller) and other Archips species, Chilo suppressalis Walker (rice stem borer), Cnaphalocrosis medinalis Guenee (rice leaf roller), Crambus caliginosellus Clemens (corn root webworm), Crambus teterrellus Zincken (bluegrass webworm), Cydia pomonella Linnaeus (codling moth), Earias insulana Boisduval (spiny bollworm), Earias vittella Fabricius (spotted bollworm), Helicoverpa armigera Hϋbner (American bollworm), Helicoverpa zea Boddie (corn earworm), Heliothis virescens Fabricius (tobacco budworm), Herpetogramma licarsisalis Walker (sod webworm), Lobesia botrana Denis & Schiffermϋller (grape berry moth), Pectinophora gossypiella Saunders (pink bollworm), Phyllocnistis citrella Stainton (citrus leafminer), Pieris brassicae Linnaeus (large white butterfly), Pieris rapae Linnaeus (small white butterfly), Plutella xylostella Linnaeus (diamondback moth), Spodoptera exigua Hϋbner (beet armyworm), Spodoptera litura Fabricius (tobacco cutworm, cluster caterpillar), Spodoptera frugiperda J. E. Smith (fall armyworm), Trichoplusia ni Hϋbner (cabbage looper) and Tuta absoluta Meyrick (tomato leafminer)).
Compounds of the invention also have significant activity on members from the order Homoptera including: Acyrthosiphon pisum Harris (pea aphid), Aphis craccivora Koch (cowpea aphid), Aphis fabae Scopoli (black bean aphid), Aphis gossypii Glover (cotton aphid, melon aphid), Aphis pomi De Geer (apple aphid), Aphis spiraecola Patch (spirea aphid), Aulacorthum solani Kaltenbach (foxglove aphid), Chaetosiphon fragaefolii Cockerell (strawberry aphid), Diuraphis noxia Kurdjumov/Mordvilko (Russian wheat aphid), Dysaphis plantaginea Paaserini (rosy apple aphid), Eriosoma lanigerum Hausmann (woolly apple aphid), Hyalopterus pruni Geoffroy (mealy plum aphid), Lipaphis erysimi Kaltenbach (turnip aphid), Metopolophium dirrhodum Walker (cereal aphid), Macrosiphum euphorbiae Thomas (potato aphid), Myzus persicae Sulzer (peach-potato aphid, green peach aphid), Nasonovia ribisnigri Mosley (lettuce aphid), Pemphigus spp. (root aphids and gall aphids), Rhopalosiphum maidis Fitch (corn leaf aphid), Rhopalosiphum padi Linnaeus (bird cherry-oat aphid), Schizaphis graminum Rondani (greenbug), Sitobion avenae Fabricius (English grain aphid), Therioaphis maculata Buckton (spotted alfalfa aphid), Toxoptera aurantii Boyer de Fonscolombe (black citrus aphid), and Toxoptera citricida Kirkaldy (brown citrus aphid); Adelges spp. (adelgids); Phylloxera devastatrix Pergande (pecan phylloxera); Bemisia tabaci Gennadius (tobacco whitefly, sweetpotato whitefly), Bemisia argentifolii Bellows & Perring (silverleaf whitefly), Dialeurodes citri Ashmead (citrus whitefly) and Tήaleurodes vaporariorum Westwood (greenhouse whitefly); Empoasca fabae Harris (potato leafhopper), Laodelphax striatellus Fallen (smaller brown planthopper), Macrolestes quadrilineatus Forbes (aster leafhopper), Nephotettix cinticeps Uhler (green leafhopper), Nephotettix nigropictus Stal (rice leafhopper), Nilaparvata lugens Stal (brown planthopper), Peregrinus maidis Ashmead (corn planthopper), Sogatella furcifera Horvath (white-backed planthopper), Sogatodes orizicola Muir (rice delphacid), Typhlocyba pomaria McAtee white apple leafhopper, Erythroneoura spp. (grape leafhoppers); Magicidada septendecim Linnaeus (periodical cicada); leery a purchasi Maskell (cottony cushion scale), Quadraspidiotus perniciosus Comstock (San Jose scale); Planococcus citri Risso (citrus mealybug); Pseudococcus spp. (other mealybug complex); Cacopsylla pyricola Foerster (pear psylla), Trioza diospyri Ashmead (persimmon psylla).
Compounds of this invention may also have activity on members from the order Hemiptera including: Acrosternum hilare Say (green stink bug), Anasa tristis De Geer (squash bug), Blissus leucopterus leucopterus Say (chinch bug), Cimex lectularius Linnaeus (bed bug) Corythuca gossypii Fabricius (cotton lace bug), Cyrtopeltis modesta Distant (tomato bug), Dysdercus suturellus Herrich-Schaffer (cotton stainer), Euchistus servus Say (brown stink bug), Euchistus variolarius Palisot de Beauvois (one-spotted stink bug), Graptosthetus spp. (complex of seed bugs), Leptoglossus corculus Say (leaf- footed pine seed bug), Lygus lineolaris Palisot de Beauvois (tarnished plant bug), Nezara viridula Linnaeus (southern green stink bug), Oebalus pugnax Fabricius (rice stink bug), Oncopeltus fasciatus Dallas (large milkweed bug), Pseudatomoscelis seriatus Reuter (cotton fleahopper). Other insect orders controlled by compounds of the invention include Thysanoptera (e.g., Frankliniella occidentalis Pergande (western flower thrips), Scirthothrips citri Moulton (citrus thrips), Sericothrips variabilis Beach (soybean thrips), and Thrips tabaci Lindeman (onion thrips); and the order Coleoptera (e.g., Leptinotarsa decemlineata Say (Colorado potato beetle), Epilachna varivestis Mulsant (Mexican bean beetle) and wireworms of the genera Agriotes, Athous or Limonius). Note that some contemporary classification systems place Homoptera as a suborder within the order Hemiptera.
Of note is use of compounds of this invention for controlling potato leafhopper {Empoasca fabae). Of note is use of compounds of this invention for controlling corn planthopper (Peregrinus maidis). Of note is use of compounds of this invention for controlling cotton melon aphid {Aphis gossypii). Of note is use of compounds of this invention for controlling green peach aphid (Myzus persicae). Of note is use of compounds of this invention for controlling diamondback moth (Plutella xylostellά). Of note is use of compounds of this invention for controlling fall armyworm (Spodoptera frugiperda).
Of note is use of compounds of this invention for controlling southern green stink bug (Nezara viridula), western tarnished plant bug (Lygus hesperus), rice water weevil {Lissorhoptrus oryzophilus), rice brown planthopper (Nilaparvata lugens), rice green leafhopper (Nephotettix virescens) and striped rice borer (Chilo suppressalis). Compounds of this invention can also be mixed with one or more other biologically active compounds or agents including insecticides, fungicides, nematocides, bactericides, acaricides, herbicides, herbicide safeners, growth regulators such as insect molting inhibitors and rooting stimulants, chemosterilants, semiochemicals, repellents, attractants, pheromones, feeding stimulants, other biologically active compounds or entomopathogenic bacteria, virus or fungi to form a multi-component pesticide giving an even broader spectrum of agronomic and nonagronomic utility. Thus the present invention also pertains to a composition comprising a biologically effective amount of a compound of Formula 1, at least one additional component selected from the group consisting of surfactants, solid diluents and liquid diluents, and at least one additional biologically active compound or agent. For mixtures of the present invention, the other biologically active compounds or agents can be formulated together with the present compounds, including the compounds of Formula 1, to form a premix, or the other biologically active compounds or agents can be formulated separately from the present compounds, including the compounds of Formula 1, and the two formulations combined together before application (e.g., in a spray tank) or, alternatively, applied in succession.
Examples of such biologically active compounds or agents with which compounds of this invention can be formulated are insecticides such as abamectin, acephate, acequinocyl, acetamiprid, acrinathrin, amidoflumet, amitraz, avermectin, azadirachtin, azinphos-methyl, bifenthrin, bifenazate, bistrifluron, borate, 3-bromo-l-(3-chloro-2-pyridinyl)-iV-[4-cyano-2- methyl-6-[(methylamino)carbonyl]phenyl]- lH-pyrazole-5-carboxamide (cyantraniliprole), buprofezin, cadusafos, carbaryl, carbofuran, cartap, carzol, chlorantraniliprole, chlorfenapyr, chlorfluazuron, chlorpyrifos, chlorpyrifos-methyl, chromafenozide, clofentezin, clothianidin, cyflumetofen, cyfluthrin, beta-cyfluthrin, cyhalothrin, gamma-cyhalothrin, lambda- cyhalothrin, cypermethrin, alpha-cypermethrin, zeta-cypermethrin, cyromazine, deltamethrin, diafenthiuron, diazinon, dieldrin, diflubenzuron, dimefluthrin, dimehypo, dimethoate, dinotefuran, diofenolan, emamectin, endosulfan, esfenvalerate, ethiprole, etofenprox, etoxazole, fenbutatin oxide, fenothiocarb, fenoxycarb, fenpropathrin, fenvalerate, fϊpronil, flonicamid, flubendiamide, flucythrinate, flufenerim, flufenoxuron, fluvalinate, tau-fluvalinate, fonophos, formetanate, fosthiazate, halofenozide, hexaflumuron, hexythiazox, hydramethylnon, imidacloprid, indoxacarb, insecticidal soaps, isofenphos, lufenuron, malathion, metaflumizone, metaldehyde, methamidophos, methidathion, methiodicarb, methomyl, methoprene, methoxychlor, metofluthrin, monocrotophos, methoxyfenozide, nitenpyram, nithiazine, novaluron, noviflumuron, oxamyl, parathion, parathion-methyl, permethrin, phorate, phosalone, phosmet, phosphamidon, pirimicarb, profenofos, profluthrin, propargite, protrifenbute, pymetrozine, pyrafluprole, pyrethrin, pyridaben, pyridalyl, pyrifluquinazon, pyriprole, pyriproxyfen, rotenone, ryanodine, spinetoram, spinosad, spirodiclofen, spiromesifen, spirotetramat, sulprofos, sulfoxaflor, tebufenozide, tebufenpyrad, teflubenzuron, tefluthrin, terbufos, tetrachlorvinphos, tetramethrin, thiacloprid, thiamethoxam, thiodicarb, thiosultap-sodium, tolfenpyrad, tralomethrin, triazamate, trichlorfon, triflumuron, Bacillus thuringiensis delta-endotoxins, entomopathogenic bacteria, entomopathogenic viruses and entomopathogenic fungi.
Of note are insecticides such as abamectin, acetamiprid, acrinathrin, amitraz, avermectin, azadirachtin, bifenthrin, 3-bromo-l-(3-chloro-2-pyridinyl)-iV-[4-cyano-2- methyl-6-[(methylamino)carbonyl]phenyl]-lH-pyrazole-5-carboxamide (cyantraniliprole), buprofezin, cadusafos, carbaryl, cartap, chlorantraniliprole, chlorfenapyr, chlorpyrifos, clothianidin, cyfluthrin, beta-cyfluthrin, cyhalothrin, gamma-cyhalothrin, lambda- cyhalothrin, cypermethrin, alpha-cypermethrin, zeta-cypermethrin, cyromazine, deltamethrin, dieldrin, dinotefuran, diofenolan, emamectin, endosulfan, esfenvalerate, ethiprole, etofenprox, etoxazole, fenothiocarb, fenoxycarb, fenvalerate, fϊpronil, flonicamid, flubendiamide, flufenoxuron, fluvalinate, formetanate, fosthiazate, hexaflumuron, hydramethylnon, imidacloprid, indoxacarb, lufenuron, metaflumizone, methiodicarb, methomyl, methoprene, methoxyfenozide, nitenpyram, nithiazine, novaluron, oxamyl, pymetrozine, pyrethrin, pyridaben, pyridalyl, pyriproxyfen, ryanodine, spinetoram, spinosad, spirodiclofen, spiromesifen, spirotetramat, tebufenozide, tetramethrin, thiacloprid, thiamethoxam, thiodicarb, thiosultap-sodium, tralomethrin, triazamate, triflumuron, Bacillus thuringiensis delta-endotoxins, all strains of Bacillus thuringiensis and all strains of Nucleo polyhydrosis viruses. One embodiment of biological agents for mixing with compounds of this invention include entomopathogenic bacteria such as Bacillus thuringiensis, and the encapsulated delta-endotoxins of Bacillus thuringiensis such as MVP® and MVPII® bioinsecticides prepared by the CellCap® process (CellCap®, MVP® and MVPII® are trademarks of Mycogen Corporation, Indianapolis, Indiana, USA); entomopathogenic fungi such as green muscardine fungus; and entomopathogenic (both naturally occurring and genetically modified) viruses including baculovirus, nucleopolyhedro virus (NPV) such as Helicoverpa zea nucleopolyhedrovirus (ΗzNPV), Anagrapha falcifera nucleopolyhedrovirus (AfNPV); and granulosis virus (GV) such as Cydia pomonella granulosis virus (CpGV). Of particular note is such a combination where the other invertebrate pest control active ingredient belongs to a different chemical class or has a different site of action than the compound of Formula 1. In certain instances, a combination with at least one other invertebrate pest control active ingredient having a similar spectrum of control but a different site of action will be particularly advantageous for resistance management. Thus, a composition of the present invention can further comprise a biologically effective amount of at least one additional invertebrate pest control active ingredient having a similar spectrum of control but belonging to a different chemical class or having a different site of action. These additional biologically active compounds or agents include, but are not limited to, sodium channel modulators such as bifenthrin, cypermethrin, cyhalothrin, lambda- cyhalothrin, cyfluthrin, beta-cyfluthrin, deltamethrin, dimefluthrin, esfenvalerate, fenvalerate, indoxacarb, metofluthrin, profluthrin, pyrethrin and tralomethrin; cholinesterase inhibitors such as chlorpyrifos, methomyl, oxamyl, thiodicarb and triazamate; neonicotinoids such as acetamiprid, clothianidin, dinotefuran, imidacloprid, nitenpyram, nithiazine, thiacloprid and thiamethoxam; insecticidal macrocyclic lactones such as spinetoram, spinosad, abamectin, avermectin and emamectin; GABA (γ-aminobutyric acid)-gated chloride channel antagonists such as avermectin or blockers such as ethiprole and fipronil; chitin synthesis inhibitors such as buprofezin, cyromazine, flufenoxuron, hexaflumuron, lufenuron, novaluron, noviflumuron and triflumuron; juvenile hormone mimics such as diofenolan, fenoxycarb, methoprene and pyriproxyfen; octopamine receptor ligands such as amitraz; molting inhibitors and ecdysone agonists such as azadirachtin, methoxyfenozide and tebufenozide; ryanodine receptor ligands such as ryanodine, anthranilic diamides such as chlorantraniliprole (see U.S. Patent 6,747,047, PCT Publications WO 2003/015518 and WO 2004/067528) and flubendiamide (see U.S. Patent 6,603,044); nereistoxin analogs such as cartap; mitochondrial electron transport inhibitors such as chlorfenapyr, hydramethylnon and pyridaben; lipid biosynthesis inhibitors such as spirodiclofen and spiromesifen; cyclodiene insecticides such as dieldrin or endosulfan; pyrethroids; carbamates; insecticidal ureas; and biological agents including nucleopolyhedro viruses (NPV), members of Bacillus thuringiensis, encapsulated delta-endotoxins of Bacillus thuringiensis, and other naturally occurring or genetically modified insecticidal viruses.
Further examples of biologically active compounds or agents with which compounds of this invention can be formulated are: fungicides such as acibenzolar, aldimorph, amisulbrom, azaconazole, azoxystrobin, benalaxyl, benomyl, benthiavalicarb, benthiavalicarb-isopropyl, binomial, biphenyl, bitertanol, blasticidin-S, Bordeaux mixture (Tribasic copper sulfate), boscalid/nicobifen, bromuconazole, bupirimate, buthiobate, carboxin, carpropamid, captafol, captan, carbendazim, chloroneb, chlorothalonil, chlozolinate, clotrimazole, copper oxychloride, copper salts such as copper sulfate and copper hydroxide, cyazofamid, cyflunamid, cymoxanil, cyproconazole, cyprodinil, dichlofluanid, diclocymet, diclomezine, dicloran, diethofencarb, difenoconazole, dimethomorph, dimoxystrobin, diniconazole, diniconazole-M, dinocap, discostrobin, dithianon, dodemorph, dodine, econazole, etaconazole, edifenphos, epoxiconazole, ethaboxam, ethirimol, ethridiazole, famoxadone, fenamidone, fenarimol, fenbuconazole, fencaramid, fenfuram, fenhexamide, fenoxanil, fenpiclonil, fenpropidin, fenpropimorph, fentin acetate, fentin hydroxide, ferbam, ferfurazoate, ferimzone, fluazinam, fludioxonil, flumetover, fluopicolide, fluoxastrobin, fluquinconazole, fluquinconazole, flusilazole, flusulfamide, flutolanil, flutriafol, folpet, fosetyl-aluminum, fuberidazole, furalaxyl, furametapyr, hexaconazole, hymexazole, guazatine, imazalil, imibenconazole, iminoctadine, iodicarb, ipconazole, iprobenfos, iprodione, iprovalicarb, isoconazole, isoprothiolane, kasugamycin, kresoxim-methyl, mancozeb, mandipropamid, maneb, mapanipyrin, mefenoxam, mepronil, metalaxyl, metconazole, methasulfocarb, metiram, metominostrobin/fenominostrobin, mepanipyrim, metrafenone, miconazole, myclobutanil, neo-asozin (ferric methanearsonate), nuarimol, octhilinone, ofurace, orysastrobin, oxadixyl, oxolinic acid, oxpoconazole, oxycarboxin, paclobutrazol, penconazole, pencycuron, penthiopyrad, perfurazoate, phosphonic acid, phthalide, picobenzamid, picoxystrobin, polyoxin, probenazole, prochloraz, procymidone, propamocarb, propamocarb-hydrochloride, propiconazole, propineb, proquinazid, prothioconazole, pyraclostrobin, pryazophos, pyrifenox, pyrimethanil, pyrifenox, pyrolnitrine, pyroquilon, quinconazole, quinoxyfen, quintozene, silthiofam, simeconazole, spiroxamine, streptomycin, sulfur, tebuconazole, techrazene, tecloftalam, tecnazene, tetraconazole, thiabendazole, thifluzamide, thiophanate, thiophanate-methyl, thiram, tiadinil, tolclofos-methyl, tolyfluanid, triadimefon, triadimenol, triarimol, triazoxide, tridemorph, trimoprhamide tricyclazole, trifloxystrobin, triforine, triticonazole, uniconazole, validamycin, vinclozolin, zineb, ziram, and zoxamide; nematocides such as aldicarb, imicyafos, oxamyl and fenamiphos; bactericides such as streptomycin; acaricides such as amitraz, chinomethionat, chlorobenzilate, cyhexatin, dicofol, dienochlor, etoxazole, fenazaquin, fenbutatin oxide, fenpropathrin, fenpyroximate, hexythiazox, propargite, pyridaben and tebufenpyrad.
In certain instances, combinations of a compound of this invention with other biologically active (particularly invertebrate pest control) compounds or agents (i.e. active ingredients) can result in a greater-than-additive (i.e. synergistic) effect. Reducing the quantity of active ingredients released in the environment while ensuring effective pest control is always desirable. When synergism of invertebrate pest control active ingredients occurs at application rates giving agronomically satisfactory levels of invertebrate pest control, such combinations can be advantageous for reducing crop production cost and decreasing environmental load.
Compounds of this invention and compositions thereof can be applied to plants genetically transformed to express proteins toxic to invertebrate pests (such as Bacillus thuringiensis delta-endotoxins). Such an application may provide a broader spectrum of plant protection and be advantageous for resistance management. The effect of the exogenously applied invertebrate pest control compounds of this invention may be synergistic with the expressed toxin proteins. General references for these agricultural protectants (i.e. insecticides, fungicides, nematocides, acaricides, herbicides and biological agents) include The Pesticide Manual, 13th Edition, C. D. S. Tomlin, Ed., British Crop Protection Council, Farnham, Surrey, U.K., 2003 and The BioPesticide Manual, 2nd Edition, L. G. Copping, Ed., British Crop Protection Council, Farnham, Surrey, U.K., 2001. For embodiments where one or more of these various mixing partners are used, the weight ratio of these various mixing partners (in total) to the compound of Formula 1 is typically between about 1 :3000 and about 3000:1. Of note are weight ratios between about 1 :300 and about 300:1 (for example ratios between about 1 :30 and about 30:1). One skilled in the art can easily determine through simple experimentation the biologically effective amounts of active ingredients necessary for the desired spectrum of biological activity. It will be evident that including these additional components can expand the spectrum of invertebrate pests controlled beyond the spectrum controlled by the compound of Formula 1 alone.
Table A lists specific combinations of a compound of Formula 1 with other invertebrate pest control agents illustrative of the mixtures, compositions and methods of the present invention. The first column of Table A lists the specific invertebrate pest control agents (e.g., "Abamectin" in the first line). The second column of Table A lists the mode of action (if known) or chemical class of the invertebrate pest control agents. The third column of Table A lists embodiment(s) of ranges of weight ratios for rates at which the invertebrate pest control agent can be applied relative to a compound of Formula 1 (e.g., "50:1 to 1 :50" of abamectin relative to a compound of Formula 1 by weight). Thus, for example, the first line of Table A specifically discloses the combination of a compound of Formula 1 with abamectin can be applied in a weight ratio between 50:1 to 1 :50. The remaining lines of Table A are to be construed similarly. Of further note Table A lists specific combinations of a compound of Formula 1 with other invertebrate pest control agents illustrative of the mixtures, compositions and methods of the present invention and includes additional embodiments of weight ratio ranges for application rates.
Table A
Figure imgf000138_0001
Figure imgf000139_0001
Figure imgf000140_0001
(a) 3-bromo-l-(3-chloro- ■2-pyridinyl)-7V-[4-cyano-2-methyl-6-[(methylamino)carbonyl]- phenyl]-l/f-pyrazole- ■5 -carboxamide (cyantraniliprole) Of note is the composition of the present invention wherein the at least one additional biologically active compound or agent is selected from the Invertebrate Pest Control Agents listed in Table A above.
The weight ratios of a compound, including a compound of Formula 1, to the additional invertebrate pest control agent typically are between 1000:1 and 1 :1000, with one embodiment being between 500:1 and 1 :500, another embodiment being between 250:1 and 1 :200 and another embodiment being between 100: 1 and 1 :50.
Listed below in Table B are embodiments of specific compositions comprising a compound of Formula 1 (compound numbers refer to compounds in Index Tables A-I) and an additional invertebrate pest control agent.
Table B
Mixture Comp. and Invertebrate Pest Control Mixture Comp. and Invertebrate Pest
No. No. Agent No. No. Control Agent
A-I 7 and Abamectin B-I 50 and Abamectin
A-2 7 and Acetamiprid B-2 50 and Acetamiprid
A-3 7 and Amitraz B-3 50 and Amitraz
A-4 7 and Avermectin B-4 50 and Avermectin
A-5 7 and Azadirachtin B-5 50 and Azadirachtin
A-6 7 and Beta-cyfluthrin B-6 50 and Beta-cyfluthrin
A-7 7 and Bifenthrin B-7 50 and Bifenthrin
A-8 7 and Buprofezin B-8 50 and Buprofezin
A-9 7 and Cartap B-9 50 and Cartap
A-10 7 and Chlorantraniliprole B-10 50 and Chlorantraniliprole
A-I l 7 and Chlorfenapyr B-I l 50 and Chlorfenapyr
A-12 7 and Chlorpyrifos B-12 50 and Chlorpyrifos
A-13 7 and Clothianidin B-13 50 and Clothianidin
A-14 7 and Cyfluthrin B-14 50 and Cyfluthrin
A-15 7 and Cyhalothrin B-15 50 and Cyhalothrin
A-16 7 and Cypermethrin B-16 50 and Cypermethrin
A-17 7 and Cyromazine B-17 50 and Cyromazine
A-18 7 and Deltamethrin B-18 50 and Deltamethrin
A-19 7 and Dieldrin B-19 50 and Dieldrin
A-20 7 and Dinotefuran B-20 50 and Dinotefuran
A-21 7 and Diofenolan B-21 50 and Diofenolan
A-22 7 and Emamectin B-22 50 and Emamectin
A-23 7 and Endosulfan B-23 50 and Endosulfan
A-24 7 and Esfenvalerate B-24 50 and Esfenvalerate
A-25 7 and Ethiprole B-25 50 and Ethiprole Mixture Comp. and Invertebrate Pest Control Mixture Comp. and Invertebrate Pest
No. No. Agent No. No. Control Agent
A-26 7 and Fenothiocarb B-26 50 and Fenothiocarb
A-27 7 and Fenoxycarb B-27 50 and Fenoxycarb
A-28 7 and Fenvalerate B-28 50 and Fenvalerate
A-29 7 and Fipronil B-29 50 and Fipronil
A-30 7 and Flonicamid B-30 50 and Flonicamid
A-31 7 and Flubendiamide B-31 50 and Flubendiamide
A-32 7 and Flufenoxuron B-32 50 and Flufenoxuron
A-33 7 and Hexaflumuron B-33 50 and Hexaflumuron
A-34 7 and Hydramethylnon B-34 50 and Hydramethylnon
A-35 7 and Imidacloprid B-35 50 and Imidacloprid
A-36 7 and Indoxacarb B-36 50 and Indoxacarb
A-37 7 and Lambda- cyhalothrin B-37 50 and Lambda- cyhalothrin
A-38 7 and Lufenuron B-38 50 and Lufenuron
A-39 7 and Metaflumizone B-39 50 and Metaflumizone
A-40 7 and Methomyl B-40 50 and Methomyl
A-41 7 and Methoprene B-41 50 and Methoprene
A-42 7 and Methoxyfenozide B-42 50 and Methoxyfenozide
A-43 7 and Nitenpyram B-43 50 and Nitenpyram
A-44 7 and Nithiazine B-44 50 and Nithiazine
A-45 7 and Novaluron B-45 50 and Novaluron
A-46 7 and Oxamyl B-46 50 and Oxamyl
A-47 7 and Pymetrozine B-47 50 and Pymetrozine
A-48 7 and Pyrethrin B-48 50 and Pyrethrin
A-49 7 and Pyridaben B-49 50 and Pyridaben
A-50 7 and Pyridalyl B-50 50 and Pyridalyl
A-51 7 and Pyriproxyfen B-51 50 and Pyriproxyfen
A-52 7 and Ryanodine B-52 50 and Ryanodine
A-53 7 and Spinetoram B-53 50 and Spinetoram
A-54 7 and Spinosad B-54 50 and Spinosad
A-55 7 and Spirodiclofen B-55 50 and Spirodiclofen
A-56 7 and Spiromesifen B-56 50 and Spiromesifen
A-57 7 and Tebufenozide B-57 50 and Tebufenozide
A-58 7 and Thiacloprid B-58 50 and Thiacloprid
A-59 7 and Thiamethoxam B-59 50 and Thiamethoxam
A-60 7 and Thiodicarb B-60 50 and Thiodicarb
A-61 7 and Thiosultap-sodium B-61 50 and Thiosultap-sodium Mixture Comp. and Invertebrate Pest Control Mixture Comp. and Invertebrate Pest
No. No. Agent No. No. Control Agent
A-62 7 and Tralomethrin B-62 50 and Tralomethrin
A-63 7 and Triazamate B-63 50 and Triazamate
A-64 7 and Triflumuron B-64 50 and Triflumuron
A-65 7 and Bacillus thuringiensis B-65 50 and Bacillus thuringiensis
A-66 7 and Bacillus thuringiensis B-66 50 and Bacillus thuringiensis delta- endotoxin delta-endotoxin
A-67 7 and NPV (e.g., Gemstar) B-67 50 and NPV (e.g., Gemstar)
A-68 7 and (a) B-68 50 and (a)
C-I 138 and Abamectin D-I 157 and Abamectin
C-2 138 and Acetamiprid D-2 157 and Acetamiprid
C-3 138 and Amitraz D-3 157 and Amitraz
C-4 138 and Avermectin D-4 157 and Avermectin
C-5 138 and Azadirachtin D-5 157 and Azadirachtin
C-6 138 and Beta-cyfluthrin D-6 157 and Beta-cyfluthrin
C-7 138 and Bifenthrin D-7 157 and Bifenthrin
C-8 138 and Buprofezin D-8 157 and Buprofezin
C-9 138 and Cartap D-9 157 and Cartap
C-IO 138 and Chlorantraniliprole D-IO 157 and Chlorantraniliprole
C-I l 138 and Chlorfenapyr D-I l 157 and Chlorfenapyr
C-12 138 and Chlorpyrifos D-12 157 and Chlorpyrifos
C-13 138 and Clothianidin D-13 157 and Clothianidin
C-14 138 and Cyfluthrin D-14 157 and Cyfluthrin
C-15 138 and Cyhalothrin D-15 157 and Cyhalothrin
C-16 138 and Cypermethrin D-16 157 and Cypermethrin
C-17 138 and Cyromazine D-17 157 and Cyromazine
C-18 138 and Deltamethrin D-18 157 and Deltamethrin
C-19 138 and Dieldrin D-19 157 and Dieldrin
C-20 138 and Dinotefuran D-20 157 and Dinotefuran
C-21 138 and Diofenolan D-21 157 and Diofenolan
C-22 138 and Emamectin D-22 157 and Emamectin
C-23 138 and Endosulfan D-23 157 and Endosulfan
C-24 138 and Esfenvalerate D-24 157 and Esfenvalerate
C-25 138 and Ethiprole D-25 157 and Ethiprole
C-26 138 and Fenothiocarb D-26 157 and Fenothiocarb
C-27 138 and Fenoxycarb D-27 157 and Fenoxycarb
C-28 138 and Fenvalerate D-28 157 and Fenvalerate Mixture Comp. and Invertebrate Pest Control Mixture Comp. and Invertebrate Pest No. No. Agent No. No. Control Agent
C-29 138 and Fipronil D-29 157 and Fipronil
C-30 138 and Flonicamid D-30 157 and Flonicamid
C-31 138 and Flubendiamide D-31 157 and Flubendiamide
C-32 138 and Flufenoxuron D-32 157 and Flufenoxuron
C-33 138 and Hexaflumuron D-33 157 and Hexaflumuron
C-34 138 and Hydramethylnon D-34 157 and Hydramethylnon
C-35 138 and Imidacloprid D-35 157 and Imidacloprid
C-36 138 and Indoxacarb D-36 157 and Indoxacarb
C-37 138 and Lambda-cyhalothrin D-37 157 and Lambda- cyhalothrin
C-38 138 and Lufenuron D-38 157 and Lufenuron
C-39 138 and Metaflumizone D-39 157 and Metaflumizone
C-40 138 and Methomyl D-40 157 and Methomyl
C-41 138 and Methoprene D-41 157 and Methoprene
C-42 138 and Methoxyfenozide D-42 157 and Methoxyfenozide
C-43 138 and Nitenpyram D-43 157 and Nitenpyram
C-44 138 and Nithiazine D-44 157 and Nithiazine
C-45 138 and Novaluron D-45 157 and Novaluron
C-46 138 and Oxamyl D-46 157 and Oxamyl
C-47 138 and Pymetrozine D-47 157 and Pymetrozine
C-48 138 and Pyrethrin D-48 157 and Pyrethrin
C-49 138 and Pyridaben D-49 157 and Pyridaben
C-50 138 and Pyridalyl D-50 157 and Pyridalyl
C-51 138 and Pyriproxyfen D-51 157 and Pyriproxyfen
C-52 138 and Ryanodine D-52 157 and Ryanodine
C-53 138 and Spinetoram D-53 157 and Spinetoram
C-54 138 and Spinosad D-54 157 and Spinosad
C-55 138 and Spirodiclofen D-55 157 and Spirodiclofen
C-56 138 and Spiromesifen D-56 157 and Spiromesifen
C-57 138 and Tebufenozide D-57 157 and Tebufenozide
C-58 138 and Thiacloprid D-58 157 and Thiacloprid
C-59 138 and Thiamethoxam D-59 157 and Thiamethoxam
C-60 138 and Thiodicarb D-60 157 and Thiodicarb
C-61 138 and Thiosultap-sodium D-61 157 and Thiosultap-sodium
C-62 138 and Tralomethrin D-62 157 and Tralomethrin
C-63 138 and Triazamate D-63 157 and Triazamate
C-64 138 and Triflumuron D-64 157 and Triflumuron Mixture Comp. and Invertebrate Pest Control Mixture Comp. and Invertebrate Pest No. No. Agent No. No. Control Agent
C-65 138 and Bacillus thuringiensis D-65 157 and Bacillus thuringiensis
C-66 138 and Bacillus thuringiensis D-66 157 and Bacillus thuringiensis delta- endotoxin delta-endotoxin
C-67 138 and NPV (e.g., Gemstar) D-67 157 and NPV (e.g., Gemstar)
C-68 138 And (a) D-68 157 And (a)
(a) 3-bromo-l-(3-chloro-2-pyridinyl)-Λ^-[4-cyano-2-methyl-6-[(metliylamino)carbonyl]plienyl]-l//-pyrazole- 5-carboxamide (cyantraniliprole)
The specific mixtures listed in Table B typically combine a compound of Formula 1 with the other invertebrate pest agent in the ratios specified in Table A. Invertebrate pests are controlled in agronomic and nonagronomic applications by applying one or more compounds of this invention, typically in the form of a composition, in a biologically effective amount, to the environment of the pests, including the agronomic and/or nonagronomic locus of infestation, to the area to be protected, or directly on the pests to be controlled. Thus the present invention comprises a method for controlling an invertebrate pest in agronomic and/or nonagronomic applications, comprising contacting the invertebrate pest or its environment with a biologically effective amount of one or more of the compounds of the invention, or with a composition comprising at least one such compound or a composition comprising at least one such compound and a biologically effective amount of at least one additional biologically active compound or agent. Examples of suitable compositions comprising a compound of the invention and a biologically effective amount of at least one additional biologically active compound or agent include granular compositions wherein the additional active compound is present on the same granule as the compound of the invention or on granules separate from those of the compound of the invention. To achieve contact with a compound or composition of the invention to protect a field crop from invertebrate pests, the compound or composition is typically applied to the seed of the crop before planting, to the foliage (e.g., leaves, stems, flowers, fruits) of crop plants, or to the soil or other growth medium before or after the crop is planted.
One embodiment of a method of contact is by spraying. Alternatively, a granular composition comprising a compound of the invention can be applied to the plant foliage or the soil. Compounds of this invention can also be effectively delivered through plant uptake by contacting the plant with a composition comprising a compound of this invention applied as a soil drench of a liquid formulation, a granular formulation to the soil, a nursery box treatment or a dip of transplants. Of note is a composition of the present invention in the form of a soil drench liquid formulation. Also of note is a method for controlling an invertebrate pest comprising contacting the invertebrate pest or its environment with a biologically effective amount of a compound of the present invention or with a composition comprising a biologically effective amount of a compound of the present invention. Of further note is this method wherein the environment is soil and the composition is applied to the soil as a soil drench formulation. Of further note is that compounds of this invention are also effective by localized application to the locus of infestation. Other methods of contact include application of a compound or a composition of the invention by direct and residual sprays, aerial sprays, gels, seed coatings, microencapsulations, systemic uptake, baits, ear tags, boluses, foggers, fumigants, aerosols, dusts and many others. One embodiment of a method of contact is a dimensionally stable fertilizer granule, stick or tablet comprising a compound or composition of the invention. The compounds of this invention can also be impregnated into materials for fabricating invertebrate control devices (e.g., insect netting).
Compounds of this invention are also useful in seed treatments for protecting seeds from invertebrate pests. In the context of the present disclosure and claims, treating a seed means contacting the seed with a biologically effective amount of a compound of this invention, which is typically formulated as a composition of the invention. This seed treatment protects the seed from invertebrate soil pests and generally can also protect roots and other plant parts in contact with the soil of the seedling developing from the germinating seed. The seed treatment may also provide protection of foliage by translocation of the compound of this invention or a second active ingredient within the developing plant. Seed treatments can be applied to all types of seeds, including those from which plants genetically transformed to express specialized traits will germinate. Representative examples include those expressing proteins toxic to invertebrate pests, such as Bacillus thuringiensis toxin or those expressing herbicide resistance such as glyphosate acetyltransferase, which provides resistance to glyphosate. One method of seed treatment is by spraying or dusting the seed with a compound of the invention (i.e. as a formulated composition) before sowing the seeds. Compositions formulated for seed treatment generally comprise a film former or adhesive agent. Therefore typically a seed coating composition of the present invention comprises a biologically effective amount of a compound of Formula 1 and a film former or adhesive agent. Seed can be coated by spraying a flowable suspension concentrate directly into a tumbling bed of seeds and then drying the seeds. Alternatively, other formulation types such as wetted powders, solutions, suspoemulsions, emulsifiable concentrates and emulsions in water can be sprayed on the seed. This process is particularly useful for applying film coatings on seeds. Various coating machines and processes are available to one skilled in the art. Suitable processes include those listed in P. Kosters et al, Seed Treatment: Progress and Prospects, 1994 BCPC Mongraph No. 57, and references listed therein.
The treated seed typically comprises a compound of the present invention in an amount from about 0.1 g to 1 kg per 100 kg of seed (i.e. from about 0.0001 to 1% by weight of the seed before treatment). A flowable suspension formulated for seed treatment typically comprises from about 0.5 to about 70% of the active ingredient, from about 0.5 to about 30% of a film- forming adhesive, from about 0.5 to about 20% of a dispersing agent, from 0 to about 5% of a thickener, from 0 to about 5% of a pigment and/or dye, from 0 to about 2% of an antifoaming agent, from 0 to about 1% of a preservative, and from 0 to about 75% of a volatile liquid diluent.
The compounds of this invention can be incorporated into a bait composition that is consumed by an invertebrate pest or used within a device such as a trap, bait station, and the like. Such a bait composition can be in the form of granules which comprise (a) active ingredients, namely a biologically effective amount of a compound of Formula 1; (b) one or more food materials; optionally (c) an attractant, and optionally (d) one or more humectants. Of note are granules or bait compositions which comprise between about 0.001-5% active ingredients, about 40-99% food material and/or attractant; and optionally about 0.05-10% humectants, which are effective in controlling soil invertebrate pests at very low application rates, particularly at doses of active ingredient that are lethal by ingestion rather than by direct contact. Some food materials can function both as a food source and an attractant. Food materials include carbohydrates, proteins and lipids. Examples of food materials are vegetable flour, sugar, starches, animal fat, vegetable oil, yeast extracts and milk solids. Examples of attractants are odorants and flavorants, such as fruit or plant extracts, perfume, or other animal or plant component, pheromones or other agents known to attract a target invertebrate pest. Examples of humectants, i.e. moisture retaining agents, are glycols and other polyols, glycerine and sorbitol. Of note is a bait composition (and a method utilizing such a bait composition) used to control at least one invertebrate pest selected from the group consisting of ants, termites and cockroaches. A device for controlling an invertebrate pest can comprise the present bait composition and a housing adapted to receive the bait composition, wherein the housing has at least one opening sized to permit the invertebrate pest to pass through the opening so the invertebrate pest can gain access to the bait composition from a location outside the housing, and wherein the housing is further adapted to be placed in or near a locus of potential or known activity for the invertebrate pest. The compounds of this invention can be applied without other adjuvants, but most often application will be of a formulation comprising one or more active ingredients with suitable carriers, diluents, and surfactants and possibly in combination with a food depending on the contemplated end use. One method of application involves spraying a water dispersion or refined oil solution of a compound of the present invention. Combinations with spray oils, spray oil concentrations, spreader stickers, adjuvants, other solvents, and synergists such as piperonyl butoxide often enhance compound efficacy. For nonagronomic uses such sprays can be applied from spray containers such as a can, a bottle or other container, either by means of a pump or by releasing it from a pressurized container, e.g., a pressurized aerosol spray can. Such spray compositions can take various forms, for example, sprays, mists, foams, fumes or fog. Such spray compositions thus can further comprise propellants, foaming agents, etc. as needed for application. Of note is a spray composition comprising a biologically effective amount of a compound or a composition of the present invention and a carrier. One embodiment of such a spray composition comprises a biologically effective amount of a compound or a composition of the present invention and a propellant. Representative propellants include, but are not limited to, methane, ethane, propane, butane, isobutane, butene, pentane, isopentane, neopentane, pentene, hydrofluorocarbons, chlorofluorocarbons, dimethyl ether, and mixtures of the foregoing. Of note is a spray composition (and a method utilizing such a spray composition dispensed from a spray container) used to control at least one invertebrate pest selected from the group consisting of mosquitoes, black flies, stable flies, deer flies, horse flies, wasps, yellow jackets, hornets, ticks, spiders, ants, gnats, and the like, including individually or in combinations. Nonagronomic uses refer to invertebrate pest control in the areas other than fields of crop plants. Nonagronomic uses of the present compounds and compositions include control of invertebrate pests in stored grains, beans and other foodstuffs, and in textiles such as clothing and carpets. Nonagronomic uses of the present compounds and compositions also include invertebrate pest control in ornamental plants, forests, in yards, along roadsides and railroad rights of way, and on turf such as lawns, golf courses and pastures. Nonagronomic uses of the present compounds and compositions also include invertebrate pest control in houses and other buildings which may be occupied by humans and/or companion, farm, ranch, zoo or other animals. Nonagronomic uses of the present compounds and compositions also include the control of pests such as termites that can damage wood or other structural materials used in buildings.
Nonagronomic uses of the present compounds and compositions also include protecting human and animal health by controlling invertebrate pests that are parasitic or transmit infectious diseases. The controlling of animal parasites includes controlling external parasites that are parasitic to the surface of the body of the host animal (e.g., shoulders, armpits, abdomen, inner part of the thighs) and internal parasites that are parasitic to the inside of the body of the host animal (e.g., stomach, intestine, lung, veins, under the skin, lymphatic tissue). External parasitic or disease transmitting pests include, for example, chiggers, ticks, lice, mosquitoes, flies, mites and fleas. Internal parasites include heartworms, hookworms and helminths. Compounds and compositions of the present invention are particularly suitable for combating external parasitic or disease transmitting pests. Compounds and compositions of the present invention are suitable for systemic and/or non- systemic control of infestation or infection by parasites on animals. Compounds and compositions of the present invention are suitable for combating parasites that infest animal subjects including those in the wild, livestock and agricultural working animals such as cattle, sheep, goats, horses, pigs, donkeys, camels, bison, buffalos, rabbits, hens, turkeys, ducks, geese and bees (e.g., raised for meat, milk, butter, eggs, fur, leather, feathers and/or wool). By combating parasites, fatalities and performance reduction (in terms of meat, milk, wool, skins, eggs, honey, etc.) are reduced, so that applying a composition comprising a compound of the present invention allows more economic and simple husbandry of animals.
Compounds and compositions of the present invention are especially suitable for combating parasites that infest companion animals and pets (e.g., dogs, cats, pet birds and aquarium fish), research and experimental animals (e.g., hamsters, guinea pigs, rats and mice), as well as animals raised for/in zoos, wild habitats and/or circuses.
In an embodiment of this invention, the animal is preferably a vertebrate, and more preferably a mammal, avian or fish. In a particular embodiment, the animal subject is a mammal (including great apes, such as humans). Other mammalian subjects include primates (e.g., monkeys), bovine (e.g., cattle or dairy cows), porcine (e.g., hogs or pigs), ovine (e.g., goats or sheep), equine (e.g., horses), canine (e.g., dogs), feline (e.g., house cats), camels, deer, donkeys, bison, buffalos, antelopes, rabbits, and rodents (e.g., guinea pigs, squirrels, rats, mice, gerbils, and hamsters). Avians include Anatidae (swans, ducks and geese), Columbidae (e.g., doves and pigeons), Phasianidae (e.g., partridges, grouse and turkeys), Thesienidae (e.g., domestic chickens), Psittacines (e.g., parakeets, macaws, and parrots), game birds, and ratites (e.g., ostriches).
Birds treated or protected by the inventive compounds can be associated with either commercial or noncommercial aviculture. These include Anatidae, such as swans, geese, and ducks, Columbidae, such as doves and domestic pigeons, Phasianidae, such as partridge, grouse and turkeys, Thesienidae, such as domestic chickens, and Psittacines, such as parakeets, macaws, and parrots raised for the pet or collector market, among others.
For purposes of the present invention, the term "fish" shall be understood to include without limitation, the Teleosti grouping of fish, i.e., teleosts. Both the Salmoniformes order (which includes the Salmonidae family) and the Perciformes order (which includes the Centrarchidae family) are contained within the Teleosti grouping. Examples of potential fish recipients include the Salmonidae, Serranidae, Sparidae, Cichlidae, and Centrarchidae, among others.
Other animals are also contemplated to benefit from the inventive methods, including marsupials (such as kangaroos), reptiles (such as farmed turtles), and other economically important domestic animals for which the inventive methods are safe and effective in treating or preventing parasite infection or infestation. Examples of invertebrate parasitic pests controlled by administering a parasiticidally effective amount of a compound of this invention to an animal to be protected include ectoparasites (arthropods, acarines, etc) and endoparasites (helminths, e.g., nematodes, trematodes, cestodes, acanthocephalans, etc.). The disease or group of diseases described generally as helminthiasis is due to infection of an animal host with parasitic worms known as helminths. The term 'helminths' is meant to include nematodes, trematodes, cestodes and acanthocephalans. Helminthiasis is a prevalent and serious economic problem with domesticated animals such as swine, sheep, horses, cattle, goats, dogs, cats and poultry. Among the Helminths, the group of worms described as nematodes causes widespread and at times serious infection in various species of animals. Nematodes that are contemplated to be treated by the compounds of this invention and by the inventive methods include, without limitation, the following genera: Acanthocheilonema, Aelurostrongylus, Ancylostoma, Angiostrongylus, Ascaridia, Ascaris, Brugia, Bunostomum, Capillaria, Chabertia, Cooperia, Crenosoma, Dictyocaulus, Dioctophyme, Dipetalonema, Diphyllobothrium, Dirofilaria, Dracunculus, Enterobius, Filaroides, Haemonchus, Heterakis, Lagochilascaris, Loa, Mansonella, Muellerius, Necator, Nematodirus, Oesophagostomum, Ostertagia, Oxyuris, Parafilaria, Parascaris, Physaloptera, Protostrongylus, Setaria, Spirocerca, Stephanofϊlaria, Strongyloides, Strongylus, Thelazia, Toxascaris, Toxocara, Trichinella, Trichonema, Trichostrongylus, Trichuris, Uncinaria, and Wuchereria.
Of the above, the most common genera of nematodes infecting the animals referred to above are Haemonchus, Trichostrongylus, Ostertagia, Nematodirus, Cooperia, Ascaris, Bunostomum, Oesophagostomum, Chabertia, Trichuris, Strongylus, Trichonema, Dictyocaulus, Capillaria, Heterakis, Toxocara, Ascaridia, Oxyuris, Ancylostoma, Uncinaria, Toxascaris and Parascaris. Certain of these, such as Nematodirus, Cooperia and Oesophagostomum attack primarily the intestinal tract while others, such as Haemonchus and Ostertagia, are more prevalent in the stomach while others such as Dictyocaulus are found in the lungs. Still other parasites may be located in other tissues such as the heart and blood vessels, subcutaneous and lymphatic tissue and the like. Trematodes that are contemplated to be treated by the compounds of this invention and by the inventive methods include, without limitation, the following genera: Alaria, Fasciola, Nanophyetus, Opisthorchis, Paragonimus and Schistosoma.
Cestodes that are contemplated to be treated by the compounds of this invention and by the inventive methods include, without limitation, the following genera: Diphyllobothrium, Diplydium, Spirometra and Taenia.
The most common genera of parasites of the gastrointestinal tract of humans are Ancylostoma, Necator, Ascaris, Strongyloides, Trichinella, Capillaria, Trichuris, and Enterobius. Other medically important genera of parasites which are found in the blood or other tissues and organs outside the gastrointestinal tract are the filarial worms such as Wuchereria, Brugia, Onchocerca and Loa, as well as Dracunculus and extra intestinal stages of the intestinal worms Strongyloides and Trichinella.
Numerous other Helminth genera and species are known to the art, and are also contemplated to be treated by the compounds of the invention. These are enumerated in great detail in Textbook of Veterinary Clinical Parasitology, Volume 1, Helminths, E. J. L. Soulsby, F. A. Davis Co., Philadelphia, Pa.; Helminths, Arthropods and Protozoa, (6th Edition of Monnig's Veterinary Helminthology and Entomology), E. J. L. Soulsby, The Williams and Wilkins Co., Baltimore, Md. It is also contemplated that the inventive compounds are effective against a number of ectoparasites of animals, e.g., arthropod ectoparasites of mammals and birds although it is also recognized that some arthropods can be endoparasites as well.
Thus, insect and acarine pests include, e.g., biting insects, such as flies and mosquitoes, mites, ticks, lice, fleas, true bugs, parasitic maggots, and the like. Adult flies include, e.g., the horn fly or Haematobia irritans, the horse fly or Tabanus spp., the stable fly or Stomoxys calcitrans, the black fly or Simulium spp., the deer fly or Chrysops spp., the louse fly or Melophagus ovinus, the tsetse fly or Glossina spp. Parasitic fly maggots include, e.g., the bot fly (Oestrus ovis and Cuterebra spp.), the blow fly or Phaenicia spp., the screwworm or Cochliomyia hominivorax, the cattle grub or Hypoderma spp., the fleeceworm and the Gastrophilus of horses. Mosquitoes include, for example, Culex spp., Anopheles spp., and Aedes spp.
Mites include Mesostigmata spp. e.g., mesostigmatids such as the chicken mite,
Dermanyssus gallinae; itch or scab mites such as Sarcoptidae spp. for example, Sarcoptes scabiei; mange mites such as Psoroptidae spp. including Chorioptes bovis and Psoroptes ovis; chiggers e.g., Trombiculidae spp. for example the North American chigger, Trombicula alfreddugesi.
Ticks include, e.g., soft-bodied ticks including Argasidae spp. for example Argas spp. and Ornithodoros spp.; hard-bodied ticks including Ixodidae spp., for example Rhipicephalus sanguineus, Dermacentor variabilis, Dermacentor andersoni, Amblyomma americanum, Ixodes scapularis and Boophilus spp.
Lice include, e.g., sucking lice, e.g., Menopon spp. and Bovicola spp.; biting lice, e.g., Haematopinus spp., Linognathus spp. and Solenopotes spp.
Fleas include, e.g., Ctenocephalides spp., such as dog flea (Ctenocephalides canis) and cat flea (Ctenocephalides felis); Xenopsylla spp. such as oriental rat flea (Xenopsylla cheopis); and Pulex spp. such as human flea (Pulex irritans).
True bugs include, e.g., Cimicidae or e.g., the common bed bug (Cimex lectularius); Triatominae spp. including triatomid bugs also known as kissing bugs; for example Rhodnius prolixus and Triatoma spp. Generally, flies, fleas, lice, mosquitoes, gnats, mites, ticks and helminths cause tremendous losses to the livestock and companion animal sectors. Arthropod parasites also are a nuisance to humans and can vector disease-causing organisms in humans and animals.
Numerous other arthropod pests and ectoparasites are known to the art, and are also contemplated to be treated by the compounds of the invention. These are enumerated in great detail in Medical and Veterinary Entomology, D. S. Kettle, John Wiley & Sons, New York and Toronto; Control of Arthropod Pests of Livestock: A Review of Technology, R. O. Drummand, J. E. George, and S. E. Kunz, CRC Press, Boca Raton, FIa.
The compounds and compositions of this invention may also be effective against a number of protozoa endoparasites of animals, such as those summarized by Table 1, as follows.
Figure imgf000152_0001
Figure imgf000153_0001
In particular, the compounds of this invention are effective against ectoparasites including fleas such as Ctenocephalides felis (cat flea) and Ctenocephalides canis (dog flea).
The compounds of this invention may also be effective against other ectoparasites including flies such as Haematobia (Lyperosia) irritans (horn fly), Stomoxys calcitrans (stable fly), Simulium spp. (blackfly), Glossina spp. (tsetse flies), Hydrotaea irritans (head fly), Musca autumnalis (face fly), Musca domestica (house fly), Morellia simplex (sweat fly), Tabanus spp. (horse fly), Hypoderma bovis, Hypoderma lineatum, Lucilia sericata,
Lucilia cuprina (green blowfly), Calliphora spp. (blowfly), Protophormia spp., Oestrus ovis
(nasal botfly), Culicoides spp. (midges), Hippobosca equine, Gastrophilus instestinalis, Gastrophilus haemorrhoidalis and Gastrophilus naslis; lice such as Bovicola (Damalinia) bovis, Bovicola equi, Haematopinus asini, Felicola subrostratus, Heterodoxus spiniger, Lignonathus setosus and Trichodectes canis; keds such as Melophagus ovinus; mites such as Psoroptes spp., Sarcoptes scabei, Chorioptes bovis, Demodex equi, Cheyletiella spp., Notoedres cati, Trombicula spp. and Otodectes cyanotis (ear mites); and ticks such as Ixodes spp., Boophilus spp., Rhipicephalus spp., Amblyomma spp., Dermacentor spp., Hyalomma spp. and Haemaphysalis spp.
Biologically active compounds or agents useful in the compositions of the present invention include the organophosphate pesticides. This class of pesticides has very broad activity as insecticides and, in certain instances, anthelmintic activity. Organophosphate pesticides include, e.g., dicrotophos, terbufos, dimethoate, diazinon, disulfoton, trichlorfon, azinphos-methyl, chlorpyrifos, malathion, oxydemeton-methyl, methamidophos, acephate, ethyl parathion, methyl parathion, mevinphos, phorate, carbofenthion and phosalone. It is also contemplated to include combinations of the inventive methods and compounds with carbamate type pesticides, including, e.g., carbaryl, carbofuran, aldicarb, molinate, methomyl, carbofuran, etc., as well as combinations with the organochlorine type pesticides. It is further contemplated to include combinations with biological pesticides, including repellents, the pyrethrins (as well as synthetic variations thereof, e.g., allethrin, resmethrin, permethrin, tralomethrin), and nicotine, that is often employed as an acaricide. Other contemplated combinations are with miscellaneous pesticides including: bacillus thuringensis, chlorobenzilate, formamidines (e.g., amitraz), copper compounds (e.g., copper hydroxide and cupric oxychloride sulfate), cyfluthrin, cypermethrin, dicofol, endosulfan, esenfenvalerate, fenvalerate, lambda-cyhalothrin, methoxychlor and sulfur. Of note are additional biologically active compounds or agents selected from art- known anthelmintics, such as, for example, avermectins (e.g., ivermectin, moxidectin, milbemycin), benzimidazoles (e.g., albendazole, triclabendazole), salicylanilides (e.g., closantel, oxyclozanide), substituted phenols (e.g., nitroxynil), pyrimidines (e.g., pyrantel), imidazothiazoles (e.g., levamisole) and praziquantel.
Other biologically active compounds or agents useful in the compositions of the present invention can be selected from Insect Growth Regulators (IGRs) and Juvenile Hormone Analogues (JHAs) such as diflubenzuron, triflumuron, fluazuron, cyromazine, methoprene, etc., thereby providing both initial and sustained control of parasites (at all stages of insect development, including eggs) on the animal subject, as well as within the environment of the animal subject.
Of note are biologically active compounds or agents useful in the compositions of the present invention selected from the antiparasitic class of avermectin compounds. As stated above, the avermectin family of compounds is a series of very potent antiparasitic agents known to be useful against a broad spectrum of endoparasites and ectoparasites in mammals.
A notable compound for use within the scope of the present invention is ivermectin. Ivermectin is a semi-synthetic derivative of avermectin and is generally produced as a mixture of at least 80% 22,23-dihydroavermectin Bla and less than 20% 22,23- dihydroavermectin Blb. Ivermectin is disclosed in U.S. 4,199,569. Abamectin is an avermectin that is disclosed as Avermectin Bla/Blb in U.S. 4,310,519.
Abamectin contains at least 80% of avermectin Bla and not more than 20% of avermectin
Bib-
Another notable avermectin is Doramectin, also known as 25-cyclohexyl-avermectin
B1. The structure and preparation of Doramectin is disclosed in U.S. 5,089,480. Another notable avermectin is Moxidectin. Moxidectin, also known as LL-F28249 alpha, is known from U.S. 4,916,154.
Another notable avermectin is Selamectin. Selamectin is 25-cyclohexyl-25-de(l- methylpropyl)-5 -deoxy-22,23 -dihydro-5 -(hydroxyimino)-avermectin B 1 monosaccharide .
Milbemycin, or B41, is a substance which is isolated from the fermentation broth of a Milbemycin producing strain of Streptomyces. The microorganism, the fermentation conditions and the isolation procedures are more fully described in U.S. 3,950,360 and U.S.
3,984,564.
Emamectin (4"-deoxy-4"-epi-methylaminoavermectin B1), which can be prepared as described in U.S. 5,288,710 or U.S. 5,399,717, is a mixture of two homologues, 4"-deoxy- 4"-epi-methylaminoavermectin Bla and 4"-deoxy-4"-epi-methylaminoavermectin Blb.
Preferably, a salt of Emamectin is used. Non- limiting examples of salts of Emamectin which can be used in the present invention include the salts described in U.S. 5,288,710, e.g., salts derived from benzoic acid, substituted benzoic acid, benzenesulfonic acid, citric acid, phosphoric acid, tartaric acid, maleic acid, and the like. Most preferably, the Emamectin salt used in the present invention is Emamectin benzoate.
Eprinomectin is chemically known as 4"-epi-acetylamino-4"-deoxy-avermectin B1. Eprinomectin was specifically developed to be used in all cattle classes and age groups. It was the first avermectin to show broad-spectrum activity against both endo- and ectoparasites while also leaving minimal residues in meat and milk. It has the additional advantage of being highly potent when delivered topically.
The composition of the present invention optionally comprises combinations of one or more of the following antiparasite compounds: imidazo[l,2-b]pyridazine compounds as described by U.S. application Ser. No. 11/019,597, filed on Dec. 22, 2004; l-(4-mono and di-halomethylsulphonylphenyl)-2-acylamino-3-fluoropropanol compounds, as described by U.S. application Ser. No. 11/018,156, filed on Dec. 21, 2004; trifluoromethanesulfonanilide oxime ether derivatives, as described by U.S. application Ser. No. 11/231,423, filed on Sep. 21, 2005; and /?-[(phenyloxy)phenyl]-l,l,l-trifluoromethanesulfonamide and n- [(phenylsulfanyl)phenyl]-l,l,l-trifluoromethanesulfonamide derivatives, as described by U.S. Provisional Application Ser. No. 60/688,898, filed on Jun. 9, 2005.
The compositions of the present invention can also further comprise a flukicide. Suitable flukicides include, for example, triclabendazole, fenbendazole, albendazole, Clorsulon and oxibendazole. It will be appreciated that the above combinations can further include combinations of antibiotic, antiparasitic and anti-fluke active compounds.
In addition to the above combinations, it is also contemplated to provide combinations of the inventive methods and compounds, as described herein, with other animal health remedies such as trace elements, antiinflammatories, anti-infectives, hormones, dermatological preparations, including antiseptics and disinfectants, and immunobiologicals such as vaccines and antisera for the prevention of disease.
For example, such antinfectives include one or more antibiotics that are optionally coadministered during treatment using the inventive compounds or methods, e.g., in a combined composition and/or in separate dosage forms. Art-known antibiotics suitable for this purpose include, for example, those listed herein below. One useful antibiotic is Florfenicol, also known as D-(threo)-l-(4- methylsulfonylphenyl)-2-dichloroacetamido-3-fluoro-l-propanol. Another notable antibiotic compound is D-(threo)- 1 -(4-methylsulfonyphenyl)-2-difluoroacetamido-3 -fluoro- 1 - propanol. Another useful antibiotic is Thiamphenicol. Processes for the manufacture of these antibiotic compounds, and intermediates useful in such processes, are described in U.S. 4,311,857; U.S. 4,582,918; U.S. 4,973,750; U.S. 4,876,352; U.S. 5,227,494; U.S. 4,743,700; U.S. 5,567,844; U.S. 5,105,009; U.S. 5,382,673; U.S. 5,352,832; and U.S. 5,663,361. Other florfenicol analogs and/or prodrugs have been disclosed and such analogs also can be used in the compositions and methods of the present invention (see e.g., U.S. Patent Application Publication No: 2004/0082553, and U.S. patent application Ser. No. 11/016,794).
Another useful antibiotic compound is Tilmicosin. Tilmicosin is a macrolide antibiotic that is chemically defined as 20-dihydro-20-deoxy-20-(cώ-3,5-dimethylpiperidin-l-yl)- desmycosin and which is reportedly disclosed in U.S. 4,820,695.
Another useful antibiotic for use in the present invention is tulathromycin. Tulathromycin is also identified as (2R,3S,4R,5R,8R,1OR,11R,12S,13S,14R) 13-[(2,6- dideoxy-3-C-methyl-3-O-methyl-4-C-[(propylamino)methyl]-alpha-L-ribo-hexopyranosyl]- oxy]-2-ethyl-3 ,4, 10-trihydroxy-3 ,5,8,10,12,14-hexamethyl- 11 -[[3 ,4,6-trideoxy-3-(dimethyl- amino)-beta-D-xylo-hexopyranosyl]oxy]- 1 -oxa-6-azacyclopentadecan-l 5 -one.
Tulathromycin can be prepared in accordance with the procedures set forth in U.S. Patent Publication No. 2003/0064939 Al.
Further antibiotics for use in the present invention include the cephalosporins such as, for example, ceftiofur, cefquinome, etc. The concentration of the cephalosporin in the formulation of the present invention optionally varies between about 1 mg/mL to 500 mg/mL.
Another useful antibiotic includes the fluoroquinolones, such as, for example, enrofloxacin, danofloxacin, difloxacin, orbifloxacin and marbofloxacin. Enrofloxacin is typically administered in a concentration of about 100 mg/mL. Danofloxacin is typically administered at a concentration of about 180 mg/mL.
Other useful macrolide antibiotics include compounds from the class of ketolides, or, more specifically, the azalides. Such compounds are described in, for example, U.S. 6,514,945, U.S. 6,472,371, U.S. 6,270,768, U.S. 6,437,151, U.S. 6,271,255, U.S. 6,239,112, U.S. 5,958,888, U.S. 6,339,063 and U.S. 6,054,434. Other useful antibiotics include the tetracyclines, particularly chlortetracycline and oxytetracycline. Other antibiotics may include β-lactams such as penicillins, e.g., penicillin, ampicillin, amoxicillin, or a combination of amoxicillin with clavulanic acid or other beta lactamase inhibitors.
Nonagronomic applications in the veterinary sector are by conventional means such as by enteral administration in the form of, for example, tablets, capsules, drinks, drenching preparations, granulates, pastes, boli, feed-through procedures, or suppositories; or by parenteral administration, such as by injection (including intramuscular, subcutaneous, intravenous, intraperitoneal) or implants; by nasal administration; by topical administration, for example, in the form of immersion or dipping, spraying, washing, coating with powder, or application to a small area of the animal, and through articles such as neck collars, ear tags, tail bands, limb bands or halters which comprise compounds or compositions of the present invention. Any of the compounds of the present invention, or a suitable combination of such compounds, may be administered directly to the animal subject and/or indirectly by applying it to the local environment in which the animal dwells (such as bedding, enclosures, or the like). Direct administration includes contacting the skin, fur or feathers of a subject animal with the compounds, or by feeding or injecting the compounds into the animal.
The compounds of the present invention may be administered in a controlled release form, e.g., in a subcutaneous slow release formulation, or in the form of a controlled release device affixed to an animal such as a fleacollar. Collars for the controlled release of an insecticide agent for long term protection against flea infestation in a companion animal are art-known, and are described, for example, by U.S. 3,852,416, U.S. 4,224,901, U.S. 5,555,848 and U.S. 5,184,573.
Typically a parasiticidal composition according to the present invention comprises a mixture of a compound of Formula 1 with one or more pharmaceutically or veterinarily acceptable carriers comprising excipients and auxiliaries selected with regard to the intended route of administration (e.g., oral, topical or parenteral administration such as injection) and in accordance with standard practice. In addition, a suitable carrier is selected on the basis of compatibility with the one or more active ingredients in the composition, including such considerations as stability relative to pH and moisture content. Therefore of note is a composition for protecting an animal from an invertebrate parasitic pest comprising a parasitically effective amount of a compound of the invention and at least one carrier.
For parenteral administration including intravenous, intramuscular and subcutaneous injection, a compound of the present invention can be formulated in suspension, solution or emulsion in oily or aqueous vehicles, and may contain adjuncts such as suspending, stabilizing and/or dispersing agents. The compounds of the present invention may also be formulated for bolus injection or continuous infusion. Pharmaceutical compositions for injection include aqueous solutions of water-soluble forms of active ingredients (e.g., a salt of an active compound), preferably in physiologically compatible buffers containing other excipients or auxiliaries as are known in the art of pharmaceutical formulation. Additionally, suspensions of the active compounds may be prepared in a lipophilic vehicle. Suitable lipophilic vehicles include fatty oils such as sesame oil, synthetic fatty acid esters such as ethyl oleate and triglycerides, or materials such as liposomes. Aqueous injection suspensions may contain substances that increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Formulations for injection may be presented in unit dosage form, e.g., in ampoules or in multi-dose containers. Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, e.g., sterile, pyrogen- free water, before use.
In addition to the formulations described supra, the compounds of the present invention may also be formulated as a depot preparation. Such long acting formulations may be administered by implantation (for example, subcutaneously or intramuscularly) or by intramuscular or subcutaneous injection. The compounds of the present invention may be formulated for this route of administration with suitable polymeric or hydrophobic materials (for instance, in an emulsion with a pharmacologically acceptable oil), with ion exchange resins, or as a sparingly soluble derivative such as, without limitation, a sparingly soluble salt.
For administration by inhalation, the compounds of the present invention can be delivered in the form of an aerosol spray using a pressurized pack or a nebulizer and a suitable propellant, e.g., without limitation, dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane or carbon dioxide. In the case of a pressurized aerosol, the dosage unit may be controlled by providing a valve to deliver a metered amount. Capsules and cartridges of, for example, gelatin for use in an inhaler or insufflator may be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch. Compounds of the present invention have been discovered to have favorable pharmacokinetic and pharmacodynamic properties providing systemic availability from oral administration and ingestion. Therefore after ingestion by the animal to be protected, parasiticidally effective concentrations of compounds of the invention in the bloodstream protect the treated animal from blood-sucking pests such as fleas, ticks and lice. Therefore of note is a composition for protecting an animal from an invertebrate parasite pest in a form for oral administration (i.e. comprising, in addition to a parasiticidally effective amount of a compound of the invention, one or more carriers selected from binders and fillers suitable for oral administration and feed concentrate carriers).
For oral administration in the form of solutions (the most readily available form for absorption), emulsions, suspensions, pastes, gels, capsules, tablets, boluses, powders, granules, rumen-retention and feed/water/lick blocks, a compound of the present invention can be formulated with binders/fillers known in the art to be suitable for oral administration compositions, such as sugars and sugar derivatives (e.g., lactose, sucrose, mannitol, sorbitol), starch (e.g., maize starch, wheat starch, rice starch, potato starch), cellulose and derivatives (e.g., methylcellulose, carboxymethylcellulose, ethylhydroxycellulose), protein derivatives (e.g., zein, gelatin), and synthetic polymers (e.g., polyvinyl alcohol, polyvinylpyrrolidone). If desired, lubricants (e.g., magnesium stearate), disintegrating agents (e.g., cross-linked polyvinylpyrrolidinone, agar, alginic acid) and dyes or pigments can be added. Pastes and gels often also contain adhesives (e.g., acacia, alginic acid, bentonite, cellulose, xanthan gum, colloidal magnesium aluminum silicate) to aid in keeping the composition in contact with the oral cavity and not being easily ejected.
If the parasiticidal compositions are in the form of feed concentrates, the carrier is typically selected from high-performance feed, feed cereals or protein concentrates. Such feed concentrate-containing compositions can, in addition to the parasiticidal active ingredients, comprise additives promoting animal health or growth, improving quality of meat from animals for slaughter or otherwise useful to animal husbandry. These additives can include, for example, vitamins, antibiotics, chemotherapeutics, bacteriostats, fungistats, coccidiostats and hormones.
The compounds of Formula 1 may also be formulated in rectal compositions such as suppositories or retention enemas, using, e.g., conventional suppository bases such as cocoa butter or other glycerides.
Formulations for topical administration are typically in the form of a powder, cream, suspension, spray, emulsion, foam, paste, aerosol, ointment, salve or gel. More typically a topical formulation is a water-soluble solution, which can be in the form of a concentrate that is diluted before use. Parasiticidal compositions suitable for topical administration typically comprise a compound of the present invention and one or more topically suitable carriers. In applications of a parasiticidal composition topically to the exterior of an animal as a line or spot (i.e. "spot-on" treatment), the active ingredient migrates over the surface of the animal to cover most or all of its external surface area. As a result, the treated animal is particularly protected from invertebrate pests that feed off the epidermis of the animal such as ticks, fleas and lice. Therefore formulations for topical localized administration often comprise at least one organic solvent to facilitate transport of the active ingredient over the skin and/or penetration into the epidermis of the animal. Carriers in such formulations include propylene glycol, paraffins, aromatics, esters such as isopropyl myristate, glycol ethers, alcohols such as ethanol, n-propanol, 2-octyl dodecanol or oleyl alcohol; solutions in esters of monocarboxylic acids, such as isopropyl myristate, isopropyl palmitate, lauric acid oxalic ester, oleic acid oleyl ester, oleic acid decyl ester, hexyl laurate, oleyl oleate, decyl oleate, caproic acid esters of saturated fatty alcohols of chain length C^-Cjg; solutions of esters of dicarboxylic acids, such as dibutyl phthalate, diisopropyl isophthalate, adipic acid diisopropyl ester, di-n-butyl adipate or solutions of esters of aliphatic acids, e.g., glycols. It may be advantageous for a crystallization inhibitor or a dispersant known from the pharmaceutical or cosmetic industry also to be present. A pour-on formulation may also be prepared for control of parasites in an animal of agricultural worth. The pour-on formulations of this invention can be in the form of a liquid, powder, emulsion, foam, paste, aerosol, ointment, salve or gel. Typically, the pour-on formulation is liquid. These pour-on formulations can be effectively applied to sheep, cattle, goats, other ruminants, camelids, pigs and horses. The pour-on formulation is typically applied by pouring in one or several lines or in a spot-on the dorsal midline (back) or shoulder of an animal. More typically, the formulation is applied by pouring it along the back of the animal, following the spine. The formulation can also be applied to the animal by other conventional methods, including wiping an impregnated material over at least a small area of the animal, or applying it using a commercially available applicator, by means of a syringe, by spraying or by using a spray race. The pour-on formulations include a carrier and can also include one or more additional ingredients. Examples of suitable additional ingredients are stabilizers such as antioxidants, spreading agents, preservatives, adhesion promoters, active solubilisers such as oleic acid, viscosity modifiers, UV blockers or absorbers, and colourants. Surface active agents, including anionic, cationic, non-ionic and ampholytic surface active agents, can also be included in these formulations.
The formulations of this invention typically include an antioxidant, such as BHT (butylated hydroxytoluene). The antioxidant is generally present in amounts of at 0.1-5% (wt/vol). Some of the formulations require a solubilizer, such as oleic acid, to dissolve the active agent, particularly if spinosad is used. Common spreading agents used in these pour- on formulations are: IPM, IPP, caprylic/capric acid esters of saturated C^-C^g fatty alcohols, oleic acid, oleyl ester, ethyl oleate, triglycerides, silicone oils and DPM. The pour- on formulations of this invention are prepared according to known techniques. Where the pour-on is a solution, the parasiticide/insecticide is mixed with the carrier or vehicle, using heat and stirring where required. Auxiliary or additional ingredients can be added to the mixture of active agent and carrier, or they can be mixed with the active agent prior to the addition of the carrier. If the pour-on is an emulsion or suspension, these formulations are similarly prepared using known techniques. Other delivery systems for relatively hydrophobic pharmaceutical compounds may be employed. Liposomes and emulsions are well-known examples of delivery vehicles or carriers for hydrophobic drugs. In addition, organic solvents such as dimethylsulfoxide may be used, if needed.
For agronomic applications, the rate of application required for effective control (i.e. "biologically effective amount") will depend on such factors as the species of invertebrate to be controlled, the pest's life cycle, life stage, its size, location, time of year, host crop or animal, feeding behavior, mating behavior, ambient moisture, temperature, and the like. Under normal circumstances, application rates of about 0.01 to 2 kg of active ingredients per hectare are sufficient to control pests in agronomic ecosystems, but as little as 0.0001 kg/hectare may be sufficient or as much as 8 kg/hectare may be required. For nonagronomic applications, effective use rates will range from about 1.0 to 50 mg/square meter but as little as 0.1 mg/square meter may be sufficient or as much as 150 mg/square meter may be required. One skilled in the art can easily determine the biologically effective amount necessary for the desired level of invertebrate pest control. In general for veterinary use, a compound of Formula 1 is administered in a parasiticidally effective amount to an animal to be protected from invertebrate parasite pests. A parasiticidally effective amount is the amount of active ingredient needed to achieve an observable effect diminishing the occurrence or activity of the target invertebrate parasite pest. One skilled in the art will appreciate that the parasitically effective dose can vary for the various compounds and compositions of the present invention, the desired parasitical effect and duration, the target invertebrate pest species, the animal to be protected, the mode of application and the like, and the amount needed to achieve a particular result can be determined through simple experimentation.
For oral administration to homeothermic animals, the daily dosage of a compound of the present invention typically ranges from about 0.01 mg/kg to about 100 mg/kg, more typically from about 0.5 mg/kg to about 100 mg/kg, of animal body weight. For topical (e.g., dermal) administration, dips and sprays typically contain from about 0.5 ppm to about 5000 ppm, more typically from about 1 ppm to about 3000 ppm, of a compound of the present invention.
The compounds of this invention prepared by the methods described herein are shown in Index Tables A-F. See Index Table G for 1H NMR data. For mass spectral data (AP+ (M+ 1)), the numerical value reported is the molecular weight of the parent molecular ion (M) formed by addition of H+ (molecular weight of 1) to the molecule to give a M+l peak observed by mass spectrometry using atmospheric pressure chemical ionization (AP+). The alternate molecular ion peaks (e.g., M+2 or M+4) that occur with compounds containing multiple halogens are not reported. The variable "Ra" in Index Table C represents one or a combination of substituents as listed in Index Table C. The following additional abbreviations are used in the Index Tables which follow:
Cmpd means Compound, Me is methyl, Et is ethyl, z-Pr is isopropyl, n-Bu is /?ormα/-butyl, t- Bu is tertiary-butyl, Ph is phenyl, CHO is formyl, Ac is acetyl (i.e. C(O)CH3) and SO2Me is methyl sulfonyl.
Fragments A-I through A-42 and B-I through B-4 shown below are referred to in the Index Tables. The asterisk * denotes the attachment point of the fragment to the remainder of the molecule.
Figure imgf000161_0001
Figure imgf000162_0001
Figure imgf000163_0002
INDEX TABLE A
Figure imgf000163_0001
AP+
Cmpd S-: Ra E-Z R£ R£ m.D. (°C) (M+l
1 CH2CF3 H Br H H H 233-234
2 CH2CF3 H OCH3 H H H 124-125
3 CH2CF3 H Cl H H H *
5 CH2CF3 H H F H H 205-206
6 CH2CF3 H CF3 H H H 178-179
7 CH2CF3 H H H H H **
8 CH2CH2CH3 H OCF3 H H H *
9 CH2CF3 Cl Cl H H H *
10 CH2CF3 F H F H H *
11 CH2CF3 F H H H H 211-212 AP+
Cmpd R2 Ra Rb RC Rd R£ m.D. (°α (M+l
12 CH2CH2CH3 H CF3 H H H *
13 CH2CF3 H OCH2CF3 H H H 162-163
14 CH2CF3 F H H OCF3 H *
15 CH2CF3 H Cl H Cl H *
16 CH2CF3 H CH3 F H H 239-240
17 CH2CF3 OCH3 H H H H *
18 A-3 H OCF3 H H H *
19 A-3 H H F H H 188-189
20 CH2CH2CH3 H F H F H *
21 CH2CF3 F H Cl H H *
22 A-8 H OCF3 H H H *
23 CH2CF3 H F F H H 118-119
24 CH2CF3 H Br F H H 213-214
25 CH2CF3 OCH3 H H Cl H *
26 CH2CF3 H H Cl H H 226-227
27 A-8 H H F H H *
28 CH2CH2CH3 H H H H H *
29 A-3 Cl H F H H 191-192
30 A-8 F H F H H *
31 A-3 F H F H H 204-205
32 CH2CF3 H F H F H *
33 CH2CF2CF3 H OCF3 H H H *
34 CH2CF2CF3 H H H H H *
35 CH2CF2CF3 H H F H H *
36 CH2CF2CF3 F H F H H *
37 CH2CF=CF2 H H H H H *
38 CH2CH2CF3 H H H H H *
39 A-3 H H H H H *
40 CH2CF3 H OCF3 H H H 140-141
41 CH2CH2CH3 H H cyano H H *
122 CH2CH=CH2 H H H H H **
42 A-I H H F H H *
43 A-I H H H H H 233-235
44 A-I F H F H H *
45 A-I H OCF3 H H H 123-125
46 A-I H CF, H H H 152-153 AP+
Cmpd R2 Ra Rb RC Rd R£ m.D. (°α (M+l
47 A-I H Cl H H H 235-237
48 A-I H H OCHF2 H H 182-183
49 A-I H H OCH3 H H 215-217
50 A-I F H H H H *
51 A-2 H Br H H H *
52 A-2 H Cl H CF3 H *
53 A-2 H CF3 H H H *
54 A-2 H OCF3 H H H *
55 A-2 H Br H OCF3 H *
56 A-2 H Cl H H H *
57 A-2 H H F H H *
58 A-2 F H H OCF3 H **
59 A-2 H H H H H **
60 A-2 H H OCHF2 H H *
61 A-2 H F H H H *
62 A-2 F H H Br H *
63 A-2 F H F H H *
64 A-2 Cl H F H H *
65 A-2 H H F H H 211-213
66 A-2 F H H CF3 H *
67 A-2 Cl H H OCF3 H *
68 A-2 F CF3 H H H *
70 A-2 F H H Cl H *
71 A-2 F H F H H 226-228
72 A-2 F H H H H *
73 A-2 H H OCF3 H H *
74 A-2 H CF3 F H H *
75 A-2 H H OCH3 H H *
76 A-2 H H CF3 H H *
77 A-2 Cl H Cl H H *
78 A-2 F H F F H *
79 A-2 F H CF3 H H *
80 A-2 F F F H H *
81 A-2 H H H H H 241-243
82 A-2 H F F H H *
83 A-2 H OCH3 H H H * AP+
Cmpd R2 Ra Rb RC Rd R£ (M+l
84 A-2 H H CH3 H H *
85 A-2 F H Br H H *
86 A-2 H CH2CH2O H H *
87 A-4 H H F H H *
88 A-2 F H H F H *
89 A-2 F F H H H *
90 A-2 CH3 H cyano H H *
91 A-2 CH3 H Br H H *
92 A-2 H Br F H H *
93 A-2 H Br H CF3 H *
94 A-2 F H cyano H H *
95 A-2 F H OCH3 H H *
96 A-2 CH3 H F H H *
97 A-5 H OCF3 H H H *
98 A-2 H OCH2O H H *
99 A-2 Br H F H H *
100 A-4 H H H H H *
101 A-2 H OCH3 F H H *
102 A-2 H F OCH3 H H *
103 A-7 H Br H OCF3 H *
104 A-2 H H Br H H *
105 A-2 H H cyano H H *
106 A-2 H H Cl H H *
107 A-2 H cyano H H H *
108 A-2 F H F H F *
109 A-6 H H F H H *
123 A-I H OCH3 H H H 184-186
124 A-I H Br H H H 224-226
161 CH2CH2CH3 H Br H H H 359
162 CH2CH2CH3 F F H H H 317
163 CH2CH2CH3 F H F H H 317
164 CH2CH2CH3 H H z-Pr H H 323
165 CH2CH2CH3 H H Ph H H 357
166 A-I F H H CF3 H 456
167 A-2 F H H CF3 H 434
168 A-I F H H H F 406 AP+
Cmpd Sf Ra Rb RC Rd R£ m.D. r°α (M+l
169 A-I H Cl H Cl H 438
170 A-9 H H H H H 208-210
171 A-3 F H cyano H H *
172 A-IO F H F H H 365
173 A-I F H H Cl H 422
174 A-I l H H H H H 404
175 A-I l H H H H 422
176 A-I l F H F H H 440
177 A-I l H CF3 H H H 472
178 A-12 H H H H H 354
179 A-I H OCH3 H Br H 478
180 A-I H OCH3 H H F 418
181 A-13 H H H H H 384
182 A-13 H H F H H 402
183 A-13 F H H H 420
184 A-13 H CF3 H H H 452
185 A-I H OCH3 H OCH3 H 430
186 A-I H CF3 H CF3 H 506
187 A-3 H CF3 H CF3 H 429
188 A-3 H CF3 H Br H 439
189 CH2CF3 H CF3 H Br H 189-190
190 A-14 H H H H H 354
191 A-14 H H H H 372
192 A-I F OCH3 H H H 418
193 A-I H OCF3 H H 472
194 A-15 H H H H H 370
195 A-15 H H H H 388
196 A-16 H H H H H 334
197 A-16 H H H H 175-177
198 A-2 H OCH3 H OCH3 H 424
199 CH2CF3 H OCH3 H OCH3 H 381
200 A-I OCH3 H H H H 400
201 A-I OCH3 H OCH3 H H 430
202 A-17 H OCH3 H OCH3 H 408
203 A-17 H CF3 H H H 416
204 A-17 F H F F H 215-217 AP+
Cmpd R2 Ra Rb RC Rd R£ m.D. (°α (M+l
205 CH2CF=CH2 H H F H H 315
206 CH2CF=CH2 H OCF3 H H H 381
207 A-17 H H cyano H H 373
208 A-17 H OCH3 H H H 378
209 CH2CF3 F OCH3 H H H *
210 A-2 F OCH3 H H H 412
211 A-18 H H H H H 384
212 A-18 H H F H H 402
213 A-19 H H H H H 333
214 A-19 H H F H H 210-211
215 A-I H CF3 H F H 456
216 CH(CH3)CF3 H H F H H 353
217 CH(CH3)CF3 H OCF3 H H H 419
218 A-20 H H H H H 350
219 A-20 H H F H H 368
220 A-21 H H H H H 336
221 A-21 H H F H H 354
222 CH(CH3)CF3 F H F H H 371
223 CH2CF3 F H cyano H H 364
224 A-16 F H H H H 352
225 A-17 F H H H H 366
226 A-17 H OCF3 H H H 432
227 CH2CHFCF2Cl H H F H H 387
228 CH2CHFCF2Cl F H F H H 405
229 A-18 F H H H H *
230 A-19 H H cyano H H 358
231 A-19 F H F H H 369
232 A-19 H OCF3 H H H 417
233 A-19 F H H H H 431
234 A-19 OCH3 H H H H 363
235 A-2 OCH3 H H Br H 474
236 A-2 Cl H H CF3 H 466
237 CH(CH3)CF3 F H H H H 353
238 A-19 F H H CF3 H 419
239 A-19 F H cyano H H 376
240 CH(CH3)CF3 H Br H H H 353 AP+
Cmpd R2 Ra Rb RC Rd Re m.D. (°α (M+l
241 A-22 H H H H H 335
242 CH(CH3)CF3 H Br H CF3 H 481
243 CH(CH3)CF3 H OCH3 H H H 365
244 CH(CH3)CF3 OCH3 H H H H 365
245 A-I H SF5 H H Cl 530
246 A-2 OCH3 H H CF3 H 549
247 A-2 OCH3 H H Cl H 428
248 A-23 H OCF3 H H H 438
249 A-17 OCH3 H H H H 378
250 A-2 CH3 H CH3 H CH3 406
251 A-I CH3 H CH3 H CH3 412
252 CH(CH3)CF3 Cl H H OCF3 H 453
253 CH(CH3)CF3 H Br H OCF3 H 497
254 A-2 H SF5 H H H 490
255 CH2CF3 H SF5 H H H 447
256 A-19 H Br H OCF3 H 495
257 A-24 F H H H H 380
258 A-24 OCH3 H H H H 392
259 A-24 H OCF3 H H H 446
260 A-24 F H F H H 398
261 A-6 H Br H CF3 H 524
262 A-6 OCH3 H H H H 408
263 A-I H SF5 H H H 497
264 A-17 Cl H H OCF3 H 466
265 A-25 H H H H H 181-183
266 A-17 F CF3 H H H 434
267 A-25 H OCF3 H H H 431
268 A-17 OCF3 H H H H 432
269 A-17 CF3 H H H H 416
270 A-I OCF3 H H H H 454
271 A-I CF3 H H H H 438
272 A-6 H OCF3 H H H 462
273 A-6 F H H H H 396
274 A-I I H H H H 496
275 A-I H I H H H 496
276 A-I H Br OCH3 H H 478 AP+
Cmpd S-: Ra Rb RC Rd R£ m.D. (°α (M+l
277 A-I OCH3 H H Br H 478
278 CH2CH3 H H H H H 267
279 CH2CH(CH3)2 H H H H H 295
280 CH2CH2CH3 F H H H H 299
281 CH2CH2CH3 H H F H H 299
282 CH2CH2CH3 H cyano H H H 306
283 CH2CH2CH3 cyano H H H H 306
284 CH2CH2CH3 H F H H H 299
285 CH2CH2CH3 CH3 H H H H 295
286 CH2CH2CH3 H H CH3 H H 295
287 CH2CH2CH3 H CF3 H CF3 H 417
288 CH2CH2CH3 H H CF3 H H 349
289 CH2CH2CH3 H CH3 H H H 295
290 CH2CH2CH2CH3 H H H H H 295
291 CH2CH2OCH3 H H H H H 297
292 CH2CH2CH3 OCH3 H H H H 311
293 CH2CH2CH3 H H OCH3 H H 311
294 CH2CH2CH3 H H Cl H H 315
295 CH2CH2CH3 H OCH3 H H H 311
296 CH2CO2Et H H H H H 325
297 CH(CH3)2 H H H H H 281
298 CH2CH2CH3 H F F F H 335
299 CH2(CH2)3CH3 H H H H H 309
300 CH2CH2CH3 H nitro H H H 326
301 CH2CH2CH3 H Cl H H H 315
302 CH2CH2CH3 H H OCF3 H H 365
303 CH2CH2CH3 H NHAc H H H 338
304 CH2CO2CH3 H H H H H 311
305 CH2CH2CH3 H CHO H H H 309
306 CH2CH2CH3 H Ac H H H 323
307 CH2CH2CH3 H CO2Et H H H 353
308 CH2CH2CH3 CF3 H H H H ** 349
309 CH2CH2CH3 F H H F H 317
310 CH2CH2CH3 H Cl H Cl H 349
311 CH2CF3 H H CF3 H H 389
312 CH2CF3 H CF3 H CF3 H 457 AP+
Cmpd S-: Ra Rb RC Rd R£ m.D. (°α (M+l
313 CH2CF3 H H F H 357
314 CH2CH2CH3 F H H Br H 377
315 CH2CH2CH3 H OCH3 H Br H 389
316 CH2CH2CH3 H OCH3 OCH3 H H 341
317 CH2CH2CH3 OCH3 H H F H 329
318 CH2CH2CH3 OCH3 H H Cl H 345 pH
319 CH2CH2CH3 F CH3 H Cl H 347
320 CH2CF3 H OCH3 H Br H 429
321 CH2CF3 CF3 H H H H 389
322 CH2CH2CH3 OCF3 H H H H 365
323 CH2CF3 OCF3 H H H H 405
324 CH2CF3 H H OCF3 H H 405
325 CH2CF3 H H cyano H H 346
326 CH2CH2CH3 OCH3 OCH3 H H H 341
327 A-8 H H H H H 383
328 CH2CF3 H OCH3 OCH3 H H 381
329 CH2CF3 F CH3 H Cl H 387
330 CH2CF3 F F H H H 357
331 CH2CH2CH3 H H SCH3 H H 327
332 CH2CH2CH3 H OCH3 Cl H F 363
333 CH2CH2CH3 H H ^-Bu H H 337
334 CH2CH2CH3 NHCO^-Bu H H CH3 H 394
335 CH2CH2CH3 H H SO2Me H H 359
336 CH2CF3 H OCH3 Cl H F 403
337 CH2CH2CH3 H CF3 OCH3 H H 379
338 CH2CF3 H CF3 OCH3 H H 419
339 CH2CH2CH3 H «-Bu H H H 337
340 CH2CH2CH3 F H CF3 H H 367
341 CH2CH2CH3 H OCF3 H H 383
342 CH2CH2CH3 H H CO2Et H H 353
343 CH2CH2CH3 H CH3 H CH3 H 309
344 CH2CH2CH3 OCH3 H H CF3 H 379
345 CH2CH2CH3 OCH2CH3 H H CF3 H *
346 CH2CF3 OCH2CH3 H H CF3 H *
347 CH2CH2CH3 CF3 H H H 367
348 CH2CH2CH3 OCH3 Br H CH3 H * AP+
Cmpd S-: Ra Rb RC Rd R£ m.D. (°α (M+l
349 CH2CH2CH3 CH3 H H CH3 H *
350 CH2CF3 F CF3 H H H 407
351 A-8 H H cyano H H *
352 CH2CF3 F H H F H *
353 CH2CF3 H Cl F H H 373
354 CH2CF3 H H w-Bu H H 377
355 CH2CF3 H CF3 F H H 407
356 CH2CF3 H F cyano H H 338
357 CH2CF3 Cl H F H H 373
358 CH2CF3 OCH3 H F H H 368
359 CH2CF3 OCH3 H H CF3 H 419
360 CH2CF3 H F H H H 339
361 CH2CF3 H H CH3 H H 335
362 CH2CF3 H H OCH3 H H 351
363 CH2CF3 H CH3 H H H 335
364 CH2CF3 H H Br H H 399
365 CH2CH2CF3 H H F H H 353
366 CH2CH2CF=CF2 H H F H H 365
367 CH2CH2CF=CF2 H OCF3 H H H 431
368 CH2CH2CF=CF2 F H F H H 383
369 CH2CF3 H cyano F H H *
370 CH2CF2CF3 H CF3 H H H 439
371 CH2CH2CF=CF2 H CF3 H H H 415
372 A-8 H CF3 H H H 451
373 CH2CH2CF=CF2 Cl H Cl H H 415
374 A-8 Cl H Cl H H 451
375 CH2CF2CF3 Cl H Cl H H 439
376 CH2CF3 CH3 H H H H 335
377 CH2CF3 Br H H H H 399
378 CH2CF3 Cl H H H H 355
379 CH2CF3 H «-Bu I H H 503
380 CH2CF3 H «-Bu H H H 377
381 CH2CF3 Cl H Cl H Cl 423
382 CH2CH2CF=CF2 Cl H Cl H Cl 449
383 A-8 Cl H Cl H Cl 485
384 CH2CF3 Cl H H H Cl 389 AP+
Cmpd S-: Ra Rb RC Rd R£ m.D. (°α (M+l
385 CH2CF3 CH3 H CH3 H H 349
386 CH2CF3 H cyano H H H 346
387 CH2CF3 «-Bu H H H H 377
388 CH2CF2CF3 Cl H Cl H Cl 473
389 A-26 H H F H H 383
390 A-26 F H F H H 401
391 A-26 H OCF3 H H H 449
392 CH2CF3 F F F H H 375
393 CH2CF3 F H F F H 375
394 CH2CF3 F H F H F 375
395 CH2CF3 H F F F H 375
396 CH2CF3 CF3 H F H H 407
397 CH2CF3 H OCF3 H H Cl 439
398 CH2CF3 H CHO F H H 367
399 CH2CF3 cyano H H H H 346
400 CH2CH2CH3 H Br F H H 377
401 CH2CH2CH3 H CF3 F H H 367
402 CH2CO2CH3 H H F H H 329
403 CH2CF3 F H Br H H 417
404 CH2CF3 F H F H Br 435
405 CH2CH2CH3 H F F H H 317
406 CH2CH2CH3 H Cl F H H 333
407 CH2CH2CH3 Cl H F H H 333
408 CH2CH2CH3 F H F H H 317
409 CH2CH2CH3 OCH3 H F H H 329
410 A-8 H cyano F H H 426
411 A-7 H OCF3 H H H 414
412 A-7 H H F H H 348
413 A-7 F H F H H 365
414 A-7 H H H H H 330
415 A-2 CF3 H F H H 450
416 A-34 H H H H H *
417 A-2 H H SCH3 H H 410
418 A-2 H Cl H Cl H *
419 A-2 Cl H F H H 398
420 A-2 CH, H H H H 378 AP+
Cmpd Ei Ra Rb RC Rd R£ m.D. (°α (M+l
421 A-2 OCF3 H H H H 448
422 A-2 cyano H H H H 389
423 A-2 OCH3 H H H H 394
424 A-3 H OCH3 H H H 323
425 A-2 H SCH3 H H H *
426 CH2CF3 H nitro H H H *
427 A-2 H Si(CH3)3 H H H *
428 A-27 H H H H H 323
429 A-27 F H H H 359
430 A-2 H H Si(CH3)3 H H *
431 CH2CF3 H OCH2O H H 365
432 CH2CF3 H OH H H H 337
433 CH2CF3 CH3 H H H *
434 CH2CF3 H OAc H H H 379
435 CH2CF3 H CH2CH2O H H 363
436 A-4 H OCF3 H H H *
437 A-4 F H H H 434
438 CH2CF3 H OCF2O H H 401
439 A-27 H H H H 341
440 A-2 H CF3 H CF3 H 500
441 A-2 H nitro H H H 409
442 A-2 OCH3 H OCH3 H H 424
443 A-4 H H OCH3 H H *
444 A-4 F H H H H 416
445 A-2 H CF3 OCH3 H H 462
446 A-2 H OCF2O H H 444
447 A-2 H OAc H H H 422
448 A-2 F F OCH3 H H 430
449 A-5 H H H H 363
450 A-5 H H H H H 345
451 A-28 H H F H H 416
452 A-29 H H H H H 398
453 A-28 H OCF3 H H H *
454 A-29 H H F H H 416
455 A-29 F H F H H 434
456 A-30 H H H H H 355 AP+
Cmpd R2 Ra Rb RC Rd R£ m.D. (°α (M+l
457 A-30 H H F H H 373
458 A-30 F H F H H 391
459 A-2 H OCH2CF3 H H H *
460 A-6 H H H H H 378
461 A-2 F H H H F 400
462 A-17 F H cyano H H 391
463 A-31 H H H H H 344
464 A-31 H H F H H 362
465 A-31 F H F H H 380
466 A-32 H H H H H 323
467 A-32 H H F H H 341
468 A-32 F H F H H 359
469 A-I F H cyano H H 413
470 A-33 H H H H H 408
471 A-33 H H F H H 426
472 A-33 F H F H H 444
473 A-I H CF3 F H H 455
474 A-I Cl H F H H 422
475 A-I H H cyano H H 395
476 A-2 H F H F H 400
477 A-I H F H H H 388
478 A-I H H CF3 H H 438
479 A-I H H OCF3 H H 454
480 A-I H H CH3 H H 384
481 A-I cyano H H H H 395
482 A-I H F F H H 406
483 A-IO H H F H H *
484 A-IO H OCF3 H H H 413
485 A-IO H H H H H 329
486 A-I H OCH3 F H H *
487 A-I Br H F H H 466
488 A-I CH3 H cyano H H 409
489 A-I Cl H Cl H H 438
490 A-I H OCF3 H H Cl 488
491 A-I H OCF3 H Br H 209-210
492 A-I F F F H H 196-198 424 AP+
Cmpd R2 Ra Rb RC Rd R£ m.D. r°α (M+l
493 A-I F H F F H 195-197 424
494 A-I H OCH2O H H >250 414
495 A-I H CH2CH2O H H 188-190 412
496 A-I F H H Br H 466
497 A-6 F H F H H 414
498 A-I H CF3 H Br H 188-190 516
499 A-I H F H F H 406
500 A-I H F OCH3 H H 205-207 418
501 A-I F H F H F *
502 A-33 H OCF3 H H H 153-155 504
503 A-33 H OCH3 H H H 438
604 A-35 H H H H H 330
605 A-36 H H H H H 330
606 A-35 H H F H H *
618 A-I F F H H F 424
619 A-I H CF3 H Cl F 490
621 A-2 H SF5 H H Cl 524
622 A-I H OCF3 H Cl H 488
623 A-37 F H H H H 432
624 A-37 H H F H H 432
625 A-37 H OCF3 H H H 498
627 A-37 H CF3 H Br H 560
629 CH2CO2H H H H H H 297
631 A-38 H H H H H 335
632 A-2 I H H H H 490
634 A-I H CF3 H Cl H 472
642 A-40 F H F H H 159-160
648 A-40 OCH3 H H H H *
649 CH2CH2CH(OMe)2 H H H H H 341
650 CH2CH(OMe)2 H H H H H 327
651 A-2 F F H H F 418
652 A-2 H CF3 H Cl F 484
654 A-I F H OCH3 H H 418
663 A-I F Cl H H F 440
664 A-I OCH3 H H F F 436
665 A-2 OCH3 H H F F 430 AP+
Cmpd Ei Ra Rb RC Rd Re m.D. (0C) (M+l
666 A-2 F Cl H H 434
673 A-41 H H H H H 360
674 A-41 F H H H H 378
675 A-40 F H H H H 365
676 A-41 H H H H 378
677 A-17 H H F H H 372
678 A-41 F H H H 396
679 A-41 H OCF3 H H H 444
720 CH2CF3 H H SF5 H H 447
721 A-I H H SF5 H H 496
722 A-2 H H SF5 H H 490
737 A-37 H Br H OCF3 H 576
740 A-2 OCH3 H H 430
741 A-2 F OCH3 H H F 430
742 A-I OCH3 H F H 436
743 A-I F OCH3 H H F 436
744 A-2 F H H OCH3 H 412
745 CH2CF3 F H H OCH3 H 369
746 A-17 F H H H 384
* See Index Table G for 1H NMR data. ** See synthesis example for ^H NMR data.
INDEX TABLE B
Figure imgf000177_0001
AP+
Compound El R-: m.p. (0C) (M+l)
110 Br CH2CH2CH3 *
111 I CH2CF3
112 I CH2CH2CH3 AP+
Compound Ei R2 (M+ 1
113 I A-8 *
114 I CH2CF2CF3 *
115 CH(CH3)2 CH2CF3 *
116 CH2CH(CH3)2 CH2CF3 *
117 CH2CH2CF=CF2 CH2CF3 *
118 I A-2 **
125 H A-I **
119 6-fluoro-3 -pyridinyl A-2 *
120 6-chloro-3 -pyridinyl A-2 *
121 3 -chloro-4-pyridinyl CH2CF3 248-249
521 4-trifluoromethyl-2-pyridinyl CH2CF3 *
522 4-trifluoromethyl-2-pyridinyl A-17 417
537 2-bromo-4-pyridinyl A-2 443
540 2-bromo-4-pyridinyl A-I 449
547 6-trifluoromethyl-2-pyridinyl A-17 *
550 2-cyano-4-pyridinyl A-I 396
552 2 -pyridinyl CH2CH2CH3 282
553 3 -pyridinyl CH2CH2CH3 282
554 phenyl CH2CO2CH(CH3)2 339
555 2-naphthalenyl CH2CH2CH3 331
556 1 -naphthalenyl CH2CH2CH3 331
561 4-pyridinyl CH2CH2CH3 282
562 2-chloro-4-pyridinyl CH2CH2CH3 316
564 4-fluoro- 1 -naphthalenyl CH2CH2CH3 *
570 6-chloro-3 -pyridinyl CH2CF3 356
571 6-fluoro-3 -pyridinyl CH2CF3 340
573 4-fluoro- 1 -naphthalenyl A-2 432
574 6-methoxy-2-naphthalenyl A-2 444
575 6-methoxy-3 -pyridinyl A-2 395
576 5-fluoro-2-pyridinyl A-2 383
577 5 -trifluoromethyl- 3 -pyridinyl A-2 433
579 2-fluoro-3 -pyridinyl A-2 383
584 3 -fluoro-4-pyridinyl A-2 383
585 5-methoxy-2-pyridinyl A-2 395
586 3 -fluoro-2-pyridinyl A-2 383
587 3 -chloro-2-pyridinyl A-2 399 AP+
Compound Ei m.D. r°α (M+ 1
591 4-trifluoromethyl-2-pyridinyl A-2 433
593 6-trifluoromethyl-2-pyridinyl A-2 433
597 4-trifluoromethyl-2-pyridinyl A-I 225-227 439
598 2-chloro-4-pyridinyl A-I 242-243 405
600 6-trifluoromethyl-2-pyridinyl A-I *
608 I A-I **
609 H CH2CH2CH3 **
610 H CH2CF3 214-215
611 H A-2 **
612 H A-7 *
628 2-bromo-4-pyridinyl A-37 493
636 2-methoxy-4-pyridinyl A-I 401
637 C(=NOCH3)CF3 CH2CF3 **
638 CC=NOCH2CH3)CF3 CH2CF3 *
653 2-trifluoromethyl-4-pyridinyl A-I 439
656 CC=NOCH2CHMe2)CF3 CH2CF3 *
657 CC=NOCMe3)CF3 CH2CF3 *
658 CC=NOCH2CMe3)CF3 CH2CF3 *
659 CC=NOCH2CO2Et)CF3 CH2CF3 *
660 C(O)NHphenyl A-I 413
661 C(O)NH(3 -methoxyphenyl) A-I 443
687 C(O)OEt CH2CH2CH3 277
688 C(O)NH(4-fluorophenyl) CH2CH2CH3 342
689 C(O)NH(2-chlorophenyl) CH2CH2CH3 358
690 C(O)NH(3 -chlorophenyl) CH2CH2CH3 358
691 C(O)NH(4-chlorophenyl) CH2CH2CH3 358
692 C(O)NHphenyl CH2CH2CH3 324
693 C(O)O(4-nitrophenyl) CH2CH2CH3 370
694 C(O)phenyl CH2CH2CH3 309
695 C(O)(2-fluorophenyl) CH2CH2CH3 327
696 C(O)(3 -fluorophenyl) CH2CH2CH3 327
697 C(O)(4-fluorophenyl) CH2CH2CH3 327
698 C(O)(2-methylphenyl) CH2CH2CH3 323
699 C(O)(3-methylphenyl) CH2CH2CH3 323
700 C(O)OEt A-I *
701 C(O)phenyl A-I * AP+
Compound R^ R2 m.D. (0O (M+l
702 C(O)CF3 A-I 236-238
703 C(O)(4-fluorophenyl) A-I 235-237
704 C(O)(3 -fluorophenyl) A-I 226-228
706 C(O)(2-fluorophenyl) A-I 190-192
707 C(O)[3 -(trifluoromethyl)phenyl] A-I 225-226
708 C(O)(2-thienyl) A-I 214-216
709 C(O)[4-(trifluoromethyl)phenyl] A-I 242-243
710 C(O)CH3 A-I 183-185
711 C(O)CF3 CH2CF3 202-203
712 C(O)CF3 A-2 209-210
713 C(O)CF2CF3 A-I 204-205
714 C(O)CF2CF3 A-2 189-190
715 C(O)CF2CF2CF3 A-I 156-157
716 C(O)CF2CF2CF3 A-2 134-135
729 C(=NOC(CH3)3)H CH2CF3 *
730 C(=NOCH2CH3)H CH2CF3 *
731 C(=NOCH2C(CH3)3)H CH2CF3 *
758 C(=NOCH3)H CH2CF3 *
759 C(=NOCH2Ph)H CH2CF3 *
* See Index Table G for 1H NMR data.
** See synthesis example for ^H NMR data.
INDEX TABLE C
Figure imgf000180_0001
AP+
Compound ga E-? m.p. (0C) (M+ 1)
523 3-(3-pyridinyl) A-2 441
524 3 -(6-chloro-3 -pyridinyl) A-2 474 AP+
Compound ga R2 m.D. r°α (M+ 1
525 3 -(6-fluoro-3 -pyridinyl) A-2 459
527 3-(6-fluoro-3-pyridinyl), 6-fluoro A-2 477
528 4-(6-chloro-3 -pyridinyl) A-2 475
529 3 -(6-methoxy-3 -pyridinyl) A-2 471
530 3 -(6-chloro-3 -pyridinyl) A-I 481
531 3 -(6-fluoro-3 -pyridinyl), A-2 527
5 -trifluoromethyl
534 3 -(6-chloro-3 -pyridinyl) CH(CH3)CF3 446
536 3 -(6-lluoro-3 -pyridinyl), 4-fluoro A-2
539 3 -(6-chloro-3 -pyridinyl), 6-methoxy A-2 505
541 3-(6-chloro-3-pyridinyl), 4-fluoro A-I 499
542 3 -(6- fluoro-3 -pyridinyl) A-I 465
543 3 -(6-chloro-3 -pyridinyl), A-I 549
5 -trifluoromethyl
544 3 -(6-fluoro-3 -pyridinyl), A-I 533
5 -trifluoromethyl
545 3 -(6- fluoro-3 -pyridinyl) A-19 428
546 3 -(6- fluoro-3 -pyridinyl) A-6 473
549 3 -(6-fluoro-3 -pyridinyl), A-I 549
5-trifluoromethoxy
551 2-(6-chloro-3 -pyridinyl) A-I 481
557 3 -phenyl CH2CH2CH3 357
558 4-phenoxy CH2CH2CH3 373
559 2-phenoxy CH2CH2CH3 373
560 2 -phenyl CH2CH2CH3 357
563 3-phenoxy CH2CH2CH3 373
565 3-benzyloxy CH2CH2CH3 387
566 3-benzyloxy CH2CF3 178-179 427
567 4-benzyloxy CH2CF3 203-204 427
568 2-benzyloxy CH2CF3 165-166 427
578 2-(B-I), 4-fluoro CH2CF3 480
580 3-(B-2) CH2CF3 223-225 428
581 3-(B-I) CH2CF3 462
582 3-(B-I) A-2 505
594 3-(B-3), 4-fluoro A-2 446
595 3-(B-3), 4-fluoro CH2CF3 446 AP+
Compound ga R2 m.D. (°C) (M+ 1
596 3-(B-4) CH2CF3 170-172 462
616 3 -(6-bromo-3 -pyridinyl) A-I 525
617 3 -(6-trifluoromethyl-3 -pyridinyl) A-I 515
626 3 -(6-chloro-3 -pyridinyl) A-37 525
635 3 -(6-chloro-3 -pyridinyl), A-I 565
5-trifluoromethoxy
655 3 -(6-chloro-3 -pyridinyl), 5-methoxy A-I 511
682 3 -(6-trifluoromethyl-3 -pyridinyl), A-I 599
5 -trifluoromethoxy
684 3 -(6-trifluoromethyl-3 -pyridinyl), A-I 583
5 -trifluoromethyl
685 3 -(6-trifluoromethyl-3 -pyridinyl), A-I 545
4-methoxy
717 3 -(6-chloro-3 -pyridinyl), 4-methoxy A-I 511
734 3 -(6-trifluoromethyl-3 -pyridinyl) A-17 493
735 3 -(6-trifluoromethyl-3 -pyridinyl) A-2 509
736 3 -(6-trifluoromethyl-3 -pyridinyl) A-37 559
738 3-(6-trifluoromethyl-3-pyridinyl), A-I 533
6-fluoro
739 3-(6-trifluoromethyl-3-pyridinyl), A-37 577
6-fluoro
INDEX TABLE D
Figure imgf000182_0001
AP+
Cmpd R^ R^ R^ RC R^ R£ m.p. (0C)
126 CH2CH2CH3 H H H H H 161-168
127 CH2CH2CH3 F H H H Cl 216-219 AP+
Cmpd R2 Ra Rb RC R£ m.D. (°C) (M+ 1
128 CH2CH2CH3 H Cl H Cl H 180-183
129 CH2CH2CH3 Cl Cl H H H 188-192
130 CH2CH2CH3 F H H H F 207-210
131 CH2CH2CH3 CH3 H H H H 223-225
132 CH2CH2CH3 H H z-Pr H H *
133 CH2CF3 F H F H H *
134 CH2CF3 H H H H H *
135 CH2CF3 H OCF3 H H H *
136 A-2 H H H H H *
137 A-2 H H F H H *
138 A-2 H OCF3 H H H **
139 A-I H H H H H *
140 A-I H H F H H *
141 A-I H OCF3 H H H *
142 CH2CH2CH3 F H F H H *
143 CH2CH2CH3 H H Ph H H 363
144 CH2CO2CH2CH3 H H H H H 331
145 A-I H OCF3 H Br H 538
146 A-I F H F H H 412
147 A-I H OCH3 H H H *
148 A-I F H H Cl H 428
149 A-2 H OCH3 H H H 400
150 A-2 H OCH3 H OCH3 H 430
151 A-2 F H F H H 406
152 A-I F H H CF3 H *
153 A-2 F H H CF3 H 456
154 A-2 F H H Cl H 422
155 A-2 H OCF3 H Br H 532
156 A-I H OCH3 H OCH3 H 436
157 A-2 F H H H H 216-218 388
158 A-2 OCH3 H H H H 99-100
159 A-I F H H H H 192-194
160 A-I OCH3 H H H H *
630 A-17 H H H H H 223-225
633 A-2 I H H H H 496
639 A-17 H OCF, H H H * AP+
Cmpd R2 Ra R£ R£ m.D. (°C) (M+ 1
640 A-39 H OCF3 H H H 147-149
641 A-17 F H F H H 235-237
643 A-17 F H H H H 223-225
644 A-39 F H H H H 169-171
645 A-39 H H H H H 190-192
646 A-17 OCH3 H H H H *
647 A-39 OCH3 H H H H *
747 A-17 H OCH3 H H H 384
748 A-2 F F H H H 406
749 A-I F F H H H 412
750 A-17 F F H H H 390
* See Index Table G for 1H NMR data. ** See synthesis example for ^H NMR data.
INDEX TABLE E
Figure imgf000184_0001
AP+
Cmpd El R2 R3 ** R4 ** m.D. (°C) (M+ 1
504 phenyl A-2 CH3 phenyl 404
505 phenyl A-2 phenyl CH3 404
506 4-fluorophenyl A-2 CH3 phenyl 422
507 phenyl CH2CF3 phenyl CH3 361
508 4-fluorophenyl CH2CF3 phenyl CH3 379
509 phenyl CH2CH2CH3 CH3 CH3 259
510 4-fluorophenyl CH2CH2CH3 CH3 CH3 276
511 phenyl A-2 CH3 CH3 *
512 phenyl CH2CF3 CH3 CH3 299
513 4-fluorophenyl A-2 CH3 CH3 360
514 phenyl A-I CH3 CH3 222-224 388 AP+
Cmpd Ei S-: R3 ** R4 ** m.D. (°C) (M+ 1
515 3 -(trifluoromethoxy)- CH2CH2CH3 CH2CH2CH2CH2 369 phenyl
516 4-fluorophenyl CH2CH2CH3 CH2CH2CH2CH2 303
517 phenyl A-2 354
518 3-(trifluoromethoxy)- A-2 phenyl
519 phenyl CH2CH2CH3 284
588 4-fluorophenyl A-2 400
589 3-(trifluoromethoxy)- A-2 466 phenyl
590 2,4-difluorophenyl A-2 418
592 phenyl A-2 382
Figure imgf000185_0001
AP+
Cmpd Rl S-: Rj R4 ; m.p. (0C) (M+ 1)
667 2 -fluorophenyl A-I 406
668 2 -fluorophenyl A-2 400
669 2-methoxyphenyl A-2 412
670 2-methoxyphenyl A-I 418
671 4-fluorophenyl A-I 406
672 3-(trifluoromethoxy)- A-I 472 phenyl
683 3-bromo- A-I 550
5 -(trifluoromethoxy) phenyl
Figure imgf000186_0001
718 2 -fluorophenyl A-2 CH3 CH3 249-252 360
719 2-fluorophenyl A-I CH3 CH3 190-193 366 AP+
Cmpd Ei S-: Rj R4 ; m.p. (0C) (M+ 1) 751 2 -fluorophenyl A-2 450
752 4-fluorophenyl A-2 450
753 3 -(trifluoromeihoxy)- A-2 516 phenyl
754 3-(1xifluoromethoxy)- A-I 522 phenyl
755 2 -fluorophenyl A-I 456
756 4-fluorophenyl A-I 456
Figure imgf000187_0001
* See Index Table G for 1H NMR data.
** When R^ and R^ are taken together with the contiguous linking nitrogen and carbon atoms to form a ring, the wavy line indicates that the ring is attached to the remainder of the molecule with the orientation shown below.
Figure imgf000188_0001
INDEX TABLE F
m.p. AP+
Cmpd Structure (°C) (M+l)
Figure imgf000188_0002
m.p. AP+
Figure imgf000189_0001
m.p. AP+
Figure imgf000190_0001
m.p. AP+
Figure imgf000191_0001
m.p. AP+
Cmpd Structure (0C) (M+n
Figure imgf000192_0001
m.p. AP+
Figure imgf000193_0001
* See Index Table G for 1H NMR data. ** See synthesis example for ^H NMR data. INDEX TABLE G
Cmpd No. 1H NMR Data a> b
3 δ (acetone-d6) 9.5 (m, IH), 8.5 (m, IH), 8.1 (m, IH), 7.97 (s, IH), 7.75 (dd, IH), 7.69 (m, IH), 7.31 (t, IH), 7.15 (m, IH), 5.35 (br s, 2H).
8 δ 9.51 (d, IH), 8.09 (m, IH), 7.85-7.69 (m, 2H), 7.45 (d, IH), 7.38 (t, IH), 7.32 (t, IH), 7.07 (d, IH), 4.29 (t, 2H), 1.87-1.75 (m, 2H), 1.08 (t, 3H).
9 δ 9.57 (d, IH), 8.23 (t, IH), 7.61 (d, IH), 7.49 (t, 2H), 7.41 (d, IH), 7.29 (d, IH), 5.2 (br s, 2H).
10 δ 9.57 (d, IH), 8.23 (t, IH), 7.61 (d, IH), 7.49 (m, 2H), 6.8-6.95 (m, 2H), 5.2 (br s, 2H). 12 δ 9.52 (dd, IH), 8.15-8.07 (m, 2H), 8.03-7.98 (m, IH), 7.47 (t, 3H), 7.34 (m, IH), 4.30 (t,
2H), 1.91-1.74 (m, 2H), 1.09 (t, 3H).
14 δ 9.58 (d, IH), 8.23 (t, IH), 7.61 (d, IH), 7.51 (t, IH), 7.48 (d, IH), 7.14 (m, 2H).
15 δ 9.60 (d, IH), 8.23 (t, IH), 7.75 (d, 2H), 7.59 (d, IH), 7.51 (t, 2H), 7.24 (m, 2H).
17 δ (acetone-d6) 9.45 (d, IH), 8.45 (m, IH), 8.1 (d, IH), 7.63 (t, IH), 7.3 (d, IH), 7.22 (m, IH), 7.95 (dd, IH), 6.9 (t, IH), 5.35 (br s, 2H), 3.73 (s, 3H).
18 δ 9.5 (m, IH), 8.1 (m, IH), 7.75 (m, 2H), 7.63 (dd, IH), 7.4-7.3 (m, 2H), 7.05 (m, IH), 4.30 (m, 2H), 1.2 (m, IH), 0.62 (m, 4H).
20 δ 9.51 (dd, IH), 8.12 (ddd, 2H), 7.51-7.42 (m, 3H), 7.38-7.31 (m, IH), 6.72-6.60 (m, IH), 4.29 (t, 2H), 1.93-1.68 (m, 2H), 1.09 (t, 3H).
21 δ 9.56 (d, IH), 8.23 (t, IH), 7.59 (d, IH), 7.49 (m, 2H), 7.16 (t, 2H), 5.2 (br s, 2H).
22 δ 9.57 (d, IH), 8.19 (t, IH), 7.78 (dd, IH), 7.67 (dd, IH), 7.35-7.55 (m, 3H), 7.09 (d, IH), 4.7-5.05 (m, 2H), 4.37 (m, IH), 2.2-2.55 (m, 2H).
25 δ 9.57 (d, IH), 8.23 (t, IH), 7.58 (d, IH), 7.46 (t, 2H), 7.38(s, IH), 6.90 (d, IH), 3.79 (s, 3H).
27 δ 9.57 (d, IH), 8.17 (t, IH), 7.74 (m, 2H), 7.49 (d, IH), 7.41 (t, IH), 7.08 (t, 2H), 4.7-5.05 (m, 2H), 4.37 (m, IH), 2.2-2.55 (m, 2H).
28 δ 9.53 (dd, IH), 8.07 (ddd, IH), 7.81-7.72 (m, 2H), 7.45 (d, IH), 7.42-7.36 (m, 2H), 7.31 (m, IH), 7.25-7.20 (m, IH), 4.30 (d, IH), 1.90-1.73 (m, 2H), 1.08 (t, 3H).
30 δ 9.54 (d, IH), 8.21 (t, IH), 7.51 (m, 2H), 7.42 (t, IH), 6.9 (m, 2H), 4.7-5.05 (m, 2H), 4.37 (m, IH), 2.2-2.55 (m, 2H).
32 δ 9.61 (d, IH), 8.24 (t, IH), 7.78 (dd, IH), 7.67 (d, IH), 7.50 (t, IH), 7.44 (d, 2H), 6.69 (t, IH).
33 δ 9.61 (d, IH), 8.21 (t, IH), 7.76 (d, IH), 7.71 (s, IH), 7.55 (dt, IH), 7.49 (t, IH), 7.39 (t, IH), 7.10 (d, IH).
34 δ 9.59 (d, IH), 8.15 (t, IH), 7.72 (d, 2H), 7.52 (d, IH), 7.44 (t, IH), 7.38 (t, 2H), 7.23 (t, IH), 5.5 (br s, 2H).
35 δ 9.61 (d, IH), 8.21 (t, IH), 7.73 (m, 2H), 7.56 (d, IH), 7.49 (t, IH), 7.08 (t, 2H).
36 δ 9.59 (d, IH), 8.23 (t, IH), 7.58 (d, IH), 7.50 (m, 2H), 7.50 (t, IH), 6.85-6.95 (m, 2H). δ 9.57 (d, IH), 8.13 (t, IH), 7.74 (d, 2H), 7.49 (d, IH), 7.40 (m, 3H), 7.26 (m, IH), 4.54 (t, 2H), 2.85 (m, 2H). δ 9.58 (d, IH), 8.16 (t, IH), 7.74 (d, 2H), 7.49 (d, IH), 7.40 (t, 3H), 7.25 (m, IH), 4.58 (dd, 2H), 2.85 (m, 2H). δ 9.49 (dd, IH), 8.03 (ddd, IH), 7.73 (d, 2H), 7.58 (d, IH), 7.36 (t, 2H), 7.28 (m, IH), 7.23- 7.17 (m, IH), 4.28 (d, 2H), 1.24-1.09 (m, IH), 0.69-0.45 (m, 4H). δ 9.51 (dd, IH), 8.13 (ddd, IH), 8.03-7.97 (m, 2H), 7.68-7.62 (m, 2H), 7.48 (d, IH), 7.39- 7.33 (m, IH), 4.29 (t, 2H), 1.90-1.72 (m, 2H), 1.09 (t, 3H). δ 9.55 (m, IH), 8.15 (m, IH), 7.75 (m, 2H), 7.67 (s, IH), 7.6 (dd, IH), 7.42 (m, IH), 7.1 (m, 2H), 5.58 (br s, 2H). δ 9.5 (m, IH), 8.15 (m, IH), 7.65 (s, IH), 7.6 (dd, IH), 7.5 (m, IH), 7.4 (m, IH), 6.9 (m,
2H), 5.55 (br s, 2H). δ (acetone-d6) 9.4 (m, IH), 8.45 (m, IH), 8.1 (dd, IH), 7.95 (s, IH), 7.6 (m, IH), 7.55 (m, IH), 7.3 (m, IH), 7.1 (m, 2H), 5.74 (d, 2H). δ 9.54 (d, IH), 8.47 (s, IH), 8.07 (dd, IH), 7.99 (s, IH), 7.76 (d, IH), 7.68 (d, IH), 7.25-7.45 (m, 5H), 5.58 (br s, 2H). δ 9.55 (d, IH), 8.48 (s, IH), 8.10 (m, 3H), 7.67 (d, IH), 7.48 (s, IH), 7.42 (m, 2H), 7.36 (d, IH), 5.59 (br s, 2H). δ 9.56 (d, IH), 8.48 (s, IH), 8.14 (s, IH), 8.09 (dd, IH), 8.07 (d, IH), 7.69 (dd, IH), 7.51 (m, 2H), 7.40 (m, 2H), 5.6 (br s, 2H). δ 9.56 (d, IH), 8.47 (s, IH), 8.08 (dd, IH), 7.81 (d, IH), 7.77 (s, IH), 7.68 (dd, IH), 7.3-7.45 (m, 4H), 7.12 (d, IH), 5.59 (br s, 2H). δ 9.52 (d, IH), 8.47 (s, IH), 8.10 (dd, IH), 8.04 (s, IH), 7.78 (s, IH), 7.66 (dd, IH), 7.3-7.45 (m, 4H), 5.57 (br s, 2H). δ 9.55 (d, IH), 8.48 (s, IH), 8.08 (dd, IH), 7.83 (d, IH), 7.77 (dd, IH), 7.3-7.45 (m, 4H), 7.24 (d, IH), 5.59 (br s, 2H). δ 9.56 (d, IH), 8.48 (s, IH), 8.05 (dd, IH), 7.79 (d, IH), 7.77 (dd, IH), 7.3-7.45 (m, 4H), 7.24 (d, IH), 5.59 (br s, 2H). δ 9.56 (d, IH), 8.48 (s, IH), 8.05 (dd, IH), 7.79 (d, 2H), 7.70 (dd, IH), 7.2-7.45 (m, 6H), 5.59 (br s, 2H). δ 9.56 (d, IH), 8.48 (s, IH), 8.05 (dd, IH), 7.81 (d, 2H), 7.69 (dd, IH), 7.3-7.45 (m, 3H), 7.17 (d, 2H), 6.52 (t, IH), 5.59 (br s, 2H). δ 9.56 (d, IH), 8.48 (s, IH), 8.08 (dd, IH), 7.70 (dd, IH), 7.63 (d, IH), 7.58 (m, IH), 7.3- 7.45 (m, 4H), 6.95 (td, IH), 5.58 (br s, 2H). δ 9.51 (d, IH), 8.48 (s, IH), 8.10 (dd, IH), 7.10 (m, 2H), 7.3-7.45 (m, 4H), 7.03 (dd, IH), 5.58 (br s, 2H). δ 9.51 (d, IH), 8.48 (s, IH), 8.08 (dd, IH), 7.69 (ddd, IH), 7.54 (q, IH), 7.3-7.45 (m, 4H), 6.85-7.0 (m, 2H), 5.57 (br s, 2H). δ 9.52 (d, IH), 8.48 (s, IH), 8.10 (dd, IH), 7.70 (d, IH), 7.48 (dd, IH), 7.42 (m, 2H), 7.34 (d,
IH), 7.25 (d, IH), 7.06 (td, IH), 5.59 (br s, 2H). δ 9.53 (d, IH), 8.49 (s, IH), 8.12 (dd, IH), 7.90 (d, IH), 7.69 (dd, IH), 7.65 (m, IH), 7.2- 7.45 (m, 4H), 5.59 (br s, 2H). δ 9.53 (d, IH), 8.48 (s, IH), 8.11 (dd, IH), 7.79 (d, IH), 7.70 (dd, IH), 7.51 (d, IH), 7.4 (m, 3H), 7.35 (d, IH), 7.15 (d, IH), 5.75 (br d, IH), 5.4 (br d, IH). δ 9.53 (d, IH), 8.48 (s, IH), 8.11 (dd, IH), 7.79 (t, IH), 7.69 (dd, IH), 7.25-7.45 (m, 4H),
5.58 (br s, 2H). δ 9.52 (d, IH), 8.49 (s, IH), 8.10 (dd, IH), 7.69 (dd, IH), 7.56 (dd, IH), 7.4 (m, 2H), 7.09 (t,
IH), 5.58 (br s, 2H). δ 9.50 (d, IH), 8.47 (s, IH), 8.03 (dd, IH), 7.69 (dd, IH), 7.57 (td, IH), 7.26-7.45 (m, 4H), 7.19 (t, IH), 7.12 (dd, IH), 5.56 (br s, 2H). δ 9.56 (d, IH), 8.48 (s, IH), 8.08 (dd, IH), 7.86 (d, 2H), 7.69 (dd, IH), 7.3-7.45 (m, 3H), 7.26 (d, IH), 5.59 (br s, 2H). δ 9.54 (d, IH), 8.47 (s, IH), 8.0-8.15 (m, 3H), 7.67 (dd, IH) , 7.4 (m, 2H), 7.33 (d, IH), 7.21 (dd, IH), 5.59 (br s, 2H). δ 9.56 (d, IH), 8.48 (s, IH), 8.03 (dd, IH), 7.74 (d, 2H), 7.69 (dd, IH), 7.3-7.4 (m, 3H), 6.97 (d, 2H), 5.59 (br s, 2H). δ 9.56 (d, IH), 8.48 (s, IH), 8.10 (dd, IH), 7.97 (d, 2H), 7.6-7.75 (m, 3H), 7.41 (m, 2H), 7.33 (d, IH), 5.60 (br s, 2H). δ 9.50 (d, IH), 8.47 (s, IH), 8.08 (dd, IH), 7.68 (dd, IH), 7.50 (d, IH), 7.3-7.45 (m, 5H), 5.7 (br d, lH) , 5.4 (br d, IH). δ 9.52 (d, IH), 8.48 (s, IH), 8.11 (dd, IH), 7.68 (dd, 2H), 7.35-7.45 (m, 3H), 7.34 (d, IH), 6.95-7.05 (m, IH), 5.57 (br s, 2H). δ 9.52 (d, IH), 8.48 (s, IH), 8.12 (dd, IH), 7.65-7.75 (m, 2H), 7.47 (d, IH), 7.42 (t, 2H), 7.37 (d, IH), 5.58 (br s, 2H). δ 9.51 (d, IH), 8.48 (s, IH), 8.12 (dd, IH), 7.69 (dd, IH), 7.4-7.5 (m, 2H), 7.33 (d, IH), 7.27 (m, IH), 7.02 (dd, IH), 5.58 (br s, 2H). δ 9.55 (d, IH), 8.48 (s, IH), 8.09 (dd, IH), 7.65-7.75 (m, 2H), 7.6 (m, IH), 7.41 (m, 2H), 7.33 (d, IH), 7.17 (q, IH), 5.58 (br s, 2H). δ 9.56 (d, IH), 8.48 (s, IH), 8.05 (dd, IH), 7.70 (d, IH), 7.28-7.40 (m, 6H), 6.84 (m, IH),
5.59 (br s, 2H), 3.84 (s, 3H). δ 9.56 (d, IH), 8.48 (s, IH), 8.03 (dd, IH), 7.68 (m, 3H), 7.36 (m, IH), 7.31 (d, IH), 7.23 (d, IH), 5.58 (br s, 2H), 2.37 (s, 3H). δ 9.52 (d, IH), 8.48 (s, IH), 8.10 (dd, IH), 7.68 (dd, 2H), 7.3-7.5 (m, 6H), 5.57 (br s, 2H). δ (acetone-d6) 9.45 (d, IH), 8.55 (d, IH), 8.25 (m, IH), 7.9-7.8 (m, 2H), 7.75 (s, IH), 7.6 (dd, IH), 7.5 (m, IH), 7.4 (d, IH), 6.65 (d, IH), 5.72 (br s, 2H), 4.53 (m, 2H), 3.2 (m, 2H). 87 δ 9.59 (d, IH), 8.38 (s, IH), 8.10 (dd, IH), 7.8 (m, 3H), 7.42 (t, IH), 7.36 (d, IH), 7.11 (t, 2H), 5.59 (br s, 2H).
88 δ 9.53 (d, IH), 8.49 (s, IH), 8.10 (dd, IH), 7.70 (dd, IH), 7.26-7.45 (m, 4H), 7.10 (td, IH), 7.00 (m, IH), 5.58 (br s, 2H).
89 δ 9.51 (d, IH), 8.48 (s, IH), 8.10 (dd, IH), 7.70 (dd, IH), 7.28-7.45 (m, 4H), 7.12 (m, 2H), 5.57 (br s, 2H).
90 δ 9.53 (d, IH), 8.47 (s, IH), 8.13 (dd, IH), 7.68 (d, IH), 7.60 (s, IH), 7.53 (s, 2H), 7.43 (m, 2H), 7.35 (d, IH) 5.60 (br d, 2H).
91 δ 9.52 (d, IH), 8.46 (s, IH), 8.06 (dd, IH), 7.68 (d, IH), 7.3-7.55 (m, 5H), 7.25 (d, IH), 5.6 (br dd, 2H), 2.26 (s, 3H).
92 δ 9.54 (d, IH), 8.48 (s, IH), 8.1 (m, 2H), 7.75 (m, IH), 7.68 (dd, IH), 7.4 (m, 3H), 7.37 (d, IH), 7.15 (t, IH), 5.58 (br s, 2H).
93 δ 9.55 (d, IH), 8.48 (s, IH), 8.25 (s, IH), 8.14 (s, IH), 8.11 (dd, IH), 7.66 (m, 2H), 7.4 (m, 2H), 7.34 (d, IH), 5.59 (br s, 2H).
94 δ 9.53 (d, IH), 8.48 (s, IH), 8.14 (t, IH), 7.75 (t, IH), 7.68 (dd, IH), 7.51 (d, IH), 7.4 (m, 3H), 7.34 (d, IH), 5.58 (br s, 2H).
95 δ 9.53 (d, IH), 8.48 (s, IH), 8.07 (t, IH), 7.71 (d, IH), 7.47 (t, IH), 7.38 (m, 2H), 7.32 (d, IH), 6.75 (m, 2H), 5.58 (br s, 2H).
96 δ 9.53 (d, IH), 8.47 (s, IH), 8.08 (dd, IH), 7.69 (t, IH), 7.3-7.45 (m, 4H), 6.9-7.05 (m, 2H), 5.6 (br dd, 2H), 2.28 (s, 3H).
97 δ 9.52 (d, IH), 8.77 (s, IH), 8.34 (t, IH), 8.08 (dd, IH), 7.98 (d, IH), 7.78 (m, 2H), 7.4 (m, 2H), 7.10 (d, IH), 5.67 (br s, 2H), 2.55 (s, 3H).
98 δ 9.55 (dd, IH), 8.48 (d, IH), 8.04 (ddd, IH), 7.69 (dd, IH), 7.40-7.34 (m, 2H), 7.32 (d, IH), 7.29-7.26 (m, 2H), 6.88 (d, IH), 5.95 (s, 2H), 5.58 (br s, 2H).
99 δ 9.52 (d, IH), 8.48 (s, IH), 8.10 (dd, IH), 7.72 (dd, IH), 7.3-7.5 (m, 5H), 7.11 (td, IH), 5.8 (br d, lH), 5.4 (br d, IH).
100 δ 9.58 (d, IH), 8.38 (s, IH), 8.07 (dd, IH), 7.8 (m, 3H), 7.3-7.45 (m, 4H), 7.26 (m, IH), 5.57 (br s, 2H).
101 δ 9.56 (d, IH), 8.48 (s, IH), 8.07 (dd, IH), 7.69 (d, IH), 7.49 (d, IH), 7.3-7.45 (m, 4H), 7.12 (dd, IH), 5.59 (br s, 2H), 3.93 (s, 3H).
102 δ 9.55 (d, IH), 8.48 (s, IH), 8.05 (dd, IH), 7.55-7.95 (m, 3H), 7.3-7.45 (m, 3H), 7.02 (dd, IH), 5.58 (br s, 2H), 3.91 (s, 3H).
103 δ 9.53 (d, IH), 8.69 (s, IH), 8.60 (d, IH), 8.07 (m, 2H), 7.80 (s, IH), 7.66 (d, IH), 7.4 (m, 2H), 7.25 (m, 2H), 5.63 (br s, 2H).
104 δ 9.55 (d, IH), 8.47 (s, IH), 8.07 (dd, IH), 1.65-1.15 (m, 3H), 7.53 (d, 2H), 7.51 (d, IH), 7.4 (m, 2H), 7.32 (d, IH), 5.58 (br s, 2H).
105 δ 9.56 (d, IH), 8.48 (s, IH), 8.12 (dd, IH), 8.02 (d, 2H), 7.67 (d, 2H), 7.4 (m, 3H), 7.34 (d, IH), 5.59 (br s, 2H). 106 δ 9.55 (d, IH), 8.48 (s, IH), 8.07 (dd, IH), 7.78 (d, 2H), 7.69 (dd, IH), 7.4 (m, 4H), 7.32 (d, IH), 5.59 (br s, 2H).
107 δ 9.53 (d, IH), 8.48 (s, IH), 8.20 (s, IH), 8.11 (m, 2H), 7.68 (dd, IH), 7.4-7.55 (m, 4H), 7.34 (d, IH), 5.59 (br s, 2H).
108 δ 9.51 (d, IH), 8.48 (s, IH), 8.11 (dd, IH), 7.68 (dd, IH), 7.4 (m, 3H), 7.34 (d, IH), 6.76 (dd, 2H), 5.58 (br s, 2H).
109 δ 9.57 (d, IH), 8.46 (s, IH), 7.88 (dd, IH), 7.77 (m, 2H), 7.57 (dd, IH), 7.3 (m, 3H), 7.1 (m, 3H), 5.35 (br m, IH), 2.00 (s, 3H).
110 δ 9.46 (dd, IH), 8.14 (ddd, IH), 7.47 (d, IH), 7.36 (m, IH), 4.31 (t, 2H), 1.87-1.70 (m, 2H), 1.07 (t, 3H).
111 δ 9.54 (d, IH), 8.26 (dd, IH), 7.61 (d, IH), 7.49 (t, IH), 5.12 (br s, 2H).
112 δ 9.45 (d, IH), 8.14 (dd, IH), 7.49 (d, IH), 7.33 (t, IH), 4.32 (t, 2H), 1.78 (m, 2H), 1.07 (t, 3H).
113 δ 9.50 (d, IH), 8.23 (dd, IH), 7.52 (d, IH), 7.41 (t, IH), 4.96 (m, IH), 4.77 (m, IH), 4.40 (m, IH), 2.40 (m, IH), 2.25 (m, IH).
114 δ (acetone-d6) 9.42 (d, IH), 8.53 (m, IH), 8.09 (d, IH), 7.69 (t, IH), 5.42 (br s, 2H).
115 δ 8.12 (d, IH), 7.45 (dd, IH), 6.68 (dd, IH), 6.48 (d, IH), 4.6 (br s, 2H), 2.4 (m, IH), 1.01 (d, 6H).
116 δ 8.12 (d, IH), 7.45 (dd, IH), 6.68 (dd, IH), 6.49 (d, IH), 4.6 (br s, 2H), 1.6 (m, IH), 0.92 (d, 6H).
117 δ 9.51 (d, IH), 8.18 (dd, IH), 7.58 (d, IH), 7.46 (t, IH), 5.10 (br s, 2H), 2.91 (t, 2H), 2.60 (m, 2H).
118 δ 9.49 (d, IH), 8.45 (s, IH), 8.12 (dd, IH), 7.65 (dd, IH), 7.4 (m, 2H), 7.32 (d, IH), 5.60 (br s, 2H).
119 δ 9.55 (d, IH), 8.71 (s, IH), 8.47 (s, IH), 8.30 (dd, IH), 8.11 (dd, IH), 7.67 (dd, IH), 7.42 (m, 2H), 7.33 (d, IH), 5.60 (br s, 2H).
120 δ 9.56 (d, IH), 8.92 (s, IH), 8.47 (s, IH), 8.21 (dd, IH), 8.11 (dd, IH), 7.3-7.45 (m, 4H), 5.59 (br s, 2H).
132 δ 8.23 (d, IH), 7.64 (d, 2H), 7.23 (d, 2H), 4.06 (dd, 2H), 2.89 (m, IH), 1.89 (q, 2H), 1.25 (d, 6H), 1.06 (t, 3H).
133 δ 8.30 (d, IH), 7.46 (m, IH), 7.16 (d, IH), 6.8-6.9 (m, 2H), 4.8 (br s, 2H).
134 δ 8.32 (d, IH), 7.72 (d, 2H), 7.38 (dd, 2H), 7.23 (dd, IH), 7.13 (d, IH), 4.81 (q, 2H).
135 δ 8.32 (d, IH), 7.73 (d, IH), 7.69 (s, IH), 7.37 (t, IH), 7.15 (d, IH), 7.08 (d, IH), 4.81 (q, 2H).
136 δ 8.52 (d, IH), 8.28 (d, IH), 7.91 (dd, IH), 7.72 (d, 2H), 7.35-7.4 (m, 3H), 7.25 (m, IH, partially obscured by solvent peak), 7.03 (d, IH), 5.31 (s, 2H). 137 δ (acetone-d6) 8.61 (d, IH), 8.20 (d, IH), 7.98 (d, IH), 7.89 (m, 2H), 7.55 (dd, IH), 7.47 (m, IH), 7.03 (dd, 2H), 5.46 (s, 2H).
138 δ 8.49 (d, IH), 8.23 (d, IH), 7.86 (dd, IH), 7.75 (d, IH), 7.70 (s, IH), 7.37 (dd, 2H), 7.08 (d, IH), 7.03 (d, IH), 5.29 (s, 2H).
139 δ 8.29 (d, IH), 7.67-7.72 (m, 3H), 7.25 (m, IH, partially obscured by solvent peak), 7.09 (d, IH), 5.34 (s, 2H).
140 δ 8.28 (d, IH), 7.67-7.73 (m, 3H), 7.04-7.11 (m, 3H), 5.33 (s, 2H).
141 δ 8.25 (s, IH), 7.65-7.75 (m, 3H), 7.38 (dd, IH), 7.08 (d, IH), 5.32 (d, IH).
142 δ 8.01 (d, IH), 7.39 (m, IH), 6.95 (d, IH), 6.92-6.88 (m, 2H), 4.31 (m, 2H), 1.70 (m, 2H), 0.92 (t, 3H).
147 δ 8.27 (d, IH), 7.67 (s, IH), 7.31 (m, 3H), 7.07 (d, IH), 6.80 (m, IH), 5.33 (s, 2H), 3.82 (s,
3H). 152 δ 8.27 (d, IH), 7.82 (m, IH), 7.69 (s, IH), 7.56 (m, IH), 7.23 (m, IH), 7.14 (d, IH), 5.35 (s,
2H). 160 δ (acetone-d6) 8.17 (d, IH), 7.88 (s, 1 H), 7.59 (d, IH), 7.21-7.29 (m, 2H), 6.99 (d, IH), 6.88
(t, IH), 5.45 (d, 2H), 3.76 (s, 3H). 171 δ 9.49 (dd, IH), 8.18 (t, IH), 7.65-7.75 (m, 2H), 7.38-7.49 (m, 2H), 4.31 (d, 2H), 1.15-1.22
(m, IH), 0.62 (m, 4H). 209 δ (acetone-d6) 9.45 (d, IH), 8.48 (t, 1 H), 8.13 (d, IH), 7.63 (t, IH), 6.98-7.08 (m, 3H), 5.38
(br d, 2H), 3.87 (s, 3H). 229 δ 9.58 (d, IH), 8.02 (t, 1 H), 7.47-7.59 (m, 3H), 7.38 (t, IH), 7.15-7.35 (m, 4H), 2.01 (d, 3H).
345 δ 9.47 (dd, IH), 8.08 (d, IH), 7.68 (m, IH), 7.45-7.55 (m, 3H), 7.31 (t, 2H), 7.00 (d, 2H), 4.15-4.4 (m, 2H), 4.11 (q, 2H), 1.7-1.85 (m, 2H), 1.31 (t, 3H), 1.07 (t, 3H).
346 δ 9.55 (dd, IH), 8.17 (t, IH), 7.67 (d, IH), 7.59 (d, IH), 7.52 (dd, IH), 7.45 (t, IH), 6.99 (d, Ih), 5.3 (br s, IH), 4.9 (br s, IH), 4.10 (q, 2H), 1.31 (t, 3H).
348 δ 9.49 (dd, IH), 8.11 (t, IH), 7.48 (d, IH), 7.34 (m, 2H), 7.13 (s, IH), 4.32 (m, 2H), 3.71 (s, 3H), 2.29 (s, 3H),1.7-1.85 (m, 2H), 1.06 (t, 3H).
349 δ 9.49 (d, IH), 8.05 (t, IH), 7.48 (d, IH), 7.29 (t, IH), 7.16 (m, 2H), 7.01 (d, IH) 4.31 (m, 2H), 2.31 (s, 3H), 2.20 (s, 3H) 1.7-1.85 (m, 2H), 1.06 (t, 3H).
351 δ 9.55 (d, IH), 8.23 (t, IH), 7.98 (d, 2H), 7.66 (d, 2H), 7.52 (d, IH), 7.44 (t, IH), 4.85-5.05 (m, IH), 4.75 (m, IH), 4.40 (m, IH), 2.2-2.6 (m, 2H).
352 δ 9.59 (dd, IH), 8.25 (t, IH), 7.59 (d, IH), 7.50 (t, IH), 7.23-7.28 (m, IH), 7.07 (td, IH), 7.04 (m, IH), 5.10 (br s, 2H).
369 δ 9.60 (dd, IH), 8.26 (t, IH), 8.16 (d, IH), 8.12 (m, IH), 7.62 (d, IH), 7.53 (t, IH), 7.20 (t,
IH), 5.10 (br s, 2H). 416 δ 9.51 (d, IH), 8.50 (s, IH), 8.08 (d, 2H), 7.75 (d, 2H), 7.66 (dd, 2H), 7.3-7.45 (m, 3H), 7.2-
7.25 (m, IH), 5.69 (s, 2H). 418 δ 9.54 (dd, IH), 8.47 (d, IH), 8.10 (m, IH), 7.79 (d, IH), 7.67(dd, IH), 7.33-7.43 (m, 2H), 7.2-7.3 (m, 3H), 5.58 (br s, 2H).
425 δ 9.56 (d, IH), 8.48 (s, IH), 8.06 (t, IH), 7.74 (s, IH), 7.66 (dd, 2H), 7.3-7.4 (m, 3H), 7.19 (d, IH), 5.59 (br s, IH), 2.51 (s, 3H).
426 δ 9.62 (dd, IH), 8.75 (t, IH), 8.26 (m, IH), 8.20 (d, IH), 7.63 (d, IH), 7.53 (m, 2H), 5.3 (br s, 2H).
427 δ 9.57 (dd, IH), 8.48 (s, IH), 8.04 (m, IH), 7.93 (s, IH), 7.70 (dd, 2H), 7.42 (s, 2H), 7.35 (m, 3H), 5.60 (br s, 2H), 0.29 (s, 9H).
430 δ 9.56 (dd, IH), 8.76 (s, IH), 8.04 (m, IH), 7.93 (d, IH), 7.7-7.8 (m, 3H), 7.60 (m, 3H), 7.34
(m, mH), 5.65 (br s, 2H), 0.28 (s, 9H). 433 δ 9.58 (d, IH), 8.22 (m, IH), 7.61 (d, IH), 7.48 (t, IH), 7.30 (m, IH), 6.98 (d, IH), 6.93 (m,
IH), 5.2 (br s, 2H), 2.24 (s, 3H). 436 δ 9.58 (dd, IH), 8.38 (s, IH), 8.11 (t, IH), 7.80 (m, 3H), 7.42 (m, 2H), 7.36 (d, IH), 7.11 (d,
IH), 5.58 (br s, 2H). 443 δ 9.59 (dd, IH), 8.38 (s, IH), 8.07 (t, IH), 7.82 (s, IH), 7.74 (d, 2H), 7.40 (t, IH), 7.37 (d,
IH), 6.98 (d, 2H), 5.58 (br s, 2H), 3.84 (s, 3H). 453 δ 9.58 (dd, IH), 8.12 (m, IH), 7.82 (d, IH), 7.78 (s, IH), 7.49 (d, IH), 7.42 (m, 2H), 7.26 (m,
2H), 7.12 (d, IH), 5.67 (br s, 2H). 459 δ 9.55 (d, IH), 8.45 (d, IH), 8.05 (t, IH), 7.66 (dd, IH), 7.52 (d, IH), 7.42 (s, IH), 7.31-7.39
(m, 4H), 6.85 (d, IH), 5.59 (br s, 2H), 4.38 (q, 2H). 483 δ 9.57 (dd, IH), 8.15 (m, IH), 7.74 (m, 2H), 7.59 (d, IH), 7.40 (t, IH), 7.08(t, 2H), 5.0 (m,
IH), 4.0 (m, IH), 2.07 (m, IH), 1.5-1.65 (m, 4H). 486 δ (acetone-d6) 9.43 (d, IH), 8.41 (t, IH), 8.18 (d, IH), 7.96 (s, IH), 7.75 (d, IH), 7.59 (t,
IH), 7.50-7.56 (m, IH), 7.05 (dd, IH), 5.77 (s, 2H), 3.88 (s, 3H).
501 δ 9.51 (d, IH), 8.21 (t, IH), 7.67 (s, IH), 7.62 (d, IH), 7.42 (t, IH), 6.75 (t, 2H), 5.59 (s, 2H). 511 δ (acetone-d6) 7.87 (dd, IH), 7.84-7.82 (m, 2H), 7.50 (d, IH), 7.45 (d, IH), 7.25-7.21 (m,
2H), 7.10-7.05 (m, IH), 5.58 (s, 2H), 3.64 (s, 3H), 2.29 (s, 3H). 518 δ (acetone-d6) 8.60 (d, IH), 8.13 (s, 1 H), 8.04 (s, IH), 8.00 (d, IH), 7.92-7.97 (m, 2H), 7.43
(d, IH), 7.38 (t, IH), 7.03 (d, IH), 5.42 (s, 2H). 521 δ (acetone-d6) 9.50 (d, IH), 8.85 (d, 1 H), 8.55 (t, IH), 8.17 (d, IH), 7.92 (s, IH), 7.71 (t,
IH), 7.45 (d, IH), 5.39 (br d, 2H). 547 δ (acetone-d6) 9.41 (d, IH), 8.35-8.43 (m, 2H), 7.98-8.05 (m, 2H), 7.88-7.92 (m, 2H), 7.63
(d, IH), 7.59 (t, IH), 7.05 (d, IH), 5.74 (s, 2H). 564 δ 9.53 (dd, IH), 8.14 (m, IH), 7.73 (m, 2H), 7.4-7.6 (m, 4H), 7.36 (t, 2H), 7.20 (m, IH), 5.58
(br s, 2H), 4.32 (m, 2H), 1.84 (m, 2H), 1.09 (t, 3H). 569 δ 9.48 (dd, IH), 8.70 (s, IH), 8.43 (d, IH), 8.22 (d, IH), 8.17 (m, 2H), 7.78 (d, IH), 7.52 (d,
Ih), 7.37 (t, IH) 4.3 (t, 2H), 1.83 (m, 2H), 1.09 (t, 3H). 583 δ (acetone-d6) 9.42 (dd, IH), 8.35 (t, IH), 8.15 (d, IH), 7.82 (d, 2H), 7.52 (t, IH), 7.25-7.31
(m, 2H), 7.13 (t, IH), 5.34 (Br s, IH), 4.05 (dd, 2H), 3.58 (td, 2H), 2.91 (qd, 2H), 1.80 (dd, 2H).
599 δ 9.57 (dd, IH), 8.76 (d, IH), 8.03 (m, IH), 7.7-7.83 (m, 4H), 7.34-7.57 (m, 6H), 7.2-7.3 (m, 2H), 6.98 (dd, IH), 5.65 (br s, 2H).
600 δ (acetone-d6) 9.41 (d, IH), 8.45 (t, IH), 8.20 (d, IH), 7.95-8.05 (m, 2H), 7.88 (d, IH), 7.59- 7.65 (m, 2H), 5.75 (br s, 2H).
601 δ 9.57 (dd, IH), 9.14 (s, IH), 8.52 (s, IH), 8.05-8.10 (m, 2H), 7.91 (s, 26H), 7.78-7.82 (m, 2H), 7.38-7.43 (d, 2H), 7.11 (t, 2H), 5.67 (Br s, 2H).
606 δ 9.49 (d, IH), 8.53 (d, IH), 8.05 (s, 2H), 7.78 (m, 2H), 7.68 (t, IH), 7.55 (d, IH), 7.33 (m,
IH), 7.09 (t, 2H), 5.68 (br s, 2H). 612 δ 9.44 (dd, IH), 8.65 (d, IH), 8.57 (dd, IH), 8.03 (m, IH), 7.62 (dt, IH), 7.27-7.37 (m, 3H),
5.55 (br s, 2H), 5.47 (s, IH).
638 δ 9.49 (d, 0.5H), 9.47 (d, 0.5H), 8.23 (t, IH), 7.61 (d, IH), 7.50 (m, IH), 5.00 (m, 2H), 4.35 (q, IH), 4.32 (q, IH), 1.35 (t, 1.5H), 1.28 (t, 1.5H) (1:1 mix of E and Z isomers).
639 δ (acetone-d6) 8.45 (d, IH), 8.19 (m, IH), 8.10 (m, IH), 8.00 (m, 2H), 7.53 (m, IH), 7.38 (m, IH), 7.10-7.00 (m, 2H), 5.45 (s, 2H).
646 δ (acetone-d6) 8.45 (s, IH), 8.10 (m, 2H), 7.50 (m, IH), 7.30 (m, IH), 7.20 (m, IH), 7.15 (m, IH), 6.95 (m, IH), 6.90 (m, IH), 5.50-5.30 (dd, 2H), 3.76 (s, 3H).
647 δ (acetone-d6) 8.10 (m, IH), 7.70 (s, IH), 7.55 (s, IH), 7.50 (d, IH), 7.25 (m, IH), 7.20 (m, IH), 6.95 (m, IH), 6.90 (m, IH), 5.13 (m, 2H), 3.83 (s, 3H), 3.74 (s, 3H).
648 δ (acetone-d6) 9.40 (m, IH), 8.10 (m, IH), 7.70 (m, IH), 7.60 (dd, IH), 7.45-7.35 (m, 3H), 7.20 (m, IH), 7.05 (m, IH), 6.95 (m, IH), 6.90 (m, IH), 3.83 (m, 3H), 3.75 (m, 3H), 1.90 (m, 3H).
656 δ 9.50 (m, IH), 8.23 (t, IH), 7.61 (d, IH), 7.50 (m, IH), 5.00 (m, 2H), 4.09 (d, 2H), 2.00 (m, IH), 0.98 (d, 4H), 0.89 (d, 2H) (2:1 mix of E and Z isomers).
657 δ 9.50 (d, IH), 8.23 (t, IH), 7.61 (d, IH), 7.50 (t, IH), 5.00 (m, 2H), 1.38 (s, 9H) (single isomer).
658 δ 9.50 (m, IH), 8.23 (t, IH), 7.61 (d, IH), 7.50 (m, IH), 5.00 (m, 2H), 4.00 (s, 2H), 0.99 (s, 6H), 0.89 (s, 3H) (2:1 mix of E and Z isomers).
659 δ 9.50 (m, IH), 8.23 (t, IH), 7.61 (d, IH), 7.50 (m, IH), 5.00 (m, 2H), 4.82 (s, 0.66H), 4.76 (s, 1.34H), 4.22 (q, 0.66H), 4.20 (q, 1.34H), 1.29 (t, IH), 1.27 (t, 2H) (2: 1 mix of E and Z isomers).
700 δ 9.44 (d, IH), 8.22 (t, IH), 7.64 (s, IH), 7.58 (d, IH), 7.42 (t, IH), 5.55 (br s, 2H), 4.42 (q, 2H), 1.04 (t, 3H).
701 δ 9.44 (d, IH), 8.26 (t, IH), 7.91 (d, 2H), 7.65 (s, IH), 7.63 (d, IH), 7.55 (t, IH), 7.44 (m, 3H), 5.56 (br s, 2H). 729 δ 9.49 (d, IH), 8.23 (s, IH), 8.21 (t, IH), 7.52 (d, IH), 7.47 (t, IH), 5.05 (br m, 2H), 1.38 (s, 9H).
730 δ 9.53 (d, IH), 8.42 (s, IH), 8.21 (t, IH), 7.53 (d, IH), 7.46 (t, IH), 5.05 (br m, 2H), 4.22 (q, 2H), 1.32 (t, 3H).
731 δ 9.53 (d, IH), 8.44 (s, IH), 8.21 (t, IH), 7.53 (d, IH), 7.49 (t, IH), 5.05 (br m, 2H), 3.93 (s, 2H), 0.98 (s, 9H).
758 δ 9.53 (d, IH), 8.40 (s, IH), 8.22 (t, IH), 7.54 (d, IH), 7.50 (t, IH), 5.05 (br m, 2H), 3.91 (s, 3H).
759 δ 9.53 (d, IH), 8.41 (s, IH), 8.18 (t, IH), 7.47 (m, 3H), 7.37 (m, 3H), 7.30 (t, IH), 5.24 (s, 2H), 5.05 (br m, 2H). a ^H NMR data are in ppm downfield from tetramethylsilane. CDCI3 solution unless indicated otherwise; "acetone-d5" is CD3C(=O)CD3. Couplings are designated by (s)-singlet, (d)-doublet, (t)-triplet, (m)-multiplet, (dd)-doublet of doublets, (ddd)-doublet of doublet of doublets, (dt)-doublet of triplets, (td)- triplet of doublets, (br)-broad. " ^H NMR spectra of compounds wherein R^ is CH2CF3 often do not show peaks corresponding to the
CH2CF3 protons.
The following Tests demonstrate the control efficacy of compounds of this invention on specific pests. "Control efficacy" represents inhibition of invertebrate pest development (including mortality) that causes significantly reduced feeding. The pest control protection afforded by the compounds is not limited, however, to these species. See Index Tables A-F for compound descriptions.
BIOLOGICAL EXAMPLES OF THE INVENTION
TEST A For evaluating control of diamondback moth (Plutella xylostellά) the test unit consisted of a small open container with a 12-14-day-old radish plant inside. This was pre-infested with ~50 neonate larvae that were dispensed into the test unit via corn cob grits using a bazooka inoculator. The larvae moved onto the test plant after being dispensed into the test unit. Test compounds were formulated using a solution containing 10% acetone, 90% water and 300 ppm X-77® Spreader Lo-Foam Formula non-ionic surfactant containing alkylarylpolyoxyethylene, free fatty acids, glycols and isopropanol (Loveland Industries, Inc. Greeley, Colorado, USA). The formulated compounds were applied in 1 mL of liquid through a SUJ2 atomizer nozzle with 1/8 JJ custom body (Spraying Systems Co. Wheaton, Illinois, USA) positioned 1.27 cm (0.5 inches) above the top of each test unit. Test compounds were sprayed at 250 ppm and replicated three times. After spraying of the formulated test compound, each test unit was allowed to dry for 1 h and then a black, screened cap was placed on top. The test units were held for 6 days in a growth chamber at 25 0C and 70% relative humidity. Plant feeding damage was then visually assessed based on foliage consumed.
Of the compounds of Formula 1 tested the following provided very good to excellent levels of control efficacy (40% or less feeding damage and/or 100% mortality): 1, 2, 3, 5, 6, 7, 8, 9, 10, 12, 13, 14, 15, 16, 17, 18, 19, 20, 22, 23, 24, 25, 26, 27, 28, 32, 33, 37, 39, 40, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 70, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 95, 97, 98, 100, 101, 102, 103, 104, 106, 107, 108, 109, 120, 121, 122, 123, 128, 135, 136, 137, 138, 139, 140, 141, 145, 146, 147, 148, 149, 150, 152, 153, 154, 155, 156, 159, 161, 162, 164, 166, 167, 168, 169, 170, 173, 178, 179, 180, 185, 186, 187, 188, 189, 190, 192, 193, 196, 197, 198, 199, 200, 201, 202, 203, 205, 206, 207, 208, 209, 210, 211, 212, 215, 216, 217, 218, 219, 220, 221, 222, 226, 227, 229, 232, 235, 236, 237, 240, 242, 243, 245, 246, 247, 248, 252, 253, 254, 255, 256, 257, 259, 261, 262, 263, 264, 266, 267, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 281, 282, 284, 286, 287, 288, 289, 290, 291, 293, 294, 295, 297, 298, 299, 300, 301, 302, 307, 310, 311, 312, 313, 314, 319, 321, 323, 324, 327, 330, 332, 339, 340, 341, 342, 343, 347, 350, 351, 352, 353, 355, 359, 361, 362, 363, 364, 366, 367, 370, 371, 372, 374, 377, 379, 380, 386, 389, 391, 400, 401, 405, 406, 412, 414, 418, 421, 422, 424, 426, 427, 431, 436, 438, 440, 441, 446, 459, 460, 461, 463, 469, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479, 480, 481, 482, 483, 484, 485, 486, 487, 488, 489, 490, 491, 492, 493, 494, 495, 496, 498, 499, 500, 501, 502, 503, 511, 515, 524, 525, 527, 528, 529, 530, 531, 532, 534, 536, 537, 539, 540, 541, 542, 544, 545, 546, 548, 549, 550, 551, 557, 562, 563, 566, 567, 575, 581, 582, 589, 596, 597, 598, 600, 603, 608, 609, 613, 616, 617, 618, 619, 620, 621, 622, 623, 624, 625, 626, 627, 628, 630, 632, 634, 635, 636, 639, 640, 651, 652, 653, 654, 655, 663, 664, 666, 667, 670, 671, 672, 679, 682, 683, 684, 685, 701, 702, 713, 715, 717, 732, 733, 753, 754, 755 and 756.
TEST B
For evaluating control of fall armyworm (Spodoptera frugiperda) the test unit consisted of a small open container with a 4-5-day-old maize (corn) plant inside. This was pre -infested (using a core sampler) with 10-15 1 -day-old larvae on a piece of insect diet.
Test compounds were formulated and sprayed at 250 ppm as described for Test A. The applications were replicated three times. After spraying, the test units were maintained in a growth chamber at 25 0C and 70% relative humidity and then visually rated as described for Test A. Of the compounds of Formula 1 tested the following provided very good to excellent levels of control efficacy (40% or less feeding damage and/or 100% mortality): 1, 3, 8, 15, 18, 22, 40, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 53, 54, 55, 56, 58, 59, 60, 62, 65, 66, 68, 70, 73, 74, 75, 76, 79, 81, 83, 84, 92, 93, 95, 103, 123, 141, 145, 166, 168, 169, 173, 179, 180, 185, 186, 187, 188, 189, 192, 193, 196, 200, 215, 217, 226, 232, 240, 242, 245, 252, 253, 254, 255, 256, 261, 270, 272, 275, 276, 277, 310, 312, 372, 418, 427, 436, 440, 451, 461, 473, 475, 476, 477, 478, 479, 480, 481, 482, 484, 486, 489, 490, 491, 493, 495, 496, 498, 499, 500, 501, 502, 524, 525, 530, 531, 534, 540, 541, 542, 544, 549, 550, 574, 598, 609, 616, 617, 618, 619, 620, 622, 623, 624, 625, 626, 627, 628, 634, 635, 636, 652, 653, 654, 655, 663, 671, 672, 682, 683, 684, 685, 717, 733 and 754.
TEST C
For evaluating control of green peach aphid (Myzus persicae) through contact and/or systemic means, the test unit consisted of a small open container with a 12- 15 -day-old radish plant inside. This was pre-infested by placing on a leaf of the test plant 30-40 aphids on a piece of leaf excised from a culture plant (cut-leaf method). The aphids moved onto the test plant as the leaf piece desiccated. After pre-infestation, the soil of the test unit was covered with a layer of sand.
Test compounds were formulated and sprayed at 250 ppm as described for Test A. The applications were replicated three times. After spraying of the formulated test compound, each test unit was allowed to dry for 1 h and then a black, screened cap was placed on top. The test units were held for 6 days in a growth chamber at 19-21 0C and 50- 70% relative humidity. Each test unit was then visually assessed for insect mortality.
Of the compounds of Formula 1 tested, the following resulted in at least 80% mortality: 5, 10, 19, 29, 30, 31, 42, 43, 44, 49, 50, 53, 57, 59, 60, 63, 64, 65, 66, 68, 71, 72, 74, 75, 77, 78, 79, 80, 82, 83, 87, 94, 99, 100, 101, 102, 105, 108, 109, 111, 118, 119, 120, 123, 139, 140, 151, 153, 157, 166, 171, 172, 173, 178, 180, 185, 192, 193, 196, 197, 198, 200, 203, 207, 213, 214, 216, 218, 220, 224, 231, 232, 238, 256, 277, 357, 365, 373, 389, 390, 394, 396, 397, 404, 407, 411, 422, 437, 443, 444, 445, 463, 464, 469, 471, 472, 476, 477, 481, 482, 483, 486, 491, 492, 493, 495, 496, 498, 499, 500, 501, 503, 513, 530, 531, 536, 537, 540, 544, 549, 550, 575, 577, 590, 593, 597, 598, 600, 608, 617, 623, 626, 627, 628, 636, 651, 653, 654, 655, 660, 700, 714 and 717.
TEST D
For evaluating control of cotton melon aphid {Aphis gossypiϊ) through contact and/or systemic means, the test unit consisted of a small open container with a 6-7-day-old cotton plant inside. This was pre-infested with 30-40 insects on a piece of leaf according to the cut- leaf method described for Test C, and the soil of the test unit was covered with a layer of sand.
Test compounds were formulated and sprayed at 250 ppm as described for Test C. The applications were replicated three times. After spraying, the test units were maintained in a growth chamber and then visually rated as described for Test C. Of the compounds of Formula 1 tested, the following resulted in at least 80% mortality: 5, 10, 30, 31, 49, 54, 66, 75, 87, 94, 95, 166, 167, 192, 193, 198, 204, 210, 213, 214, 220, 230, 231, 235, 238, 264, 277, 486, 490, 540, 544, 550, 617, 619, 623, 627, 636, 653 and 654. TEST E
For evaluating control of corn planthopper (Peregrinus maidis) through contact and/or systemic means, the test unit consisted of a small open container with a 3-4-day-old maize plant (spike) inside. White sand was added to the top of the soil prior to application. Test compounds were formulated and sprayed at 250 and 50 ppm and replicated three times as described for Test A. After spraying, the test units were allowed to dry for 1 h before they were post-infested with -15-20 nymphs (18 to 21 day old) by sprinkling them onto the sand with a salt shaker. A black, screened cap was placed on the top of the cylinder. The test units were held for 6 days in a growth chamber at 22-24 0C and 50-70% relative humidity. Each test unit was then visually assessed for insect mortality. Of the compounds of Formula 1 tested at 250 ppm, the following resulted in at least
80% mortality: 1, 2, 3, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 21, 22, 23, 24, 25, 26, 27, 29, 30, 31, 32, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 93, 94, 95, 96, 97, 98, 99, 100, 101, 103, 104, 105, 106, 107, 108, 109, 111, 114, 115, 116, 118, 119, 120, 121, 122, 123, 161, 162, 163, 237, 278, 279, 280, 281, 282, 283, 284, 285, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 301, 302, 304, 306, 308, 309, 314, 317, 318, 319, 320, 321, 322, 323, 324, 325, 327, 329, 330, 336, 340, 341, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 368, 375, 376, 377, 378, 384, 386, 389, 390, 392, 393, 394, 396, 397, 399, 400, 402, 403, 404, 406, 407, 408, 409, 411, 412, 413, 414, 415, 416, 419, 420, 421, 422, 423, 424, 425, 426, 428, 431, 433, 435, 436, 437, 438, 441, 442, 443, 444, 445, 446, 447, 449, 450, 459, 460, 461, 462, 463, 464, 465, 466, 467, 468, 469, 470, 471, 472, 474, 475, 476, 477, 479, 481, 482, 483, 484, 485, 519, 556, 562, 564, 568, 570, 571, 573, 574, 575, 576, 577, 579, 582, 583, 584, 586, 587, 588, 590, 591, 592, 593, 594, 604, 606, 608, 611, 612, 613, 687 and 757.
Of the compounds of Formula 1 tested at 50 ppm the following provided very good to excellent levels of control efficacy (80% or more mortality): 1, 2, 3, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 16, 17, 18, 19, 20, 21, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 36, 38, 39, 40, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 107, 108, 109, 111, 118, 119, 120, 121, 123, 124, 125, 134, 136, 137, 138, 139, 140, 141, 146, 147, 148, 149, 150, 151, 154, 156, 157, 161, 166, 167, 168, 171, 172, 173, 180, 185, 192, 193, 196, 197, 198, 199, 200, 201, 202, 203, 204, 207, 208, 209, 210, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 243, 244, 245, 246, 247, 248, 249, 252, 254, 255, 256, 257, 259, 260, 262, 264, 266, 278, 280, 284, 289, 290, 291, 292, 293, 295, 297, 301, 304, 314, 318, 319, 320, 321, 323, 324, 325, 327, 330, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 357, 359, 360, 361, 362, 363, 365, 376, 377, 378, 390, 392, 393, 394, 399, 400, 403, 404, 408, 411, 412, 413, 414, 419, 420, 421, 422, 423, 424, 425, 426, 431, 433, 435, 436, 437, 438, 441, 442, 443, 444, 446, 448, 449, 450, 456, 459, 460, 461, 462, 463, 464, 466, 468, 469, 470, 471, 472, 473, 474, 475, 476, 477, 481, 482, 483, 485, 486, 487, 488, 489, 490, 491, 492, 493, 495, 496, 497, 498, 499, 500, 501, 502, 503, 511, 513, 514, 522, 523, 524, 525, 527, 530, 531, 536, 537, 539, 540, 542, 544, 546, 547, 570, 571, 573, 574, 575, 576, 577, 579, 584, 586, 587, 588, 591, 592, 593, 597, 598, 599, 600, 604, 608, 613, 621, 622, 623, 625, 626, 630, 631, 632, 634, 636, 637, 639, 640, 641, 643, 645, 651, 652, 663, 664, 665, 666, 677, 700, 701, 702, 708, 713, 718, 751, 752, 756 and 757. TEST F
For evaluating control of potato leafhopper (Empoasca fabae) through contact and/or systemic means, the test unit consisted of a small open container with a 5-6-day-old Soleil bean plant (primary leaves emerged) inside. White sand was added to the top of the soil and one of the primary leaves was excised prior to application. Test compounds were formulated and sprayed at 250 and 50 ppm, and the tests were replicated three times as described for Test A. After spraying, the test units were allowed to dry for 1 h before they were post-infested with 5 potato leafhoppers (18-21 -day-old adults). A black, screened cap was placed on the top of the cylinder. The test units were held for 6 days in a growth chamber at 24 0C and 70% relative humidity. Each test unit was then visually assessed for insect mortality.
Of the compounds of Formula 1 tested at 250 ppm the following provided very good to excellent levels of control efficacy (80% or more mortality): 1, 2, 3, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 16, 17, 18, 19, 21, 23, 24, 25, 26, 27, 28, 29, 30, 31, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 67, 68, 70, 71, 72, 73, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 104, 105, 106, 108, 109, 111, 113, 116, 117, 118, 120, 120, 122, 123, 163, 163, 237, 278, 279, 280, 281, 283, 285, 286, 288, 289, 291, 292, 295, 297, 302, 308, 311, 314, 315, 317, 318, 324, 325, 327, 328, 330, 340, 341, 343, 344, 345, 347, 349, 352, 357, 358, 359, 360, 361, 362, 363, 364, 365, 369, 375, 376, 377, 378, 381, 385, 389, 390, 392, 393, 394, 396, 397, 399, 400, 403, 404, 405, 406, 407, 408, 409, 410, 411, 415, 416, 417, 419, 422, 423, 424, 425, 426, 431, 433, 435, 437, 438, 443, 444, 445, 446, 449, 450, 459, 460, 461, 462, 463, 464, 465, 466, 467, 468, 469, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479, 480, 481, 482, 483, 484, 485, 515, 568, 570, 571, 573, 574, 575, 581, 588, 591, 593, 604, 606, 608, 609 and 613.
Of the compounds of Formula 1 tested at 50 ppm the following provided very good to excellent levels of control efficacy (80% or more mortality): 1, 2, 3, 5, 6, 7, 9, 10, 11, 12, 13, 14, 16, 17, 19, 21, 23, 24, 25, 26, 27, 28, 29, 30, 31, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 67, 68, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 104, 105, 106, 108, 109, 111, 118, 119, 120, 123, 124, 136, 137, 138, 139, 140, 141, 146, 147, 151, 153, 155, 156, 157, 160, 166, 167, 168, 171, 172, 173, 178, 180, 185, 186, 189, 192, 193, 194, 196, 197, 198, 199, 200, 201, 202, 203, 204, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 222, 223, 224, 225, 226, 232, 233, 235, 236, 237, 238, 240, 243, 244, 245, 246, 247, 252, 254, 255, 256, 258, 259, 260, 261, 262, 264, 266, 273, 274, 277, 280, 318, 324, 327, 330, 340, 341, 357, 359, 361, 362, 363, 364, 369, 374, 377, 381, 389, 390, 392, 394, 396, 397, 399, 403, 404, 407, 408, 411, 416, 417, 423, 424, 431, 433, 435, 437, 449, 460, 461, 462, 463, 464, 466, 467, 469, 470, 471, 472, 473, 474, 475, 476, 477, 479, 480, 481, 482, 483, 486, 487, 488, 489, 490, 491, 492, 493, 494, 495, 496, 497, 498, 500, 501, 502, 503, 514, 515, 524, 525, 530, 531, 534, 536, 537, 539, 540, 541, 542, 544, 545, 551, 570, 575, 591, 597, 598, 600, 608, 609, 617, 618, 619, 620, 621, 622, 623, 624, 627, 634, 635, 641, 645, 651, 652, 653, 654, 663, 666, 671, 672, 682, 702, 711, 713, 715, 717, 753, 755 and 756.
TEST G
For evaluating control of the Western Flower Thrip {Frankliniellla occidentalis) through contact and/or systemic means, the test unit consisted of a small open container with a 5-7-day-old Soleil bean plant inside. Test compounds were formulated and sprayed at 250 ppm and replicated three times as described for Test A. After spraying, the test units were allowed to dry for 1 hour and then 22-27 adult thrips were added to the unit and then a black, screened cap was placed on top. The test units were held for 7 days at 25 0C and 45-55% relative humidity.
Of the compounds of Formula 1 tested the following provided very good to excellent levels of control efficacy (30% or less plant damage and/or 100% mortality): 158, 211, 212, 229, 235, 257, 258, 262, 273, 497, 528, 531, 544, 549, 579, 608, 617, 635 and 682.
TEST H
For evaluating control of the cat flea (Ctenocephalides felis), a test compound was solubilized in propylene glycol/glycerol formal (60:40) and then diluted in bovine blood to a final test rate of 30 ppm. The treated blood was placed in a tube with the bottom of the tube covered with a membrane. Approximately 10 adult cat fleas were allowed to feed through the membrane on the treated blood. The adult fleas were evaluated for mortality 72 h later. Of the compounds of Formula 1 tested, the following compounds resulted in 50% or greater mortality: 1, 2, 3, 5, 6, 8, 9, 10, 12, 14, 16, 17, 19, 21, 26, 29, 34, 36, 37, 38, 39, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 52, 53, 54, 55, 56, 57, 58, 59, 61, 62, 65, 66, 71, 72, 75, 76, 78, 81, 82, 83, 88, 90, 92, 98, 100, 101, 103, 104, 105, 106, 107, 114, 118, 119, 120, 121, 123, 124, 125, 134, 135, 136, 137, 138, 149, 150, 153, 154, 155, 156, 157, 161, 166, 167, 169, 172, 179, 186, 188, 189, 190, 191, 192, 193, 196, 199, 203, 204, 206, 207, 208, 210, 211, 216, 217, 218, 219, 223, 224, 225, 230, 280, 281, 289, 290, 294, 295, 301, 312, 314, 318, 319, 323, 324, 327, 331, 343, 346, 348, 350, 360, 361, 362, 363, 364, 369, 371, 372, 373, 374, 378, 382, 383, 385, 389, 391, 393, 406, 411, 420, 421, 422, 423, 431, 435, 438, 440, 461, 466, 468, 469, 470, 471, 473, 475, 476, 477, 478, 479, 480, 490, 491, 492, 493, 494, 495, 496, 497, 498, 500, 503, 511, 513, 521, 528, 589, 590, 592, 596, 597, 599, 604 and 606.
TEST I
For evaluating control of the cat flea (Ctenocephalides felis), a test compound was solubilized in acetone:water (75:25) to a final test rate of 500 ppm. Then 20 μL of the 500 ppm solution was applied to filter paper in the bottom of a tube. The tube was allowed to dry for 3 hours. Then approximately 10 adult fleas were added to the tube and the tube was capped. The fleas were evaluated for mortality 48 hours later.
Of the compounds of Formula 1 tested, the following compounds resulted in 50% or greater mortality: 5, 6, 10, 12, 19, 21, 22, 23, 26, 27, 28, 38, 39, 40, 41, 42, 43, 44, 45, 47,
48, 50, 54, 56, 57, 59, 61, 62, 63, 65, 70, 71, 72, 75, 81, 82, 83, 102, 107, 108, 114, 115, 121,
124, 136, 138, 141, 151, 154, 161, 166, 173, 186, 193, 196, 197, 203, 204, 208, 211, 216,
218, 224, 229, 232, 281, 290, 291, 295, 301, 310, 321, 343, 350, 353, 357, 360, 361, 364,
408, 419, 424, 437, 446, 450, 461, 464, 466, 468, 470, 471, 474, 476, 483, 485, 487, 490, 491, 492, 493, 494, 496, 498, 501, 507, 520, 521, 576, 597 and 599.
TEST J
For evaluating control of the cat flea {Ctenocephalides felis) following oral adminstration of the test compound to a mouse, a CD-I® mouse (about 30 g, male, obtained from Charles River Laboratories, Wilmington, MA) was orally dosed with a test compound in an amount of 10 mg/kg solubilized in propylene glycol/glycerol formal (60:40). Two hours after oral administration of the test compound, approximately 8 to 16 adult fleas were applied to each mouse. The fleas were then evaluated for mortality 48 hours after flea application to the mouse.
Of the compounds of Formula 1 tested, the following compounds resulted in 20% or greater mortality: 2, 10, 19, 41, 42, 43, 44, 45, 46, 47, 51, 56, 57, 59, 61, 63, 72, 75, 80, 81, 82, 83, 88, 92, 96, 101, 104, 105, 106, 107, 111, 119, 120, 121, 123, 124, 136, 137, 140, 148, 151, 154, 169, 186, 319, 461, 475, 476, 477, 493, 497, 498, 588 and 599.

Claims

CLAIMSWhat is claimed is:
1. A compound of Formula 1 ,
Figure imgf000209_0001
1 wherein
X is O or S; Y is O or S;
R1 is H, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C2-C6 alkenyl, C2-C6 haloalkenyl, C2-C6 alkynyl, C2-C6 haloalkynyl, CR24=C(R24)R10 or C≡CR10; or
R1 is C3-C7 cycloalkyl, C4-Cg cycloalkylalkyl or C5-C7 cycloalkenyl, each optionally substituted with 1 to 4 substituents independently selected from the group consisting of halogen, C1-C2 alkyl, C1-C2 alkoxy, 1 cyclopropyl, 1 CF3 and 1 OCF3; or R1 is phenyl, naphthalenyl or a 5- or 6-membered heteroaromatic ring, each optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, cyano, nitro, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C1-C4 haloalkyl, C2-C4 haloalkenyl, C2-C4 alkylcarbonyl, C2-C4 haloalkylcarbonyl, C2-C4 alkoxycarbonyl, C2-C4 alkylaminocarbonyl, C3-C7 dialkylaminocarbonyl, C(O)N-f CH2Z2CH2^-, C1-C4 alkoxy, C1-C4 haloalkoxy, C2-C6 alkoxyalkyl, S(O)nR12, S(O)2R13, C1-C4 alkylamino, C2-C6 dialkylamino, SF5, Si(CH3)3, CHO, hydroxy, OC(O)R19 and N(R20)C(O)R19; or RMs
Figure imgf000209_0002
R1 is C(Xi)R18, C(=NOR23)R18, C(O)NR16R18a, C(=NNR20aR23)R18,
C(=NNR20aC(O)R23)R18, C(=NNR20aC(O)OR23a)R18 or C(=NNR20aC(O)NR20aR23)R18; or R1 is an 8- to 10-membered heteroaromatic bicyclic ring system optionally substituted on carbon ring members with up to 3 substituents independently selected from the group consisting of halogen, cyano, nitro, SF5, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C1-C4 haloalkyl, C2-C4 alkylcarbonyl, C2-C4 haloalkylcarbonyl, C2-C4 alkoxycarbonyl, C2-C4 alkylaminocarbonyl, C3-C7 dialkylaminocarbonyl, C(O)NfCH2Z2CH2^-, C1-C4 alkoxy, C1-C4 haloalkoxy, C2-C6 alkoxyalkyl, S(O)nR12, S(O)2R13, C1-C4 alkylamino, C2-C6 dialkylamino, Si(CH3)3, CHO, hydroxy, OC(O)R19 and N(R20)C(O)R19, and optionally further substituted on nitrogen ring members with methyl; or R1 is phenyl or a 5- or 6-membered heteroaromatic ring, each substituted with GQ1, each optionally substituted with 1 Q2 and each optionally substituted with 1 or 2 substituents independently selected from the group consisting of halogen, cyano, nitro, SF5, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C1-C4 haloalkyl, C2-C4 alkylcarbonyl, C2-C4 haloalkylcarbonyl, C2-C4 alkoxycarbonyl, C2-C4 alkylaminocarbonyl, C3-C7 dialkylaminocarbonyl, C(O)N-f CH2Z2CH2^, C1-
C4 alkoxy, C1-C4 haloalkoxy, C2-C6 alkoxyalkyl, S(O)nR12, S(O)2R13, C1-C4 alkylamino, C2-C6 dialkylamino, Si(CH3)3, CHO, hydroxy, OC(O)R19 and N(R20)C(O)R19; or
R1 is phenyl or a 5- or 6-membered heteroaromatic ring, each substituted with LQ1 and optionally substituted with 1 or 2 substituents independently selected from the group consisting of halogen, cyano, nitro, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C1-C4 haloalkyl, C2-C4 alkylcarbonyl, C2-C4 haloalkylcarbonyl, C2- C4 alkoxycarbonyl, C2-C4 alkylaminocarbonyl, C3-C7 dialkylaminocarbonyl, C(O)NfCH2Z2CH2^-, C1-C4 alkoxy, C1-C4 haloalkoxy, C2-C6 alkoxyalkyl, S(O)nR12, S(O)2R13, C1-C4 alkylamino and C2-C6 dialkylamino; each A is independently C(R16)2, O, S(O)n or NR15; each A1 is independently C(R17)2;
X1 is O or S;
G is a direct bond, O, S(O)n, NH, N(CH3), CH2, CH2O, OCH2, C(O), C(O)O, OC(O), C(O)NH or NHC(O);
L is a phenyl or 5- or 6-membered heteroaromatic ring optionally substituted with 1 or 2 substituents independently selected from the group consisting of halogen, cyano, nitro, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C1-C4 haloalkyl, C2- C4 alkylcarbonyl, C2-C4 haloalkylcarbonyl, C2-C4 alkoxycarbonyl, C2-C4 alkylaminocarbonyl, C3-C7 dialkylaminocarbonyl, C(O)N-fCH2Z2CH2>, C1- C4 alkoxy, C1-C4 haloalkoxy, C2-C6 alkoxyalkyl, S(O)nR12, S(O)2R13, C1-C4 alkylamino and C2-C6 dialkylamino; Q1 is phenyl or a 5- or 6-membered heteroaromatic ring, each optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, cyano, nitro, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C1-C4 haloalkyl, C2-C4 alkylcarbonyl, C2-C4 haloalkylcarbonyl, C2-C4 alkoxycarbonyl, C2-C4 alkylaminocarbonyl, C3-C7 dialkylaminocarbonyl, C(O)N-f CH2Z2CH2^-, C1-C4 alkoxy, C1-C4 haloalkoxy, C2-C6 alkoxyalkyl, S(O)nR12, S(O)2R13, C1-C4 alkylamino, C2-C6 dialkylamino, SF5, Si(CH3)3, CHO, hydroxy, OC(O)R19 and N(R20)C(O)R19;
Q2 is phenyl or a 5- or 6-membered heteroaromatic ring, each optionally substituted with 1 or 2 substituents independently selected from the group consisting of halogen, cyano, nitro, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C1-C4 haloalkyl, C2-C4 alkylcarbonyl, C2-C4 haloalkylcarbonyl, C2-C4 alkoxycarbonyl, C2-C4 alkylaminocarbonyl, C3-C7 dialkylaminocarbonyl,
C(O)N-f- CH2Z2CH2^-, C1-C4 alkoxy, C1-C4 haloalkoxy, C2-C6 alkoxyalkyl, S(O)nR12, S(O)2R13, C1-C4 alkylamino and C2-C6 dialkylamino; R2 is C2-C6 alkyl, C1-C6 haloalkyl, C3-C6 alkenyl, C3-C6 haloalkenyl, C3-C6 alkynyl, C3-C6 haloalkynyl, CH2CO2R21, CR5R6CH2OR21, CR5R6CH2CH2OR21, CR5R6CH2S(O)nR21 or CR5R6CH2CH2S(O)nR21; or
R2 is C3-C6 cycloalkyl or C4-C7 cycloalkylalkyl, each optionally substituted with 1 to 4 substituents selected from the group consisting of halogen, C1-C2 alkyl, 1 cyclopropyl and 1 CF3; or R2 is CR5R6Q; or R2 is
Figure imgf000211_0001
R3 is H, C1-C6 alkyl, C1-C6 haloalkyl, C2-C6 alkenyl, C2-C6 haloalkenyl, C2-C6 alkynyl, C2-C6 haloalkynyl or C≡CR10; or
R3 is C3-C6 cycloalkyl or C4-C7 cycloalkylalkyl, each optionally substituted with 1 to 4 substituents independently selected from the group consisting of halogen, C1-
C2 alkyl, 1 cyclopropyl and 1 CF3; or R3 is phenyl, naphthalenyl or a 5- or 6-membered heteroaromatic ring, each optionally substituted with 1 or 2 substituents independently selected from the group consisting of halogen, cyano, nitro, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C1-C4 haloalkyl, C2-C4 alkylcarbonyl, C2-C4 haloalkylcarbonyl, C2-C4 alkoxycarbonyl, C2-C4 alkylaminocarbonyl, C3-C7 dialkylaminocarbonyl, C(O)N-f CH2Z2CH2^-, C1-C4 alkoxy, C1-C4 haloalkoxy, C2-C6 alkoxyalkyl, S(O)nR12, S(O)2R13, C1-C4 alkylamino and C2-C6 dialkylamino; R4 is C1-C6 alkyl, C1-C6 haloalkyl, C2-C6 alkenyl, C2-C6 haloalkenyl, C2-C6 alkynyl, C2-C6 haloalkynyl or C≡CR10; or
R4 is C3-C6 cycloalkyl or C4-C7 cycloalkylalkyl, each optionally substituted with 1 to 4 substituents independently selected from the group consisting of halogen, C1- C2 alkyl, 1 cyclopropyl and 1 CF3; or R4 is phenyl, naphthalenyl or a 5- or 6-membered heteroaromatic ring, each optionally substituted with 1 or 2 substituents independently selected from the group consisting of halogen, cyano, nitro, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C1-C4 haloalkyl, C2-C4 alkylcarbonyl, C2-C4 haloalkylcarbonyl, C2-C4 alkoxycarbonyl, C2-C4 alkylaminocarbonyl, C3-C7 dialkylaminocarbonyl, C(O)N-f CH2Z2CH2^-, C ^C4 alkoxy, C ^C4 haloalkoxy, C2-C6 alkoxyalkyl,
S(O)nR12, S(O)2R13, C1-C4 alkylamino and C2-C6 dialkylamino; or R3 and R4 are taken together with the contiguous linking nitrogen and carbon atoms to form an optionally substituted ring R-I
Figure imgf000212_0001
R-I or ring R-2
Figure imgf000212_0002
R-2
Z is C(R8a)=C(R8b), S, O or NCH3, provided that the C(R8a)=C(R8b) moiety is oriented so the carbon atom bonded to R8b is connected as R3 in Formula 1; each R5 is independently H, F, Cl, cyano or C1-C4 alkyl; each R6 is independently H, F, Cl or CH3;
Q is
Figure imgf000213_0001
Q-I Q-2 Q-3 Q-4 Q-5
Figure imgf000213_0002
Q-6 Q-8 Q-9 Q-IO Q-I l
Figure imgf000213_0003
Q-12 Q-13 Q-14 Q-15 Q-16
ZMs O5 S Or NR14; each R7 is independently H, halogen, cyano, CF3, C^-C 3 alkyl or C3-C6 cycloalkyl;
R8a is H or F; R8b is H, F, CF2H or CF3; each R9a is independently H, halogen, cyano, nitro, Q-C4 alkyl, Q-C4 haloalkyl, C2- C4 alkenyl, C2-C4 haloalkenyl, C2-C4 alkynyl, C2-C4 haloalkynyl, C1-C4 alkoxy, C1-C4 haloalkoxy, Q-C4 alkylcarbonyl, C2-C4 haloalkylcarbonyl, C2- C4 alkoxycarbonyl, C2-C4 haloalkoxycarbonyl, C(O)NH2, C2-C4 alkylaminocarbonyl, C3-C7 dialkylaminocarbonyl, C(O)N-f CH2Z2CH2^, C2-
C4 haloalkylaminocarbonyl, C3-C7 halodialkylaminocarbonyl, SF5, S(O)nR12 or S(O)2R13; or C3-C6 cycloalkyl or C4~C7 cycloalkylalkyl, each optionally substituted with 1 to 4 substituents selected from the group consisting of halogen, Q-C2 alkyl, 1 cyclopropyl and 1 CF3; or phenyl or a 5- or 6-membered heteroaromatic ring, each optionally substituted with 1 or 2 substituents independently selected from the group consisting of halogen, cyano, nitro, C^- C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C1-C4 haloalkyl, C2-C4 alkylcarbonyl, C2-C4 haloalkylcarbonyl, C2-C4 alkoxycarbonyl, C2-C4 alkylaminocarbonyl, C3-C7 dialkylaminocarbonyl, C(O)N-f CH2Z2CH2^, C1-C4 alkoxy, C1-C4 haloalkoxy, C2-C6 alkoxyalkyl, S(O)nR12, S(O)2R13, C1-C4 alkylamino and C2-C6 dialkylamino; each R9b is independently H, halogen, cyano, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 alkoxy or C1-C4 haloalkoxy; or phenyl or pyridinyl, each optionally substituted with 1 or 2 substituents independently selected from the group consisting of halogen, cyano, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, S(O)nR12 and S(O)2R13; each R10 is independently Si(R1 ^3; or phenyl or pyridinyl, each optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, cyano, nitro, SF5, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C1-C4 haloalkyl, C2-C4 alkylcarbonyl, C2-C4 haloalkylcarbonyl, C2-C4 alkoxycarbonyl, C2-C4 alkylaminocarbonyl, C3-C7 dialkylaminocarbonyl, C(O)N-f CH2Z2CH2^-, C2-C6 alkoxyalkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, S(O)nR12, S(O)2R13, C1-C4 alkylamino and C2-C6 dialkylamino; each R11 is independently C1-C4 alkyl; each R12 is independently C1-C4 alkyl or C1-C4 haloalkyl; each R13 is independently C1-C4 alkylamino, C2-C6 dialkylamino or -N-f CH2Z2CH2^- ;
R14 is H, C1-C4 alkyl, C1-C4 haloalkyl, C2-C5 alkoxycarbonyl, C2-C5 alkylaminocarbonyl, C3-C7 dialkylaminocarbonyl, C(O)N-f CH2Z2CH2^,
S(O)nR12 or S(O)2R13; or phenyl or pyridinyl, each optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, cyano, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, S(O)nR12 and S(O)2R13; each R15 is independently C1-C4 alkyl; each R16 is independently H or C1-C4 alkyl; each R17 is independently H, F or CH3;
R18 is H, C1-C6 alkyl, C1-C6 haloalkyl, C3-C6 cycloalkyl, C1-C6 alkoxy, C1-C6 alkylamino or C2-C7 dialkylamino; or phenyl or a 5- or 6-membered heteroaromatic ring, each optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, C1-C4 alkyl, C1-
C4 alkoxy, C1-C4 haloalkoxy, S(O)nR12 and S(O)2R13;
R18a is phenyl or a 5- or 6-membered heteroaromatic ring, each optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, S(O)nR12 and S(O)2R13; each R19 is independently C1-C4 alkyl; each R20 is independently H or C1-C4 alkyl; each R2Oa ιs independently C1-C4 alkyl; each R21 is independently H or C1-C4 alkyl;
R23 is H, C1-C6 alkyl, C1-C6 haloalkyl, C3-C6 alkenyl, C3-C6 haloalkenyl, C3-C6 alkynyl, C3-C6 haloalkynyl or CH2CO2R21 ; or
R23 is C3-C6 cycloalkyl or C4-C7 cycloalkylalkyl, each optionally substituted with 1 to 4 substituents independently selected from the group consisting of halogen, C1-C2 alkyl, 1 cyclopropyl and 1 CF3; or
R23 is phenyl or a 5- or 6-membered heteroaromatic ring, each optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, cyano, nitro, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C1-C4 haloalkyl, C2-C4 alkylcarbonyl, C2-C4 haloalkylcarbonyl, C2-C4 alkoxycarbonyl, C2-C4 alkylaminocarbonyl, C3-C7 dialkylaminocarbonyl, C(O)N-f- CH2Z2CH2^-, C1-C4 alkoxy, C1-C4 haloalkoxy, C2-C6 alkoxyalkyl, S(O)nR12, S(O)2R13, C1-C4 alkylamino and C2-C6 dialkylamino;
R23a is C1-C6 alkyl, C2-C6 haloalkyl, C3-C6 alkenyl or C3-C6 cycloalkyl; each R24 is independently H, F or CH3; m is 0, 1, 2 or 3; each n is independently 0, 1 or 2; p is 0, 1, 2, 3 or 4; each q is independently 0, 1 or 2; y is 1 or 2; and each Z2 is independently CH2CH2, CH2CH2CH2 or CH2OCH2; provided that (a) when R2 is CH2CH=CH2, R3 and R4 are taken together to form ring R-2, Z is
CH=CH, X is O and Y is O, then R1 is other than H, CH(CH3)2, CH2CH2CH2CH3, CH2CH=CH2 or unsubstituted phenyl;
(b) when R1 is H, R3 and R4 are taken together to form ring R-2, Z is CH=CH, X is O and Y is O, then R2 is other than CH2CH=CH2 or CH2C=CH; (c) when R1 is CH2CH3, R3 and R4 are taken together to form ring R-2, Z is CH=CH,
X is O and Y is O, then R2 is other than CH2(CH2)3CH3;
(d) when R3 is H, R2 and R4 are both cyclohexyl, X is O and Y is O, then R1 is other than CH3;
(e) when R1 is H or C1-C3 n-alkyl, R3 and R4 are taken together to form ring R-2, Z is S, X is O and Y is O, then R2 is other than C1-C6 alkyl or C3-C4 alkoxyalkyl; (f) when R2 is cyclopropylmethyl, R3 and R4 are taken together to form ring R-2, Z is
S, X is O and Y is O, then R1 is other than CH3, CH2CH3 or CH2CH2CH3;
(g) when R1 is unsubstituted phenyl, R3 and R4 are taken together to form ring R-2, Z is S, X is O and Y is O, then R2 is other than C3-C4 alkoxyalkyl; and (h) when R1 is Br, R3 and R4 are taken together to form ring R-2, Z is S, X is O and Y is O, then R2 is other than CH2CH3.
2. A compound of Claim 1 wherein
X is O;
Y is O; R1 is H or halogen; or
R1 is phenyl or a 6-membered heteroaromatic ring, each optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, cyano, nitro, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C1-C4 haloalkyl, C2- C4 haloalkenyl, C2-C4 alkylcarbonyl, C2-C4 haloalkylcarbonyl, C2-C4 alkoxycarbonyl, C2-C4 alkylaminocarbonyl, C3-C7 dialkylaminocarbonyl,
C(O)N-f- CH2Z2CH2^-, C1-C4 alkoxy, C1-C4 haloalkoxy, C2-C6 alkoxyalkyl, S(O)nR12, S(O)2R13, C1-C4 alkylamino, C2-C6 dialkylamino, SF5, Si(CH3)3, CHO, hydroxy, OC(O)R19 and N(R20)C(O)R19; or
RMs
Figure imgf000216_0001
R1 is C(Xi)R18 or C(=NOR23)R18; or
R1 is an 8- to 10-membered heteroaromatic bicyclic ring system optionally substituted on carbon ring members with up to 3 substituents independently selected from the group consisting of halogen, cyano, nitro, SF5, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C1-C4 haloalkyl, C2-C4 alkylcarbonyl, C2-C4 haloalkylcarbonyl, C2-C4 alkoxycarbonyl, C2-C4 alkylaminocarbonyl, C3-C7 dialkylaminocarbonyl, C(O)N-f CH2Z2CH2^-, C1-C4 alkoxy, C1-C4 haloalkoxy, C2-C6 alkoxyalkyl, S(O)nR12, S(O)2R13, C1-C4 alkylamino, C2-C6 dialkylamino, Si(CH3)3, CHO, hydroxy, OC(O)R19 and N(R20)C(O)R19, and optionally substituted on nitrogen ring members with methyl; or
R1 is phenyl or a 5- or 6-membered heteroaromatic ring, each substituted with GQ1, each optionally substituted with 1 Q2 and each optionally substituted with 1 or 2 substituents independently selected from the group consisting of halogen, cyano, nitro, SF5, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C1-C4 haloalkyl, C2-C4 alkylcarbonyl, C2-C4 haloalkylcarbonyl, C2-C4 alkoxycarbonyl, C2-C4 alkylaminocarbonyl, C3-C7 dialkylaminocarbonyl, C(O)N-f CH2Z2CH2^, C1- C4 alkoxy, C1-C4 haloalkoxy, C2-C6 alkoxyalkyl, S(O)nR12, S(O)2R13, C1-C4 alkylamino, C2-C6 dialkylamino, Si(CH3)3, CHO, hydroxy, OC(O)R19 and
N(R20)C(O)R19;
G is a direct bond;
Q1 is phenyl or a 5- or 6-membered heteroaromatic ring, each optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, cyano, nitro, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C1-C4 haloalkyl, C2-C4 alkylcarbonyl, C2-C4 haloalkylcarbonyl, C2-C4 alkoxycarbonyl, C2-C4 alkylaminocarbonyl, C3-C7 dialkylaminocarbonyl, C(O)N-f CH2Z2CH2^-, C1-C4 alkoxy, C1-C4 haloalkoxy, C2-C6 alkoxyalkyl, S(O)nR12, S(O)2R13, C1-C4 alkylamino, C2-C6 dialkylamino, SF5, Si(CH3)3, CHO, hydroxy, OC(O)R19 and N(R20)C(O)R19;
R2 is C2-C6 alkyl, C1-C6 haloalkyl, CH2CO2R21, CR5R6CH2OR21,
CR5R6CH2CH2OR21, CR5R6CH2S(O)nR21 or CR5R6CH2CH2S(O)nR21; or
R2 is C3-C6 cycloalkyl or C4-C7 cycloalkylalkyl, each optionally substituted with 1 to
4 substituents selected from the group consisting of halogen, C1-C2 alkyl, 1 cyclopropyl and 1 CF3; or
R2 is CR5R6Q;
R3 is H, C1-C6 alkyl, C1-C6 haloalkyl, C2-C6 alkenyl, C2-C6 haloalkenyl, C2-C6 alkynyl, C2-C6 haloalkynyl or C≡CR10; or
R3 is C3-C6 cycloalkyl or C4-C7 cycloalkylalkyl, each optionally substituted with 1 to 4 substituents independently selected from the group consisting of halogen, C1-
C2 alkyl, 1 cyclopropyl and 1 CF3;
R4 is C1-C6 alkyl, C1-C6 haloalkyl, C2-C6 alkenyl, C2-C6 haloalkenyl, C2-C6 alkynyl, C2-C6 haloalkynyl or C≡CR10; or
R4 is C3-C6 cycloalkyl or C4-C7 cycloalkylalkyl, each optionally substituted with 1 to 4 substituents independently selected from the group consisting of halogen, C1-
C2 alkyl, 1 cyclopropyl and 1 CF3; or
R3 and R4 are taken together with the contiguous linking nitrogen and carbon atoms to form an optionally substituted ring R-I
Figure imgf000218_0001
R-2
Z is C(R8a)=C(R8b) or S, provided that the C(R8a)=C(R8b) moiety is oriented so the carbon atom bonded to R8b is connected as R3 in Formula 1; each R5 is independently H, F, Cl, cyano or Q-C4 alkyl; each R6 is independently H, F, Cl or CH3; and Q is
Figure imgf000218_0002
Q-I Q-5 Q-6 Q-9
3. A compound of Claim 2 wherein
R3 is C1-C6 alkyl or C1-C6 haloalkyl; and R4 is C1-C6 alkyl or C1-C6 haloalkyl.
4. A compound of Claim 3 wherein R3 is CH3; and
R4 is CH3.
5. A compound of Claim 2 wherein
R3 and R4 are taken together with the contiguous linking nitrogen and carbon atoms to form an optionally substituted ring R-I; m is 2 or 3; and p is 0.
6. A compound of Claim 2 wherein R3 and R4 are taken together with the contiguous linking nitrogen and carbon atoms to form an optionally substituted ring R-2; and
Z is CH=CH or CH=CF, provided that the CH=CF moiety is oriented so the carbon atom bonded to F is connected as R3 in Formula 1.
7. A compound of Claim 2 wherein
R3 and R4 are taken together with the contiguous linking nitrogen and carbon atoms to form an optionally substituted ring R-2; and Z is S.
8. A compound of Claim 2 wherein
R1 is H or halogen.
9. A compound of any one of Claims 3 through 7 wherein R1 is phenyl or pyridinyl, each optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, cyano, nitro, C1-
C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C1-C4 haloalkyl, C2-C4 haloalkenyl, C2-C4 alkylcarbonyl, C2-C4 haloalkylcarbonyl, C2-C4 alkoxycarbonyl, C2-C4 alkylaminocarbonyl, C3-C7 dialkylaminocarbonyl, C(O)N-f CH2Z2CH2^, C1- C4 alkoxy, C1-C4 haloalkoxy, C2-C6 alkoxyalkyl, S(O)nR12, S(O)2R13, C1-C4 alkylamino, C2-C6 dialkylamino, SF5, Si(CH3)3, CHO, hydroxy, OC(O)R19 and
N(R20)C(O)R19.
10. A compound of Claim 9 wherein
R1 is phenyl or pyridinyl, each optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, cyano, C1-C4 alkyl, C1-C4 haloalkyl, C2-C4 alkylcarbonyl, C2-C4 alkoxycarbonyl, C2-C4 alkylaminocarbonyl, C3-C7 dialkylaminocarbonyl, C(O)N-f CH2Z2CH2^, C1- C4 alkoxy, C1-C4 haloalkoxy, C2-C6 alkoxyalkyl, S(O)nR12 and S(O)2R13.
11. A compound of any one of Claims 3 through 7 wherein R1 is C(Xi)R18 or Q=NOR2^R18; and X1 is O.
12. A compound of any one of Claims 3 through 7 wherein R1 is phenyl or pyridinyl, each substituted with GQ1 and further optionally substituted with 1 or 2 substituents independently selected from the group consisting of halogen, cyano, nitro, SF5, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C1-C4 haloalkyl, C2-C4 alkylcarbonyl, C2-C4 haloalkylcarbonyl, C2-C4 alkoxycarbonyl, C2-C4 alkylaminocarbonyl, C3-C7 dialkylaminocarbonyl, C(O)N-f CH2Z2CH2^-, C ^C4 alkoxy, C ^C4 haloalkoxy, C2-C6 alkoxyalkyl,
S(O)nR12, S(O)2R13, C1-C4 alkylamino, C2-C6 dialkylamino, Si(CH3)3, CHO, hydroxy, OC(O)R19 and N(R20)C(O)R19.
13. A compound of Claim 12 wherein R1 is phenyl or pyridinyl, each substituted with GQ1 and further optionally substituted with 1 or 2 substituents independently selected from the group consisting of halogen, cyano, SF5, C1-C4 alkyl, C1-C4 haloalkyl, C2-C4 alkylcarbonyl, C2- C4 alkoxycarbonyl, C2-C4 alkylaminocarbonyl, C3-C7 dialkylaminocarbonyl, C(O)N-f CH2Z2CH2^-, C1-C4 alkoxy, C1-C4 haloalkoxy, C2-C6 alkoxyalkyl, S(O)nR12 and S(O)2R13; and
Q1 is phenyl or pyridinyl, each optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, cyano, C1-C4 alkyl, C1-C4 haloalkyl, C2-C4 alkylcarbonyl, C2-C4 alkoxycarbonyl, C2-C4 alkylaminocarbonyl, C3-C7 dialkylaminocarbonyl, C(O)N-f CH2Z2CH2^, C1- C4 alkoxy, C1-C4 haloalkoxy, C2-C6 alkoxyalkyl, S(O)nR12 and S(O)2R13.
14. A compound of any one of Claims 3 through 7 wherein R2 is C2-C6 alkyl, C1-C6 haloalkyl or CR5R6CH2OR21; or
R2 is C4-C7 cycloalkylalkyl optionally substituted with 1 to 4 substituents selected from the group consisting of halogen, C1-C2 alkyl, 1 cyclopropyl and 1 CF3.
15. A compound of any one of Claims 3 through 7 wherein R2 is CR5R6Q.
16. A compound of Claim 15 wherein Q is Q-I, Q-5, Q-6 or Q-9;
R5 is H or methyl; R6 is H; each R9a is independently H, halogen, cyano, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, SF5 or S(O)nR12; or C3-C6 cycloalkyl or C4-C7 cycloalkylalkyl, each optionally substituted with 1 to 4 substituents selected from the group consisting of halogen, C1-C2 alkyl, 1 cyclopropyl and 1 CF3; and each R9b is independently H, halogen, cyano, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 alkoxy or C1-C4 haloalkoxy.
17. A compound of Claim 1 that is selected from the group consisting of
3-(2,4-difluorophenyl)-2-hydroxy-4-oxo-l-(2,2,2-trifluoroethyl)-4H- pyrido[l,2-α]pyrimidinium inner salt;
3-(4-fiuorophenyl)-2-hydroxy-4-oxo-l-(2,2,2-trifluoroethyl)-4H-pyrido[l,2- αjpyrimidinium inner salt; l-[(6-chloro-3-pyridinyl)methyl]-3-(2,4-difluorophenyl)-2-hydroxy-4-oxo-
4H-pyrido[l,2-α]pyrimidinium inner salt; l-[(6-chloro-3-pyridinyl)methyl]-3-(4-fluorophenyl)-2-hydroxy-4-oxo-4H- pyrido[l,2-α]pyrimidinium inner salt;
3-(3-chlorophenyl)-l-[(2-chloro-5-thiazolyl)methyl]-2-hydroxy-4-oxo-4H- pyrido[l,2-α]pyrimidinium inner salt; l-[(2-chloro-5-thiazolyl)methyl]-2-hydroxy-4-oxo-3-[3-
(trifluoromethyl)phenyl]-4H-pyrido[l,2-α]pyrimidinium inner salt; l-[(2-chloro-5-thiazolyl)methyl]-2-hydroxy-4-oxo-3-[3-
(trifluoromethoxy)phenyl]-4H-pyrido[l,2-α]pyrimidinium inner salt; l-[(2-chloro-5-thiazolyl)methyl]-3-(4-fluorophenyl)-2-hydroxy-4-oxo-4H- pyrido[l,2-α]pyrimidinium inner salt;
1 -[(2-chloro-5-thiazolyl)methyl]-2-hydroxy-4-oxo-3-phenyl-4H-pyrido[ 1 ,2- αjpyrimidinium inner salt; l-[(2-chloro-5-thiazolyl)methyl]-3-(2,4-difluorophenyl)-2-hydroxy-4-oxo-
4H-pyrido[l,2-α]pyrimidinium inner salt; l-[(2-chloro-5-thiazolyl)methyl]-2-hydroxy-3-(4-methoxyphenyl)-4-oxo-4H- pyrido[l,2-α]pyrimidinium inner salt; l-[(2-chloro-5-thiazolyl)methyl]-2-hydroxy-3-(3-methoxyphenyl)-4-oxo-4H- pyrido[l,2-α]pyrimidinium inner salt; l-[(6-fluoro-3-pyridinyl)methyl]-3-(4-fluorophenyl)-2-hydroxy-4-oxo-4H- pyrido[l,2-α]pyrimidinium inner salt; 3-(3-bromophenyl)-l-[(2-chloro-5-thiazolyl)methyl]-2-hydroxy-4-oxo-4H- pyrido[l,2-α]pyrimidinium inner salt;
3 -(3 -bromophenyl)- 1 -[(6-chloro-3 -pyridinyl)methyl] -2-hydroxy-4-oxo-4H- pyrido[l,2-α]pyrimidinium inner salt; l-[(6-chloro-3-pyridinyl)methyl]-2-hydroxy-4-oxo-3-[3-
(trifluoromethoxy)phenyl]-4H-pyrido[l,2-α]pyrimidinium inner salt; l-[(2-chloro-5-thiazolyl)methyl]-2-hydroxy-4-oxo-3-[4-(trifluoromethyl)-2- pyridinyl]-4H-pyrido[l,2-α]pyrimidinium inner salt; l-[(2-chloro-5-thiazolyl)methyl]-3-(2-cyanophenyl)-2-hydroxy-4-oxo-4H- pyrido[l,2-α]pyrimidinium inner salt;
8-[(6-chloro-3-pyridinyl)methyl]-7-hydroxy-5-oxo-6-phenyl-5H-thiazolo[3,2- αjpyrimidinium inner salt;
8-[(6-chloro-3-pyridinyl)methyl]-6-(4-fluorophenyl)-7-hydroxy-5-oxo-5H- thiazolo[3,2-α]pyrimidinium inner salt;
8-[(6-chloro-3-pyridinyl)methyl]-7-hydroxy-5-oxo-6-[3-
(trifluoromethoxy)phenyl]-5H-thiazolo[3,2-α]pyrimidinium inner salt;
8-[(2-chloro-5-thiazolyl)methyl]-7-hydroxy-5-oxo-6-phenyl-5H-thiazolo[3,2- αjpyrimidinium inner salt;
8-[(2-chloro-5-thiazolyl)methyl]-6-(4-fluorophenyl)-7-hydroxy-5-oxo-5H- thiazolo[3,2-α]pyrimidinium inner salt;
8-[(2-chloro-5-thiazolyl)methyl]-7-hydroxy-5-oxo-6-[3-
(trifluoromethoxy)phenyl]-5H-thiazolo[3,2-α]pyrimidinium inner salt;
3-[3-(6-chloro-3-pyridinyl)phenyl]-l-[(2-chloro-5-thiazolyl)methyl]-2- hydroxy-4-oxo-4H-pyrido[l,2-α]pyrimidinium inner salt;
1 -[(6-fluoro-3 -pyridinyl)methyl] -2-hydroxy-4-oxo-3 - [3 -
(trifluoromethoxy)phenyl]-4H-pyrido[l,2-α]pyrimidinium inner salt;
3-(5-chloro-2-fluorophenyl)-l-[(2-chloro-5-thiazolyl)methyl]-2-hydroxy-4- oxo-4H-pyrido[l,2-α]pyrimidinium inner salt;
1 -[(2-chloro-5 -thiazolyl)methyl]-3 - [2-chloro-5 -(trifluoromethoxy)phenyl] -2- hydroxy-4-oxo-4H-pyrido[l,2-α]pyrimidinium inner salt;
3-(4-fluorophenyl)-2-hydroxy- 1 -[( 1 -methyl- lH-pyrazol-4-yl)methyl]-4-oxo-
4H-pyrido[l,2-α]pyrimidinium inner salt;
2-hydroxy- 1 -[(1 -methyl- lH-pyrazol-4-yl)methyl]-4-oxo-3-phenyl-4H- pyrido[l,2-α]pyrimidinium inner salt; l-[(2-chloro-5-thiazolyl)methyl]-3-(3,5-dimethoxyphenyl)-2-hydroxy-4-oxo-
4H-pyrido[l,2-α]pyrimidinium inner salt; l-[(2-chloro-5-thiazolyl)methyl]-3-[2-fluoro-5-(trifluoromethoxy)phenyl]-2- hydroxy-4-oxo-4H-pyrido[l,2-α]pyrimidinium inner salt;
3-(2-chloro-4-pyridinyl)-l-[(2-chloro-5-thiazolyl)methyl]-2-hydroxy-4-oxo-
4H-pyrido[l,2-α]pyrimidinium inner salt; l-[(2-chloro-5-thiazolyl)methyl]-3-(2-fluoro-5-bromophenyl)-2-hydroxy-4- oxo-4H-pyrido[l,2-α]pyrimidinium inner salt; l-[(2-chloro-5-thiazolyl)methyl]-2-hydroxy-4-oxo-3-(2,4,5-trifluorophenyl)-
4H-pyrido[l,2-α]pyrimidinium inner salt;
3 -[3 -bromo-5 -(trifluoromethoxy)phenyl] - 1 - [(2-chloro-5 -thiazolyl)methyl] -2- hydroxy-4-oxo-4H-pyrido[l,2-α]pyrimidinium inner salt;
3 -[3 -bromo-5 -(trifluoromethyl)phenyl] - 1 - [(2-chloro-5 -thiazolyl)methyl] -2- hydroxy-4-oxo-4H-pyrido[l,2-α]pyrimidinium inner salt; l-[(2-chloro-5-thiazolyl)methyl]-3-[2-fluoro-5-(trifluoromethyl)phenyl]-2- hydroxy-4-oxo-4H-pyrido[l,2-α]pyrimidinium inner salt; l-[(2-chloro-5-thiazolyl)methyl]-2-hydroxy-3-(2-methoxyphenyl)-4-oxo-4H- pyrido[l,2-α]pyrimidinium inner salt; l-[(2-chloro-5-thiazolyl)methyl]-3-(2-fluorophenyl)-2-hydroxy-4-oxo-4H- pyrido[l,2-α]pyrimidinium inner salt; l-[(6-chloro-3-pyridinyl)methyl]-3-(2-fluorophenyl)-2-hydroxy-4-oxo-5H- thiazolo[3,2-α]pyrimidinium inner salt;
2-hydroxy-4-oxo-3-phenyl-l-(2,2,2-trifluoroethyl)-4H-pyrido[l,2- αjpyrimidinium inner salt; and
3 -[(6-chloro-3 -pyridinyl)methyl] -5 -(4-fluorophenyl)-3 ,6-dihydro-4-hydroxy- l,2-dimethyl-6-oxopyrimidinium inner salt; l-[(2-chloro-5-thiazolyl)methyl]-3-[3-(6-fluoro-3-pyridinyl)-5-
(trifluoromethyl)phenyl]-2-hydroxy-4-oxo-4H-pyrido[l,2-α]pyrimidinium inner salt;
1 -[ 1 -(6-chloro-3-pyridinyl)ethyl]-3-(4-fluorophenyl)-2-hydroxy-4-oxo-4H- pyrido[l,2-α]pyrimidinium inner salt; l-[(2-chloro-5-thiazolyl)methyl]-3-(ethoxycarbonyl)-2-hydroxy-4-oxo-4H- pyrido[l,2-α]pyrimidinium inner salt;
3 -benzoyl- l-[(2-chloro-5 -thiazolyl)methyl]-2-hydroxy-4-oxo-4H-pyrido[ 1,2- αjpyrimidinium inner salt;
3 -(2,4-difluorophenyl)- 1 - [(6-fluoro-3 -pyridinyl)methyl] -2-hydroxy-4-oxo-
4H-pyrido[l,2-α]pyrimidinium inner salt;
1 -[(6-chloro-3 -pyridinyl)methyl] -2-hydroxy-3 -(3 -methoxyphenyl)-4-oxo-4H- pyrido[l,2-α]pyrimidinium inner salt; l-[(6-chloro-3-pyridinyl)methyl]-3-(2,3-difluorophenyl)-2-hydroxy-4-oxo-
4H-pyrido[l,2-α]pyrimidinium inner salt;
1 -[(6-chloro-3 -pyridinyl)methyl] -3 -(2-fluoro-3 -methoxyphenyl)-2-hydroxy-4- oxo-4H-pyrido[l,2-α]pyrimidinium inner salt;
3 -(3 ,5 -dimethoxyphenyl)- 1 - [(6-fluoro-3 -pyridinyl)methyl] -2-hydroxy-4-oxo-
4H-pyrido[l,2-α]pyrimidinium inner salt;
1 -[(6-fluoro-3 -pyridinyl)methyl] -2-hydroxy-4-oxo-3 - [3 -
(trifluoromethyl)phenyl]-4H-pyrido[l,2-α]pyrimidinium inner salt;
3-(4-fluorophenyl)-2-hydroxy-l-[(2-methyl-5-thiazolyl)methyl]-4-oxo-4H- pyrido[l,2-α]pyrimidinium inner salt;
2-hydroxy-4-oxo-3 -phenyl- 1 - [(5 -thiazolyl)methyl]-4H-pyrido [ 1 ,2- αjpyrimidinium inner salt;
3-(4-fluorophenyl)-2-hydroxy-4-oxo- 1 -[(5-thiazolyl)methyl]-4H-pyrido[ 1 ,2- αjpyrimidinium inner salt;
3 -(2-fluorophenyl)- 1 -[(6-fluoro-3 -pyridinyl)methyl] -2-hydroxy-4-oxo-4H- pyrido[l,2-α]pyrimidinium inner salt;
1 -[(6-chloro-3 -pyridinyl)methyl] -3 - [2-chloro-5 -(trifluoromethyl)phenyl] -2- hydroxy-4-oxo-4H-pyrido[l,2-α]pyrimidinium inner salt;
3 -(2-fluoro-4-cyanophenyl)- 1 - [(6-fluoro-3 -pyridinyl)methyl]-2-hydroxy-4- oxo-4H-pyrido[l,2-α]pyrimidinium inner salt;
1 -[(6-fluoro-3 -pyridinyl)methyl] -3 -[2-fluoro-5 -(trifluoromethyl)phenyl] -2- hydroxy-4-oxo-4H-pyrido[l,2-α]pyrimidinium inner salt; and l-[(2-chloro-5-thiazolyl)methyl]-2-hydroxy-4-oxo-3-[3-(6-trifluoromethyl-3- pyridinyl)phenyl]-4H-pyrido[l,2-α]pyrimidinium inner salt.
18. A composition comprising a compound of Claim 1 and at least one additional component selected from the group consisting of surfactants, solid diluents and liquid diluents, said composition optionally further comprising at least one additional biologically active compound or agent.
19. The composition of Claim 18 wherein the at least one additional biologically active compound or agent is selected from the group consisting of abamectin, acephate, acequinocyl, acetamiprid, acrinathrin, amidoflumet, amitraz, avermectin, azadirachtin, azinphos-methyl, bifenthrin, bifenazate, bistrifluron, borate, 3-bromo-l-(3-chloro-2- pyridinyl)-Λ/-[4-cyano-2-methyl-6-[(methylamino)carbonyl]phenyl]- lH-pyrazole-5- carboxamide (cyantraniliprole), buprofezin, cadusafos, carbaryl, carbofuran, cartap, carzol, chlorantraniliprole, chlorfenapyr, chlorfluazuron, chlorpyrifos, chlorpyrifos-methyl, chromafenozide, clofentezin, clothianidin, cyflumetofen, cyfluthrin, beta-cyfluthrin, cyhalothrin, gamma-cyhalothrin, lambda-cyhalothrin, cypermethrin, alpha-cypermethrin, zeta-cypermethrin, cyromazine, deltamethrin, diafenthiuron, diazinon, dieldrin, diflubenzuron, dimefluthrin, dimehypo, dimethoate, dinotefuran, diofenolan, emamectin, endosulfan, esfenvalerate, ethiprole, etofenprox, etoxazole, fenbutatin oxide, fenothiocarb, fenoxycarb, fenpropathrin, fenvalerate, fϊpronil, flonicamid, flubendiamide, flucythrinate, flufenerim, flufenoxuron, fluvalinate, tau-fluvalinate, fonophos, formetanate, fosthiazate, halofenozide, hexaflumuron, hexythiazox, hydramethylnon, imidacloprid, indoxacarb, insecticidal soaps, isofenphos, lufenuron, malathion, metaflumizone, metaldehyde, methamidophos, methidathion, methiodicarb, methomyl, methoprene, methoxychlor, metofluthrin, monocrotophos, methoxyfenozide, nitenpyram, nithiazine, novaluron, noviflumuron, oxamyl, parathion, parathion-methyl, permethrin, phorate, phosalone, phosmet, phosphamidon, pirimicarb, profenofos, profluthrin, propargite, protrifenbute, pymetrozine, pyrafluprole, pyrethrin, pyridaben, pyridalyl, pyrifluquinazon, pyriprole, pyriproxyfen, rotenone, ryanodine, spinetoram, spinosad, spirodiclofen, spiromesifen, spirotetramat, sulprofos, sulfoxaflor, tebufenozide, tebufenpyrad, teflubenzuron, tefluthrin, terbufos, tetrachlorvinphos, tetramethrin, thiacloprid, thiamethoxam, thiodicarb, thiosultap- sodium, tolfenpyrad, tralomethrin, triazamate, trichlorfon, triflumuron, Bacillus thuringiensis delta-endotoxins, entomopathogenic bacteria, entomopathogenic viruses and entomopathogenic fungi.
20. The composition of Claim 19 wherein the at least one additional biologically active compound or agent is selected from the group consisting of abamectin, acetamiprid, acrinathrin, amitraz, avermectin, azadirachtin, bifenthrin, 3-bromo-l-(3-chloro-2-pyridinyl)- N- [4-cyano-2-methyl-6- [(methylamino)carbonyl]phenyl] - lH-pyrazole-5 -carboxamide (cyantraniliprole), buprofezin, cadusafos, carbaryl, cartap, chlorantraniliprole, chlorfenapyr, chlorpyrifos, clothianidin, cyfluthrin, beta-cyfluthrin, cyhalothrin, gamma-cyhalothrin, lambda-cyhalothrin, cypermethrin, alpha-cypermethrin, zeta-cypermethrin, cyromazine, deltamethrin, dieldrin, dinotefuran, diofenolan, emamectin, endosulfan, esfenvalerate, ethiprole, etofenprox, etoxazole, fenothiocarb, fenoxycarb, fenvalerate, fϊpronil, flonicamid, flubendiamide, flufenoxuron, fluvalinate, formetanate, fosthiazate, hexaflumuron, hydramethylnon, imidacloprid, indoxacarb, lufenuron, metaflumizone, methiodicarb, methomyl, methoprene, methoxyfenozide, nitenpyram, nithiazine, novaluron, oxamyl, pymetrozine, pyrethrin, pyridaben, pyridalyl, pyriproxyfen, ryanodine, spinetoram, spinosad, spirodiclofen, spiromesifen, spirotetramat, tebufenozide, tetramethrin, thiacloprid, thiamethoxam, thiodicarb, thiosultap-sodium, tralomethrin, triazamate, triflumuron, Bacillus thuringiensis delta-endotoxins, all strains of Bacillus thuringiensis and all strains oϊNucleo polyhydrosis viruses.
21. A composition for protecting an animal from an invertebrate parasitic pest comprising a parasiticidally effective amount of a compound of Claim 1 and at least one carrier.
22. The composition of Claim 21 in a form for oral administration.
23. The composition of Claim 21 in a form for topical administration.
24. A method for controlling an invertebrate pest comprising contacting the invertebrate pest or its environment with a biologically effective amount of a compound of Claim 1.
25. The method of Claim 24 wherein the environment is a plant.
26. The method of Claim 24 wherein the environment is an animal.
27. The method of Claim 24 wherein the environment is a seed.
28. The method of Claim 27 wherein the seed is coated with a composition comprising a compound of Claim 1 and optionally a film former or adhesive agent.
29. A treated seed comprising a compound of Claim 1 in an amount of from about 0.0001 to 1 % by weight of the seed before treatment.
PCT/US2009/032584 2008-02-06 2009-01-30 Mesoionic pesticides WO2009099929A1 (en)

Priority Applications (27)

Application Number Priority Date Filing Date Title
ES09709044T ES2416083T3 (en) 2008-02-06 2009-01-30 Mesoionic Pesticides
SI200930653T SI2240454T1 (en) 2008-02-06 2009-01-30 Mesoionic pesticides
EP09709044.3A EP2240454B1 (en) 2008-02-06 2009-01-30 Mesoionic pesticides
NZ586799A NZ586799A (en) 2008-02-06 2009-01-30 Mesoionic pesticides
KR1020137027699A KR101495468B1 (en) 2008-02-06 2009-01-30 Mesoionic pesticides
US12/866,462 US8552007B2 (en) 2008-02-06 2009-01-30 Mesoionic pesticides
PL09709044T PL2240454T3 (en) 2008-02-06 2009-01-30 Mesoionic pesticides
MX2013013073A MX352783B (en) 2008-02-06 2009-01-30 Mesoionic pesticides.
AU2009212715A AU2009212715B2 (en) 2008-02-06 2009-01-30 Mesoionic pesticides
BRPI0905936A BRPI0905936B1 (en) 2008-02-06 2009-01-30 compound, composition, composition for protecting an animal from an invertebrate parasitic pest, non-therapeutic method for controlling an invertebrate pest and treated seed
CA2713347A CA2713347C (en) 2008-02-06 2009-01-30 Mesoionic pesticides
JP2010545938A JP5068378B2 (en) 2008-02-06 2009-01-30 Mesoionic pest control agent
RS20130222A RS52788B (en) 2008-02-06 2009-01-30 Mesoionic pesticides
DK09709044.3T DK2240454T3 (en) 2008-02-06 2009-01-30 Mesoionic pesticides
KR1020107019689A KR101404291B1 (en) 2008-02-06 2009-01-30 Mesoionic pesticides
CN200980104397.6A CN101939302B (en) 2008-02-06 2009-01-30 Mesoionic pesticides
UAA201009923A UA103473C2 (en) 2008-02-06 2009-01-30 Mesoionic pyrimidine derivatives as pesticides and compositions comprising thereof
EA201070926A EA019955B1 (en) 2008-02-06 2009-01-30 Mesoionic pesticides
MX2010008532A MX2010008532A (en) 2008-02-06 2009-01-30 Mesoionic pesticides.
ZA2010/05035A ZA201005035B (en) 2008-02-06 2010-07-15 Mesoionic pesticides
MA33029A MA32026B1 (en) 2008-02-06 2010-07-16 Mesoionic pesticides
IL207087A IL207087A (en) 2008-02-06 2010-07-19 Pyrimidinium inner salts, compositions comprising them and method of controlling invertebrate pests using the same
TNP2010000356A TN2010000356A1 (en) 2009-01-30 2010-07-30 Mesoionic pesticides
IL226126A IL226126A0 (en) 2008-02-06 2013-05-02 Mesoionic pesticides
HRP20130501AT HRP20130501T1 (en) 2008-02-06 2013-06-06 Mesoionic pesticides
US13/967,629 US9018220B2 (en) 2008-02-06 2013-08-15 Mesoionic pesticides
PH12014500760A PH12014500760A1 (en) 2008-02-06 2014-04-04 Mesoionic pesticides

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US6378908P 2008-02-06 2008-02-06
US61/063,789 2008-02-06
US4342808P 2008-04-09 2008-04-09
US61/043,428 2008-04-09

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/866,462 A-371-Of-International US8552007B2 (en) 2008-02-06 2009-01-30 Mesoionic pesticides
US13/967,629 Division US9018220B2 (en) 2008-02-06 2013-08-15 Mesoionic pesticides

Publications (1)

Publication Number Publication Date
WO2009099929A1 true WO2009099929A1 (en) 2009-08-13

Family

ID=40524655

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/032584 WO2009099929A1 (en) 2008-02-06 2009-01-30 Mesoionic pesticides

Country Status (29)

Country Link
US (2) US8552007B2 (en)
EP (2) EP2559687A1 (en)
JP (2) JP5068378B2 (en)
KR (2) KR101495468B1 (en)
CN (2) CN101939302B (en)
AR (1) AR071644A1 (en)
AU (1) AU2009212715B2 (en)
BR (1) BRPI0905936B1 (en)
CA (1) CA2713347C (en)
CL (1) CL2009000252A1 (en)
CO (1) CO6321190A2 (en)
DK (1) DK2240454T3 (en)
EA (2) EA019955B1 (en)
ES (1) ES2416083T3 (en)
HR (1) HRP20130501T1 (en)
IL (2) IL207087A (en)
MA (1) MA32026B1 (en)
MX (2) MX352783B (en)
MY (1) MY153886A (en)
NZ (2) NZ598147A (en)
PH (1) PH12014500760A1 (en)
PL (1) PL2240454T3 (en)
PT (1) PT2240454E (en)
RS (1) RS52788B (en)
SI (1) SI2240454T1 (en)
TW (2) TWI468407B (en)
UY (1) UY31633A1 (en)
WO (1) WO2009099929A1 (en)
ZA (2) ZA201005035B (en)

Cited By (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010072598A1 (en) * 2008-12-22 2010-07-01 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
WO2011017351A2 (en) 2009-08-05 2011-02-10 E. I. Du Pont De Nemours And Company Mixtures of mesoionic pesticides
WO2011017347A3 (en) * 2009-08-05 2011-04-21 E. I. Du Pont De Nemours And Company Mesoionic pesticides
WO2011017334A3 (en) * 2009-08-05 2011-04-28 E. I. Du Pont De Nemours And Company Mesoionic pesticides
WO2011017342A3 (en) * 2009-08-05 2011-05-19 E. I. Du Pont De Nemours And Company Mesoionic pesticides
WO2011134819A1 (en) * 2010-04-27 2011-11-03 Syngenta Participations Ag Methods of controlling neonicotinoid resistant aphids
WO2012092115A1 (en) 2010-12-29 2012-07-05 E. I. Du Pont De Nemours And Company Mesoionic pyrido [1,2 -a] pyrimidine pesticides
WO2012090515A1 (en) * 2010-12-27 2012-07-05 Sumitomo Chemical Company, Limited Arthropod pest control composition and method for controlling arthropod pests
WO2012090514A1 (en) * 2010-12-27 2012-07-05 Sumitomo Chemical Company, Limited Arthropod pest control composition and method for controlling arthropod pests
WO2012090516A1 (en) * 2010-12-27 2012-07-05 Sumitomo Chemical Company, Limited Arthropod pest control composition and method for controlling arthropod pests
WO2012090910A1 (en) * 2010-12-27 2012-07-05 住友化学株式会社 Harmful arthropod control composition and method for controlling harmful arthropod
US8232271B2 (en) 2008-10-30 2012-07-31 Roche Palo Alto Llc Heterocyclic antiviral compounds
WO2012106495A1 (en) 2011-02-03 2012-08-09 E. I. Du Pont De Nemours And Company Mesoionic pesticides
WO2012136724A1 (en) 2011-04-06 2012-10-11 Basf Se Substituted pyrimidinium compounds for combating animal pests
EP2559687A1 (en) * 2008-02-06 2013-02-20 E. I. du Pont de Nemours and Company Mesoionic pesticides
WO2013090547A1 (en) 2011-12-15 2013-06-20 E. I. Du Pont De Nemours And Company Malonic acid di-salts and a method for preparing malonyl dihalides
WO2013144228A1 (en) 2012-03-29 2013-10-03 Basf Se Pesticidal methods using heterocyclic compounds and derivatives for combating animal pests
WO2014005982A1 (en) 2012-07-05 2014-01-09 Bayer Cropscience Ag Insecticide and fungicide active ingredient combinations
RU2503666C1 (en) * 2012-06-25 2014-01-10 Открытое акционерное общество "Государственный научно-исследовательский институт "Кристалл" (ОАО "ГосНИИ "Кристалл") Method of producing 2-methylpyrimidine-4,6-(3h,5h)-dione
EP2684879A1 (en) 2012-07-09 2014-01-15 Basf Se Substituted mesoionic compounds for combating animal pests
WO2014093606A1 (en) 2012-12-13 2014-06-19 Novartis Ag Pyridone derivatives and uses thereof in the treatment of tuberculosis
CN104082333A (en) * 2014-07-03 2014-10-08 广西农喜作物科学有限公司 Insecticidal composition containing clothianidin
WO2014167084A1 (en) * 2013-04-11 2014-10-16 Basf Se Substituted pyrimidinium compounds and derivatives for combating animal pests
WO2014202582A1 (en) * 2013-06-17 2014-12-24 Basf Se Substituted pyrimidinium compounds and derivatives for combating animal pests
KR20150023374A (en) 2012-06-21 2015-03-05 스미또모 가가꾸 가부시끼가이샤 Arthropod pest control composition and arthropod pest control method
CN104397004A (en) * 2014-10-23 2015-03-11 北京燕化永乐生物科技股份有限公司 Pesticide composition
WO2015055554A1 (en) 2013-10-14 2015-04-23 Bayer Cropscience Ag Active substance for treating seed and soil
WO2015059088A1 (en) 2013-10-23 2015-04-30 Bayer Cropscience Ag Substituted quinoxaline derivatives as pest control agent
WO2015101622A1 (en) 2014-01-03 2015-07-09 Bayer Cropscience Ag Novel pyrazolyl-heteroarylamides as pesticides
AU2014201144B2 (en) * 2008-02-06 2015-07-16 Fmc Corporation Mesoionic pesticides
WO2015107133A1 (en) 2014-01-20 2015-07-23 Bayer Cropscience Ag Quinoline derivatives as insecticides and acaricides
EP2910126A1 (en) 2015-05-05 2015-08-26 Bayer CropScience AG Active compound combinations having insecticidal properties
WO2015150300A1 (en) 2014-04-02 2015-10-08 Bayer Cropscience Ag N-(1-(hetero)aryl-1h-pyrazol-4-yl)-(hetero)arylamide derivatives and use thereof as pesticides
WO2015169776A1 (en) 2014-05-08 2015-11-12 Bayer Cropscience Ag Pyrazolopyridine sulfonamides as nematicides
WO2015185531A1 (en) 2014-06-05 2015-12-10 Bayer Cropscience Aktiengesellschaft Bicyclic compounds as pesticides
WO2016001119A1 (en) 2014-07-01 2016-01-07 Bayer Cropscience Aktiengesellschaft Insecticide and fungicide active ingredient combinations
WO2016008830A1 (en) 2014-07-15 2016-01-21 Bayer Cropscience Aktiengesellschaft Aryl-triazolyl pyridines as pest control agents
WO2016055431A1 (en) * 2014-10-06 2016-04-14 Basf Se Substituted pyrimidinium compounds for combating animal pests
WO2016055096A1 (en) 2014-10-07 2016-04-14 Bayer Cropscience Ag Method for treating rice seed
WO2016091857A1 (en) 2014-12-11 2016-06-16 Bayer Cropscience Aktiengesellschaft Five-membered c-n bonded aryl sulphide and aryl sulphoxide derivatives as pest control agents
WO2016124563A1 (en) 2015-02-05 2016-08-11 Bayer Cropscience Aktiengesellschsaft 2-(het)aryl-substituted condensed bicyclic heterocycle derivatives as pest control agents
WO2016124557A1 (en) 2015-02-05 2016-08-11 Bayer Cropscience Aktiengesellschaft 2-(het)aryl-substituted condensed bicyclic heterocycle derivatives as pest control agents
WO2016128298A1 (en) 2015-02-09 2016-08-18 Bayer Cropscience Aktiengesellschaft Substituted 2-thioimidazolyl-carboxamides as pest control agents
WO2016142394A1 (en) 2015-03-10 2016-09-15 Bayer Animal Health Gmbh Pyrazolyl-derivatives as pest control agents
WO2016162318A1 (en) 2015-04-08 2016-10-13 Bayer Cropscience Aktiengesellschaft Condensed bicyclic heterocycle derivatives as pest control agents and intermediate product
EP3081085A1 (en) 2015-04-14 2016-10-19 Bayer CropScience AG Method for improving earliness in cotton
WO2016171053A1 (en) * 2015-04-21 2016-10-27 日本化薬株式会社 Mesoionic compound
WO2016174049A1 (en) 2015-04-30 2016-11-03 Bayer Animal Health Gmbh Anti-parasitic combinations including halogen-substituted compounds
WO2016180802A1 (en) 2015-05-13 2016-11-17 Bayer Cropscience Aktiengesellschaft Insecticidal arylpyrrolidines, method for synthesizing same, and use thereof as agents for controlling animal pests
WO2017005717A1 (en) 2015-07-06 2017-01-12 Bayer Cropscience Aktiengesellschaft Heterocyclic compounds as pesticides
WO2017093214A1 (en) 2015-12-03 2017-06-08 Bayer Cropscience Aktiengesellschaft Mesoionic halogenated 3-(acetyl)-1-[(1,3-thiazol-5-yl)methyl]-1h-imidazo[1,2-a]pyridin-4-ium-2-olate derivatives and related compounds as insecticides
WO2017097870A1 (en) * 2015-12-11 2017-06-15 Bayer Cropscience Aktiengesellschaft Substituted malonic acid amides as insecticides
EP3210468A1 (en) 2016-02-26 2017-08-30 Bayer CropScience Aktiengesellschaft Solvent-free formulations of low-melting point agents
US9776967B2 (en) 2013-10-14 2017-10-03 Bayer Animal Health Gmbh Carboxamide derivatives as pesticidal compounds
WO2018013382A1 (en) 2016-07-11 2018-01-18 Covestro Llc, Et Al Aqueous compositions for treating seeds, seeds treated therewith, and methods for treating seeds
WO2018013380A1 (en) 2016-07-11 2018-01-18 Covestro Llc, Et Al. Methods for treating seeds with an aqueous compostion and seeds treated therewith
WO2018011111A1 (en) 2016-07-12 2018-01-18 Bayer Cropscience Aktiengesellschaft Bicyclic compounds as pest control agents
WO2018013381A1 (en) 2016-07-11 2018-01-18 Covestro Llc, Et Al. Aqueous compositions for treating seeds, seeds treated therewith, and methods for treating seeds
WO2018069842A1 (en) 2016-10-14 2018-04-19 Pi Industries Ltd 4-amino substituted phenylamidine derivatives and their use to protect crops by fighting undesired phytopathogenic micoorganisms
WO2018069841A1 (en) 2016-10-14 2018-04-19 Pi Industries Ltd 4-substituted phenylamine derivatives and their use to protect crops by fighting undesired phytopathogenic micoorganisms
WO2018104500A1 (en) 2016-12-09 2018-06-14 Bayer Cropscience Aktiengesellschaft Plant health effect of purpureocillium lilacinum
WO2018108730A1 (en) 2016-12-16 2018-06-21 Bayer Aktiengesellschaft Mesoionic imidazopyridines for use as insecticides
WO2018116072A1 (en) 2016-12-20 2018-06-28 Pi Industries Ltd. Heterocyclic compounds
WO2018116073A1 (en) 2016-12-21 2018-06-28 Pi Industries Ltd. 1, 2, 3-thiadiazole compounds and their use as crop protecting agent
WO2018177970A1 (en) 2017-03-31 2018-10-04 Basf Se Process for preparing chiral 2,3-dihydrothiazolo[3,2-a]pyrimidin-4-ium compounds
WO2018177993A1 (en) 2017-03-31 2018-10-04 Bayer Cropscience Aktiengesellschaft Pyrazoles for controlling arthropods
WO2018177995A1 (en) 2017-03-31 2018-10-04 Bayer Cropscience Aktiengesellschaft Tricyclic carboxamides for controlling arthropods
WO2018189077A1 (en) 2017-04-12 2018-10-18 Bayer Aktiengesellschaft Mesoionic imidazopyridines for use as insecticides
WO2018192872A1 (en) 2017-04-21 2018-10-25 Bayer Aktiengesellschaft Mesoionic imidazopyridines as insecticides
WO2018193385A1 (en) 2017-04-20 2018-10-25 Pi Industries Ltd. Novel phenylamine compounds
WO2018229202A1 (en) 2017-06-16 2018-12-20 Basf Se Mesoionic imidazolium compounds and derivatives for combating animal pests
WO2018234202A1 (en) 2017-06-19 2018-12-27 Basf Se Substituted pyrimidinium compounds and derivatives for combating animal pests
WO2019007887A1 (en) 2017-07-06 2019-01-10 Bayer Aktiengesellschaft Insecticide and fungicide active ingredient combinations
WO2019007891A1 (en) 2017-07-06 2019-01-10 Bayer Aktiengesellschaft Insecticidal active ingredient combinations
WO2019007888A1 (en) 2017-07-06 2019-01-10 Bayer Aktiengesellschaft Insecticidal active ingredient combinations
WO2019072906A1 (en) 2017-10-13 2019-04-18 Basf Se Imidazolidine pyrimidinium compounds for combating animal pests
EP3473103A1 (en) 2017-10-17 2019-04-24 Bayer AG Aqueous suspension concentrates based on 2- [(2,4-dichlorophenyl) -methyl] -4,4 '-dimethyl-3-isoxazolidinone
WO2019086474A1 (en) 2017-10-31 2019-05-09 Syngenta Participations Ag Pesticidally active mesoionics heterocyclic compounds
WO2019115404A1 (en) 2017-12-13 2019-06-20 Syngenta Participations Ag Pesticidally active mesoionic heterocyclic compounds
WO2019123196A1 (en) 2017-12-20 2019-06-27 Pi Industries Ltd. Fluoralkenyl compounds, process for preparation and use thereof
WO2019150311A1 (en) 2018-02-02 2019-08-08 Pi Industries Ltd. 1-3 dithiol compounds and their use for the protection of crops from phytopathogenic microorganisms
WO2019173173A1 (en) 2018-03-05 2019-09-12 E. I. Du Pont De Nemours And Company Process and intermidiates for the preparation of certain mesoionic pesticides
CN110317200A (en) * 2018-03-28 2019-10-11 东莞东阳光科研发有限公司 Pyrimidine compound and application thereof
WO2020002189A1 (en) 2018-06-27 2020-01-02 Bayer Aktiengesellschaft Active substance combinations
WO2020021082A1 (en) 2018-07-27 2020-01-30 Bayer Aktiengesellschaft Controlled release formulations for agrochemicals
WO2020025650A1 (en) 2018-07-31 2020-02-06 Bayer Aktiengesellschaft Controlled release formulations with lignin for agrochemicals
WO2020035826A1 (en) 2018-08-17 2020-02-20 Pi Industries Ltd. 1,2-dithiolone compounds and use thereof
WO2020058010A1 (en) 2018-09-19 2020-03-26 Basf Se Pesticidal mixtures comprising a mesoionic compound
EP3628157A1 (en) 2018-09-28 2020-04-01 Basf Se Method of controlling insecticide resistant insects and virus transmission to plants
EP3628158A1 (en) 2018-09-28 2020-04-01 Basf Se Pesticidal mixture comprising a mesoionic compound and a biopesticide
EP3628156A1 (en) 2018-09-28 2020-04-01 Basf Se Method for controlling pests of sugarcane, citrus, rapeseed, and potato plants
WO2020126591A1 (en) 2018-12-18 2020-06-25 Basf Se Substituted pyrimidinium compounds for combating animal pests
WO2020239517A1 (en) 2019-05-29 2020-12-03 Basf Se Mesoionic imidazolium compounds and derivatives for combating animal pests
EP3769623A1 (en) 2019-07-22 2021-01-27 Basf Se Mesoionic imidazolium compounds and derivatives for combating animal pests
WO2021048188A1 (en) 2019-09-11 2021-03-18 Bayer Aktiengesellschaft Highly effective formulations on the basis of 2-[(2,4-dichlorphenyl)-methyl]-4,4'-dimethyl-3-isoxazolidinones and preemergence herbicides
WO2021151034A1 (en) 2020-01-24 2021-07-29 Fmc Corporation Mesoionic insecticides
EP3896066A2 (en) 2015-08-07 2021-10-20 Bayer CropScience Aktiengesellschaft 2-(het)aryl-substituted condensed heterocycle derivatives as pesticides
US11344029B2 (en) 2017-06-01 2022-05-31 Sumitomo Chemical Company, Limited Heterocyclic compound and composition containing same
WO2022162129A1 (en) 2021-01-28 2022-08-04 Rhodia Operations Method for treating rice seed with improved retention of agrochemical, micronutrient and colorant
US11407756B2 (en) 2017-12-25 2022-08-09 Sumitomo Chemical Company, Limited Heterocyclic compounds and noxious arthropod control agent containing same
WO2023078915A1 (en) 2021-11-03 2023-05-11 Bayer Aktiengesellschaft Bis(hetero)aryl thioether (thio)amides as fungicidal compounds
WO2023086802A1 (en) 2021-11-10 2023-05-19 Corteva Agriscience Llc Processes for the preparation of certain mesoionic pesticides
WO2023092050A1 (en) 2021-11-20 2023-05-25 Bayer Cropscience Lp Beneficial combinations with recombinant bacillus cells expressing a serine protease
WO2023099445A1 (en) 2021-11-30 2023-06-08 Bayer Aktiengesellschaft Bis(hetero)aryl thioether oxadiazines as fungicidal compounds
WO2023110656A1 (en) 2021-12-15 2023-06-22 Bayer Aktiengesellschaft Spectroscopic solution for non-destructive quantification of one or more chemical substances in a matrix comprising coating and bulk material in a sample, such as coated seeds, using multivariate data analysis
WO2024040111A1 (en) 2022-08-18 2024-02-22 Corteva Agriscience Llc Process for the preparation and isolation of intermediates of certain mesoionic pesticides

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2012002973A (en) * 2009-09-09 2012-04-19 Du Pont Herbicidal pyrimidone derivatives.
WO2012154537A1 (en) * 2011-05-06 2012-11-15 Dow Agrosciences Llc Controlling planthoppers
WO2012154533A2 (en) * 2011-05-06 2012-11-15 Dow Agrosciences Llc Controlling planthoppers
CN102246774B (en) * 2011-05-17 2013-05-15 德强生物股份有限公司 Insecticidal synergistic composition containing thiocyclam
JP6272843B2 (en) * 2012-06-21 2018-01-31 イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニーＥ．Ｉ．Ｄｕ Ｐｏｎｔ Ｄｅ Ｎｅｍｏｕｒｓ Ａｎｄ Ｃｏｍｐａｎｙ Solid form of pyridopyrimidinium inner salt
JP2014024830A (en) * 2012-06-21 2014-02-06 Sumitomo Chemical Co Ltd Delphacidae control method
JP2017141250A (en) * 2012-06-21 2017-08-17 住友化学株式会社 Harmful arthropod control composition and harmful arthropod control method
CN108289443A (en) * 2015-07-22 2018-07-17 哈佛大学校长及研究员协会 Composition for controlling mosquito populations
EP3521287A4 (en) * 2016-09-28 2020-03-25 Nippon Kayaku Kabushiki Kaisha Novel mesoionic insecticidal compound
WO2018202654A1 (en) * 2017-05-03 2018-11-08 Basf Se Process for preparing chiral 2,3-dihydrothiazolo[3,2-a]pyrimidin-4-ium compounds
WO2018208595A1 (en) * 2017-05-09 2018-11-15 Fmc Corporation Mesoionic insecticides
WO2019042932A1 (en) * 2017-08-31 2019-03-07 Basf Se Method of controlling rice pests in rice
CN109553615B (en) * 2017-09-26 2020-09-22 沈阳中化农药化工研发有限公司 Pyrimidine salt compound and application thereof
CN110452238B (en) * 2018-04-18 2020-08-11 东莞市东阳光农药研发有限公司 Pyrimidinium compounds and uses thereof
CN109006842A (en) * 2018-08-13 2018-12-18 广东顾地丰生物科技有限公司 A kind of highly efficiency compositional composition pesticide of pyrimidine containing trifluoro-benzene and paichongding
CN111153900B (en) * 2018-11-07 2021-09-28 东莞市东阳光农药研发有限公司 Pyrimidinium compounds, process for their preparation and their use
CN111620867A (en) * 2019-02-28 2020-09-04 东莞市东阳光农药研发有限公司 Mesoionic insecticides
CN112442026B (en) * 2019-08-27 2023-08-08 东莞市东阳光农药研发有限公司 Mesoionic derivative and preparation method and application thereof
CN112851665B (en) * 2019-11-28 2023-08-08 东莞市东阳光农药研发有限公司 Novel mesoionic compounds and their use in agriculture
CN113563327A (en) * 2020-04-28 2021-10-29 东莞市东阳光农药研发有限公司 Novel mesoionic compound and synthesis and application thereof
CN111592539B (en) * 2020-06-03 2022-11-15 江西农业大学 Preparation method of trifluoro-benzene pyrimidine
CN113651811B (en) * 2021-08-12 2022-06-07 贵州大学 Isoxazole-containing pyridopyrimidone compound and preparation method and application thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089501A (en) * 1989-09-01 1992-02-18 Ciba Geigy Corp Anthelmintics

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1815604A (en) 1922-10-31 1931-07-21 Winthrop Chem Co Organic mercury compound
US1679404A (en) 1926-02-04 1928-08-07 Rockwood Sprinkler Co Massachusetts Constant-alarm device for alarm valves
BE392862A (en) 1931-12-08
US2891855A (en) 1954-08-16 1959-06-23 Geigy Ag J R Compositions and methods for influencing the growth of plants
US3235361A (en) 1962-10-29 1966-02-15 Du Pont Method for the control of undesirable vegetation
US3060084A (en) 1961-06-09 1962-10-23 Du Pont Improved homogeneous, readily dispersed, pesticidal concentrate
US3299566A (en) 1964-06-01 1967-01-24 Olin Mathieson Water soluble film containing agricultural chemicals
US3309192A (en) 1964-12-02 1967-03-14 Du Pont Method of controlling seedling weed grasses
US4144050A (en) 1969-02-05 1979-03-13 Hoechst Aktiengesellschaft Micro granules for pesticides and process for their manufacture
US3852416A (en) 1971-05-27 1974-12-03 L Grubb Tick and flea collar of solid solution plasticized vinylic resin-carbamate insecticide
US3984564A (en) 1972-06-08 1976-10-05 Sankyo Company Limited Antibiotic substances B-41, their production and their use as insecticides and acaricides
US3950360A (en) 1972-06-08 1976-04-13 Sankyo Company Limited Antibiotic substances
US3920442A (en) 1972-09-18 1975-11-18 Du Pont Water-dispersible pesticide aggregates
SE434277B (en) 1976-04-19 1984-07-16 Merck & Co Inc SET TO MAKE NEW ANTIHELMINTICALLY EFFECTIVE ASSOCIATIONS BY CULTIVATING STREPTOMYCS AVERMITILIS
US4172714A (en) 1976-12-20 1979-10-30 E. I. Du Pont De Nemours And Company Dry compactible, swellable herbicidal compositions and pellets produced therefrom
DE2703712A1 (en) * 1977-01-29 1978-08-03 Bayer Ag SUBSTITUTED PYRIMIDINONE ANGLE CLAMP ON (DI) -THIO ANGLE CLAMP ON -PHOSPHORUS- (PHOSPHONE) -ACIDESTER OR. -ESTERAMIDES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS INSECTICIDES, ACARICIDES AND NEMATICIDES
US4199569A (en) 1977-10-03 1980-04-22 Merck & Co., Inc. Selective hydrogenation products of C-076 compounds and derivatives thereof
ES8104203A1 (en) 1979-02-05 1981-04-16 Schering Corp 1-Aryl-2-acylamido-3-fluoro-1-propanol acylates, methods for their manufacture and intermediates useful therein, methods for their use as antibacterial agents and compositions useful therefor
US4224901A (en) 1979-04-16 1980-09-30 Carey Jr Sam H Combination inner flea-tick collar and outer protective collar, for animals
GB2095558B (en) 1981-03-30 1984-10-24 Avon Packers Ltd Formulation of agricultural chemicals
US4820695A (en) 1982-09-13 1989-04-11 Eli Lilly And Company C-20-dihydro-deoxy-(cyclic amino)-derivatives of macrolide antibiotics
DE3246493A1 (en) 1982-12-16 1984-06-20 Bayer Ag, 5090 Leverkusen METHOD FOR PRODUCING WATER-DISPERSIBLE GRANULES
US5105009A (en) 1983-06-02 1992-04-14 Zambon S.P.A. Intermediates for the preparation of 1-(phenyl)-1-hydroxy-2-amino-3-fluoropropane derivatives
IT1173213B (en) 1984-02-03 1987-06-18 Zambon Spa PROCEDURE TO FLUORINE SOME DERIVATIVES FROM 1L-FENYL-2-AMINO-1,3-PROPANDIOL AND THEIR INTERMEDIATES
US5332835A (en) 1984-02-03 1994-07-26 Zambon S.P.A. Process for fluorinating 1-phenyl-2-amino-1,3-propanediol compounds and new oxazoline compounds useful in this process
US4582918A (en) 1984-09-19 1986-04-15 Schering Corporation Preparation of intermediates for (threo)-1-aryl-2-acylamido-3-fluoro-1-propanols
US4973750A (en) 1984-09-19 1990-11-27 Schering Corporation Preparation of (threo)-1-aryl-2-acylamido-3-fluoro-1-propanols
ES8800986A1 (en) 1985-07-27 1987-12-01 Pfizer Antiparasitic avermectin and milbemycin derivatives and process for their preparation.
US4916154A (en) 1986-09-12 1990-04-10 American Cyanamid Company 23-Imino derivatives of LL-F28249 compounds
US5149810A (en) * 1988-04-22 1992-09-22 Imperial Chemical Industries Plc Pyrimidine compounds
US5180587A (en) 1988-06-28 1993-01-19 E. I. Du Pont De Nemours And Company Tablet formulations of pesticides
US4876352A (en) 1988-09-14 1989-10-24 Schering Corporation Pressurized fluorination of hydroxy alkyl groups
US5227494A (en) 1988-09-14 1993-07-13 Schering Corporation Process for preparing oxazoline compounds
IE63502B1 (en) * 1989-04-21 1995-05-03 Zeneca Ltd Aminopyrimidine derivatives useful for treating cardiovascular disorders
ATE208560T1 (en) 1989-08-30 2001-11-15 Kynoch Agrochemicals Proprieta PRODUCTION OF A DOSAGE AGENT
EP0430885A3 (en) 1989-12-01 1991-11-06 Ciba-Geigy Ag Anthelmintical compounds
EP0430883A3 (en) 1989-12-01 1991-11-06 Ciba-Geigy Ag Anthelmintical compounds
JPH05504964A (en) 1990-03-12 1993-07-29 イー・アイ・デユポン・ドウ・ヌムール・アンド・カンパニー Water-dispersible or water-soluble pest control granules from heat-activated binders
IL98599A (en) 1990-06-28 1995-06-29 Merck & Co Inc Stable salts of 4"-deoxy-4"-epi-methylamino avermectin b1a/b1b and insecticidal compositions containing them
EP0480679B1 (en) 1990-10-11 1996-09-18 Sumitomo Chemical Company Limited Pesticidal composition
PL166385B1 (en) 1990-10-25 1995-05-31 Schering Corp Method of obtaining oxazoline compound
US5184573A (en) 1992-02-21 1993-02-09 Stevens Jr John L Animal collar
US5352832A (en) 1992-12-18 1994-10-04 Schering Corporation Asymmetric process for preparing florfenicol, thiamphenicol chloramphenicol and oxazoline intermediates
US5399717A (en) 1993-09-29 1995-03-21 Merck & Co., Inc. Glycosidation route to 4"-epi-methylamino-4"-deoxyavermectin B1
US5555848A (en) 1995-05-17 1996-09-17 Trujillo; Wendy J. Pet/flea collar
US5958888A (en) 1996-07-02 1999-09-28 Merial, Inc. Water miscible macrolide solutions
US6271255B1 (en) 1996-07-05 2001-08-07 Biotica Technology Limited Erythromycins and process for their preparation
US5663361A (en) 1996-08-19 1997-09-02 Schering Corporation Process for preparing intermediates to florfenicol
JP2003512290A (en) 1997-09-10 2003-04-02 メルク エンド カムパニー インコーポレーテッド 8a-azalide as a livestock antibacterial agent
US6339063B1 (en) 1997-09-10 2002-01-15 Merck & Co., Inc. 9a-azalides as veterinary antimicrobial agents
AP9801420A0 (en) 1998-01-02 1998-12-31 Pfizer Prod Inc Novel macrolides.
US6239112B1 (en) 1998-07-09 2001-05-29 Merial, Inc. Water miscible macrolide solutions
CZ299375B6 (en) 1998-11-30 2008-07-09 Nihon Nohyaku Co., Ltd. Phthalimide derivatives or salts thereof, agricultural- horticultural insecticidal agent and application method thereof
CA2411293A1 (en) 1999-01-28 2000-07-28 Pfizer Products Inc. Novel azalides and methods of making same
PT1250343E (en) 2000-01-27 2003-11-28 Pfizer Prod Inc COMPOSITIONS OF AZALIDA ANTIBIOTICS
MY138097A (en) 2000-03-22 2009-04-30 Du Pont Insecticidal anthranilamides
BR0209241A (en) 2001-04-27 2004-06-15 Pfizer Prod Inc Process for preparing the 4-substituted 9-deoxo-9a-aza-9a-homoerythromycin derivatives
TWI312274B (en) 2001-08-13 2009-07-21 Du Pont Method for controlling particular insect pests by applying anthranilamide compounds
TWI283164B (en) 2001-09-21 2007-07-01 Du Pont Anthranilamide arthropodicide treatment
IL163749A0 (en) 2002-03-08 2005-12-18 Schering Plough Ltd Novel florfenicol-type antibiotics
UA81791C2 (en) 2003-01-28 2008-02-11 Е.І. Дю Пон Дэ Нэмур Энд Компани Cyanoantranilamide compounds, composition and methods for controlling number of pests
TWI468407B (en) * 2008-02-06 2015-01-11 Du Pont Mesoionic pesticides
IN2012DN00709A (en) 2009-08-05 2015-06-19 Du Pont
UA110924C2 (en) 2009-08-05 2016-03-10 Е. І. Дю Пон Де Немур Енд Компані Mesoionic pesticides
UA107804C2 (en) 2009-08-05 2015-02-25 Du Pont Mixtures of pesticides mezoionnyh
JP2013501063A (en) 2009-08-05 2013-01-10 イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー Mesoionic insecticide
TWI528899B (en) 2010-12-29 2016-04-11 杜邦股份有限公司 Mesoionic pesticides
WO2012106495A1 (en) 2011-02-03 2012-08-09 E. I. Du Pont De Nemours And Company Mesoionic pesticides

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089501A (en) * 1989-09-01 1992-02-18 Ciba Geigy Corp Anthelmintics

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
BOTTCHER, ANDREAS ET AL: "Magnetic circular dichroism of cyclic .pi.-electron systems. 27. Mesoionic compounds", JOURNAL OF ORGANIC CHEMISTRY, vol. 50, no. 25, 1985, pages 5050 - 5055, XP002523764 *
COBURN R A ET AL: "Mesoionic purinone analogs. III. The synthesis and properties of mesoionic thiazolo[3,2 a]pyrimidine 5,7 diones", JOURNAL OF HETEROCYCLIC CHEMISTRY, vol. 10, no. 4, 1973, pages 487 - 494, XP002532803, ISSN: 0022-152X *
GIANDINOTO S ET AL: "A facile preparation of some novel Class II mesoionic xanthine acyclonucleosides", JOURNAL OF HETEROCYCLIC CHEMISTRY, vol. 33, no. 6, 1996, pages 1839 - 1824, XP002532802, ISSN: 0022-152X *
GLENNON R A ET AL: "Imidazo[1,2-]pyrimidines and 1,2,4-triazolo[1,5-]pyrimidines: Two new examples of mesoionic xanthine analogs", JOURNAL OF HETEROCYCLIC CHEMISTRY, vol. 17, no. 2, 1980, pages 337 - 340, XP002532901, ISSN: 0022-152X *
GLENNON R A ET AL: "MESOIONIC XANTHINE ANALOGS AS INHIBITORS OF CYCLIC AMP PHOSPHODIESTERASE", JOURNAL OF PHARMACEUTICAL SCIENCE, vol. 67, no. 12, 1978, pages 1762 - 1765, XP000650826, ISSN: 0022-3549 *
HELLBERG M ET AL: "A preliminary investigation of Mesoionic Xanthine analogues as inhibitors of platelet aggregation", BIOORGANIC AND MEDICINAL CHEMISTRY, vol. 8, no. 8, 2000, pages 1917 - 1923, XP002532798, ISSN: 0968-0896 *
ROGERS M E ET AL: "Mesoionic purinone analogues as inhibitors of cyclic-AMP phosphodiesterase: A comparison of several ring systems", JOURNAL OF MEDICINAL CHEMISTRY 1981 US, vol. 24, no. 11, 1981, pages 1284 - 1287, XP002532800, ISSN: 0022-2623 *
SCHUBERT E M ET AL: "Mass spectrometry of modified nucleic acid bases and nucleosides. 2. Class II mesoionic nucleosides and bases derived from thiazolo[3,2-a]pyrimidine-5,7-diones [1,2]", JOURNAL OF HETEROCYCLIC CHEMISTRY, vol. 22, no. 3, 1985, pages 889 - 905, XP002532801, ISSN: 0022-152X *
URBAN R. ET AL: "Alkylation des <malonyl-alpha-aminopyridines>", HELVETICA CHIMICA ACTA, vol. 53, no. 5, 1970, pages 905 - 922, XP002532799, ISSN: 0018-019X *

Cited By (166)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014201144B2 (en) * 2008-02-06 2015-07-16 Fmc Corporation Mesoionic pesticides
EP2559687A1 (en) * 2008-02-06 2013-02-20 E. I. du Pont de Nemours and Company Mesoionic pesticides
US8232271B2 (en) 2008-10-30 2012-07-31 Roche Palo Alto Llc Heterocyclic antiviral compounds
JP2012513434A (en) * 2008-12-22 2012-06-14 エフ．ホフマン−ラ ロシュ アーゲー Heterocyclic antiviral compounds
WO2010072598A1 (en) * 2008-12-22 2010-07-01 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
JP2013501061A (en) * 2009-08-05 2013-01-10 イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー Mesoionic insecticide
US20160066577A1 (en) * 2009-08-05 2016-03-10 E I Du Pont De Nemours And Company Mesoionic pesticides
WO2011017351A3 (en) * 2009-08-05 2011-08-18 E. I. Du Pont De Nemours And Company Mixtures of mesoionic pesticides
US20140206536A1 (en) * 2009-08-05 2014-07-24 E I Du Pont De Nemours And Company Mesoionic pesticides
AU2010279591B2 (en) * 2009-08-05 2014-07-17 Corteva Agriscience Llc Mixtures of mesoionic pesticides
AU2010279582B2 (en) * 2009-08-05 2014-12-11 Fmc Agro Singapore Pte. Ltd. Mesoionic pesticides
CN102665415B (en) * 2009-08-05 2015-05-20 杜邦公司 Mixtures of mesoionic pesticides
KR101817810B1 (en) 2009-08-05 2018-01-11 이 아이 듀폰 디 네모아 앤드 캄파니 Mesoionic pesticides
WO2011017342A3 (en) * 2009-08-05 2011-05-19 E. I. Du Pont De Nemours And Company Mesoionic pesticides
EP2679583A1 (en) * 2009-08-05 2014-01-01 E. I. du Pont de Nemours and Company Mesoionic pesticides
CN102665415A (en) * 2009-08-05 2012-09-12 杜邦公司 Mixtures of mesoionic pesticides
US9210932B2 (en) * 2009-08-05 2015-12-15 E I Du Pont De Nemours And Company Mesoionic pesticides
US20120277100A1 (en) * 2009-08-05 2012-11-01 Wenming Zhang Mesoionic pesticides
US9596856B2 (en) * 2009-08-05 2017-03-21 E I Du Pont De Nemours And Company Mesoionic pesticides
WO2011017334A3 (en) * 2009-08-05 2011-04-28 E. I. Du Pont De Nemours And Company Mesoionic pesticides
US8722690B2 (en) * 2009-08-05 2014-05-13 E I Du Pont De Nemours And Company Mesoionic pesticides
WO2011017347A3 (en) * 2009-08-05 2011-04-21 E. I. Du Pont De Nemours And Company Mesoionic pesticides
KR101811458B1 (en) 2009-08-05 2017-12-21 이 아이 듀폰 디 네모아 앤드 캄파니 Mixtures of mesoionic pesticides
WO2011017351A2 (en) 2009-08-05 2011-02-10 E. I. Du Pont De Nemours And Company Mixtures of mesoionic pesticides
WO2011134819A1 (en) * 2010-04-27 2011-11-03 Syngenta Participations Ag Methods of controlling neonicotinoid resistant aphids
WO2012090514A1 (en) * 2010-12-27 2012-07-05 Sumitomo Chemical Company, Limited Arthropod pest control composition and method for controlling arthropod pests
EP2658378A4 (en) * 2010-12-27 2014-06-04 Sumitomo Chemical Co Arthropod pest control composition and method for controlling arthropod pests
US20130289051A1 (en) * 2010-12-27 2013-10-31 Sumitomo Chemical Company, Limited Arthropod pest control composition and method for controlling arthropod pests
EP2658378A1 (en) * 2010-12-27 2013-11-06 Sumitomo Chemical Company, Limited Arthropod pest control composition and method for controlling arthropod pests
US20130281466A1 (en) * 2010-12-27 2013-10-24 Sumitomo Chemical Company, Limited Arthropod pest control composition and method for controlling arthropod pests
CN103269588A (en) * 2010-12-27 2013-08-28 住友化学株式会社 Arthropod pest control composition and method for controlling arthropod pests
CN103260408A (en) * 2010-12-27 2013-08-21 住友化学株式会社 Arthropod pest control composition and method for controlling arthropod pests
CN103260413A (en) * 2010-12-27 2013-08-21 住友化学株式会社 Harmful arthropod control composition and method for controlling harmful arthropod
CN103260407A (en) * 2010-12-27 2013-08-21 住友化学株式会社 Arthropod pest control composition and method for controlling arthropod pests
WO2012090515A1 (en) * 2010-12-27 2012-07-05 Sumitomo Chemical Company, Limited Arthropod pest control composition and method for controlling arthropod pests
WO2012090516A1 (en) * 2010-12-27 2012-07-05 Sumitomo Chemical Company, Limited Arthropod pest control composition and method for controlling arthropod pests
WO2012090910A1 (en) * 2010-12-27 2012-07-05 住友化学株式会社 Harmful arthropod control composition and method for controlling harmful arthropod
CN103459387A (en) * 2010-12-29 2013-12-18 杜邦公司 Mesoionic pyrido [1,2 -A] pyrimidine pesticides
RU2585616C2 (en) * 2010-12-29 2016-05-27 Е.И. Дюпон Де Немур Энд Компани MESOIONIC PYRIDO [1,2-a] PYRIMIDINE PESTICIDES
JP2014503550A (en) * 2010-12-29 2014-02-13 イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー Mesoionic pyrido [1,2-a] pyrimidine pest control agent
WO2012092115A1 (en) 2010-12-29 2012-07-05 E. I. Du Pont De Nemours And Company Mesoionic pyrido [1,2 -a] pyrimidine pesticides
WO2012106495A1 (en) 2011-02-03 2012-08-09 E. I. Du Pont De Nemours And Company Mesoionic pesticides
JP2014512359A (en) * 2011-04-06 2014-05-22 ビーエーエスエフ ソシエタス・ヨーロピア Substituted pyrimidinium compounds for controlling animal pests
WO2012136724A1 (en) 2011-04-06 2012-10-11 Basf Se Substituted pyrimidinium compounds for combating animal pests
US9179680B2 (en) 2011-04-06 2015-11-10 Basf Se Substituted pyrimidinium compounds for combating animal pests
WO2013090547A1 (en) 2011-12-15 2013-06-20 E. I. Du Pont De Nemours And Company Malonic acid di-salts and a method for preparing malonyl dihalides
US9108965B2 (en) 2011-12-15 2015-08-18 E I Du Pont De Nemours And Company Malonic acid di-salts and a method for preparing malonyl dihalides
WO2013144228A1 (en) 2012-03-29 2013-10-03 Basf Se Pesticidal methods using heterocyclic compounds and derivatives for combating animal pests
KR20150023374A (en) 2012-06-21 2015-03-05 스미또모 가가꾸 가부시끼가이샤 Arthropod pest control composition and arthropod pest control method
RU2503666C1 (en) * 2012-06-25 2014-01-10 Открытое акционерное общество "Государственный научно-исследовательский институт "Кристалл" (ОАО "ГосНИИ "Кристалл") Method of producing 2-methylpyrimidine-4,6-(3h,5h)-dione
WO2014005982A1 (en) 2012-07-05 2014-01-09 Bayer Cropscience Ag Insecticide and fungicide active ingredient combinations
EP2684879A1 (en) 2012-07-09 2014-01-15 Basf Se Substituted mesoionic compounds for combating animal pests
WO2014093606A1 (en) 2012-12-13 2014-06-19 Novartis Ag Pyridone derivatives and uses thereof in the treatment of tuberculosis
US11019820B2 (en) 2013-04-11 2021-06-01 Basf Se Substituted pyrimidinium compounds and derivatives for combating animal pests
WO2014167084A1 (en) * 2013-04-11 2014-10-16 Basf Se Substituted pyrimidinium compounds and derivatives for combating animal pests
US9730451B2 (en) 2013-04-11 2017-08-15 Basf Se Substituted pyrimidinium compounds and derivatives for combating animal pests
AU2014253086B2 (en) * 2013-04-11 2018-01-18 Basf Se Substituted pyrimidinium compounds and derivatives for combating animal pests
KR102223216B1 (en) 2013-04-11 2021-03-04 바스프 에스이 Substituted pyrimidinium compounds and derivatives for combating animal pests
KR20150142025A (en) * 2013-04-11 2015-12-21 바스프 에스이 Substituted pyrimidinium compounds and derivatives for combating animal pests
US9975895B2 (en) 2013-06-17 2018-05-22 Basf Se Substituted pyrimidinium compounds and derivatives for combating animal pests
WO2014202582A1 (en) * 2013-06-17 2014-12-24 Basf Se Substituted pyrimidinium compounds and derivatives for combating animal pests
WO2015055554A1 (en) 2013-10-14 2015-04-23 Bayer Cropscience Ag Active substance for treating seed and soil
US9776967B2 (en) 2013-10-14 2017-10-03 Bayer Animal Health Gmbh Carboxamide derivatives as pesticidal compounds
WO2015059088A1 (en) 2013-10-23 2015-04-30 Bayer Cropscience Ag Substituted quinoxaline derivatives as pest control agent
WO2015101622A1 (en) 2014-01-03 2015-07-09 Bayer Cropscience Ag Novel pyrazolyl-heteroarylamides as pesticides
WO2015107133A1 (en) 2014-01-20 2015-07-23 Bayer Cropscience Ag Quinoline derivatives as insecticides and acaricides
WO2015150300A1 (en) 2014-04-02 2015-10-08 Bayer Cropscience Ag N-(1-(hetero)aryl-1h-pyrazol-4-yl)-(hetero)arylamide derivatives and use thereof as pesticides
WO2015169776A1 (en) 2014-05-08 2015-11-12 Bayer Cropscience Ag Pyrazolopyridine sulfonamides as nematicides
WO2015185531A1 (en) 2014-06-05 2015-12-10 Bayer Cropscience Aktiengesellschaft Bicyclic compounds as pesticides
WO2016001119A1 (en) 2014-07-01 2016-01-07 Bayer Cropscience Aktiengesellschaft Insecticide and fungicide active ingredient combinations
CN104082333A (en) * 2014-07-03 2014-10-08 广西农喜作物科学有限公司 Insecticidal composition containing clothianidin
WO2016008830A1 (en) 2014-07-15 2016-01-21 Bayer Cropscience Aktiengesellschaft Aryl-triazolyl pyridines as pest control agents
US10149477B2 (en) 2014-10-06 2018-12-11 Basf Se Substituted pyrimidinium compounds for combating animal pests
WO2016055431A1 (en) * 2014-10-06 2016-04-14 Basf Se Substituted pyrimidinium compounds for combating animal pests
WO2016055096A1 (en) 2014-10-07 2016-04-14 Bayer Cropscience Ag Method for treating rice seed
CN104397004A (en) * 2014-10-23 2015-03-11 北京燕化永乐生物科技股份有限公司 Pesticide composition
WO2016091857A1 (en) 2014-12-11 2016-06-16 Bayer Cropscience Aktiengesellschaft Five-membered c-n bonded aryl sulphide and aryl sulphoxide derivatives as pest control agents
WO2016124563A1 (en) 2015-02-05 2016-08-11 Bayer Cropscience Aktiengesellschsaft 2-(het)aryl-substituted condensed bicyclic heterocycle derivatives as pest control agents
WO2016124557A1 (en) 2015-02-05 2016-08-11 Bayer Cropscience Aktiengesellschaft 2-(het)aryl-substituted condensed bicyclic heterocycle derivatives as pest control agents
WO2016128298A1 (en) 2015-02-09 2016-08-18 Bayer Cropscience Aktiengesellschaft Substituted 2-thioimidazolyl-carboxamides as pest control agents
WO2016142394A1 (en) 2015-03-10 2016-09-15 Bayer Animal Health Gmbh Pyrazolyl-derivatives as pest control agents
WO2016162318A1 (en) 2015-04-08 2016-10-13 Bayer Cropscience Aktiengesellschaft Condensed bicyclic heterocycle derivatives as pest control agents and intermediate product
EP3081085A1 (en) 2015-04-14 2016-10-19 Bayer CropScience AG Method for improving earliness in cotton
WO2016171053A1 (en) * 2015-04-21 2016-10-27 日本化薬株式会社 Mesoionic compound
WO2016174049A1 (en) 2015-04-30 2016-11-03 Bayer Animal Health Gmbh Anti-parasitic combinations including halogen-substituted compounds
EP2910126A1 (en) 2015-05-05 2015-08-26 Bayer CropScience AG Active compound combinations having insecticidal properties
WO2016180802A1 (en) 2015-05-13 2016-11-17 Bayer Cropscience Aktiengesellschaft Insecticidal arylpyrrolidines, method for synthesizing same, and use thereof as agents for controlling animal pests
WO2017005717A1 (en) 2015-07-06 2017-01-12 Bayer Cropscience Aktiengesellschaft Heterocyclic compounds as pesticides
EP3896066A2 (en) 2015-08-07 2021-10-20 Bayer CropScience Aktiengesellschaft 2-(het)aryl-substituted condensed heterocycle derivatives as pesticides
EP3896065A1 (en) 2015-08-07 2021-10-20 Bayer CropScience Aktiengesellschaft 2-(het)aryl-substituted condensed heterocycle derivatives as pesticides
WO2017093214A1 (en) 2015-12-03 2017-06-08 Bayer Cropscience Aktiengesellschaft Mesoionic halogenated 3-(acetyl)-1-[(1,3-thiazol-5-yl)methyl]-1h-imidazo[1,2-a]pyridin-4-ium-2-olate derivatives and related compounds as insecticides
CN108602819A (en) * 2015-12-03 2018-09-28 拜耳作物科学股份公司 Mesoionically halogenated 3- (acetyl) -1- [ (1, 3-thiazol-5-yl) methyl ] -1H-imidazo [1, 2-a ] pyridin-4-ium-2-alkoxide derivatives and related compounds as pesticides
WO2017097870A1 (en) * 2015-12-11 2017-06-15 Bayer Cropscience Aktiengesellschaft Substituted malonic acid amides as insecticides
EP3210468A1 (en) 2016-02-26 2017-08-30 Bayer CropScience Aktiengesellschaft Solvent-free formulations of low-melting point agents
WO2017144497A1 (en) 2016-02-26 2017-08-31 Bayer Cropscience Aktiengesellschaft Solvent-free formulations of low-melting active substances
US10750750B2 (en) 2016-07-11 2020-08-25 Covestro Llc Aqueous compositions for treating seeds, seeds treated therewith, and methods for treating seeds
WO2018013381A1 (en) 2016-07-11 2018-01-18 Covestro Llc, Et Al. Aqueous compositions for treating seeds, seeds treated therewith, and methods for treating seeds
WO2018013382A1 (en) 2016-07-11 2018-01-18 Covestro Llc, Et Al Aqueous compositions for treating seeds, seeds treated therewith, and methods for treating seeds
WO2018013380A1 (en) 2016-07-11 2018-01-18 Covestro Llc, Et Al. Methods for treating seeds with an aqueous compostion and seeds treated therewith
US10653135B2 (en) 2016-07-11 2020-05-19 Covestro Llc Methods for treating seeds with an aqueous composition and seeds treated therewith
US10653136B2 (en) 2016-07-11 2020-05-19 Covestro Llc Aqueous compositions for treating seeds, seeds treated therewith, and methods for treating seeds
WO2018011111A1 (en) 2016-07-12 2018-01-18 Bayer Cropscience Aktiengesellschaft Bicyclic compounds as pest control agents
WO2018069842A1 (en) 2016-10-14 2018-04-19 Pi Industries Ltd 4-amino substituted phenylamidine derivatives and their use to protect crops by fighting undesired phytopathogenic micoorganisms
WO2018069841A1 (en) 2016-10-14 2018-04-19 Pi Industries Ltd 4-substituted phenylamine derivatives and their use to protect crops by fighting undesired phytopathogenic micoorganisms
US11155517B2 (en) 2016-10-14 2021-10-26 Pi Industries Ltd. 4-substituted phenylamine derivatives and their use to protect crops by fighting undesired phytopathogenic micoorganisms
WO2018104500A1 (en) 2016-12-09 2018-06-14 Bayer Cropscience Aktiengesellschaft Plant health effect of purpureocillium lilacinum
WO2018108730A1 (en) 2016-12-16 2018-06-21 Bayer Aktiengesellschaft Mesoionic imidazopyridines for use as insecticides
WO2018116072A1 (en) 2016-12-20 2018-06-28 Pi Industries Ltd. Heterocyclic compounds
WO2018116073A1 (en) 2016-12-21 2018-06-28 Pi Industries Ltd. 1, 2, 3-thiadiazole compounds and their use as crop protecting agent
WO2018177995A1 (en) 2017-03-31 2018-10-04 Bayer Cropscience Aktiengesellschaft Tricyclic carboxamides for controlling arthropods
WO2018177970A1 (en) 2017-03-31 2018-10-04 Basf Se Process for preparing chiral 2,3-dihydrothiazolo[3,2-a]pyrimidin-4-ium compounds
WO2018177993A1 (en) 2017-03-31 2018-10-04 Bayer Cropscience Aktiengesellschaft Pyrazoles for controlling arthropods
US11825838B2 (en) 2017-03-31 2023-11-28 Bayer Cropscience Aktiengesellschaft Tricyclic carboxamides for controlling arthropods
EP3978504A1 (en) 2017-03-31 2022-04-06 Basf Se Chiral 2,3-dihydrothiazolo[3,2-a]pyrimidine derivatives for combating animal pests
WO2018189077A1 (en) 2017-04-12 2018-10-18 Bayer Aktiengesellschaft Mesoionic imidazopyridines for use as insecticides
WO2018193385A1 (en) 2017-04-20 2018-10-25 Pi Industries Ltd. Novel phenylamine compounds
US11524934B2 (en) 2017-04-20 2022-12-13 Pi Industries Ltd Phenylamine compounds
CN110536891A (en) * 2017-04-21 2019-12-03 拜耳公司 Mesoionic imidazopyridine as insecticide
WO2018192872A1 (en) 2017-04-21 2018-10-25 Bayer Aktiengesellschaft Mesoionic imidazopyridines as insecticides
US10993439B2 (en) 2017-04-21 2021-05-04 Bayer Aktiengesellschaft Mesoionic imidazopyridines as insecticides
EP3400801A1 (en) 2017-05-10 2018-11-14 Bayer CropScience Aktiengesellschaft Plant health effect of purpureocillium lilacinum
US11344029B2 (en) 2017-06-01 2022-05-31 Sumitomo Chemical Company, Limited Heterocyclic compound and composition containing same
WO2018229202A1 (en) 2017-06-16 2018-12-20 Basf Se Mesoionic imidazolium compounds and derivatives for combating animal pests
US11542280B2 (en) 2017-06-19 2023-01-03 Basf Se Substituted pyrimidinium compounds and derivatives for combating animal pests
CN110678469A (en) * 2017-06-19 2020-01-10 巴斯夫欧洲公司 Substituted pyrimidinium compounds and derivatives for combating animal pests
WO2018234202A1 (en) 2017-06-19 2018-12-27 Basf Se Substituted pyrimidinium compounds and derivatives for combating animal pests
CN110678469B (en) * 2017-06-19 2023-03-03 巴斯夫欧洲公司 Substituted pyrimidinium compounds and derivatives for combating animal pests
WO2019007888A1 (en) 2017-07-06 2019-01-10 Bayer Aktiengesellschaft Insecticidal active ingredient combinations
WO2019007887A1 (en) 2017-07-06 2019-01-10 Bayer Aktiengesellschaft Insecticide and fungicide active ingredient combinations
WO2019007891A1 (en) 2017-07-06 2019-01-10 Bayer Aktiengesellschaft Insecticidal active ingredient combinations
WO2019072906A1 (en) 2017-10-13 2019-04-18 Basf Se Imidazolidine pyrimidinium compounds for combating animal pests
US11399543B2 (en) 2017-10-13 2022-08-02 Basf Se Substituted 1,2,3,5-tetrahydroimidazo[1,2-a]pyrimidiniumolates for combating animal pests
EP3473103A1 (en) 2017-10-17 2019-04-24 Bayer AG Aqueous suspension concentrates based on 2- [(2,4-dichlorophenyl) -methyl] -4,4 '-dimethyl-3-isoxazolidinone
WO2019076744A1 (en) 2017-10-17 2019-04-25 Bayer Aktiengesellschaft Aqueous [2-(2,4-dichlorophenyl)methyl]-4,4-dimethyl-3-isoxazolidinone-based suspension concentrates
WO2019086474A1 (en) 2017-10-31 2019-05-09 Syngenta Participations Ag Pesticidally active mesoionics heterocyclic compounds
WO2019115404A1 (en) 2017-12-13 2019-06-20 Syngenta Participations Ag Pesticidally active mesoionic heterocyclic compounds
WO2019123196A1 (en) 2017-12-20 2019-06-27 Pi Industries Ltd. Fluoralkenyl compounds, process for preparation and use thereof
US11407756B2 (en) 2017-12-25 2022-08-09 Sumitomo Chemical Company, Limited Heterocyclic compounds and noxious arthropod control agent containing same
WO2019150311A1 (en) 2018-02-02 2019-08-08 Pi Industries Ltd. 1-3 dithiol compounds and their use for the protection of crops from phytopathogenic microorganisms
WO2019173173A1 (en) 2018-03-05 2019-09-12 E. I. Du Pont De Nemours And Company Process and intermidiates for the preparation of certain mesoionic pesticides
CN110317200A (en) * 2018-03-28 2019-10-11 东莞东阳光科研发有限公司 Pyrimidine compound and application thereof
WO2020002189A1 (en) 2018-06-27 2020-01-02 Bayer Aktiengesellschaft Active substance combinations
WO2020021082A1 (en) 2018-07-27 2020-01-30 Bayer Aktiengesellschaft Controlled release formulations for agrochemicals
WO2020025650A1 (en) 2018-07-31 2020-02-06 Bayer Aktiengesellschaft Controlled release formulations with lignin for agrochemicals
WO2020035826A1 (en) 2018-08-17 2020-02-20 Pi Industries Ltd. 1,2-dithiolone compounds and use thereof
WO2020058010A1 (en) 2018-09-19 2020-03-26 Basf Se Pesticidal mixtures comprising a mesoionic compound
WO2020064408A1 (en) 2018-09-28 2020-04-02 Basf Se Method of controlling insecticide resistant insects and virus transmission to plants
WO2020064480A1 (en) 2018-09-28 2020-04-02 Basf Se Pesticidal mixture comprising a mesoionic compound and a biopesticide
EP3628157A1 (en) 2018-09-28 2020-04-01 Basf Se Method of controlling insecticide resistant insects and virus transmission to plants
EP3628158A1 (en) 2018-09-28 2020-04-01 Basf Se Pesticidal mixture comprising a mesoionic compound and a biopesticide
EP3628156A1 (en) 2018-09-28 2020-04-01 Basf Se Method for controlling pests of sugarcane, citrus, rapeseed, and potato plants
WO2020064511A1 (en) 2018-09-28 2020-04-02 Basf Se Method for controlling pests of potato plants
WO2020064503A1 (en) 2018-09-28 2020-04-02 Basf Se Method for controlling pests of rapeseed plants
WO2020064501A1 (en) 2018-09-28 2020-04-02 Basf Se Method for controlling pests of citrus plants
WO2020126591A1 (en) 2018-12-18 2020-06-25 Basf Se Substituted pyrimidinium compounds for combating animal pests
WO2020239517A1 (en) 2019-05-29 2020-12-03 Basf Se Mesoionic imidazolium compounds and derivatives for combating animal pests
EP3769623A1 (en) 2019-07-22 2021-01-27 Basf Se Mesoionic imidazolium compounds and derivatives for combating animal pests
WO2021048188A1 (en) 2019-09-11 2021-03-18 Bayer Aktiengesellschaft Highly effective formulations on the basis of 2-[(2,4-dichlorphenyl)-methyl]-4,4'-dimethyl-3-isoxazolidinones and preemergence herbicides
WO2021151034A1 (en) 2020-01-24 2021-07-29 Fmc Corporation Mesoionic insecticides
WO2022162129A1 (en) 2021-01-28 2022-08-04 Rhodia Operations Method for treating rice seed with improved retention of agrochemical, micronutrient and colorant
WO2023078915A1 (en) 2021-11-03 2023-05-11 Bayer Aktiengesellschaft Bis(hetero)aryl thioether (thio)amides as fungicidal compounds
WO2023086802A1 (en) 2021-11-10 2023-05-19 Corteva Agriscience Llc Processes for the preparation of certain mesoionic pesticides
WO2023092050A1 (en) 2021-11-20 2023-05-25 Bayer Cropscience Lp Beneficial combinations with recombinant bacillus cells expressing a serine protease
WO2023099445A1 (en) 2021-11-30 2023-06-08 Bayer Aktiengesellschaft Bis(hetero)aryl thioether oxadiazines as fungicidal compounds
WO2023110656A1 (en) 2021-12-15 2023-06-22 Bayer Aktiengesellschaft Spectroscopic solution for non-destructive quantification of one or more chemical substances in a matrix comprising coating and bulk material in a sample, such as coated seeds, using multivariate data analysis
WO2024040111A1 (en) 2022-08-18 2024-02-22 Corteva Agriscience Llc Process for the preparation and isolation of intermediates of certain mesoionic pesticides

Also Published As

Publication number Publication date
EA201200715A1 (en) 2012-10-30
NZ598147A (en) 2012-04-27
CA2713347A1 (en) 2009-08-13
HRP20130501T1 (en) 2013-08-31
IL226126A0 (en) 2013-06-27
KR20100118594A (en) 2010-11-05
KR20130128472A (en) 2013-11-26
ZA201005035B (en) 2011-09-28
CN101939302B (en) 2014-10-29
KR101404291B1 (en) 2014-06-20
JP2011511080A (en) 2011-04-07
BRPI0905936A2 (en) 2015-06-30
TW200936051A (en) 2009-09-01
BRPI0905936B1 (en) 2019-12-24
AU2009212715B2 (en) 2014-04-10
PL2240454T3 (en) 2013-09-30
JP2012214491A (en) 2012-11-08
JP5068378B2 (en) 2012-11-07
PH12014500760B1 (en) 2016-07-11
SI2240454T1 (en) 2013-08-30
AR071644A1 (en) 2010-07-07
JP5613726B2 (en) 2014-10-29
CL2009000252A1 (en) 2010-10-08
CN104311554A (en) 2015-01-28
US9018220B2 (en) 2015-04-28
ZA201105120B (en) 2013-04-24
MX2010008532A (en) 2010-08-23
US8552007B2 (en) 2013-10-08
EA019955B1 (en) 2014-07-30
CA2713347C (en) 2016-10-18
UY31633A1 (en) 2009-09-30
TWI401023B (en) 2013-07-11
CN101939302A (en) 2011-01-05
PT2240454E (en) 2013-07-11
EP2559687A1 (en) 2013-02-20
CO6321190A2 (en) 2011-09-20
EP2240454A1 (en) 2010-10-20
IL207087A (en) 2015-07-30
NZ586799A (en) 2012-03-30
PH12014500760A1 (en) 2016-07-11
TW201247667A (en) 2012-12-01
EP2240454B1 (en) 2013-04-24
IL207087A0 (en) 2010-12-30
AU2009212715A1 (en) 2009-08-13
RS52788B (en) 2013-10-31
CN104311554B (en) 2017-05-24
US20100323887A1 (en) 2010-12-23
TWI468407B (en) 2015-01-11
EA201070926A1 (en) 2011-04-29
MA32026B1 (en) 2011-01-03
DK2240454T3 (en) 2013-07-22
ES2416083T3 (en) 2013-07-30
MX352783B (en) 2017-12-08
US20130338002A1 (en) 2013-12-19
KR101495468B1 (en) 2015-02-23
MY153886A (en) 2015-04-15

Similar Documents

Publication Publication Date Title
US9018220B2 (en) Mesoionic pesticides
US9596856B2 (en) Mesoionic pesticides
AU2010279591B2 (en) Mixtures of mesoionic pesticides
US20120122680A1 (en) Mesoionic pesticides
US20120122679A1 (en) Mesoionic pesticides
AU2014201144B2 (en) Mesoionic pesticides
AU2015201191B2 (en) Mesoionic pesticides

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980104397.6

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09709044

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 586799

Country of ref document: NZ

Ref document number: 2009212715

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 207087

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 5275/DELNP/2010

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2713347

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/A/2010/008532

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 10095278

Country of ref document: CO

Ref document number: 2009709044

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2009212715

Country of ref document: AU

Date of ref document: 20090130

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2010545938

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 12866462

Country of ref document: US

Ref document number: 12010501814

Country of ref document: PH

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: PI 2010003384

Country of ref document: MY

ENP Entry into the national phase

Ref document number: 20107019689

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 201070926

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: A201009923

Country of ref document: UA

WWE Wipo information: entry into national phase

Ref document number: 226126

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: P-2013/0222

Country of ref document: RS

ENP Entry into the national phase

Ref document number: PI0905936

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20100806